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ABSTRACT 
Aim: The aims of this study were to investigate the treatment outcomes of patients with MDR-
TB and its determinants at referral hospitals in Ethiopia. The study also aims to develop a 
conceptual model for enhancing treatment of patients with MDR-TB in Ethiopia. 
Design and methods: A concurrent mixed methods design with quantitative dominance was 
used to investigate treatment outcomes of patients with MDR-TB and its determinants.  
Results: A total of 136 (n=136) patients with MDR-TB participated in the study, 74 (54%) 
were male and 62 (46%) were female. Forty-one (31%) of the patients had some co-morbidity 
with MDR-TB at baseline, and 64% had body mass index less than 18.5kg/m2. Eight (6%) of 
the patients were diagnosed among household contacts. At 24 months, 76/110 (69%) of the 
patients had successfully completed treatment, but 30/110 (27%) were died of MDR-TB. Multi-
variable logistic regression revealed that the odds of unfavourable treatment outcomes were 
significantly higher among patients with low body mass index (BMI <18.5kg/m2) (AOR=2.734, 
95% CI: 1.01-7.395; P<0.048); and those with some co-morbidity with MDR-TB at the 
baseline (AOR=4.260, 95%CI: 1.607-11.29; p<0.004).  
The majority of the patients were satisfied with the clinical care they received at hospitals.  
But as no doctor was exclusively dedicated for the MDR-TB centre, patients could not receive 
timely medical attention and this was especially the case with those with emergency medical 
conditions. The caring practice of caregivers at the hospitals was supportive and empathic 
but it was desperate and alienating at treatment follow up centres. Patients were dissatisfied 
with the quality and adequacy of the socio-economic support they got from the programme. 
Despite the high MDR-TB and HIV/AIDS co-infection rate, services for both diseases was not 
available under one roof.  
Conclusions: Low body mass index and the presence of any co-morbidity with MDR-TB at 
the baseline are independent predictors of death among patients with MDR-TB. Poor 
communication between patients and their caregivers and inadequate socio-economic 
support were found to determine patients’ perceived quality of care and patients’ satisfaction 
with care given for MDR-TB.   
Keywords: MDR-TB, treatment outcomes, perceived quality of care, patient satisfaction  
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Chapter 1 
1. Orientation to the study 
1.1 Introduction   
Tuberculosis is a chronic infectious disease caused by the bacillus Mycobacterium 
tuberculosis. Although the disease typically affects the lung, it can affect any part of the 
human body (Davies, Gordon & Davies 2014:130; Munsab, Santanu, Ravinder, Pradeep 
& Ankur 2013:123). According to the World Health Organisation (2014b:1), the bacillus 
Mycobacterium tuberculosis is transmitted through the air when a person with the disease 
coughs or sneezes. As a result, persons in the surroundings may become infected when 
they breathe in the bacteria. Given this mode of transmission, Dye (2015:4) describes 
tuberculosis as an airborne disease.  
 
Davies, Gordon and Davies (2014:80) report that the Mycobacterium tuberculosis is a 
resistant bacterium that is protected by a lipid coat, and thus it can survive adverse 
conditions like acidic environments. Added to this, the bacteria have the ability to survive 
diverse environmental conditions. They are found widespread in the environment, 
particularly in soils and water (Davies et al 2014:48). The bacteria have the ability to 
survive for long periods in dust, especially in the dark, warm and moist environments as 
these environmental conditions protect them from the lethal effects of ultraviolet rays of 
the sunshine (Lucas & Gilles 2003:153). Moreover, the Mycobacterium tuberculosis has 
the ability to survive for years within the host in small but viable populations (Dye 2015:2). 
 
Tuberculosis is an ancient disease (Fmusick 2004:6). Yet, the disease continues to be the 
leading cause of morbidity and mortality worldwide (Lewis & Sloan 2015:780; Zwerling, 
Hanrahan & Dowdy 2016: 407-409). Globally, tuberculosis is responsible for about 1.4 
million deaths every year (Zwerling, Hanrahan & Dowdy 2016: 407-409). Moreover, the 
emergence of the MDR-TB makes the disease to be more challenging today (WHO 
2016:1).  
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MDR-TB is a strain of tuberculosis that is resistant to the two most potent first line anti-
tuberculosis drugs: rifampicin and isoniazid (Adams & Butterly 2015:1-2). This strain of 
tuberculosis affects both the clinical management of patients with the disease and patients’ 
treatment outcomes (Caminero 2013:39-44). According to Pinto and Menzies (2011:129-
30), about 17% of all new tuberculosis cases worldwide have some forms of drug 
resistance. Dheda and Migliori (2011:1) agree with this assertion and state that about 5-
10% of global MDR-TB cases are extensively drug resistant tuberculosis. The extensively 
drug resistant tuberculosis (XDR-TB) is a form of MDR-TB that is resistant to the two most 
powerful anti-tuberculosis drugs, isoniazid and rifampicin, in addition to resistance to any 
of the fluoroquinolones (like levofloxacin or moxifloxacin), and one of the three injectable 
second-line drugs: amikacin, capreomycin or kanamycin (Dheda, Gumbo, Gandhi, Murray, 
Theron, Udwadia, Migliori & Warren 2014:321). 
 
The empirical literature sources indicate that XDR-TB cases are present among patients 
with MDR-TB in Ethiopia (Agonafir, Lemma, Wolde-Meskel, Goshu, Santhanam, 
Girmachew, Demissie, Getahun, Gebeyehu & Soolingen 2010:1259-65). The prevalence 
of MDR-TB in newly notified tuberculosis cases has increased in Ethiopia from 1.6% in 
2005 to 2.3% in 2014 despite the utilisation of the Directly Observed Treatment short 
course strategy (Federal Ministry of Health of Ethiopia (FMOH) 2014:2). Yet, there is a 
dearth of research in Ethiopia on the programmatic management of drug-resistant 
tuberculosis. Added to this, there is presently limited empirical evidence in Ethiopia, 
particularly in the Oromia Region, on the medico-socio-economic and demographic 
determinants of the process and outcomes of the treatment for MDR-TB. This gap in 
knowledge warrants the need to conduct this study that focuses on investigating treatment 
outcomes of patients with MDR-TB and its determinants at referral hospitals in the Oromia 
Region of Ethiopia.  
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1.2 Background   
Tuberculosis is considered the second leading global cause of mortality in the context of 
infectious diseases (Nelson, Hesse & Croyle.2009:137). Acknowledging this, it is not 
surprising for tuberculosis to be consistently noted in the empirical literature sources to be 
responsible for illnesses among millions of people each year in the world (The Economist 
2014:2; Yuen, Amanullah, Dharmadhikari, Nardell, Seddon, Vasilyeva, Zhao, Keshavjee 
& Becerra 2015:2334). Given this, tuberculosis can be safely described as a global public 
health problem that has been exacerbated by the emergence of MDR-TB and XDR-TB. 
Yet, the global response to this problem (tuberculosis and its variants) has been reported 
to be inadequate. In 2010, for example, from the globally estimated 650 000 cases of 
tuberculosis, less than 5% were tested for the MDR-TB (Toczek, Cox, du Cros, Cooke & 
Ford 2012:29). In 2012, only 9% of tuberculosis cases, considered at risk of MDR-TB, 
were diagnosed as MDR-TB, and only one in five of these cases were notified by the 
national tuberculosis programmes (Global Fund for Tuberculosis, HIV/AIDS and Malaria 
(GFATM): 2014:1). 
 
Ethiopia is among the 30 countries in the world described by the World Health Organization 
(WHO) as high burden for both tuberculosis and MDR-TB (Biadglegne, Sack & Rodloff 
2014:3; WHO 2014a: 147). This descriptor of ‘high burden’ is a function of the high 
prevalence and incidence of tuberculosis cases in Ethiopia. The 2010-2011 population-
based national tuberculosis survey revealed that the prevalence of bacteriologically 
confirmed cases of tuberculosis  were estimated at 277 per 100 000 population (Kebede, 
Alebachew, Tsegaye, Lemma, Abebe, Agonafir, Kebede, Demissie, Girmachew, Yaregal, 
Dana, Getahun, Fiseha, Meaza, Dirse, Timimi, Sismanidis, Tadolini & Onozaki 2014:635). 
The annual incidence of MDR-TB cases in Ethiopia for the year 2011 was estimated at 
2,200 (WHO 2010: 24; Falzon, Jaramillo, Wares, Zignol, Floyed & Raviglione 2013:691). 
The incidence of all forms of tuberculosis in 2012 was estimated at 247 per 100 000 
population (Federal Ministry of Health of Ethiopia 2013:12). While this is the case, the 
result of the tuberculosis drug-resistance survey of Ethiopia revealed an increase in the 
prevalence of MDR-TB among new tuberculosis cases from 1.6% in 2005 to 2.3% in 2014. 
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Added to this, the national prevalence of MDR-TB among previously treated tuberculosis 
cases was noted in the same survey to increase from 11.8% in 2005 to 17.8% in 2014 
(Federal Ministry of Health of Ethiopia (FMOH) 2013:48; FMOH 2014:2).  
 
The high prevalence of MDR-TB is a concern for the government of Ethiopia and 
healthcare workers, particularly those who are directly involved in the care and treatment 
of people with this disease. In fact, the government of Ethiopia considers tuberculosis as 
one of the top national diseases of public health importance. Despite this, the number of 
hospitals in Ethiopia with capacity to provide diagnosis and treatment services to people 
with this disease is not adequate (Falzon et al 2013:690). In 2014, only 6% (2,405) of all 
bacteriologically confirmed cases of tuberculosis had a drug sensitivity test (Biadglegne, 
Sack & Rodloff 2014:7). In the same year, 2014, only 39% (503) of the annual estimated 
prevalence of MDR-TB (1300) was notified by the national tuberculosis programme (WHO 
2015:62). Given this, the government of Ethiopia expanded its treatment services for MDR-
TB, including the diagnosis of this disease. It currently rolls out the programmatic 
management of drug-resistant tuberculosis across all the provinces of Ethiopia. Even 
though this is the case, only a few studies are available on the programmatic management 
of drug-resistant tuberculosis (Biadglegne, Sack & Rodloff 2014:3), and there are no 
studies to date on this programme in the Oromia Region of Ethiopia.  
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1.3 Motivation of the study  
Researchers’ interest and the need to solve practical problems are often the driving forces 
for researchers to engage in a study (Marczyk, DeMatteo & Festinger 2005:27-29). In this 
study, the researcher has an interest in developing an understanding of drug-resistant 
tuberculosis. This quest is a function of the high incidence and prevalence of drug-resistant 
tuberculosis in Ethiopia, which is therefore considered in the same as a public health 
problem.  
 
As a clinical officer, the researcher provided clinical care to polyclinic attendants at two 
health centres in the Oromia Region of Ethiopia. As a result, the researcher frequently 
experienced first-hand health and economic problems faced by individuals affected by 
tuberculosis. Shortly, after graduating with a master’s degree in public health in 2006, the 
researcher engaged in the programmatic management of tuberculosis and the human 
immune deficiency virus (HIV) in Ethiopia. Since then, the researcher worked on the 
tuberculosis and human immune deficiency virus (TB/HIV) programme at different 
healthcare levels in varied roles.  These roles include site level technical support for health 
caregivers and clinical mentor support for caregivers working on the tuberculosis and HIV 
programme at health centres and hospitals. During his clinical practice, the researcher 
learned that some patients treated for tuberculosis failed to recover from this disease, 
particularly when treated using the generic first-line anti-tuberculosis drugs. This, in part, 
contributed to the emergence of the varied forms of tuberculosis such as MDR-TB in 
Ethiopia.  
 
Thus, treatment centres for MDR-TB were set up in Ethiopia. During the researcher’s 
regular visits to these centres in the Oromia Region, he noted that the management of 
MDR-TB was a challenging professional task. The researcher also learnt that there was 
no evidence on the determinants of the treatment outcomes of patients with MDR-TB. 
There was also no evidence regarding the patients’ perceived quality of the care they were 
provided. These observations were the root of the researcher’s inspiration for working on 
MDR-TB, and to conduct a study on this form of tuberculosis. Given this, the researcher 
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registered for a doctoral programme at the University of South Africa with the view to 
investigate treatment outcomes of patients with MDR-TB and its determinants, as it is a 
priority subject in the Oromia Region of Ethiopia.  
 
1.4 Statement of the research problem  
Tuberculosis has claimed more lives than any other infectious disease on earth during the 
past two centuries (Heemskerk, Caws, Marais & Farra 2015:1). The existence of 
tuberculosis is as old as human history (Hatfull & Jacobs 2014:31) but the development of 
MDR-TB as a public health problem is a recent phenomenon, which emerged in the early 
1990s (Udwadia 2012:286). MDR-TB is the strain of tuberculosis bacilli that is resistant to 
the two most potent first-line anti-tuberculosis drugs, i.e. isoniazid and rifampicin 
(Caminero, Sotgiu, Zumla & Migliori 2010:621). Despite advances in treatment, prevention 
and control (vaccine, drugs and diagnostic measures), tuberculosis continues to be one of 
the major causes of morbidity and mortality worldwide (Lewis & Sloan 2015:779). This is 
particularly the case for MDR-TB. In 2013, a total of about 480 000 cases and about 210 
000 deaths were caused by MDR-TB (WHO 2014a:70).  
 
In 2016, the global disability-adjusted life-years for tuberculosis and MDR-TB was 
estimated. The disability-adjusted life-years for tuberculosis was calculated by summing 
up years of life lost to premature death caused by tuberculosis and years of productive life 
lost due to disability caused by tuberculosis. In this way the estimated disability-adjusted 
life-years for drug-susceptible tuberculosis was 39·9 million (uncertainty interval (UI):38·1 
million to 41·9 million). For the same year, the estimated global disability-adjusted life-
years for MDR-TB without extensive drug resistance was 3·32 million (UI=2·79 million to 
3·91 million). The disability-adjusted life-years for extensively drug-resistant tuberculosis 
for the same year was 369 000 (UI=301 000–445 000) (Global Health Metrics 2017:1283).  
 
Both tuberculosis and MDR-TB disproportionately affect people with conditions such as 
HIV, diabetes and malnutrition (Glaziou, Sismanidis, Floyd & Raviglione 2015:5; Rouzier, 
26 
 
 
Oxlade, Verduga, Gresely & Menzies 2010:1320). As such, MDR-TB is a serious threat to 
decades of global progress in the control of tuberculosis.  This is because it negatively 
affects the diagnosis, clinical management and treatment outcomes of tuberculosis 
(Caminero 2013:39-44). 
 
Ethiopia is one of the 30 high burden countries for tuberculosis, tuberculosis and HIV co-
morbidity and MDR-TB. Ethiopia is one of the countries that are committed to develop and 
implement plans to achieve universal access to diagnosis and treatment for MDR-TB 
(Falzon, Jaramillo, Wares, Zignol, Floyed & Raviglione 2013:694). In Ethiopia, even 
though the incidence of MDR-TB among new cases increased from 1.6% in 2005 to 2.3% 
in 2014 (Federal Ministry of Health of Ethiopia 2014:2), the number of MDR-TB cases ever 
detected and enrolled on treatment has been far below the national incident estimate 
(WHO 2010: 24; Falzon et al 2013:690). Thus, the huge pool of individuals with untreated 
MDR-TB represents an important source of disease transmission (Kendall, Azman, 
Cobelens & Dowdy 2017:2). Thus, the government of Ethiopia is expanding the services 
on the programmatic management of MDR-TB to all its regions or provinces (Biadglegne, 
Sack & Rodloff 2014:3).  
 
Treatment of MDR-TB has as high impact as prevention (Kendall, Azman, Cobelens & 
Dowdy 2017:10). However, there are certain factors that determine treatment outcomes 
of patients with MDR-TB. These factors challenge the desired impact of MDR-TB service 
expansion. The MDR-TB treatment causes extreme social, financial and employment 
hardship for the patient with the disease. Most patients with MDR-TB had to move home 
and leave their jobs, and face major stigmatisation (Baral, Aryal, Bhattrai, King & Newell 
2014:1). Treatment of MDR-TB and XDR-TB can take up to two years (WHO 2011:1). The 
lengthy treatment duration is poorly tolerated and difficult to monitor (Van Deun, Maug, 
Salim, Das, Sarker, Daru & Rieder 2010: 684). Moreover, physiological disorders (such as 
adverse drug-reactions) that may result from the use of some second-line drugs can 
sometimes be fatal (Ministry of Health of Ethiopia 2014:122-5).  
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Poverty is an additional factor that affects the treatment process and the treatment 
outcomes of patients with MDR-TB. Poverty and food insecurity are both causes and 
consequences of tuberculosis (Rusen, Squire & Billo 2010:163; WHO 2013b:3). Poverty 
and under-nutrition can enhance an individual’s vulnerability to tuberculosis and maintain 
the cycle of infection and disease (Uplekar, Weil, Lonnroth, Jaramillo, Lienhardt, Dias, 
Falzon, Floyd, Gargioni, Getahun, Gilpin, Glaziou, Grzemska, Mirzayev, Nakatani & 
Raviglione 2015:1799).  Poverty related conditions like poor living conditions and under-
nutrition may increase infection with tuberculosis and its progression to disease. For the 
poor, tuberculosis associated stigma, marginalisation, depression, and despair can 
amplify their poverty state and the disease, which is tuberculosis (Uplekar, Weil, Lonnroth, 
Jaramillo, Lienhardt, Dias, Falzon, Floyd, Gargioni, Getahun, Gilpin, Glaziou, Grzemska, 
Mirzayev, Nakatani & Raviglione 2015:1799). Therefore, without addressing the patient’s 
social problems, the diagnosis and provision of free drugs may not directly lead to curing 
tuberculosis among the poor (Saunders & Evans 2015:1-2). Besides, the level of patient 
satisfaction with care can determine patients’ adherence with treatment and the 
physician’s advice (Punnakitikashem, Buavaraporn, Maluesri & Leelartapin 2012:1232). It 
is therefore not surprising to note that the measures of patient treatment outcomes 
frequently mentioned in the literature sources, include changes in patients’ health status 
and the level of their satisfaction with care given (Longest 2015: 237-241). Yet, there is 
presently very limited empirical evidence in Ethiopia, particularly in the Oromia Region on: 
 Factors determining treatment outcomes of patients with MDR-TB who are enrolled 
on second line anti-tuberculosis drugs. 
 Patients’ perceived quality of care and their satisfaction with care given for MDR-TB.  
This gap in knowledge warrants the need to conduct this study.  The study focuses on 
investigating treatment outcomes of patients with MDR-TB and its determinants at referral 
hospitals in the Oromia Region of Ethiopia. The generations of evidence in these areas 
will contribute towards designing appropriate interventional measures for averting factors 
associated with unfavourable MDR-TB treatment outcomes among patients with MDR-TB. 
Moreover, the evidence generated on factors that may determine patients’ perceived 
quality of care and their satisfaction with care given for MDR-TB would help to institute 
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interventions that could enhance patient satisfaction and their adherence to treatment in 
the Oromia Region and the other regions of Ethiopia as a whole. 
 
1.5 Aims, objectives and hypotheses of the study  
Aims of the study 
The aim of this study is two-fold. Firstly, the study aims to investigate the treatment 
outcomes of patients with MDR-TB and its determinants at referral hospitals in the Oromia 
Region of Ethiopia. Secondly, the study aims to develop a conceptual model for enhancing 
the treatment of patients with MDR-TB in the Oromia Region of Ethiopia. 
 
1.5.1 Objectives of the study 
1.5.1.1 Quantitative component objectives 
1. Determine treatment outcomes of patients with MDR-TB who are enrolled on second line 
anti-tuberculosis drugs at the Adama and Nekemte Referral Hospitals.  
2. Assess factors associated with observed levels of treatment outcomes among patients 
with MDR-TB.  
 
1.5.1.2 Qualitative component objectives 
1. Explore the perceived quality of care and satisfaction of patients with MDR-TB with the 
overall MDR-TB related care and services provided at the Adama and Nekemte Referral 
Hospitals. 
2. Explore the perceptions and practices of caregivers for MDR-TB regarding the 
functionality of the programmatic management of drug-resistant tuberculosis at Adama 
and Nekemte Referral Hospitals. 
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1.5.1.3 Mixed method objectives  
1. Explore how the data from the interviews with patients with MDR-TB help to explain any 
quantitative results observed at Adama and Nekemte referral hospitals 
2. Explore how the data from the interviews with the caregivers for MDR-TB help to explain 
any quantitative results observed at Adama and Nekemte referral hospitals 
3. Develop a conceptual model for enhancing the treatment of patients with MDR-TB in the 
Oromia Region of Ethiopia. 
 
1.5.2 Hypotheses and research questions of the study  
A research hypothesis outlines the plausible relationship between variables that the 
investigator expects to observe (Chasan-Taber 2014:32). In other words, a research 
hypothesis is a prediction of relationships between variables of a study. Examples of these 
variables include independent and dependent variables. 
 
 
1.5.3 Quantitative component hypothesis  
1.5.3.1 There is no relationship between the treatment outcomes of patients with 
MDR-TB and the demographic and socio-economic characteristics of 
patients with this disease, MDR-TB 
1.5.3.2 There is no relationship between the baseline clinical characteristics of 
patients with MDR-TB and the treatment outcomes of patients with MDR-
TB. 
1.5.3.3 There is no relationship between adverse events from second-line drugs 
and the treatment outcome of patients with MDR-TB. 
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1.5.4 Qualitative component research questions   
1.5.4.1 What could be the perception and satisfaction of patients with the overall 
MDR-TB related care and services provided at the Adama and Nekemte 
Referral Hospitals? 
1.5.4.2 What could be the experience and practices of caregivers for MDR-TB 
regarding the functionality of the programmatic management of drug-
resistant tuberculosis at Adama and Nekemte Referral Hospitals? 
 
1.5.5 The mixed methods research questions 
1.5.5.1 Do the data of the interviews with patients with MDR-TB help to explain any 
quantitative results observed at Adama and Nekemte referral hospitals? 
1.5.5.2 Do the data of the interviews with the caregivers for MDR-TB help to explain 
any quantitative results observed at Adama and Nekemte referral hospitals? 
 
 
1.6 Significance of the study   
This study assesses multiple factors that may determine the process of MDR-TB 
treatment, adherence to treatment, patient satisfaction with treatment, and treatment 
outcomes of patients with MDR-TB. The knowledge that has been gained from this study 
may contribute to the enhancement of the treatment of patients with MDR-TB in the Oromia 
Region of Ethiopia. The outcomes of this study will serve as evidence to enable policy 
makers and health caregivers in the Oromia Region to make appropriate and timely 
decisions for supporting and treating patients with this condition. Such decisions may 
relate, for example, to the allocation of resources. This study develops a conceptual model 
that may be of practical utility for guiding healthcare workers in the provision of care and 
support services to patients with MDR-TB.  
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1.7 Conceptual and operational definitions 
1.7.1. Definitions of key concepts  
 
Drug-resistant tuberculosis 
Drug-resistant tuberculosis is a strain of tuberculosis that is resistant to first-line anti-
tuberculosis drugs (Caminero 2010:382). Strains that are resistant to only one first-line 
anti-tuberculosis drugs are referred to as mono-resistant tuberculosis (Caminero 2013:18). 
Strains that are resistant to more than one first-line anti-tuberculosis drug are designated 
as polydrug-resistant tuberculosis (WHO 2014b:18). The WHO assigned an additional 
form of drug-resistant tuberculosis called rifampicin resistant tuberculosis. Rifampicin 
resistant tuberculosis is a form of tuberculosis that is resistant to rifampicin in which the 
resistance to rifampicin is detected using phenotypic or genotypic methods, with or without 
resistance to other anti-tuberculosis drugs (WHO 2013a:5). 
 
 
Multi drug-resistant tuberculosis (MDR-TB)  
MDR-TB is defined as the Mycobacterium tuberculosis with in-vitro resistance to the two 
most potent first-line anti-tuberculosis medications, isoniazid and rifampicin (Hatfull et al 
2014:413).  
 
 
Extensively drug-resistant tuberculosis (XDR-TB) 
This relates to the Mycobacterium tuberculosis with in-vitro resistance not only to isoniazid 
and rifampicin but also to other classes of medications commonly used to treat MDR-TB, 
i.e. the injectables and fluoroquinolones (Gunther 2014:280). There is also another form 
of drug-resistance level beyond MDR-TB. It is referred to as ‘extremely’ or ‘totally drug-
resistant tuberculosis’ (XDR-TB) (Udwadia 2016:41-2; Behera 2012:190). Extremely or 
totally drug-resistant tuberculosis is defined as strains of the Mycobacterium tuberculosis 
that are resistant to all first and second-line anti-tuberculosis drugs (Tadolini, Centis, D’
Ambrosio & Migliori 2012:105; Ribon 2015:31).  
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Health service quality  
Health care quality is the degree to which health services increase the likelihood of desired 
health outcomes (Longest 2015: 237). Quality of health care is measured by certain 
attributes. These attributes include the knowledge and courtesy of caregivers (assurance), 
and their ability to deliver the promised care (assurance) (Pillai & Kumari 2016:80). The 
quality of health care is also measured by the caregivers’ ability to care (reliability), and 
the quality of interaction between caregivers and patients (interpersonal quality) (Slonim 
& Pollack 2005:267). Another measure of health care quality includes caregivers’ 
willingness to help patients (responsiveness) (Punnakitikashem, Buavaraporn, Maluesri & 
Leelartapin 2012:1232).  
 
The physical facilities like the equipment and appearance of personnel (tangibility), the 
quality of patient service related to continuity of care, cost of service, accommodation and 
accessibility (structural quality), facility set ups including sanitation, overcrowding, 
availability of basic utility, place for recreation (physical quality) and courtesy, information, 
autonomy and caregiver’s competence (process quality) are critical measures of quality of 
health care (Longest 2015:25). Added to this, Longest (2015: 237-244) considers patients’ 
perception of quality and the status of patient satisfaction with care given as significant 
aspects of the measures of healthcare quality. 
 
Patient’s perceived quality of health care  
Perceived quality is the patients’ judgment about the overall excellence or superiority of 
healthcare services they receive. It is the measure of the discrepancy between the 
patient’s expectations and their perception of the services given by an institution or by 
healthcare givers (Ramez 2012:131). Information from patients on the quality of healthcare 
is the best way to determine whether care aligns with their values, preferences, and needs 
(Tzelepis, Sanson-Fisher, CZucca & Fradgley 2015:831).  
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Patient satisfaction 
Patient satisfaction is one of the patient reported measures of treatment outcomes 
(Mosadeghrad 2012:257).  Patient satisfaction is determined by two factors. The first factor 
is patients’ expectations. Patient expectations are services that the patients search and 
want to see in health institutions. The second factor is patients’ perception of the services 
that they receive. Patient perceptions are measured on the basis of the opinions of patients 
about the services they receive and on the service production process (Dikmen & Yılmaz 
2016:1048). The level of patient satisfaction with healthcare is one of the indicators used 
to measure quality of healthcare (Longest 2015: 241). 
 
Patient adherence to treatment 
Adherence is the extent to which a patient cooperates with his or her treatment regimen 
(Gebremariam, Bjune & Frich 2010:1). A patient is said to be adherent to treatment when 
he or she implements the medical instructions recommended by the healthcare giver. 
Patients who fail to adhere to their treatment are at an increased risk of morbidity and 
mortality. In addition, this category of patient is at risk of transmitting the disease to others 
(Ndwandwe, Mahomed, Lutge & Knight 2014:59). Certain factors are associated with 
patients’ non-adherence to treatment. These include lack of education, unemployment and 
low socio-economic status. Personal factors like drug and alcohol use, presence of HIV 
and perceived severity of illness are risk factors for non-adherence to treatment (Sang, 
Obwoge, Kangethe, Ayiro & Changeiywo 2017:329).  
 
Patient treatment enablers 
Treatment enablers for patients with MDR-TB include the provision of incentives such as 
covering cost of transportation, provision of accommodation and food packages. These 
incentives or enablers can increase patients’ adherence to treatment (Lange, Abubakar,  
Alffenaar, Bothamley, Caminero, Carvalho, Chang, Codecasa, Correia, Crudu, Davies,  
Dedicoat, Drobniewski, Duarte, Ehlers, Erkens, Goletti, Gȕnther, Ibraim, Kampmann,  
Kuksa, Lange, Leth, Lunzen, Matteelli, Menzies, Monedero, Richter, Rȕsch-Gerdes,  
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Sandgren, Scardigli, Skrahina, Tortoli, Volchenkov, Wagner, Werf,  Williams, Yew,   
Zellweger & Cirillo 2014:45).   
 
1.7.2. Operational definitions  
Operationalization is the process of moving from a construct’s conceptual definition to 
specific activities or measures that allow a researcher to observe it empirically. An 
operational definition of a variable changes it into a specific operation or action so that it 
can be measured in the empirical world (Neuman 2014:207). Operationalization eliminates 
confusion in meaning and communication. It ensures researchers to precisely define what 
is to be measured or observed and how the measurement or observation will be carried 
out (Lancaster 2005:23). 
 
 
Patient registration group   
Patients with MDR-TB are registered for treatment based on their previous treatment 
history. Patients are registered under two broad categories of registration groups: new 
registration group and previously treated registration group. A patient is said be in a new 
registration group if he or she has never received anti-tuberculosis treatment or has 
received anti-tuberculosis treatment for less than 1 month. Patients in the previously 
treated registration group include those who have relapsed (relapse patient with 
tuberculosis), patients treated after lost to follow ups. The relapse patient with tuberculosis 
group relates to patients who have successfully completed treatment for tuberculosis at 
some point in time but were later diagnosed with the disease (Federal Ministry of Health) 
(FMOH 2014:45). With regard to the lost to follow ups group, this relates to patients with 
tuberculosis who after taking treatment for the disease for more than one month became 
lost to follow ups for two months or more months, but later re-commenced treatment for 
active tuberculosis. Treatment after failure is that group of patients who remain sputum or 
culture positive at five or more months after commencing anti-tuberculosis treatment. 
There are also some groups of patients with tuberculosis registered under the ‘other 
previously treated’ group of patients. These are patients who have previously been treated 
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for tuberculosis but whose most recent treatment outcome for tuberculosis is not known 
or is not documented.  
Adverse drug reactions  
Adverse drug-reactions are unwanted responses to a medicine. Common adverse drug-
reactions from the use of second-line anti-tuberculosis drugs include myelosuppression, 
anemia, neutropenia, peripheral and optical neuropathy (Caminero et al 2010:627). 
Moreover, hypothyroidism, Hypokalemia, electrolyte wasting and renal insufficiency are 
common adverse drug-reactions among patients treated for MDR-TB. These reactions are 
usually noxious and unintended (Caminero 2013:141). The adverse drug reactions can 
lead to non-adherence to treatment. Thus, the occurrence of adverse drug-reactions can 
contribute to morbidity, and treatment failure (WHO 2014b:167). 
 
Baseline clinical and laboratory tests  
Baseline clinical and laboratory tests are done for each patient with MDR-TB. The tests 
are used both for signs of the efficacy of the treatment given for MDR-TB and also to 
monitor the adverse drug reactions (Federal Ministry of Health of Ethiopia 2014:74). 
Baseline clinical and laboratory tests for patients with MDR-TB are the requirements for 
patients with MDR-TB before the initiation of second-line anti-tuberculosis drugs. Baseline 
clinical tests done for patients with MDR-TB include physical examinations, taking vital 
signs, the determination of baseline malnutrition and identification of co-morbidities with 
MDR-TB. Moreover, the baseline laboratory tests done include the sputum smear 
examination, sputum culture and the drug-sensitivity test. Baseline laboratory tests also 
include serum potassium level, creatinine, and renal as well as liver function tests. They 
also involve the HIV test, pregnancy and the thyroid-stimulating hormone tests. 
Furthermore, patients co-infected with HIV are eligible for the complete blood count and 
the T-lymphocyte cell bearing (CD4) count. Most of the clinical and laboratory tests are 
carried out at baseline and monthly thereafter. This study assessed the status of patient 
monitoring against the nationally set standard to monitor patients clinically and through 
laboratory tests (Federal Ministry of Health of Ethiopia 2014:76).  
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Patient’s baseline risk factor 
This focuses on the patients’ baseline record on certain risk factors that are believed to 
affect patients’ adherence to treatment and ultimate treatment outcomes (Djibuti, 
Mirvelashvili, Makharashvili & Magee 2014:1; HerreroI, RamosI & ArrossiI 2015:295). 
These factors include age, sex, household location, size of family, patient employment 
status, alcohol use, presence of co-morbid conditions, and history of imprisonment. In 
addition, the patient’s HIV status and previous treatment history for tuberculosis or MDR-
TB are considered to be risk factors.   
 
MDR-TB treatment outcomes  
These relate to the outcomes of treatments given for MDR-TB. Examples of these include 
interim treatment outcomes, cured, treatment completed, treatment failure, lost to follow 
ups and died. The interim treatment outcome of patients with MDR-TB is evaluated at six-
months after the initiation of treatment. The treatment outcome at month six is evaluated 
as one of the following. These include culture converted, died, lost to follow ups and not 
evaluated. 
Cured is one of the standard treatment outcomes for patients with MDR-TB. A patient is 
classified as cured if he or she has completed treatment according to the national 
recommendation standard without evidence of failure and three or more consecutive 
cultures taken at least 30 days apart are negative after the intensive phase of treatment. 
A treatment completed patient with MDR-TB is that patient who completed treatment 
according to the national recommendation without evidence of failure but no laboratory 
record indicated that three or more consecutive cultures taken at least 30 days apart were 
negative after the intensive phase of treatment.  
Treatment failure 
According to the WHO (2014b:20), treatment of patients with MDR-TB is said to have failed 
if treatment is terminated or when the patient needs a permanent regimen change for at 
least two of the anti-tuberculosis drugs because of: 
 lack of conversion by the end of the intensive phase; or 
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 bacteriological reversion in the continuation phase after conversion to negative; or 
 evidence of additional acquired resistance to fluoroquinolones or second-line 
injectable drugs; or 
 adverse drug reactions. 
Died  
A patient who dies for any reason during the course of treatment for tuberculosis is given 
the treatment outcome of ‘died’ (WHO 2013a:6).  
 
1.8 The theoretical framework of the study 
A theory consists of a series of tentative premises about ideas and concepts that lay the 
foundation for any empirical research endeavour on a given phenomenon (Imenda 
2014:185). A theory is formulated based on existing observations and insights. On top of 
serving as an overarching foundation for explaining research processes, a theory provides 
an inspirational framework that guides the research (Crano, Brewer & Lac 2015:5-6).  A 
conceptual framework on the other hand, is a set of interrelated concepts that shows the 
way in which a phenomenon of interest is viewed (Imenda 2014:186). It serves as an 
orientation lens through which a research endeavour is seen (Holloway & Wheeler 
2010:11). Conceptual frameworks are often derived from a theoretical framework(s), and 
sometimes developed by the researcher. According to Marczyk, DeMatteo and Festinger 
(2007:31), a conceptual framework is a description of a phenomenon of interest that 
attempts to show the relationships between constructs we know about the phenomenon. 
Conceptual frameworks consist of tentative premises about concepts in a research study. 
Researchers select testable research hypotheses from these premises regarding 
relationships among variables, and it is these hypotheses that are often subjected to 
research scrutiny (Crano et al 2015:5-7).  
 
This study employed a mixed method design in which both quantitative and qualitative 
data are used to address its aims and objectives. Given this, this study required an 
overarching framework to guide its research process. Thus, following a careful 
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examination of the different theoretical frameworks available, this study opted for the 
Donabedian framework to measure health service quality (see figure 1.1). The rationale 
behind using the Donabedian framework was that the framework was congruent to the 
aims and objectives of this study. This framework enabled the researcher to measure the 
different dimensions of health service quality assessed in this study.  
 
The Donabedian framework for measuring the performance of a healthcare, addresses 
factors that determine the performance of healthcare in three fundamental parts (structure, 
process and outcome) (Berwick & Fox 2016: 239). In the Donabedian framework, 
healthcare structure means the physical and organizational characteristics of health 
facilities where health care is provided. The process includes the services and treatments 
that the patient receives. The outcome is the result achieved by the treatment of the patient 
(Višnjić, Veličković & Jović 2012:54).  
 
In this study, socio-demographic and socio-economic characteristics of patients constitute 
the structure part of the Donabedian framework. Likewise, the status of the availability and 
functionality of the patient support schemes and conditions of the service set-ups and 
conditions of the staffing constitute the structural part of the framework. Similarly, the 
process includes all factors that focus on the patient treated for MDR-TB. These include 
the patient-centredness of care and the conditions of interpersonal communication 
between patients and their caregivers, the level of responsiveness of the care given to the 
patients and the respect given for patients with MDR-TB. The process also incorporates 
patient adherence to treatment. Factors that directly influence the process of the care that 
patients receive, including patients’ clinical characteristics (age, sex, body mass index, 
comorbidities) and the occurrence of adverse events from second-line drugs, are 
considered to be part of the process part of the framework used in this study. Moreover, 
the treatment outcomes of patients with MDR-TB, patients’ level of perceived quality of 
care and patient satisfaction with care given for MDR-TB constitute the outcome part of 
the framework.  
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The Donabedian framework is noted in the literature to contribute to the safety of patients 
by opening new approaches in healthcare that ensure patients’ safety and meet patients’ 
health needs. The framework helps healthcare workers to understand the potential risks 
of healthcare to the health of patients (Višnjić, Veličković & Jović 2012:54-55). In this study, 
the framework enabled the researcher to measure the various factors that determined the 
functionality and quality of the healthcare service provided to patients with MDR-TB. This 
in turn helped to answer the specific questions of the study, i.e., factors determining the 
treatment outcomes and the satisfaction of patients with MDR-TB with the healthcare they 
received.  
  
 
 
 
 
Figure 1. 1  The Donabedian Framework (Source: Višnjić, Veličković & Jović 2012:54-55) 
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1.9 The Donabedian framework for healthcare quality  
Quality of healthcare is the degree to which health services that are required to serve 
individuals and populations increase the likelihood of desired health outcomes that are 
consistent with the contemporary professional knowledge (Donabedian 1988:1743). In this 
context, quality of healthcare is defined in terms of the technical and interpersonal quality 
of healthcare. Technical quality stresses that the desired health outcomes sufficiently 
exceed anticipated health risks. Interpersonal quality is concerned with whether patients 
are treated in a humane and culturally appropriate or congruent manner. The interpersonal 
component of quality requires that the followings be maintained (Longest 2015: 240-41): 
 Patients’ values and preferences. 
 Patients’ physical comfort, including pain control. 
 Patients’ emotional and psychological comfort, including alleviation of fear and anxiety. 
 Patients’ need for information and open communication with caregivers.  
 
1.9.1. Components of the healthcare quality 
Quality of healthcare can be divided into three distinct but interrelated components 
(Ayanian & Markel 2016:206). These are the structure, the process and outcome 
measures of quality.  Structural quality includes factors that affect the conditions in which 
the healthcare occurs. Process quality is related to how the caregiver behaves towards 
patients, whether the patient is treated with respect and is involved in the treatment 
decision-making. The outcome measures of quality focus on changes in the patient’s 
health status, behaviour and satisfaction. These three dimensions of healthcare quality 
affect patients’ perception of quality and their satisfaction with the quality of care they are 
provided (Kajonius & Kazemi 2015:1-2). 
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1.9.2. Structural Quality  
The structure encompasses the setting, the qualification of the caregivers and the policy 
and administrative system in which the healthcare is provided (Ayanian & Markel 
2016:206). 
 In the context of the programmatic management of drug-resistant tuberculosis, the 
structure refers to the tangible attributes of the hospital premises where patients are cared 
for. It includes the hospital environment and the personnel involved in the care of patients 
with MDR-TB. The cleanness of the environments (buildings) of the hospital and treatment 
centres for MDR-TB and the facilities and amenities which can influence the patients’ 
satisfaction with care given. Similarly, the quantity and quality of the healthcare personnel 
that create the capacity to provide optimum healthcare services can influence patients’ 
perceived quality of care and patient satisfaction with care given for MDR-TB 
(Mosadeghrad 2012:253). The health system should be organized in a way that does not 
only guarantee the provision of optimum care on a continuous basis, but it should also be 
organized to the needs, values and expectation of patients (WHO 2014:132). Moreover, 
for a well-organized health system to provide the care needed, there should exist ready 
and motivated caregivers (Arakawa, Arcêncio, Scatolin, Scatena, Ruffino-Netto & Villa 
2011:1000). Physical facilities of the service setups, equipment used and the appearance 
of personnel providing the intended service can influence the perception of patients with 
regards to the quality of service received, including their satisfaction with the service 
(Ramez 2012:132). 
 
1.9.3. Process quality  
One approach to the assessment of healthcare quality is to examine the process of care 
rather than its outcomes (Ayanian & Markel 2016:206). This is justified by the assumption 
that one is interested not in the power of medical technology to achieve results, but in 
whether what is known to be “good medical care” has been applied. Process quality 
focuses on the way healthcare is coordinated, the continuity of the care provided, and 
whether the care is acceptable to the recipients (Višnjić, Veličković & Jović 2012:55). 
Compared to outcome measures of quality, the measurement of process quality is more 
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relevant to measure whether healthcare practice is appropriately applied (Donabedian 
2005:694-5). 
 
In the MDR-TB treatment setting, factors that may determine the quality of the process of 
the care that is provided to patients with MDR-TB include caregivers’ empathy, efficiency 
and effectiveness of the care. Empathy refers to the ability of the healthcare setting in 
understanding the needs of patients with MDR-TB and providing the care they need.  
Efficiency is the optimum use of available resources in the way that maximizes the benefits 
of patients with MDR-TB. Effectiveness focuses on the short-term clinical and non-clinical 
outcomes of patients treated for MDR-TB. This includes patients’ perception of the care 
they receive and their cooperation in treatment decision-making. As such, process quality 
deals with whether the diagnosis, care, and treatment given to patients with MDR-TB 
achieve the desired outcomes from the patients’ perspectives (Višnjić, Veličković & Jović 
2012:55). The level of healthcare effectiveness is an important attribute in determining 
satisfaction with the care of patients with MDR-TB (Mosadeghrad 2012:257).  
 
1.9.4. Outcome quality  
Outcome quality focuses on the efficacy of the clinical and non-clinical interventions on the 
quality of life and well-being of patients with MDR-TB. Patient satisfaction with healthcare 
could not be a good indicator of quality in relation to the technical clinical care because 
patient satisfaction is influenced more by the process elements of healthcare like the way 
in which the patients’ needs are preferences are accommodated and the comfort of the 
physical surroundings than the technical quality that relates to the effectiveness of the care 
given in producing the achievable health gain. The final and long-term outcomes of the 
diagnosis, care, and treatment given to the patient are expected to achieve the desired 
standard clinical outcomes of patients with MDR-TB (Mosadeghrad 2012:257). As such, 
the outcomes of healthcare are changes in the health status of individuals, which are 
attributable to interventions (Eldar 1999:75). The extent to which the agreed-upon desired 
results are achieved is the ultimate test of the assumptions inherent in the use of the 
structure and process in the assessment of the quality of healthcare. Outcome measures 
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of the healthcare quality describe the result achieved by the treatment of the patient. The 
outcome measures of medical care include recovery, restoration of function or healing, 
patient survival and mortality (Višnjić, Veličković & Jović 2012:54-5). The majority of the 
outcome measures of the results of medical care are fairly concrete. As such, outcome 
measures of medical care (e.g. death) are apparently amenable to more precise 
measurement (Donabeidn 2005: 692-3). Yet some of the outcome measures of healthcare 
are not clearly defined and are difficult to measure. These include patient attitudes, 
satisfaction, social restoration and physical disability and restoration (Donabedian 
2005:693). 
 
In summary, quality indicators are grouped into three categories. These include external 
indicators like the voice of patients or service users, process indicators like the voice of 
employees in the health system, and balanced indicators like programme monitoring from 
different angles. At different levels there is interdependence and causal relationships 
among the quality indicators. In that case, the holistic approach to measuring quality is 
appropriate. This is because a good structure can increase the likelihood of a good 
process. In turn, a good process has the potential to increase the likelihood of a good 
treatment outcome (Donabedian 1988:1745). In this way, a single indicator may not 
indicate the status of the entire quality of the healthcare.  An outcome of healthcare may, 
however, have an influence on the process. While outcome is a good indicator of the result 
of healthcare, it does not indicate some aspects of outcome like the level of satisfaction of 
patients and their caregivers. Thus, it is important to focus on all of its essential elements 
while measuring quality of healthcare (Ayanian, & Markel 2016:206).                                          
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Figure 1. 2 :  Conceptual framework of factors determining treatment outcomes of patients with 
MDR-TB and patient satisfaction (Source: Višnjić, Veličković & Jović 2012:54-55) 
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1.10 The research paradigm - its assumptions  
Researchers are required to commence research with assumptions that are aligned with 
the research methodology, methods of data collection and analysis (Creswell, 2014:3-4). 
The researchers’ assumptions that guide the conduct of a research study, are sometimes 
referred to as paradigms (Morgan 2007:49; Wagner, Kawulich & Garner, 2012). A 
paradigm is a set of beliefs that guide researchers through the research process (Morgan, 
2014:1045-7). It is a system of presuppositions within a research approach and it forms 
the framework within which solutions are sought for a research problem (Almekinders, 
Beukema &Tromp 2009:253).  
 
A paradigm is informed by philosophical assumptions about the nature of the truth or reality 
about a phenomenon (ontology), the researchers’ position or stance in understanding the 
truth or reality of that phenomenon (epistemology), the values that researchers may attach 
or react to, the entire research process and the phenomenon under study (axiology)  
(Creswell, 2014:26). There are commonly agreed worldviews. These are positivism, post-
positivism, constructivism, transformative and pragmatism worldviews (Saunders, Lewis 
& Thornhill 2007:102). These world views are the ‘legitimated ways of knowing’ (Bridges 
2017:350). The ontology, axiology and epistemology that a research endeavour adopts, 
are framed in terms of the choice made among the available research philosophies. As 
such an overarching goal of any research endeavour is to achieve valid outcomes using 
appropriate scientific methods (Edmonds & Kennedy 2017:4). This study utilises a mixed 
methods design, specifically, it uses a concurrent mixed methods design. This design, like 
other mixed methods designs, combines quantitative and qualitative methods of inquiry. 
This indicates that the logic of inquiry in mixed methods designs includes both induction 
and deduction (Edmonds & Kennedy 2017:178).  Thus, for a researcher pursuing 
knowledge development using a concurrent mixed methods design, the pragmatic 
paradigm is the paradigm of choice for a number of reasons.  
 
Pragmatism offers an alternative worldview to positivism or post-positivism and 
constructionism. Pragmatism focuses on problems to be researched and the 
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consequences of the research (Feilzer 2010:7). Quantitative methods collect quantitative 
or objective data. But quantitative methods do not recognize the individuality of the 
participants or their experience (Gunasekare 2015:364). 
In this study, an insight into the lived experiences of patients with MDR-TB on the care 
and services given to patients with this condition have positive benefits for the patients. 
These benefits need to be considered not only from the medical point of view but also from 
the individual patient’s points of view. For any medical intervention to be of benefit to 
people, it should not only focus on its effectiveness to treat a disease, but also focus on 
its acceptability to the people affected by the diseases (Ellis 2010:108). The pragmatic 
paradigm allows researchers to use a mixture of methods to address a research problem. 
So, this study explored the individualistic views of patients’ while collecting objective data 
in relation to MDR-TB. 
 
This study focuses on treatment outcomes of patients with MDR-TB and its determinants. 
It explored patients’ perceived quality of care and their satisfaction with care given for 
MDR-TB. The study also collected objective data with the help of quantitative methods in 
relation to MDR-TB. The rationale for this was to develop deeper understanding of 
treatment outcomes of patients with MDR-TB and its determinants. Such an understanding 
can be achieved if qualitative and quantitative methods are combined or mixed. A 
pragmatic paradigm allows the mixing of methods, as it recognizes the connection 
between theoretical and practical discourse (Conant & Zeglen 2002:3). Achieving a deeper 
understanding of treatment outcomes of patients with MDR-TB and its determinants, the 
researcher stresses, will facilitate an evidence-informed decision in the management of 
patients with MDR-TB in the Oromia Region of Ethiopia.  
 
The pragmatic paradigm employed is compatible or congruent with the study’s 
methodology, methods of data collection and analysis. It enabled the researcher to link the 
research questions, theories used, and the participants’ experiences and practices (Misak 
2013:21). In the context of health programmes, the current demands to demonstrate 
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evidence-informed programming and programme effectiveness fosters a competitive 
programmatic environment (Pearson, Field & Jordan 2007:8).  In this regard, mixed-
methods studies are capable of providing defensible evidence and an understanding of 
the programme context. Moreover, mixed methods research enables researchers to track 
the process and outcome of health programmes. A philosophical underpinning that 
facilitates such activities of tracking processes and outcomes of health programmes is a 
pragmatic paradigm. It is therefore employed in this study to inform the research design, 
including the research questions and objectives, and methods of data collection and 
analysis. This section will be discussed in chapter 3 in more detail.  
 
1.11 Research methodology and the research design 
1.11.1. Research Methodology 
The healthcare setting is a dynamic social context in which people, organizational and 
clinical factors interact to affect health. Therefore, healthcare research often uses a 
pragmatic approach to conceptualise evidence (Fertman & Allensworth 2010:10). The 
researcher believes that the role of any research attempt should be on the utility of 
research outputs to solve real world problems (Mertens 2015:79; Feilzer 2010:8-9). As 
such, this study used a mixed methods methodology in which quantitative and qualitative 
approaches are combined. This methodology uses both deductive and inductive 
approaches to test the different hypotheses of the different segments of the same research 
problem. The deductive (quantitative) approach is meant to test the plausible relationship 
between the independent and dependent variables regarding the empirical observations 
of the study. The inductive (subjective and contextual) approach is used to understand the 
subjective meanings attached to the reality under investigation.   
This study uses a pragmatic methodological approach with the assumption that the 
approach enables the best use of the study results to address the problem under 
investigation. This study aims to understand the complexity of the research problem under 
investigation through measuring both its objective and subjective layers. As such, this 
study uses a mixed methodology whereby both quantitative and qualitative approaches 
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are used to describe both the objective and subjective components of the same research 
question.    
 
The rationale behind the choice of both quantitative and qualitative approaches for this 
study is based on the assumption that the phenomena under investigation has both 
objective and subjective layers. Thus, knowledge of both the observable (objective) and 
the subjective meanings of the phenomena under investigation are needed to fully 
understand the problem under investigation (Saunders, Lewis & Thornhill 2009:119). For 
the phenomena investigated in this study, the use of both objective and subjective inquiry 
produce knowledge that best represent the phenomena under investigation (Gunasekare 
2015:362-3; Ihuah & Eaton 2013:937). The two methods complement each other 
(Edmonds & Kennedy 2017:231). This methodology seeks elaboration, enhancement, 
illustration and clarification of the results from one method with the results from the other 
method (Wei & Lin 2017:99). Thus, the quantitative and qualitative research results neither 
confirm nor refute each other but rather they are used to complement each other. 
Complementary helps to avoid limitation of the knowledge gained from one type of data 
that a quantitative or qualitative method alone can produce (Patton 2006:33). 
Complementarity is the ability of one type of method to compensate for the weaknesses 
of the other. The mixed methods methodology employed here combines the strengths of 
the two methods: quantitative and qualitative (Greene 2006:96). The specific research 
design used in this study is a concurrent mixed methods design. 
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1.12 The concurrent mixed methods research design  
A research design is a thoughtfully constructed link between the purposes of a research 
study and the strategies used to implement it (Creamer 2018:59). Generally, a research 
design is a plan detailing how research will be conducted, and it guides the researcher in 
planning for and implementing a study (Groat & Wang 2013:24).  
Creswell (2012:540) identifies six types of commonly used mixed methods designs. These 
include the: 
 parallel (concurrent) design 
 explanatory sequential design 
 exploratory sequential design 
 embedded or nested design 
 transformative design 
 multiphase design 
 
From these available options, this study adopted a concurrent mixed methods design. 
The concurrent design is characterized by its use of one data collection phase. That is 
both quantitative and qualitative data are collected simultaneously (Creswell 2012:540-1).  
Within the attempt made to answer the same research question, the purpose of using a 
concurrent qualitative method is to address a question that cannot be addressed by the 
dominant method, qualitative or quantitative (Gunasekare 2015:364). The qualitative 
quantitative methods often address different questions within the same phenomena under 
investigation. The mixing of the data generated from the two methods integrates the 
information gained from one method with that obtained from the other method. This 
integration of information is typically accomplished in the discussion and recommendation 
section of this study (Creswell 2009:2014:15).  
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Figure 1. 3: Graphic representation of the concurrent mixed methods design used in this study 
(Source: Edmonds & Kennedy 2017:183). 
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1.12.1. Rationale for using a concurrent mixed methods design in this study  
In relation to the concurrent mixed methods design employed in this study, there are 
two components: qualitative and quantitative. The concurrent mixed methods design 
served a complementarity function, that is, it was used to elaborate more on the 
quantitative study results. The study was conducted in one phase. That means that the 
quantitative and qualitative data were collected during a similar time period. 
The rationale behind collecting both quantitative and qualitative data in this study was 
that the sub-research question under investigation had both quantitative and qualitative 
layers. Therefore, some of the study questions needed quantitative (objectives) data 
while the other study questions needed qualitative (subjective) answers. Thus, the two 
methods were used to study the different aspects of the same research problem 
(Ponce & Pagán-Maldonado 2015:119). 
 
The quantitative component was used to assess the treatment outcomes of patients 
with MDR-TB and its determinants for patients with MDR-TB enrolled for treatment with 
second-line anti-tuberculosis drugs. Quantitative data cannot provide detailed 
information about the context in which individuals provide information for example, the 
setting. Therefore, in this study the qualitative component was used to explore the 
perceptions of patients with MDR-TB on the care they receive for MDR-TB and their 
satisfaction. The qualitative component also explored the perceptions and practices of 
caregivers for MDR-TB regarding the programmatic management of MDR-TB at 
Adama and Nekemte referral hospitals.  
 
Quantitative and qualitative data were collected and analysed separately. Then the two 
data sets were integrated at the result stage and stage of discussion and interpretation 
of the study results. Then the discussion and recommendation were made regarding 
factors determining the treatment outcomes of patients with MDR-TB, patients’ 
perceived quality of care and patients’ satisfaction with care given for MDR-TB. The 
discussion was based on both quantitative and qualitative results (Teddlie & 
Tashakkori 2006:14).  
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By avoiding the biases intrinsic to using one method alone, the two strategies helped 
to complement each other (Flick 2009: 27). The one type of data supplies strengths to 
offset the weakness of the other form. In this way a more complete understanding of 
the research problem resulted from collecting both quantitative and qualitative data 
(Creswell 2012:540-1). From this, it is believed that a stronger recommendation and 
development of a conceptual framework for enhancing the management of patients 
with MDR-TB at referral hospitals in the Oromia Region of Ethiopia is made (Creswell 
2012:540).      
   
1.13 Sampling and sampling methods 
A sample is a set of cases drawn from a larger study population with the aim of 
estimating the characteristics of the larger set or population (Andy 2009:49). This study 
used a mixed methods research design. As such, the sampling used for the study had 
two components. These were quantitative component and qualitative components.  
1.13.1. Sampling: quantitative component 
The source population for this study was all patients with MDR-TB enrolled for 
treatment with second-line anti-tuberculosis drugs at all treatment initiating centres in 
the Oromia Region of Ethiopia. As it was not practical to access all patients on 
treatment for MDR-TB in the Oromia Region of Ethiopia, patients enrolled for MDR-TB 
treatment and their caregivers at the two referral hospitals formed the accessible 
population of the study. As a result,  the study population of this study was all patients 
with laboratory confirmed MDR-TB enrolled for MDR-TB treatment with second-line 
anti-tuberculosis drugs at the two referral hospitals in the Oromia Region of Ethiopia 
(Sumerson 2014:64). All members of this patient group fulfilled the inclusion criteria of 
the study and were potentially eligible for inclusion in this study. It was assumed that 
every member of the study population had the special characteristics of the samples 
(see inclusion criteria) needed to examine the factors under investigation. Hence, the 
entire study population was included in the study and thus surveyed (Holloway et al 
 
53 
 
2010:137-38). The patients included in the study are representative of the population 
of patients with MDR-TB (Hulley, Cummings, Browner, Grady & Newman 2013:25).  
Procedures followed in the selection of the sample for the quantitative component of 
the study are depicted in figure 1.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 4: Diagrammatic representation of the selection of patients with MDR-TB for the 
quantitative survey 
 
1.13.2. Sampling: qualitative component 
Perceptions of patients with MDR-TB on the quality of care given for MDR-TB and their 
satisfaction with the care was explored through a qualitative inquiry from patients aged 
18 years and above. To enhance understanding of the perceptions and satisfaction of 
patients, participants that are presumably rich in the information needed were selected 
purposefully.  
Purposive sampling is based on the idea that the sample is selected in relation to some 
criteria (inclusion criteria) which are considered to be important for that particular study. 
All patients with MDR-TB registered between 26 
December, 2012 and 17 September, 2016 at 
Adama & Nekemte hospitals  
 
 All patients with MDR-TB who will be on 
treatment for >/= 6 months and who meet the 
inclusion criteria by the time of data collection 
at the two hospitals will be included in the 
quantitative survey  
Cases who will not meet 
inclusion criteria by the time of 
data collection will be excluded 
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Purposive sampling is also chosen for the reasons of convenience and low costs 
(Singh 2006:91; Kothari 2004:17). In this study, the use of the purposeful sampling 
method enables the researcher to select all participants that meet the criteria for 
inclusion in the study (Etikan, Musa & Alkassim 2016:2). As such, this study included 
information rich patients with MDR-TB in the semi-structured in-depth interviews with 
patients with MDR-TB. Moreover, caregivers for MDR-TB at the two study hospitals 
were selected purposively and included in the in-depth interviews based on their unique 
knowledge on the management of MDR-TB. 
 
1.14 Methods of data collection   
1.14.1. Quantitative data collection  
The quantitative data were collected from the medical records (patient clinical charts, 
the unit MDR-TB register and patient treatment cards) using a structured questionnaire. 
Socio-demographic and clinical data were collected from patients with MDR-TB who 
were enrolled for treatment with second-line anti-tuberculosis drugs. Quantitative data 
were collected on patient socio-demographics, co-morbidities at baseline, baseline 
sputum smear and culture status, patient diagnostic modalities, patients’ drug 
sensitivity test patterns and their history of treatment for tuberculosis. Quantitative data 
were also collected on patients’ HIV sero-status and thereby the T-lymphocyte cell 
bearing (CD4) count and the status of the use of cotrimoxazole preventive therapy and 
the anti-retroviral therapy for MDR-TB and HIV co-infected persons. Data on adverse 
drug-reactions from second-line drugs and patient’s interim and final treatment results, 
including the hospitals’ practice of MDR-TB infection control were also collected.  
 
1.14.2. Qualitative data collection 
Qualitative data were collected from patients with MDR-TB and their caregivers. A 
semi-structured interview guide was used to collect data. The semi-structured interview 
guide included a number of areas:  
 The perceptions of patients with MDR-TB on the health and economic impact of 
MDR-TB. 
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 The status of the availability of patient support schemes, patients’ perceptions on 
availability of care that meets patients’ expectations, patients’ perceived quality of 
care and their satisfaction with care given for MDR-TB.  
 The perceptions and practices of caregivers for MDR-TB and their experiences 
regarding the programmatic management of drug-resistant tuberculosis.  
 
1.15 Methods of data analysis  
1.15.1. Quantitative data analysis  
The quantitative data were analysed using SPSS. The plausible relationships between 
the independent variables like patients’ socio-demographic and clinical characteristics 
and the treatment outcomes of patients with MDR-TB were quantitatively analysed 
(Andrew & Halcomb 2009:121). A detailed discussion of the analysis is presented in 
chapter three. 
1.15.2. Qualitative data analysis  
The reported perceptions and experience of patients with MDR-TB and the experience 
and practice of caregivers for MDR-TB were analysed thematically (Flick 2009:24). 
This section, methodology and research design will be expanded in detail in chapter 3.  
 
1.16 Ethical considerations   
Research ethics refers to the system of moral values that are concerned with the 
degree to which the research procedures adhere to professional, legal and social 
obligations for the study participants (Council for International Organizations of Medical 
Sciences (CIOMS 2016:1-2). The researcher received ethical approval to conduct this 
study from the Department of Health Studies Research Committee at the University of 
South Africa. The researcher was granted permission by the management team of the 
study sites to conduct the study. The researcher assured the management team of the 
study sites of ensuring confidentiality and anonymity of the participants. The 
involvement of study participants in this study and access to the patients’ records was 
in line with the recommendations of international ethical guidelines (CIOMS 2008:16-
28). The objectives of the study, including its aims, benefits and significance were 
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explained to the participants. Participation was entirely voluntary and participants were 
free to withdraw from participating in the study at any time. They were informed that a 
decision not to be part of the study would not have any negative impact on the care 
and services they obtained from the hospitals.  
 
1.17 Scope and limitations of the study 
This study focused only on two referral hospitals in Oromia Region of Ethiopia, Adama 
Hospital Medical College and Nekemte Referral Hospital. These hospitals and the 
patients with MDR-TB who attended the same might be different from patients with 
MDR-TB who attended hospitals in other regions of Ethiopia. The entire study 
population was used to collect data for its quantitative component. As regards its 
qualitative component, purposive sampling was used to identify and recruit 
participants. The qualitative component of the result was based on the reported 
experiences of the study participants. This is potentially subject to memory bias. It can 
also be subject to social desirability bias whereby participants might have told the 
researcher what they think is good to hear. Thus, the outcomes of this study may be 
generalized with caution.  
 
1.18 Chapter layout of the rest of the thesis  
This thesis is divided into six chapters. The main body of the thesis begins with chapter 
one and ends with chapter six. The main themes of each of the chapters are briefly 
described here.  
1.18.1 Chapter 1 
Chapter 1 presents the overview of the study. It orients readers to the study. It also 
presents the background and rationale of the study. Chapter 1 also presents the 
objectives and hypotheses of the study. The paradigmatic, ontological, axiological, 
epistemological and methodological assumptions of the study are presented in chapter 
1. The specific methodological approach and research design used in the study and 
the ethical requirements of the study are also presented in chapter 1.   
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1.18.2. Chapter 2 
Chapter 2 presents peer reviewed scholarly articles and other academic sources such 
as books on the subject studied. The review of the literature was informed by a number 
of factors, such as the aims, objectives, research questions and hypotheses of the 
study, and the theoretical framework that guided the study.   
1.18.3. Chapter 3 
Chapter 3 presents a detailed discussion of theories, the methodological procedures 
and the research design that the researcher adopted to address the aims and 
objectives of the study. The background of the study, study sites, sources of data, and 
the research instruments used, considerations in data collection and its management 
and the ethical issues of conducting the study are also presented in chapter 3.  
1.18.4. Chapter 4 
In chapter 4, research results and their implications are presented. The results section 
begins with the introduction and profile of the study participants. Then based on the set 
objectives of the study, the chapter presents the results and their implications regarding 
treatment outcomes of patients with MDR-TB and the determinants.  
1.18.5. Chapter 5 
Through synthesis of the evidence generated from the literature review and the study 
result, a conceptual model was developed and presented in this chapter. Specific gaps 
in the current programmatic management of patients with MDR-TB were identified and 
included in this chapter. Moreover, the impacts of available gaps on the clinical care 
given for MDR-TB, patient satisfaction and adherence to treatment and patient 
treatment outcomes were identified and included in this chapter. The chapter also 
includes description of the components of the conceptual model and its practical 
application in the programmatic management of patients with MDR-TB.  
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1.18.6. Chapter 6 
In chapter 6, discussions on the major results of the study are made in line with the 
literature. Interpretations are made on the meanings of the quantitative and qualitative 
results, the connection between the two with the help of the available body of 
knowledge as indicated in the literature. In addition, the implications of the results of 
this study on the current practice in the clinical and programmatic management of 
MDR-TB in the Oromia Region of Ethiopia are also shown.  
1.18.7. Chapter 7 
Chapter 7 presents conclusion and the recommendations. The research results on 
independent predictors of treatment outcomes of patients with MDR-TB and factors 
determining patients’ satisfactions are summarised in chapter 7. This chapter also 
includes recommendations for programme managers and clinical caregivers on the 
management and treatment of MDR-TB. 
1.18.8. List of references    
The various literatures synthesized and used in this study are listed in the section of 
bibliography. For books, journals and other electronic sources used in this study, the 
authors and sources are identified and acknowledged both in the body of the thesis 
and also at the end of the thesis by means of a bibliography. As such, all the sources 
cited in the body of the thesis are listed alphabetically according to the authors’ family 
names.  
 
1.19 Summary 
This chapter sets the scene for enhancing understanding of the ensuring chapters. It 
offers discussions on a number of key issues of the study. Examples of these include 
background on factors determining treatment outcomes of patients with MDR-TB, the 
research problem investigated, the conceptual framework on which the entire study 
was based, the definition of key concepts, and the methodology and research design 
of the study. The next chapter is a literature review of the extant literature on 
tuberculosis, MDR-TB and related topics.  
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Chapter 2:  Literature Reviews   
2.1. Introduction 
Sumerson (2014:45) defines literature review as the process of presenting a theoretical 
explanation and empirical evidence regarding the problem under investigation. In any 
research attempt surveying the existing contemporary literature is key before 
embarking on the research project (Greenhalgh 2010:16). Thus, a study starts from 
variables, which are later translated into measurable constructs. These measureable 
constructs provide general shape and structure for the research (Sumerson 2014:18). 
Literature review helps the researcher to present empirical evidence to support and 
challenge the research questions and variables used in the research. The volume of 
available literature on medicine has grown at an unprecedented rate. Thus, searching 
for medical literature is as challenging as walking in a jungle. Therefore, searching and 
obtaining a literature that fits into the information need of a particular research objective 
need to be considered as a big task for a person pursuing research (Greenhalgh 
2010:15). In this study, the literature review is guided by the aims, objectives, the 
research questions and hypotheses of the study. 
2.1.1 The purpose of the literature review  
In any study, the literature review plays an important role. First, it helps to bring clarity 
and focus to the research problem. Second, it helps to broaden the knowledge base of 
the researcher in his or her research area. Third, the literature review helps to 
contextualize the research results by comparing the results of the current research with 
the existing body of knowledge (Kumar 2011:27; Polit & Beck 2012:88).  
 
In this study, the literature review presented an organized summary of the results from 
books, journals and other documents. The summary of results helped to describe the 
past and the current state of knowledge regarding tuberculosis and especially drug-
resistant tuberculosis (Creswell 2012:105-6). Thus the empirical evidence obtained 
from various sources helped to gain insight about each of the variables and research 
questions used in the research.  By providing an in-depth analysis of available scholarly 
sources on the topic of interest, literature reviews provide readers with the opportunity 
to understand what is being researched and why (Roush 2015:20-21).  
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2.1.2 The search strategy used in this study  
For this study, the researcher searched for all English language studies on drug-
resistant tuberculosis. The literature search was guided by the constructs included in 
the theoretical framework of the study. Resources used in this study were accessed 
from multiple sources. The researcher searched for relevant resources through the 
UNISA electronic library access, the Medline, PubMed, PLOS, Open Access, 
www.thelancet.com and the Google. Peer reviewed scholarly articles were researched 
for clinical and programmatic management of drug-resistant tuberculosis and on 
factors determining the treatment outcomes of patients with MDR-TB and factors 
determining patients’ perceived quality of care and patients’ satisfaction in the care 
given for MDR-TB. Furthermore, national programme guidelines of the Ministry of 
Health of Ethiopia and the Oromia Region of Ethiopia were obtained from National 
Ministry of Health and the Oromia Region Health Bureau respectively. The key words 
used for searching included the following:  
MDR-TB, treatment outcomes of patients with MDR-TB, determinants of treatment 
outcomes, perceived quality of care, patient satisfaction. 
2.1.3 Date delimitation for the literature review 
Except for historical analysis of tuberculosis, the date delimitations of the articles and 
books used in this study focused on those published from 2011 to the present. Some 
articles and books used from those published before 2011 were for the purpose of 
describing the historical overview of MDR-TB and the global trend in the response to 
the problem.  
2.1.4 Methodology used in reviewing the literature 
The literature was reviewed based on the key themes relevant to the study topic. These 
key themes are presented in the theoretical framework of the study. As much literature 
as available on the topic under investigation was surveyed. To make sure that each 
article is relevant to the purpose of the study, each article was critically appraised using 
a checklist. Then all relevant and peer reviewed literatures were selected, organized, 
synthesized and discussed in relation to the study topic.  
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2.2. The basics of tuberculosis    
Tuberculosis (TB) is a chronic infectious disease caused by the bacteria 
Mycobacterium Tuberculosis. This disease is rarely caused by the other species of the 
Mycobacterium tuberculosis complex including the Mycobacterium bovis and the 
Mycobacterium africanum (Heemskerk, Caws, Marais & Farra 2015:1). The 
Mycobacterium genus is taxonomically located in the Mycobacteriacea family. This 
genus comprises about 150 species of the mycobacteria (Ozcaglara, Shabbeera, 
Vandenbergc, Yenera & Bennetta 2012:77). Among members of the Mycobacterium 
tuberculosis complex, the Mycobacterium tuberculosis has paramount importance in 
terms of human disease (McHugh 2013:15).  
 
The Mycobacterium tuberculosis is an oxygen-seeking organism. It grows most 
successfully in tissues with high oxygen content such as the apices of the human lung. 
The Mycobacterium tuberculosis attacks the host inducing transmission by leading the 
host to its own self destruction. The Mycobacterium tuberculosis is an intracellular 
pathogen, usually infecting cells of the immune system, which helps it to hide from the 
body’s defense mechanism.  
 The Mycobacterium tuberculosis is a slow-growing bacterium. The generation time of 
12 to 18 hours for the Mycobacterium tuberculosis is by far longer than that of the 20-
30 minutes for other common human bacterial pathogen like the Escherichia Coli 
(Adams et al 2015:122-23). This makes it a challenge to grow the Mycobacterium in 
culture media. Rather than having a culture result in two to three days, it can take two 
to twelve weeks for the Mycobacterium tuberculosis to grow. The Mycobacterium is 
called acid-fast bacteria due to its staining property (Pálfi, Dutour, Perrin, Sola & Zink 
2015:2). This entails the use of special reagents to detect the Mycobacterium 
tuberculosis (Caminero 2013:14). 
 
Tuberculosis can affect almost any organ of the human body. Nevertheless, 80 percent 
of all cases of tuberculosis worldwide are pulmonary (Ribon 2015:45-46). Extra-
pulmonary tuberculosis (EPTB) occurs in less than 20% of the total tuberculosis cases. 
The most common forms of the extra-pulmonary tuberculosis are tuberculosis of the 
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lymph nodes (tuberculosis lymphadenitis) and tuberculosis of the bones (osteoarticular 
tuberculosis, also known as Potts Disease when it affects the spine).  The other form 
of extra pulmonary parts of the body affected by tuberculosis include the meninges, 
the intestine, peritoneum and the like (Babatunde, Elegbede, Ayodele, Fadare, 
Isinjaye, Ibirongbe & Kinyandenu 2013:2010). A person with tuberculosis classically 
presents as very thin, pale, feverish, and has a cough that produces bloody sputum. If 
not treated, up to two thirds of tuberculosis patients die of the disease (Bynum 
2012:12).   
 
Tuberculosis spreads through airborne transmission. When a person with infectious 
pulmonary tuberculosis coughs, sneezes, sings, or laughs, small infectious respiratory 
droplets are aerosolized and released into the airspace. These infectious droplet nuclei 
may only contain a few of the Mycobacterium tuberculosis bacilli, but a person needs 
to inhale only a few of these aerosolized droplets to be infected. Droplet nuclei can stay 
in the air for up to eight hours (Dye 2015:4). A dark room, over crowdedness, and 
poorly ventilated living quarters, create the perfect environment for tuberculosis 
transmission. In such an environment, one untreated person with infectious pulmonary 
tuberculosis, infects an average of ten to fifteen people in a year time (Adams et al 
(2015:123). The risk of acquiring tuberculosis infection is essentially determined by 
exogenous factors. These factors are largely social and economic in nature, including 
substance abuse, chronic illnesses like diabetes and HIV/AIDS, malnutrition and air 
pollution (Glaziou, Sismanidis, Floyd & Raviglione 2015:5; Heemskerk, Caws, Marais 
& Farra 2015:9).  
 
Naturally, the Mycobacterium tuberculosis is resistant to cold temperature with the 
capacity to remain viable for weeks at 4 degrees Celsius. Moreover, due to its high lipid 
content, the bacterium is also resistant to chemical decontaminations with chemicals 
like sodium hydroxide or detergents (Caminero 2013:14). However, sunlight kills the 
Mycobacterium tuberculosis and good ventilation ensure that the droplet nuclei are 
dispersed and carried outside (Davies et al 2014:131). Unfortunately sunlight and 
ventilation do not exist in all places. Thus, persons living in confined conditions like the 
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miners and prison inmates, suffer from high transmission of tuberculosis including 
drug-resistant tuberculosis. In this way, it is easy to guess how tuberculosis can be 
easily transmitted from person to person among the more than 10 million people 
currently living in prisons globally (Fazel & Baillargeon 2011:959). Despite the 
continuous effort for millennia, tuberculosis has not come under control (Kaufmann 
2011:3). 
 
2.3. The basics of multidrug-resistant tuberculosis  
Multidrug-resistant tuberculosis is the strain of tuberculosis bacilli that is resistant to 
the two most potent first-line anti-tuberculosis drugs, i.e. isoniazid and rifampicin 
(Caminero, Sotgiu, Zumla & Migliori 2010:621; Dheda et al 2014:321). The re-
emergence of tuberculosis as a global public health threat is associated with the 
emergence of multidrug-resistant strains of tuberculosis (Pálfi et al 2015:1; Sullivan & 
Amor 2013:373; Udwadia 2012:286; Migliori, Cantis, Lange, Richardson & Sotgiu 
2010:171).  
There is no difference between susceptible tuberculosis and drug-resistance in terms 
of their ways of transmission and clinical presentation. Moreover, the two strains could 
not be differentiated based on the results of smear microscopy and radiographic 
features (Scardigli & Caminero 2013:209). Nevertheless, MDR-TB is a serious public 
health problem (Nathanson, Nunn, Uplekar, Floyd, Jaramillo, Lönnroth, Weil & 
Raviglione 2010:1050; Zai, Haroon & Mehmood 2010:279-283). The development of 
MDR-TB, highly affects the diagnosis and clinical management of tuberculosis as well 
as patient monitoring parameters. Moreover, it highly compromises the effectiveness 
of the treatment given for tuberculosis (Caminero 2013:39-44; Vishakha & Sanjay 
2013:57).  MDR-TB does not respond to the standard six month tuberculosis treatment 
with first-line anti-tuberculosis drugs. Treatment of MDR-TB can take up to two years 
or more with second-line drugs. Moreover, second-line anti-tuberculosis drugs are less 
potent, more toxic and much more expensive than first-line anti-tuberculosis drugs 
(WHO 2011:1).  
Currently, the combination of poverty, HIV/AIDS and drug resistance makes 
tuberculosis a challenging disease for many people. Moreover, the political and cultural 
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conditions and stigma associated with the disease determine the occurrence of MDR-
TB. Factors associated with the performance of the health system determine patients’ 
access to diagnosis and treatment services for the disease. The combination of these 
factors affects the outcomes of patients with MDR-TB (Davies et al 2014:3-4).   
2.4. Spectrum of drug-resistance in the Mycobacterium tuberculosis 
A strain of tuberculosis that is resistant to rifampicin detected using phenotypic or 
genotypic methods, with or without resistance to other anti-tuberculosis drugs is called 
rifampicin resistant (RR) tuberculosis (WHO 2014b:18; WHO 2013a:5).  MDR-TB is 
that level of resistance with in-vitro resistance to the two most potent first-line anti-
tuberculosis medications - isoniazid and rifampicin (Hatfull et al 2014:413). Moreover, 
there is a more resistant form of drug resistance called the extensively drug-resistant 
tuberculosis (XDR-TB). XDR-TB is defined as strains of Mycobacterium tuberculosis 
with in-vitro resistance not only to isoniazid and rifampicin but also to other classes of 
medications that comprise the backbone of the regimen used to treat MDR-TB, that is 
the injectables and fluoroquinolones (Behera 2012:190).  
 
Finally, there is the extremely or totally drug-resistant case of tuberculosis (TDR-TB). 
Extremely or totally drug-resistant tuberculosis (TDR-TB) is defined as stains of the 
Mycobacterium tuberculosis that shows in-vitro resistance to all first and second-line 
anti-tuberculosis drugs tested (Dheda et al 2014:321). The naming of drug-resistance 
level beyond XDR-TB is not endorsed by the WHO, but it is provisionally named by 
researchers as ‘totally drug-resistant tuberculosis’ (Ribon 2015:31; Sullivan et al 
2013:373; Tadolini et al 2012:105). The development of TDR-TB signifies the medical 
and public health urgency associated with drug-resistant tuberculosis (Velayati, Farnia 
& Masjedi 2013:307).  
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2.5. Risk factors for development of drug-resistant tuberculosis  
Basically, bacteria achieve resistance to drugs through the naturally occurring 
spontaneous chromosomal mutations at sites of key drug targets. Then it is through 
the selection pressure that clinically significant drug-resistant bacteria are developed 
through time (Davies, Gordon & Davies 2014:46-8). There are two principal pathways 
leading to the development of drug-resistant tuberculosis in an individual. The first of 
these is the acquired drug resistance. This results from inadequate, incomplete 
treatment or treatment with poor quality of drugs that allow the selection of resistant 
strains (Laxminarayan, Duse, Wattal, Zaidi, Wertheim, Sumpradit, Vlieghe, Hara, 
Gould, Goossens, Greko, So, Bigdeli, Tomson, Woodhouse, Ombaka, Peralta, Qamar, 
Mir, Kariuki, Bhutta, Coates, Bergstrom, Wright, Brown & Cars.2013:1057-8). 
The second type is transmission of drug resistance from patients to healthy persons. 
The second type occurs in a person who is infected with a drug-resistant strain of 
tuberculosis. There is synergy between the two forms of drug-resistance in maintaining 
the continued transmission of the disease in the community (WHO 2014b:7).   
2.5.1. Clinical risk factors for the development of drug-resistant    tuberculosis   
The dominant factor for the development of MDR-TB is the use of suboptimal drug 
doses and drugs of poor quality, which cause selection pressure and provide a 
competitive advantage for naturally mutated strains of the bacteria. Furthermore, poor 
patient adherence to the standard treatment contributes to the development of drug 
resistance (Dheda, Gumbo, Gandhi, Murray, Theron, Udwadia, Migliori & Warren 
2014:332-3; WHO 2014b:107; .McHugh 2013:95; Monedero & Caminero 2010:118-
19).  
Moreover, there is individual risk factor for development of MDR-TB. These include, 
young age, male sex, a history of incarceration, infection with HIV/AIDS, a history of 
previous admission to hospital, alcohol and substance misuse, diabetes mellitus and 
(Tadesse 2015:65; Dheda et al 2014:324; Gomes, Correia, Mendonça & Duarte 
2014:111;Migliori, Sotgiu, D’Ambrosio, Centis, Lange, Bothamley, Cirillo, Lorenzo, 
Guenther, Kliiman, Muetterlein, Spinu, Villar, Zellweger, Sandgren, Huitric & Manissero 
2012:619). Moreover, migration from high MDR-TB prevalent countries has been 
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identified as the strongest risk factor for MDR-TB (Caminero 2013:43; Miglioria et al 
2010:172; Davies, Barnes & Gordon 2008:375).  
 
2.5.2. Programmatic risk factors for the development of drug-resistant 
tuberculosis   
Management of MDR-TB is new for most of the national tuberculosis programmes. As 
a result, the likelihood of clinical and programmatic errors in managing MDR-TB is high 
(Monedero & Caminero 2013:3-6; Migliori & Sotgiu 2012:955; Nathanson et al 
2010:1050). Moreover, management of MDR-TB is highly demanding in terms of 
economic and human resources. So far, small proportion of the estimated MDR-TB is 
detected by the national tuberculosis programmes (WHO 2016:66; Migliori & Sotgiu 
2012:955; Zumla, Abubakar, Raviglione, Hoelscher, Ditiu, Mchugh, Squire, Cox, Ford, 
McNerney, Marais, Grobusch, Lawn, Migliori, Mwaba, O'Grady, Pletschette, Ramsay, 
Chakaya, Schito, Swaminathan, Memish, Maeurer & Atun 2012:S228;   Nathanson et 
al 2010:1050). Furthermore, the small number of detected cases of MDR-TB are not 
treated as per the international recommendations (WHO 2014b:10-11; Parsons, 
SomoskÖvi, Gutierrez, Lee, Paramasivan, Abimiku, Spector, Roscigno & Nkengasong 
2011:317-20). This is because resource constraint countries encounter problems in 
implementing standared recommendations on the clinical management and prevention 
of the disease (Ortblad, Salomon, Bärnighausen & Atun 2015:2356; Siroka, Ponce and 
Lönnroth 2015).    
2.5.3 The risk of drug-resistant tuberculosis among contacts 
Households and close contacts of known patients with MDR-TB are at a higher risk of 
contracting MDR-TB (Yates, Khan, Knight, Taylor, McHugh, Lipman, White, Cohen, 
Cobelens, Wood, Moore & Abubakar 2016:233; Caminero 2013:49-50; Seddon, 
Warren, Enarson, Beyers & Schaaf 2012:1343-44).  A retrospective study conducted 
in Lima, Peru, indicated that 3% of the contacts of MDR-TB patients had active 
tuberculosis by the time the index MDR-TB case began treatment (Becerra, Appleton, 
Franke, Chalco, Arteaga & Bayona 2011:147). Yet, due to the absence of rapid, point-
of-care testing to identify latent and active tuberculosis  the large scale implementation 
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of active tuberculosis case finding among contacts remains low (Getahun & Raviglione 
2010:1206). Children and immunocompromised persons are at increased risk of 
getting MDR-TB if they come into close contact with infectious cases. Each year there 
are nearly two million child contacts for each adult drug-resistant tuberculosis source 
case. In the absence of effective preventive therapy, many of these children go on to 
develop MDR-TB. (Seddon, Hesseling, Finlayson, Fielding, Cox, Hughes, Faussett & 
Schaaf 2013:1677). Therefore, it is crucial to actively search for active tuberculosis 
among close contacts of infectious cases (Erkens, Kamphorst, Abubakar, Bothamley, 
Chemtob, Haase, Migliori, Rieder, Zellweger & Lange 2010:925).  
 
2.6. Epidemiology of M(X)DR-TB  
By 2011, MDR-TB accounted for 3.7 % of new and 20% of previously treated cases of 
tuberculosis (Zumla, Kim, Maeurer & Schito 2013:285; Scardigli & Caminero 
2013:208). In 2013, 9% of the total global tuberculosis cases had MDR-TB. As such, a 
total of about 480,000 cases and about 210,000 MDR-TB related deaths occurred 
(WHO 2015:2; WHO 2014a:70).  About 5 - 10% of the MDR-TB cases were thought to 
be extensively drug-resistant (XDR) tuberculosis (Ghanashyam 2016:1149; Pietersen, 
Ignatius, Streicher, Mastrapa, Padanilam, Pooran, Badri, Lesosky, Helden, Sirgel, 
Warren & Dheda 2014:123).  
There is limited surveillance data in approximately 50% of the high MDR-TB burden 
countries. Thus, there is a high probability of underestimations in determining the 
national incidence of MDR-TB (Kumar & Abubakar 2015:s37). By the end of 2012, 84 
countries had ever reported at least one case of extensively drug-resistant tuberculosis 
(Günther 2014:283; Harding, Foley, Connor & Jaramillo 2012.643). Currently, a 
combination of factors is contributing to the development and spread of MDR-TB 
globally. These factors include substance use, prevalence of co-morbidities like HIV 
and diabetes mellitus, malnutrition, incarcerations, overcrowding, migration, income 
inequality, and the cultural, political and religious factors around the community at risk 
of the disease (WHO 2014b:132).  
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In general, the prevalence of drug-resistance is lower in sub-Saharan African countries 
but it is higher in the countries of the former Soviet Union and China (Raviglione 
2010:128). In the Russian Federation and some neighbouring countries, up to 18% of 
new cases of tuberculosis are multidrug-resistant (The Institute of Medicine 2012:30). 
Most African countries are also hard hit by the epidemic of drug-resistant tuberculosis. 
South Africa has about 18% of the global burden of laboratory-confirmed cases of MDR 
tuberculosis and the highest number of confirmed cases of XDR-TB (O’Donnell & 
Schluger 2014:1193-94). As such, it shares 87.9% of the African burden of MDR-TB 
(Biadglegne, Sack & Rodloff 2014:3).  Furthermore, 97.6% of the total 2,336 XDR-TB 
patients reported from five African countries were from South Africa. In Somalia, the 
proportion of MDR-TB cases among cases of pulmonary tuberculosis was 7.7% 
(Sindani, Fitzpatrick, Falzon, Suleiman, Arube & Adam et al 2013:479).  
 
2.7. Epidemiology of drug-resistant tuberculosis in Ethiopia  
Ethiopia is among countries with high burden for MDR-TB. In 2011, there were an 
estimated 2200 (1300-3200) cases of MDR-TB in Ethiopia. Of this number, only 212 
(9.6%) were detected and only 199 (9%) of those detected were enrolled for MDR-TB 
treatment (Falzon, Jaramillo, Wares, Zignol, Floyed & Raviglione 2013:690). Moreover, 
the annual incidence of MDR-TB cases in Ethiopia for the year 2011 was estimated at 
2,200 (1300-3200).  But the number of MDR-TB cases ever detected and enrolled for 
MDR-TB treatment in the country has been far below the annual incidence estimate. 
In 2008, there were a total of approximately 5200 MDR-TB cases in Ethiopia and only 
130 (2.5%) were notified by the national tuberculosis programme (Falzon et al 
2013:691).  
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2.8. Challenges associated with M(X)-DR-TB 
2.8.1. Diagnostic challenges associated with M(X)-DR-TB   
Until recently, the diagnosis of tuberculosis was largely based on the 130-year-old 
smear microscopy technique and remains the cornerstone for the diagnosis of 
tuberculosis (McHugh 2013:1-10). However, the technique has limitations that are 
particularly associated with its low sensitivity (Tadolini, Centis, D’Ambrosio & Migliori 
2012:102). 
It worth noting that, the sputum smear microscopy cannot be used to identify strains of 
tuberculosis that are resistant to anti-tuberculosis drugs. The culture of the 
Mycobacterium tuberculosis followed by drug susceptibility test are needed for the 
diagnosis of MDR-TB (Kirwan & Gilman 2012: 103). Thus, diagnosis of MDR-TB 
requires implementation of sophisticated biosafety practices and equipment to prevent 
inadvertent infection of laboratory personnel (Minion & Pai 2010:941).  
In many resource limited countries, the high cost and the technical complexity 
associated with culture and drug susceptibility testing precludes its routine use in 
clinical diagnosis of tuberculosis. Furthermore, it takes weeks to months for culture 
results to be available for clinical decision making. This leads to delays in the diagnosis 
of patients suffering from strains of tuberculosis resistant to first-line drugs which in turn 
lead to treatment of MDR-TB cases with inappropriate regimen, leading to the further 
amplification of resistance (Dobler, Korver, Batbayar, Nyamdulam, Oyuntsetseg, 
Tsolmon, Surmaajav, Bayarjargal & Marais 2015:1451). Besides, culture is technically 
demanding, expensive and also not widely available (Scardigli et al 2013:208; WHO 
2012a:27-28). 
2.8.2. Clinical and programmatic challenges associated with M(X)DR-TB    
Clinical management of MDR-TB is challenging both for patients and clinicians. Its 
treatment is complex, expensive and needs a long treatment period (at least two 
years).  Drugs used to treat MDR-TB are expensive, toxic and less effective. Also, 
specific expertise is needed to provide a comprehensive service and care for patients 
with the disease and for the management of drug related adverse events. Furthermore, 
the treatment outcome of drug-resistant tuberculosis is generally poor (that is low 
treatment success rate) (Sotigu & Migliori 2014:364-365). As a result, multidrug-
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resistant and extensively drug-resistant tuberculosis are becoming a major health 
challenge since the second half of the 20th century (Wallis 2013:106). Globalization, 
health inequalities, competing economic interests and political instability substantially 
contribute to the development and spread of drug-resistant tuberculosis (Lange et al 
2014:23).  
2.8.3. The socio-economic challenges associated with MDR-TB  
The high incidence of tuberculosis is an indicator of poverty, healthcare inequalities 
and hardships like migration (Lange et al 2012:194). As such, the association between 
tuberculosis and socio-economic development is an insight that should be acted upon 
today. The continued global challenge due to tuberculosis and MDR-TB is largely 
attributable to the failure in how human society is structured and functions than from 
failure of medical practice (Benatar & Upshur 2010:1215-1217).   
A study conducted in India indicated that the poor are five times as likely to have 
tuberculosis as the rich (Institute of Medicine 2012:7-8). Acknowledging this, poverty 
affects patient treatment behaviours and their adherence with medical advice and 
adherence to treatment. Therefore, in many different settings, patient incentive and 
treatment enablers have been shown to improve patient adherence with medical advice 
and their adherence to treatment (Adams et al 2015:129).    
2.9. Clinical management of multidrug-resistant tuberculosis  
2.9.1. Standard approaches to the management of MDR-TB 
The treatment of multidrug-resistant or extensively drug-resistant tuberculosis is mainly 
bio-medically oriented. This means that a combination of second-line anti-tuberculosis 
drugs are used to treat the disease (Dooley, Obuku, Durakovic, Belitsky, Mitnick & 
Nuermberger 2013:1352). Second-line drugs are categorized into five groups 
according to their perceived potency and the role they play in the regimens used to 
treat M(X) DR-TB. When some of these second-line drugs are believed to have useful 
efficacy, the efficacy of others (such as amoxicillin–clavulanic, rifabutin) are queried 
because they are many others associated with significant toxicities. Second-line drug 
toxicity affects the tolerability of the regimen by the patient (Davies, Gordon & Davies 
2014:233). 
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Surgery as an adjuvant treatment for M(X)DR-TB may help treatment of MDR-TB if 
certain clinical criteria are met. Surgery may be considered as an adjuvant intervention 
to chemotherapy when four likely effective second-line drugs are not available and the 
lesion is localized so that there is sufficient respiratory reserve. Surgery is likely to have 
good impact in the case of XDR-TB where pharmacological options are extremely 
limited. When indicated, surgical intervention is recommended at the time of lowest 
bacillary load, ideally after sputum conversion (Scardigli et al 2013:213). 
 
Resection surgery as an adjuvant intervention to chemotherapy has been proved to be 
effective and safe under appropriate surgical conditions. Yet the procedure needs 
skilled thoracic surgeons and excellent post-operative care. Timing of surgical 
intervention is recommended to be earlier in the course of the disease when the 
infection is local. The M/XDR-TB patient needs to be on treatment for at least two 
months prior to considering surgical intervention.  
 
Adjuvant treatment to chemotherapy is required for certain patients with M/XDR-TB. 
Corticosteroids have the potential to affect the body’s response to fight tuberculosis; 
their use should be based on clear clinical indication. Nutrition and micronutrient 
supplementation are part of the standard management of M(X)-DR tuberculosis (WHO 
2014b:93-4).  
2.9.2. Standard registration groups for MDR-TB   
Cases of drug-resistant tuberculosis are registered based on a previous treatment 
history (that is the outcome of the latest tuberculosis treatment). In this way, patients 
are registered under two broad categories of registration groups (new and previously 
treated). A patient is new if he or she hasn’t ever received anti- tuberculosis treatment 
or received anti-tuberculosis treatment for less than 1 month. Patients in the previously 
treated group include the relapse, treatment after failure and treatment after lost to 
follow ups. A case of relapse tuberculosis patient is one in which previous tuberculosis 
treatment was successfully completed and the patient was subsequently diagnosed of 
tuberculosis (Federal Ministry of Health of Ethiopia 2014:45). Patients with tuberculosis 
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who after taking anti- tuberculosis for more than one month become lost to follow ups 
for two months or more time and then return to treatment with active tuberculosis, are 
registered as ‘treatment after lost to follow ups’. Treatment after failure is that group of 
patients who remain sputum or culture positive at five month or longer after 
commencing the treatment for tuberculosis. There are also some groups of patients 
with tuberculosis who are registered under the ‘other previously treated’ group of 
patients. These patients are those who have previously been treated for tuberculosis 
but whose most recent tuberculosis treatment outcome is not known or not 
documented. Based on their HIV sero-status, patients may be registered in the HIV 
positive or HIV negative group of patients (WHO 2013a:4). 
2.9.3. Clinical and laboratory monitoring scheme for patients with MDR-TB    
Prior to initiation of treatment with second-line anti- tuberculosis drugs, all diagnosed 
patients with MDR-TB undergo baseline clinical and laboratory tests. These include 
detailed clinical, serological, bacteriological and radiological evaluations. In that case, 
thyroid, hepatic and renal function tests and complete blood counts are done. The tests 
also include voluntary counselling and testing for HIV (Sanjay 2013:53).  
Once the patient is initiated on treatment, routine laboratory monitoring of the treatment 
process and its outcome is considered to be one of the five components of the global 
Directly Observed Treatment Short Course (DOTS) strategy. The Directly Observed 
Treatment Short Course also remains as a core element in the global Stop TB Strategy. 
Currently, routine monitoring of the patients’ sputum and culture conversion is the main 
method to assess the response to treatment of the patients with MDR-TB. For patients 
with MDR-TB, laboratory results help to make clinical decisions including determining 
the duration of chemotherapy (Glaziou et al 2015:8).  
Clinical symptoms and radiographies are used to assess the status of patients’ 
response to treatment. In the case of patients with MDR-TB, smear conversion has 
less predictive value than the culture for monitoring patients’ response to treatment. 
Thus, even though it is too demanding, culture is a better parameter for monitoring 
patients’ response to treatment (Caminero 2013:43).  
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It is recommended that patients with MDR-TB be closely monitored for their response 
to chemotherapy. For this, close laboratory monitoring helps to promptly pick up signs 
of treatment failure and drug-toxicities. Additionally, regular history taking, physical 
examination, laboratory tests and chest radiology are crucial for patients treated for 
MDR-TB. The conversion of sputum culture to negative is the most sensitive criteria 
for assessing improvement. The conversion of sputum smear microscopy to negative 
is important for monitoring the patient’s response to treatment mainly because of its 
shorter turnaround time. Yet sputum culture is most sensitive to detect the response to 
treatment (WHO 2014b:139-40).  
2.9.4. Standard treatment outcome options for patients with M(X) DR-TB  
In the same way as standard registration groups for patients with MDR-TB, there are 
standardized definitions to assign treatment outcomes to patients with M(X)DR-TB.  As 
such, there are about six standard definitions for outcomes of MDR-TB treatment 
(WHO 2013a:6). Thus, a patient with MDR-TB patient is given one of these six outcome 
definitions, mainly based on available data on results of laboratory and clinical follow 
up services. The six standards MDR-TB treatment outcome options include cured, 
treatment completed, treatment failed, died, lost to follow up and not evaluated. In the 
definition of treatment outcome, the term ‘treatment success rate’ implies the sum of 
patients with MDR-TB those who are cured and those who completed treatment 
(Federal Ministry of Health of Ethiopia 2014:47; WHO 2014b:18).   
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2.10. Factors determining the clinical management & the treatment outcomes 
of patients with MDR-TB     
2.10.1. Socio-demographic determinants of the treatment outcomes of patients 
with MDR-TB  
Tuberculosis affects all ages and both sexes. In 1988, while in prison, Nelson Mandela, 
was diagnosed with tuberculosis after presenting with pleural effusion and he received 
treatment for tuberculosis (O’Donnell & Schluger 2014:1193). 
 
There is complex interaction between patients’ socio-demographic factors and the 
management of patients with MDR-TB. Lack of education, unemployment and distance 
from health facility are associated with an increased risk of treatment interruption by 
patients with MDR-TB. Personal factors like smoking, drug and alcohol use, co-
infection with HIV and perceived severity of illness are risk factors for treatment 
interruption (Ndwandwe, Mahomed, Lutge & Knight 2014:56). Older age and the use 
of alcohol are associated with the increased risk of hepatotoxicity among patients 
treated for MDR-TB (WHO 2014b: 85; Caminero 2013:123). Being a male patient, 
inadequate knowledge of tuberculosis and the need for treatment adherence, and 
stigma may affect patients’ adherence to treatment (Muture, Keraka, Kimuu, Kabiru, 
Ombeka & Oguya. 2011:2). Male patients with tuberculosis are at a higher risk of 
treatment non-adherence than women.  Men’s breadwinner status as head of 
households explained their lower adherences to treatment (HerreroI, RamosI & 
ArrossiI 2015:295). In Nigeria, patients who live more than five kilometers away from 
treatment centres, lack of knowledge on the duration of tuberculosis treatment and 
cigarette smoking were associated with treatment interruption (Anyaike, Musa, Tunde, 
Bolarinwa, Durowade & Ajayi 2013:1441). 
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2.10.2. The socio-economic determinants of the treatment outcomes of 
patients with MDR-TB 
Tuberculosis is mainly a social disease that inequitably affects the poor in resource 
constrained regions of the world (Schaaf & Zumla 2009:19). The poor, lack access to 
the basic life resources like food, water and sanitation, and therefore poor lack control 
over their lives (Benatar & Upshur 2010:1215-6).  
 
Poverty related factors such as poor living conditions and under nutrition, increase the 
likelihood of infection by tuberculosis and its subsequent progression to an active 
disease (Rusen, Squire & Billo 2011:163). Poverty and food insecurity are both causes 
and consequences of tuberculosis. Poverty enhances the transmission of tuberculosis 
(Peltzer & Louw 2014:157). Most of the world’s high-burden tuberculosis countries 
such as Ethiopia and Kenya are poor and have a high level of unemployment. In these 
countries, tuberculosis is aggravated by poverty. It contributes to unemployment and 
lack of adequate nutrition. Poor nutrition, on the other hand, is a risk factor for the 
development of tuberculosis (Schaaf et al 2009:605). 
 
Patients with tuberculosis face the double burden of reduced income and increased 
expense. As patients are often too weak to work, their families are obliged to pay for 
the medical expenses needed in seeking diagnosis and treatment for the disease. 
Patients and their families encounter indirect costs related to travel costs and lost 
income due to the disease and its treatment (WHO 2013b:10).  In Armenia, the poor 
economic status among patients with tuberculosis is associated with an increased 
chance of default from treatment (Sanchez-Padilla, Marquer, Kalon, Qayyum, 
Hayrapetyan, Varaine, Bastard & Bonnet 2014: 160). In Georgia, the low monthly 
household income and unemployment were predictors of poor treatment outcomes 
among patients with MDR-TB (Djibuti, Mirvelashvili, Makharashvili & Magee 2014:1).  
Among the poor patients with MDR-TB, malnutrition was associated with a low cure 
rate and a high rate of death. It was evident that economically weak patients who lead 
a poor lifestyle are unable to continue with the lengthy MDR-TB treatment. Such 
patients do not appreciate the need to continue treatment once they feel improved 
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(Vishakha & Sanjay 2013:57). Therefore, for the poor patient provision of tuberculosis 
medications that are free of charge alone are not effective. Because tuberculosis is 
associated with indirect expenses and lost income, it impedes the poor patient’s 
adherence to care. Thus, increasing funding on interventions that target social 
determinants of tuberculosis is crucial to ensure the successful management of 
patients with tuberculosis (Siroka, Ponce & Lönnroth 2015:5).  
Thus, patients with tuberculosis need social and financial support that enables them to 
complete their treatment. It must be acknowledged that the availability of social support 
improves patients’ treatment outcomes (Basili, Fitzpatrick, Qadeer, Fatima, Yloyd & 
Jaramillo 2013: 278).  
 
2.10.3. The MDR-TB drug regimen as a determinant factor for the treatment 
outcomes of patients with MDR-TB  
There are two requirements in the approach to the management of drug resistant 
tuberculosis. The first is the need to use multiple drugs to avoid further resistance. The 
second is the need to treat the patient for a sufficient duration of time in order to kill the 
dormant bacilli and prevent relapse (Monedero & Caminero 2010:120).  
Currently, treatment for MDR-TB is given for at least 20 months. The recommendation 
for such a long treatment duration is based on very poor quality evidence. The available 
supporting data has not been able to provide information on whether the duration of 
the intensive phase and time of sputum conversion can influence the patient’s clinical 
outcomes (Scardigli & Caminero 2013:212-213).  
The lengthy MDR-TB treatment regimen currently in use is often poorly tolerated by 
patients. It is also difficult to monitor it (Van Deun, Maug, Salim, Das, Sarker, Daru & 
Rieder 2010: 684). In addition, optimal drug regimens for MDR-TB are poorly 
characterized. There are no fixed dose combination tablets and so patients are 
required to take many tablets per day. This makes patients’ adherence to treatment a 
major challenge during the lengthy treatment period (Zumla et al 2012:S234).  
It is apparent that the multiple anti-tuberculosis drug regimens used for the 
management of MDR-TB can be standardized or individualized regimens. It is 
suggested that standardized regimes are useful in settings with high MDR-TB burden 
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and low skilled physicians. This is because standardization facilitates prescription and 
the approach to patient management. Individualized regimens are preferred in patients 
with previous exposure to second-line drugs and for patients with XDR-TB who failed 
on the standard regimes (Scardigli & Caminero 2010:212). 
 
Compared with settings that use the individualized MDR-TB treatment regimen that is 
guided by laboratory drug-sensitivity test results and local drug-susceptibility patterns, 
settings using standardized or empiric treatment regimens under programmatic 
conditions, report poorer treatment outcomes in terms of treatment success. It was 
found that the favourable treatment outcomes of patients treated with individualized 
regimen is 10% more than the treatment outcome of patients treated with standardized 
regimen (64% for individualized vs 54% for standardized regimen) (Zumla et al 
2012:S234). Analysis of the treatment outcomes of 204 culture confirmed patients with 
MDR-TB in the United Kingdom has shown that the type of second-line drugs used 
determine the level of treatment outcomes. Furthermore, patients who are treated with 
regimen containing fluoroquinolones or a bacteriostatic drug are more likely to have a 
successful treatment outcome compared to those who did not. (Anderson, Tamne, 
Watson, Cohen, Mitnick, Brown, Drobniewski & Abubakar 2013:406).  
 
2.10.4. Factors related to the MDR-TB disease 
An individual patient with MDR-TB may be infected by mixed strains of the 
Mycobacterium tuberculosis termed as phenotypic drug sensitivity test heterogeneity. 
The presence of at least a tuberculosis bacilli that is susceptible to rifampicin and 
isoniazid in culture isolates, indicates the presence of an infection with a 
heterogeneous strain. Infection with mixed heterogenic strains of tuberculosis is a risk 
factor for unsuccessful treatment outcome. Compared with patients without phenotypic 
heterogeneity, patients infected with heterogenic strains are at greater risk of poor 
clinical outcomes (Zetola, Modongo, Moonan, Ncube, Matlhagela, Sepako, Collman & 
Bisson 2014:1760).  
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In tuberculosis and HIV co-infected patients’, the presence of heterogenetic strains 
delays culture conversion and prolongs the chance of disease transmission (Zumla et 
al 2012:S234). Similarly, the severity of the MDR-TB determines the clinical 
management of MDR-TB.  The presence of severe forms of MDR-TB, including 
bilateral and extensive lung lesions and high initial bacillary load, are associated with 
poor treatment outcomes (Vishakha & Sanjay 2013:54). Granulomatous lung lesions, 
for example, are poorly vascularized and are difficult to access with anti-tuberculosis 
drugs (Hichey 2016: 260).  Retreatment or re-treating is a predictor of treatment failure, 
death and default among patients with tuberculosis (Peltzer & Louw 2014:157).  
 
2.10.5. Adverse drug reactions from second-line drugs        
Adverse drug reactions are common among patients with MDR-TB who are treated for 
the disease (Akshata, Chakrabarthy, Swapna, Buggi & Somashekar 2015:27; Blasi, 
Barnes, Gaga & Migliori 2013:1). Seventy two (72) out of the 73 patients treated with 
second-line drugs in Addis Ababa, Ethiopia, encountered at least two adverse drug 
reactions in the course of their treatment (Bezu et al 2014:147). From a cohort of 63 
patients with MDR-TB, those treated at the LG Hospital-Ahmedabad, 36 (57.14%) of 
the patients experienced second-line anti-tuberculosis drugs related adverse reactions 
of varying severity (Vishakha & Sanjay 2013:55).  
An analysis of second-line drug related adverse drug reactions among 1027 patients 
with MDR-TB in Latvia, indicated that adverse drug reactions from second-line drugs 
are prevalent.  The study revealed that, 79% of patients experienced at least one type 
of second-line drug related Adverse drug reactions with a median of three adverse drug 
reaction events per case (Bloss, Kukša, Holtz, Riekstina, Skrip ˇconoka, Kammerer & 
Leimane 2010:275). It has been observed that adverse drug reactions lead to treatment 
interruption before completion. As such, it contributes to morbidity, treatment failure, 
reduced quality of life or death (WHO 2014b:35-6).  In Armenia, poor treatment 
tolerance because of adverse drug reactions is associated with an increased risk of 
default from treatment and poor patient response to treatment (Sanchez-Padilla et al 
2014: 164). 
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There are many risk factors for the occurrence of adverse drug reactions.  These 
include the presence of co-morbidities that demand the simultaneous use of several 
drugs. Factors related to the patient’s condition like being very young or very old age, 
allergy to drugs, pregnancy, breast feeding and diseases that alter drug metabolism 
and its elimination from the body increase the likelihood of adverse drug reactions 
(WHO 2012b:65).  
 
For example, the use of fluoroquinolones in patients with low body weight is associated 
with more adverse drug reactions. Also, there is a risk of hypoglycemia associated with 
the use of gatifloxacin in elderly patients (Caminero 2010:624). 
 
About 25-45% of patients treated with Linezolid reported severe anemia with or without 
thrombocytopenia or peripheral and optic neuropathy. It has also been noted that 
bacteriostatic second-line drugs like para-amino salicylic acid and Ethionamide are 
major causes of hypothyroidism (Caminero 2013:141; Caminero 2010:627). Moreover, 
the sodium salt formulations of para-amino salicylic acid (PAS) cause sodium retention 
resulting in excessive sodium load in the body which should be avoided in patients with 
renal insufficiency (WHO 2014b:112-13). Both Linezolid and/or Rifabutin anti-
tuberculosis medications have been associated with myelosuppression, anemia, 
neutropenia, peripheral and optical neuropathy. Thioacetazone is associated with high 
toxicity in patients with HIV co-infection (Caminero et al 2010:627). The other common 
adverse reactions from second-line drugs is loss of hearing (Seddon, Faussett, Jacobs, 
Ebrahim, Hesseling &   Schaaf 2012:1277-83).   
 
In conclusion, adverse drug reactions should be anticipated, promptly identified and 
treated to avoid defaulting from treatment due to drug side effects (D’Ambrosio, 
Tadolini, Centis, Duarte, Sotgiu, Aliberti, Dara & Migliori 2015:158-159; Blasi, Dara, 
van der Werf & Migliori 2013:493; Caminero et al 2010:621-29; Monedero et al 
2010:123).  
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2.10.6. Co-morbid conditions affecting the management of MDR-TB  
There are overlapping comorbidities between tuberculosis and other diseases. Co-
morbidities with MDR-TB have one thing in common, that is, they all reduce the host 
immune response to tuberculosis. HIV, malignancies, diabetes mellitus, and chronic 
renal failure are the best examples (Raviglione 2010:98-9). If a patient with MDR-TB is 
immunocompromised, the tuberculosis bacilli resists the phagosomes-lysosome fusion 
by which the bacteria is naturally killed. Thus, the bacilli can continue to multiply 
(Hichey 2016: 260).  As such, the presence of diseases like HIV/AIDS, diabetes 
mellitus, and renal and liver disease affect the process and outcomes of the treatment 
given for MDR-TB (Marais, Lönnroth, Lawn, Migliori, Mwaba, Glaziou, Bates, Colagiuri, 
Zijenah, Swaminathan, Memish, Pletschette, Hoelscher, Abubakar, Hasan, Zafar, 
Pantaleo, Craig, Kim, Maeurer, Schito & Zumla 2013:436). 
 
In the United Kingdom, 26.7% of the total 204 culture confirmed patients with MDR-TB 
diagnosed between 2004 and 2007 had a co-morbidity with MDR-TB. About 54.4% of 
the patients had at least one change to their treatment regimen at some point during 
the course of their treatment. The study showed that patients who have any co-
morbidity with MDR-TB are more at risk of death (p<0.0005). Specifically, co-infection 
with HIV is associated with risk of death (p<0.0005) followed by co-infection with dia-
betes mellitus (p=0.002) and chronic renal disease (p=0.002) (Anderson et al 
2013:406).  It is evident that HIV fuels the occurrence of tuberculosis and is a risk factor 
for the development of MDR-TB. A survey of patients with MDR-TB conducted in 
Ukraine indicated that HIV infection is an independent risk factor for the development 
of MDR-TB (Ayles & Godfrey-Faussett 2009:1450). Also, the HIV pandemic and the 
rising trend of MDR-TB in sub-Saharan Africa form a synergistic impact on treatment 
outcomes of drug-resistant tuberculosis. There are indications that a high degree of 
immunosuppression and drug-resistance are associated with poor treatment outcomes 
of patients with MDR-TB (Gandhi, Andrews, Brust, Montreuil, Weissman, Heo, Moll, 
Friedl & Shah 2012:90). Co-infection with HIV is associated with poor treatment 
outcome and high mortality among both patients treated for susceptible tuberculosis 
and MDR-TB (Babatunde et al 2013:213).    
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The presence of any co-morbidity with MDR-TB therefore necessitates the concomitant 
use of other medications. This increases the risk of drug interactions and overlapping 
drug toxicities (WHO 2014b:85).  Additionally, the extraordinary high pill burden that 
MDR-TB and HIV co-infected patients take needs special attention. Note that these 
treatments could amount to more than 30 tablets per day (Caminero 2013:172). A 
greater degree of immunosuppression, usually very low T-lymphocyte cell bearing 
(CD4) count, and a high level of resistance to anti-tuberculosis drugs, are associated 
with a greater risk of death (Gandhi, Andrews, Brust, Montreuil, Weissman, Heo, Moll, 
Friedland & Shah 2012:90). Thus, earlier initiation of anti-retroviral therapy is 
recommended for tuberculosis and HIV co-infected patients. This recommendation 
encompasses even those patients severely immune-compromised. A study conducted 
in Ethiopia on 512 patients, revealed that a better chance of survival was observed 
among patients with T-lymphocyte cell bearing (CD4) count of 50 cells/µl or less who 
were initiated on anti-retroviral therapy as early as 1 week (Naidooa, Baxtera & Abdool 
Karim 2013:2-7). 
 
There is a further documented link between diabetes mellitus, smoking, alcoholism, 
chronic lung diseases, cancer, immunosuppressive treatment, malnutrition and 
tuberculosis.  Diabetes mellitus is the most common co-morbidity both in MDR-TB and 
XDR-TB (14.5% for MDR-TB) and 15.4% for XDR-TB) (Yuan, Zhang, Kawakami, Zhu, 
Zheng & Li et al 2013:1). Malnutrition is one of the co-morbid conditions presenting 
with clinical tuberculosis. Malnutrition is not only a risk factor for the development of 
tuberculosis but it also occurs as a consequence of infection with tuberculosis. In 
addition, it is also associated with gastro-intestinal disorders and mal-absorption. Also, 
the Low Body Mass Index (BMI) and lack of adequate weight gain are associated with 
death and the relapse of tuberculosis. Thus, malnutrition, as a co-morbid condition, is 
an indication of the disease severity and poor patient response to treatment (WHO 
2013b:8).  In conclusion, addressing co-morbidities presenting with tuberculosis is 
crucial for improving patient response to tuberculosis treatment. In fact, the 
management of co-morbidities with MDR-TB should be considered as part of the 
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comprehensive and standard of care for tuberculosis. This entails an integrated 
management and care for tuberculosis and other co-morbidities. The aim of such an 
approach will be to improve the general health and quality of the life of patients treated 
for M(X)DR-TB (WHO 2013b:7). 
 
2.10.7. The effect of malnutrition on the management of MDR-TB and its 
treatment outcomes  
Tuberculosis, like other infections, increases energy requirements by the body. The 
presence of malnutrition with tuberculosis is an indication of disease severity. Low body 
mass index (<18.5kg/m2) and lack of adequate weight gain in the course of tuberculosis 
treatment are associated with poor response to treatment and a higher risk of death 
(WHO 2013b:8). Protein energy malnutrition is the most common form of malnutrition 
among patients with MDR-TB. Protein energy malnutrition and specific nutrient 
deficiencies debilitate the cell-mediated immune system, which is important in the 
protection against tuberculosis. Once tuberculosis develops, it induces a catabolic 
state resulting in negative nitrogen balance and micronutrient deficiencies (Cegielski & 
Vernon 2015:490). As a result of poor conditions, protein energy malnutrition affects 
those people living in poverty, the elderly and young children and is common in people 
affected by infectious diseases like tuberculosis and HIV/AIDS. Tuberculosis and 
HIV/AIDS not only depletes body proteins, but they also demand extra energy. It is 
observed that these diseases induce nutrient loss and alter metabolic pathways 
(Whitney & Rolfes 2008:197).  For people suffering from tuberculosis, poor nutrition 
intake worsens pre-existing malnutrition and impairs recovery (Caminero 2013:201).  
 
MDR-TB causes malnutrition and the second-line drugs given to treat it decrease 
appetite and exacerbate pre-existing malnutrition. Patients suffering from borderline 
hunger can also be enmeshed in a vicious cycle of malnutrition and disease (Caminero 
2013:142). Therefore, anti-tuberculosis treatment may not be fully effective if the 
problem of malnutrition is not addressed. So, provision of free food during MDR-TB 
treatment improves the patients’ weight and the quality of their lives (WHO 2014b:94). 
Hence, the recommendation is for adequate nutrition support, including vitamin 
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supplementation like vitamin B6 should be provided for patients on MDR-TB treatment 
(Lange et al 2014:44). Vitamins and minerals supplementation and adjuvant therapies 
to alleviate symptoms of pain are important interventions for patients on MDR-TB 
treatment (WHO 2014b:93-94). Patients with MDR-TB should be provided with free 
food.  Provision of free food should therefore not be considered as an incentive but 
should rather be seen as a necessary intervention to facilitate treatment success for 
MDR-TB. It has been proved that nutrition intervention improves the body’s response 
to treatment and increases chances of patient survival (Caminero 2013: 201). In this 
way, tuberculosis and especially MDR-TB is more than a medical problem (Monedero 
& Caminero 2013:7). A focus only on drug-regimens needed to treat MDR-TB is 
therefore insufficient in the absence of strong social support. It seems obvious that 
spending thousands of dollars on expensive second-line drugs makes no sense if 
patients default from treatment because of hunger (Monedero & Caminero 2010:123). 
On top of the abovementioned interventions, continuous patient counselling and follow 
up support are critical to improve the quality of the patients’ life and the safety of other 
people living around the patient with MDR-TB (Zai et al 2010:279).  
 
2.10.8. Cost of illness associated with MDR-TB 
Tuberculosis causes catastrophic health expenditure (defined as direct health 
expenditures corresponding to 40% of the annual discretionary income) during the pre-
diagnosis and pre-treatment period. As most of the expenditure occurs before the 
patient is diagnosed with tuberculosis, minimizing treatment cost in the course of 
treatment does not guarantee financial risk (Tanimura, Jaramillo, Weil, Raviglione & 
LÖnnroth 2014:1770) especially because patients with tuberculosis still encounter 
financial risk during treatment. In Swaziland, transport cost and user fees for 
registration at health facilities are among factors that limit patients’ access to care 
(Sanchez-Padilla, Dlamini, Ascorra, Rüsch-Gerdes, Tefera and Calain, Tour, Jochims, 
Richter & Bonnet 2012:35).  In Argentina, the burden of transportation costs and the 
type of health facility where patients get treatment for tuberculosis are major 
explanatory factors of patients’ adherence to treatment. Patients with tuberculosis that 
are employed and are also getting social protection had higher levels of treatment 
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adherence than those patients with employment but with no social protection (HerreroI 
et al 2015:295).  
 
For patients with tuberculosis is around half of their annual income (Burki 2015:21). In 
some settings, patients with MDR-TB and their families spend over half of their annual 
income due to tuberculosis. About 60% of this cost is due to days off work and out of 
pocket expenditure (Ortblad et al 2015:2356). Even when treatment is free, patients 
face a high financial burden during their attendance to treatment (Arakawa et al 
2011:1000). Costs incurred by patients and their families include direct medical 
expenses, travel costs and lost income due to illness. In Nigeria, the cost incurred due 
to tuberculosis is 37% of the median annual household income (Ukwaja, Alobu, lgwenyi 
& Hopewell 2013:1). In China, the poorest are disproportionately affected by 
tuberculosis. Excluding the income losses due to the disease, the direct out-of-pocket 
expenditure due to tuberculosis is 55.5% of the average annual household income. 
Thus, the family falls into heavy debt. In Tanzania, 68–98% of tuberculosis related 
costs incurred by patients and their families is associated with patients’ loss of income 
related to reduced capacity to work. Therefore, families are forced to sell productive 
assets or are forced into migrant labour (Jackson, Sleigh, Wang & Liu 2006:1104). In 
Ethiopia, the annual cost incurred by TB-HIV co-infected patients and their family is 
documented to range from 49% to 71% of the annual household income (Vassall, 
Seme, Compernolle & Meheus 2010:604).  
 
The greater economic burden borne by MDR-TB is associated with its total duration of 
illness. Compared to the average of 12 months from symptom onset to end of treatment 
for susceptible tuberculosis, the average total of 40 months from symptom onset to end 
of treatment for MDR-TB is much longer. This indicates that the high economic burden 
imposed by tuberculosis on patients and their families is much greater than the average 
annual household income (Rouzier, Oxlade, Verduga, Gresely & Menzies 2010:1316). 
In Equador, the total per capita MDR-TB related cost was found to be USṨ 6880, which 
is 223% of the average Ecuadorian annual income (Vassall, Seme, Compernolle & 
Meheus 2010:604). As a result, some cases of depression among MDR-TB patients 
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are associated with socio-economic problems rather that due to the drugs used to treat 
MDR-TB (IUATLD 2010:129-30). In this way, tuberculosis is described as a driver of 
poverty, a condition that causes perpetuation of the disease.  Tuberculosis and 
especially TB-HIV co-infected patients face loss of employment, reduced income, 
stigma and discrimination. They also face gender violence and family separation. On 
the other hand, these patients require additional resources to achieve good treatment 
results. Thus if patients with tuberculosis are made to pay for diagnosis and or 
treatment, their chance to delay seeking medical service or interrupt treatment is very 
high (Caminero 2013:142). 
 
2.10.9. Model of treatment delivery as a factor determining MDR-TB treatment 
outcomes  
One of the key components of the Directly Observed Treatment Short Course (DOTS) 
Strategy is the direct observation of the tuberculosis treatment. Direct observation of 
every dose of anti-tuberculosis drugs is effective in making sure that each daily dose 
of anti-tuberculosis drugs is taken by the patient (Caminero 2013:164). In order to 
achieve a cure, it is of utmost importance to ensure that the patient takes all the daily 
drugs according to medical instructions. Thus, treatment must be administered by a 
trained treatment supporter (preferably health caregivers) who will observe the patient 
taking all doses of prescribed drugs under direct observation (Lange et al 2014:37). 
Introduction of the direct observation of treatment for MDR-TB, has enabled dealing 
with the increasing number of drug-resistant tuberculosis (The Institute of Medicine 
(IOM) 2012:22).  
Yet from the perspective of the patient with MDR-TB, there are many important 
concerns that impair their adherence to the ideal treatment under daily Directly 
Observed Treatment support (Caminero 2013:192-193). 
Available evidence estimates that up to 60 percent of patients with chronic disorders, 
poorly adhere to treatment (Robinson, Gould & Strosahl 2010:87). It is documented 
that as many as 50% of patients with tuberculosis miss an occasional appointment for 
medication. Thus, the acceptable tuberculosis treatment process and its optimum 
treatment outcome depend on the continued commitment of the patient and particularly 
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of the healthcare workers to ensure a high level of adherence to standard medical 
advice (Bosworth, Oddone & Weinberger 2006:147). For a patient who is treated for a 
clinically established diagnosis and using drugs of established efficacy, adherence to 
treatment may be established by following certain ethical approaches. The patient 
should get ongoing treatment support and the patient’s interest regarding the 
treatment, should be respected. Patients should be able to comfortably discuss any 
problem when it arises to minimize chances of treatment interruption (Bosworth, 
Oddone & Weinberger 2006:13).  
However, the daily observed treatment approach is interpreted differently by patients 
in different settings. According to a studies conducted in South Africa and Vietnam, 
patients interpret daily observed treatment as a sign of patient distrust (Arnadottir & 
Iceland 2009:679-82). Distance from the treatment centre and economic barriers are 
risk factors for non-adherence to treatment Therefore, reduced distance between the 
patients’ home and the facility where tuberculosis treatment is given reduces the cost 
of round-trip transportation. As such, it is noted that patients treated at primarily health 
facilities have better adherence and treatment outcome (Herrero, Ramos & Arrossi 
2015:287; Loveday, Wallengren, Brust, Roberts, Voce, Margot, Ngozo, Master, Cassell 
& Padayatchi 2015:167; Alobu, Oshi, SN, Oshi, DC & Ukwaja 2014:782-3). 
Community-based models of MDR-TB management help to reduce the cost of illness 
and improve treatment outcomes (Scardigli & Caminero 2013:214).   
Yet, decentralized care model requires strong coordination between health 
professionals at formal health facilities and community level social workers (Heller, 
Lessells, Wallrauch, Bärnighausen, Cooke, Mhlongo, Master & Newell 2010: 423). The 
Institute of Medicine (IOM) states two things that are of priority concern in the 
decentralization of Daily Observed Treatment support for patients with MDR-TB who 
are treated with second-line drugs. The first of these concerns is that, if second-line 
drugs are given erratically without strict supervision and especially with doses that are 
not correct, more severe forms of drug-resistance like extreme and total drug-resistant 
tuberculosis can develop. The second concern is the issue of disease transmission if 
the household level infection control is not strong (The Institute of Medicine 2012: 17, 
39). 
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Moreover, the choice of a treatment supporter by the patient and the willingness of 
treatment supporters to take on the responsibility for the Daily Observed Treatment 
support is another challenge on the effectiveness of daily observed treatment. An 
overworked and poorly paid healthcare worker may not be motivated to take 
responsibility for Daily Observed Treatment. Such practical issues make the 
usefulness of the Daily Observed Treatment strategies to be questionable in the long 
run. Furthermore, laypersons other than family members, are sometimes rejected by 
the patient usually relating to the issue of confidentiality (Arnadottir et al 2009:682).  
 
Nevertheless, every patient with MDR-TB who is linked to outpatient and community 
based treatment support, needs to have a dedicated worker as a single point of contact 
for any challenge he/she faces in the course of treatment. Additionally, there should be 
a system whereby patients are regularly appointed to hospitals for follow-up adherence 
support and for scheduled clinical assessment. Moreover, facilities initiating treatment 
should be responsible for contact investigations and the assignment of the appropriate 
treatment outcome upon treatment completion by the patient (Lange et al 2014:45). 
2.11. Factors determining patients’ perceived quality of care and patient 
satisfaction with care given for MDR-TB  
2.11.1. Factors related to the health service quality 
Quality is elusive, means that, it is difficult to define. Quality is context-dependent and 
multidimensional (Kajonius & Kazemi 2015:2). According to Avedis Donabedian 
(2005:691) “the definition of quality may be almost anything anyone wishes it to be, 
although it is, ordinarily, a reflection of values and goals current in the medical care 
system and in the larger society of which it is a part” (Donabedian 2005:691-2). The 
Institute of Medicine defines quality in the context of health services. In this way, quality 
is the degree to which a health service is meant to serve individuals and populations 
and increase the likelihood of desired health outcomes also consistent with 
contemporary professional knowledge (Višnjić, Veličković & Jović 2012: 54). 
 There is a definition of quality put forward by Donabedian. He defines health service 
quality in terms of technical and interpersonal quality. Technical quality stresses that 
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the desired health outcome of procedures, tests and services that the patient receives 
sufficiently exceeds anticipated health risks. The second segment of the Donabedian 
aspect of quality, that is, interpersonal quality, argues that all patients are treated in a 
humane and culturally appropriate manner and they are also part of the decision made 
regarding the services they take.  The other aspects of quality include content (service) 
quality. There is also an ethical dimension of quality that focuses on the need for health 
services to be safe, effective and patient-centred (Donabedian 1988:1743).  
 
2.11.2. Dimensions of the health service quality  
Quality of care can be decomposed into three distinct but interrelated components. 
These are structure, process and outcome.  Structural quality includes factors that 
affect the conditions in which the care occurs. Structural quality also includes 
parameters like resources, the number and the training level of the staff who provide 
care for patients. Structure encompasses factors like the payment methods and the 
availability of basic facilities and equipment in the premises in which care is provided. 
The second component of quality, that is, process quality is related to how the caregiver 
behaves towards patients, whether the patient is treated with respect and is involved 
in the treatment decision making process. Outcome measures of quality focus on 
changes in the patient’s health status, behaviour and satisfaction. These three 
dimensions of quality affect patients’ perception of quality of care and their satisfaction 
(Kajonius & Kazemi 2015:1-2). Thus the measurement of the quality of healthcare 
entails the assessment of structural variables like the setting in which the services are 
given and the characteristics of caregivers. It also entails assessing what service givers 
do to their patients and caregivers’ adherence to service standards and 
recommendations. It also entails measuring the effect of the treatment received. That 
is, what happens to patients or including changes in their perception of the quality of 
the services they received and their satisfaction with care they received (Longest 2015: 
237-244).  
 
Patient-centredness of healthcare is one of the main measures of quality. The 1998 
conference held at Salzburg, Austria, developed a self-described vision for a patient-
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centred health care system. According to this vision, there are certain characteristics 
of a patient-centred healthcare. These characteristics include that the care is easily 
accessible to the patient, the patient takes part in the care decision making process 
and the patient is well informed of the care he or she receives. It also entails that the 
care is provided through a well-coordinated care team so that the patient is given 
integrated comprehensive care. In addition, routine feedback from the patient, leads to 
practice improvement and lastly there is information that enables the patient to choose 
a caregiver that meets his or her service needs (Davis, Schoenbaum & Audet 
2005:953-4). Patient-centredness of healthcare can also be measured, based on six 
dimensions of patient-centredness of services. These dimensions advocate for the fact 
that the care must be respectful to patients’ values, preferences, and expressed needs. 
 
2.11.3. The effect of health care quality on patients’ perceived quality of care 
and their satisfaction  
The level of interaction between caregivers and patients and whether patients and their 
surrogates get the necessary information, determine the level of understanding about 
the services that the patient gets and the patients’ perceived quality of care, patient’s 
adherence to medical advice and their overall satisfaction (Bosworth, Oddone & 
Weinberger 2006:329). Quality of health communication between patients and their 
caregivers is one important measure of quality of care. Communication between the 
patients and their caregivers is an art and a technique of informing, influencing, 
motivating and engaging individuals towards achieving a desired common health 
outcome. Health communication helps to create meaning in relation to the physical, 
mental and social wellbeing of individuals and enhance their quality of life in the 
community. Caregiver-patient communication is required   in the patient’s best interest 
and towards arriving at restoring the patient’s health or relieve the patient’s suffering 
(Harrington 2015:9-10). Barriers to effective patient-caregiver communication are the 
patients’ anxiety, doctors’ burden of work, fear of physical or verbal abuse and 
unrealistic patient expectations (Fong Ha & Longnecker 2010:39). Health 
communication is fundamentally interpersonal regardless of the setting. Interpersonal 
communication refers to the interactions between two individuals who know each other 
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and share common goals (Slonim & Pollack 2005:264-7). Communication can be 
verbal or non-verbal. Thus, caregivers need to be conscious of the implications, 
rewards or risks associated with any communication that they make with their patients. 
In relation to tuberculosis treatment, low patient awareness about tuberculosis and 
unpleasant staff behaviour, determine patient satisfaction with care given. Similarly, 
long waiting hours for a service, drug related side effects and the lengthy treatment 
period for MDR-TB negatively impacts the process and outcome of MDR-TB treatment 
(Zai et al 2010:280-2). 
 
Equally important, is that patients are actively involved in the decision made regarding 
the care and services they receive. Moreover, care and services given are well 
coordinated and integrated, and also that patients get appropriate information, 
communication, and education. This ensures physical comfort and provides emotional 
support for patients (Pagano 2015:1-2). In this regard, patient-reported data is a 
reliable means of measuring the patient-centredness of the healthcare service (Slonim 
& Pollack 2005:267; Tzelepis, Sanson-Fisher, CZucca & Fradgley 2015:831).  
 
2.11.4. Factors determining patient adherence to MDR-TB treatment  
A meta-analytic study of all published empirical literature from 1948 through 1998 using 
different samples and measurement techniques, has revealed that one out of every 
four patients leaves do not adhere to treatment.   In the case of patients with MDR-TB, 
the presence of social support and a passionate behaviour of the health caregivers 
promote patients’ adherence to treatment. On the other hand, adverse drug reactions, 
poor communication with caregivers, lack of food, stigma, pill burden and economic 
constraints negatively affect patient adherence to treatment (Gebremariam, Bjune & 
Frich 2010:1-7). An individual’s action or lack of action to change his or her behaviour 
results from the evaluation of several constructs. The patient’s adherence to treatment 
is determined by interplay of multiple factors. These factors include the type of the 
disease, beliefs and expectations of patients and their perceived disease severity and 
its curability. The complexity of the treatment regimen and the socio-cultural factors 
 
91 
 
around the patient are factors determining patient adherence to treatment (Fertman & 
Allensworth 2010:346-7).  
 
2.11.5. The effect of communication between patients and their caregivers on 
patients’ adherence to treatment  
According to the information-motivation strategy model, people fail to adhere to 
treatment recommendations due to three level factors. Firstly, people may not 
understand what they are supposed to do. This is associated with poor communication 
between patients and their caregivers. Secondly, patients may not be motivated to 
carry out recommended actions. Lack of motivation may be associated with lack of 
belief in the efficacy of the treatment and the resultant negative attitude towards it. 
Thirdly, patients may not have workable strategies to accomplish treatment 
recommendations as they face practical barriers in their lives (Martin & DiMatteo 
2014:10-13). According to the theory of social learning, the majority of re-inforcers of 
human behaviour are social in nature including acceptance and smiles. The cognitive 
aspect of learning behaviour is influenced by outcome expectancies (or response 
efficacy). According to the cognitive social learning theory, the expectancy that a 
positive outcome or consequence will occur is a function of behaviour (Bosworth, 
Oddone & Weinberger 2006:13). If patients with MDR-TB feel well and if the behaviour 
of the caregivers is unfriendly, patients with MDR-TB are more likely to interrupt 
treatment (Ibrahim, Hadejia, Nguku, Dankoli, Waziri, Akhimien, Ogiri, Oyemakinde, 
Dalhatu, Nwanyanwu & Nsubuga 2014:1). Therefore, caregivers need to be polite, kind 
and responsive to the care needs of patients with MDR-TB (Dheda et al 2014:326). 
Good communication between caregivers and the patients helps to increase treatment 
adherence. Effective caregiver–patient communication can improve adherence by: 
 Increasing patient knowledge and understanding,  
 Changing patient beliefs and attitudes, and 
 Increasing patient motivation by encouraging patients to actively participate in their 
healthcare (Bosworth, Oddone & Weinberger 2006:330). 
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Tuberculosis is predominately a disease of socially vulnerable groups. This makes 
adherence to the extended course of tuberculosis treatment a considerable challenge. 
Thus, ensuring patients’ adherence to tuberculosis treatment is a major programmatic 
challenge in many settings (Kaliakbarova, Pak, Zhaksylykova, Raimova, Temerbekova 
& van den Hof 2013:62). Without effective strategies to ensure patient adherence, the 
chance for further development of drug resistance will increase among patients with 
MDR-TB. The World Health Organization recommends that non-adherence to standard 
tuberculosis treatment should be less than 5% (HerreroI et al 2015:288). 
 
2.11.6. The effect of the duration of treatment on patient adherence  
At the outset of the lengthy MDR-TB treatment period, it is difficult to predict the 
patients’ adherence to treatment. The lengthy time needed for the completion of MDR-
TB treatment exhausts patients’ financial and practical abilities. It also exhausts 
patients’ families to provide the continued support needed to complete treatment 
(Maswanganyi, Lebese, Mashau & Khoza 2014:2). Compared with patients who are 
treated for a short period of time, patients treated for a longer period are at an increased 
risk of an unfavourable treatment outcome (Ukwaja, Oshi, Alobu & Oshi DC 2016:122-
3). In the case of patients with tuberculosis who live in remote rural areas of China, the 
cost of transport to meet the scheduled facility visits imposes a high economic burden 
and affects adherence to treatment. Some patients move from one place to another 
without reporting to the treatment supporter and they end up discontinuing treatment. 
Besides, patients with tuberculosis who experience adverse effects from anti-
tuberculosis drugs cannot complete their treatment (Zhao, Wang, Tao & Xu 2013:6). 
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2.11.7. The effect of performance of the healthcare system on patients’ 
satisfaction    
Patient satisfaction is indicative of the health system’s performance.  The quality of 
healthcare given by a healthcare setting is the major determinant factor of client 
satisfaction, client retention and their adherence to medical advice.  In turn, the clients’ 
perception of the quality of healthcare is affected by multiple factors. These factors are 
related to the hospital environment and the demographic as well as socio-economic 
characteristics of clients (Brahmbhatt, Baser & Joshi 2011:27-28). Patients’ judgement 
or perception on the quality of healthcare that he or she receives determine patients’ 
satisfaction (Donabedian 1988:1746). A satisfied patient does not present with formal 
complaints and does not go into initiating malpractices. Moreover, a satisfied patient 
benefits the doctor in terms of job satisfaction, reduced stress and less burn-out (Fong 
Ha & Longnecker 2010:39). 
 
2.11.8. The effect of healthcare quality on patient satisfaction  
In the course of the management of MDR-TB, patient satisfaction with healthcare is 
among the major factors that determine the management and the clinical outcome of 
the disease (Punnakitikashem, Buavaraporn, Maluesri & Leelartapin 2012:1232; 
Menedero et al 2010:124). As it is to be expected, optimum adherence to treatment 
prevents treatment failure, relapse and development of further drug-resistance. As 
such, when good adherence to treatment contributes to better MDR-TB treatment 
outcome, poor adherence to treatment leads to the development of acquired forms of 
drug resistance like the extensively drug-resistant tuberculosis (Zai et al 2010:279; 
Dheda et al 2014:326).   
It has been noted that there is a positive relationship between the quality of healthcare 
provided and patient satisfaction. Understanding the patients’ perception of quality of 
the clinical services given and their satisfaction with the care they receive is important 
for hospital managers and doctors. It helps them to identify points of strength and 
weakness and gear the care given for the patient towards the preferences of patients. 
As such, it helps to work towards improving the quality of the services given and patient 
satisfaction overtime (Ramez 2012:132-139). 
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Patients with MDR-TB must receive ongoing counselling and support. This is because 
sub-optimal patient adherence to treatment leads to the further development of drug-
resistance and would render patients practically untreatable (Ferguson & Rhoads 
2009:607). During the lengthy and toxic treatment period, interventions that improve 
patient satisfaction are essential for patients on treatment. These include the provision 
of comprehensive psychosocial and economic support, including nutritional support.  
 
The condition of treatment set-ups and the availability of patient-centred care are other 
factors determining client satisfaction and their adherence to treatment (Caminero 
2013:202). The availability of an appropriate treatment environment such as supportive 
accommodation with access to continuous counselling and palliative care, improves 
patient satisfaction and promotes patient adherence to treatment (Cox, Hughes, Ford 
& London 2012:178).   
 
2.11.9. The effects of stigma on patients with MDR-TB on patient’s satisfaction  
The word stigma is derived from the Greek meaning “a mark or a stain”. Stigmatisation 
is a complex and dynamic process of devaluation of individuals that significantly 
discredits the individual in the eyes of others. Within particular cultures or settings, 
certain attributes are seized upon and defined by others as discreditable or unworthy. 
When stigma is acted upon, the result is discrimination that may take the form of actions 
or omissions (Stop TB Partnership 2015:12). A study conducted in Urban Zambia, 
revealed that 82% of patients with tuberculosis reported some form of stigma 
associated with tuberculosis. The study indicated that the consequences of 
stigmatisation similarly prevailed among children and adults with tuberculosis. The 
consequences of the stigmatisation included low self-esteem, insults, ridicule, 
discrimination, social exclusion and isolation, resulting in the decreased quality of 
patients’ life and social status (Cremers, de Laat, Kapata, Gerrets, Klipstein-Grobusch 
& Grobusch 2015:2). 
 
In case a control study conducted in Sudan, both cases and controls (who had 
tuberculosis) reported the presence of a mild level of tuberculosis related stigma. The 
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study revealed that a higher TB related stigma was observed among the older, 
unemployed patients and those living in rural areas. Thus, the study concluded that the 
TB related stigma impaired the quality of life of tuberculosis patients due to concerns 
about disclosure, effects on work, education, marriage and family life (Suleiman, Sahal, 
Sodemann, El Sony & Aro 2013: 390-92). The World Health Organization states that 
palliative care and issues related to stigma and discrimination are essential 
components of the comprehensive management of MDR-TB (WHO 2014:66). Patients’ 
psychosocial problems and how the community perceives and interprets tuberculosis, 
determine how the patient copes with the disease and its treatment (Caminero 
2010:47). Hence, the stigma towards patients with tuberculosis is one of the major 
factors that determine patient adherence to treatment. Therefore, on-going education 
support is needed for patients with tuberculosis and their families in order to reduce 
the effect of stigma and to make sure that patients continue treatment for the entire 
duration of treatment (Lange et al 2014:45).  
 
2.11.10. The role of psychosocial support on patient satisfaction  
The MDR-TB treatment has impacts on patients’ mental health. This impact is greater 
among patients with limited social and financial support (Khanal, Elsey, King, Baral, 
Bhatta & Newell 2017: e0167559-1). The patients’ psychological stress, including the 
perception of illness, affects patients’ adherence to treatment. On its own, the 
perception of illness and illness behavior is affected by the patients’ cultural, 
educational, ethnicity, family structure and socio-economic differences. Very often, 
patients with tuberculosis suffer from feeling ignored. Usually, patients experience a 
wide range of psychological reactions including fear, depression and anger (Munsab, 
Santanu, Ravinder, Pradeep & Ankur 2013:123-125). It has also been observed that 
patients with MDR-TB sometimes show abnormal behaviour. Such behaviour is often 
associated with alcohol or substance misuse. The misuse of substance by patients with 
MDR-TB is associated with repeated default from treatment. Such patients are 
sometimes difficult to manage in hospitals and will often escape from hospitals and 
even threaten or assault hospital staff and other patients (Gandhi, Nunn, Dheda, 
Schaaf, Zignol, Soolingen, Jensen & Bayona 2010:1838). However, the abnormal 
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behaviour of patients need not be criticized. Rather, it should entail working towards 
gradually transforming such behaviour so as to restore the individual’s function within 
his or her environment and culture. Working towards enabling patients to regain 
wellness requires the physician’s intervention in such behaviour in various ways. Such 
intervention includes not only healing the patient’s body from prevailing ailments but it 
also needs addressing the patient’s psychosocial problems to facilitate the restoration 
of the patient’s function (Fulford, Davies, Gipps, Graham, Sadler, Stanghellini & 
Thornton 2013:65).  
 
Currently, the management of MDR-TB is shifted from the predominantly hospitalized 
model to the outpatient model of care. This entails strong emotional and social support 
towards improving treatment outcome (Skrahina, Rusovich, Dara, Zhylevich & 
Hurevich 2014:79). A study conducted in East Kazakhstan region, revealed that 
patients with MDR-TB suffered from a myriad of social and psychological problems. 
These include alcoholism, unemployment, very low-income, absence of social support, 
homelessness, and lack of official documentation that prevented access to the state 
social support. A programme on psychosocial support for patients with MDR-TB, was 
aimed at improving treatment adherence for patients at high risk of treatment 
interruption. This study revealed that there were no defaulters among patients with 
MDR-TB who were covered in the psychosocial support programme. This study 
highlighted the importance and the need for psychological counselling and support for 
patients on treatment (Kaliakbarova et al 2013:60-64). Therefore, understanding 
problems that patients with MDR-TB face during treatment and the knowledge of 
patients’ perceptions, may help the national tuberculosis programme to take 
appropriate interventions to alleviate these problems. Ongoing social and 
psychological support should therefore be an essential element of the national MDR-
TB control programme to enhance patients’ adherence to treatment. Furthermore, 
psychosocial support should be available in the context of the outpatient model of 
MDR-TB treatment. Moreover, the care and services provided should be comfortable 
for and acceptable by patients with MDR-TB (Lange et al 2014:44).  
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2.11.11. The effect of service set-ups and the caring practice of caregivers on 
patient satisfaction    
 It has also been revealed that the setup of the healthcare organization and the 
performance of a health system influence the tuberculosis control. This influence lies 
more in the way the health services are organized to detect and treat tuberculosis than 
in the rate of tuberculosis case detection and treatment success (Loveday, Padayatchi, 
Wallengren, Roberts, Brust, Ngozo, Master & Voce 2014:1; Arakawa et al 2011:995).   
The physical facilities of the service setups, the equipment and appearance of the 
personnel who provide the service, influence the satisfaction of patients with MDR-TB. 
Likewise, caregivers’ ability to perform the services accurately and dependably affects 
patients’ perception of the quality of care and patient satisfaction with the care and 
services they receive. Added to this, the degree of caregivers’ willingness to attentively 
assist clients and provide prompt service determines patients’ satisfaction with care 
given. Similarly, other parameters, including caregivers’ empathy and assurance, 
(ability to convey trust and confidence) determine client satisfaction with clinical care 
(Ramez 2012:132). There is also a correlation between patients’ perception of quality 
of care that they receive at hospitals and the level of their satisfaction. Dimensions like 
reliability, responsiveness, assurance, empathy, including tangibles, play a pivotal role 
in determining patients’ perceptions of quality and their satisfaction with care given on 
MDR-TB (Kavitha 2012:157). 
 
2.12. Summary  
Guided by the aims, objectives of the study and the theoretical framework of the study, 
chapter 2 presents the literatures reviewed to explore and understand the available 
body of knowledge on treatment outcomes of patients with MDR-TB and its 
determinants. The next chapter, chapter three, presents the philosophical, 
methodological assumptions and the specific methods that guided the study. 
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Chapter 3: Research Design and Methods  
3.1. Introduction   
Research methodology is a subfield of epistemology. It is concerned with the 
procedures followed in scientific investigations (Babbie 2014:4). It relates to the 
principles and ideas on which the research procedures and strategies (methods) are 
based (Holloway & Wheeler 2010:21). In other words, research methodology is a 
detailed account of exactly what the researcher is going to do or has done. Simply, it 
tells the readers whether the results of a study are valid and reliable, and serves as the 
means researchers use to systematically solve research problems (Roush 2015:38).  
 
This chapter discusses the research methodology used in this study. It also describes 
the study design and the specific research methods or techniques used in this study. 
It provides a description of the study setting and study population. The chapter 
encompasses the procedures used for sampling and recruitment of the study 
participants. It also includes the steps used for the development of the study instrument 
and the procedures of data collection, and data management or data processing. 
Procedures used for ensuring the validity, reliability and trustworthiness of the study 
results, and ethical considerations of the study are also presented in this chapter.  
3.2. Study setting and study population 
3.2.1. Study setting  
Study setting describes the organization or community in which a research endeavour 
is conducted. It covers the characteristics of the community being studied. This 
includes the community history, its size, composition and structure. Regarding the 
organization in which a study is conducted, it encompasses the administrative structure 
of the organization, and the type of services that the organization provides (Kumar 
2011:186). In a nutshell, the research setting is the situation, or environment that 
surrounds the population or group being studied.  Simply, a study setting may be 
physical locations like organizations or schools.  It may also be historical contexts of 
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the population studied like religion, politics, economy, and the environment in which 
they live (Creswell 2012:473). 
3.2.1.1. Background of Ethiopia  
This study was conducted at two sites in the Oromia Region of Ethiopia. Ethiopia is 
located in the horn of Africa. It lies between 3 and 15 degrees, north latitude and 33 
and 48 degrees east longitude. With its total area of about 1.1 million square 
kilometres, Ethiopia borders Eritrea to the north, Djibouti to the east, Sudan to the west, 
Kenya to the south and Somalia to the south-east. Its topographical features range 
from as high as 4620 metres above sea level at Ras Dashen mount to as deep as 110 
metres below sea level in the Afar Depression. The Great East African Rift Valley 
divides the highland of Ethiopia into two (Federal Ministry of Health of Ethiopia 
2013:28). 
 
Ethiopia is governed by a federal government called the Federal Democratic Republic 
of Ethiopia (FDRE). The Federal Democratic Republic of Ethiopia is composed of nine 
regional states. These are the Afar, Amhara, Benshangul Gumuz, Harari, Gambella, 
Oromia, Somali, Southern Nations Nationalities and Peoples Region and Tigrai 
regions. In addition to the nine regional states, Ethiopia has two city administrative 
councils, which are Addis Ababa and Dire Dawa city administrations. Figure 3.1 below 
depicts the political map of Ethiopia. 
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Figure 3. 1:  Political map of Ethiopia with provincial/state boundaries (Source: World Trade 
Press. 2015. Best country reports: Political map of Ethiopia with provincial/state boundaries. 
 
3.2.1.2. The Oromia Regional State of Ethiopia 
The Oromia Region is one of the nine regional states of the Federal Democratic 
Republic of Ethiopia. This region is the biggest of all the regional states in terms of its 
total population and landmass. According to regional population projection estimates 
made by the national central statistical agency of Ethiopia, the total population of the 
Oromia Region for the year 2016 and 2017 was estimated to be 35,875,159. The region 
covers an area 359,619.8km2 stretching from the Sudan border in the West up to the 
Somali regional state of Ethiopia in the East. It borders Kenya in the South.  
Administratively, the Oromia region is sub-divided into 38 provincial and 326 district 
administrative units. The districts are further sub-divided into 7,011 ‘kebeles’ (the 
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lowest administrative unit in Ethiopia). About 6,521 (93%) of the ‘kebeles’ are rural, 
while 490 (7%) of them are urban (Oromia Region Health Bureau/ORHB/ 2015:3-4).  
 
Except the Tigrai Region, Oromia Region shares borders with all the other regional 
states of Ethiopia and the two city administrations of Ethiopia (Central Statistical 
Agency of Ethiopia 2015:1). Geographically, the Oromia Region of Ethiopia is located 
centrally and is stretched from East to West of the country. As the Oromia Region 
shares borders with the majority of the Federal States of Ethiopia, it has patient referral 
links with all its neighbouring regional states. It was for this reason that the Oromia 
Region was selected with the assumption that the results of the study would reflect the 
programmatic management of drug-resistant tuberculosis in the other regions of 
Ethiopia.      
3.2.1.3. Health service coverage of the Oromia Regional State   
The Oromia Region Health Bureau (ORHB) is responsible for providing comprehensive 
health services in the Region of Oromia. The healthcare delivery system of the Oromia 
Region of Ethiopia aligns with the national three-tier arrangement system for healthcare 
delivery to the regional populations. The first or basic level in the tier is the primary care 
level. The primary care level consists of the community health post, which is 
responsible for providing preventive public health services to a median population of 
5,000. It also encompasses a health centre, which is responsible for providing first level 
preventive and curative healthcare for an average population of 25,000. The primary 
level also consists of the primary hospital that is responsible for providing inpatient and 
ambulatory healthcare to a median population of 100,000. The second level in the tier 
consists of all general hospitals in the country. Each general hospital is responsible for 
providing curative care and services in all areas of specialties for a median population 
of one million. The third or tertiary level consists of all specialized hospitals each of 
which is designed to provide tertiary level care for a median population of five million 
(Federal Ministry of Health of Ethiopia 2010:74-5).  
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There are 66 public hospitals, 1,363 government owned health centres and 7,011 
health posts in the Oromia Region. Furthermore, there are 2 regional reference 
laboratories and 7 blood banks to support the quality of diagnosis and clinical care 
provided by the regional healthcare facilities. There are also private health facilities in 
the Oromia Region. The private health facilities provide tuberculosis case detection 
and treatment services in partnership with the government health facilities. Simply, the 
private health facilities contribute to the regional tuberculosis case detection and 
treatment.  
 
The regional health care network model implemented in the Oromia Region, notes that 
health care professionals at health centres are responsible for supporting community 
health posts within their respective catchment populations. The urban health extension 
package is supported by the respective and health offices in the towns. The respective 
health centres and health offices in the towns support the urban health extension 
package. The primary hospitals are required to support health centres in their 
catchment areas. The primary hospitals are supported by the general hospitals which 
in turn are supported by specialized hospitals. In 2014, the health service coverage of 
the Oromia Region was 97% (Oromia Region Health Bureau (ORHB) 2015:2).  
3.3. Study sites   
This study was conducted between the 10th of November 2016 and 7th of February 
2017 at two referral provincial hospitals located in the Oromia Region of Ethiopia. The 
two referral hospitals were Adama Hospital Medical College and Nekemte Referral 
Hospital. Adama hospital medical college is located 98 Km to the east of Addis Ababa 
while Nekemte Referral hospital is located 328 Km to the west of the capital, Addis 
Ababa.  The two hospitals included in this study were selected based on convenience 
(Etikan, Musa & Alkassim 2016:4; Crano et al 2015:234; Huck 2012:101). The rationale 
for selecting the two hospitals was that, given the time and resources at hand, it was 
not practical to access all hospitals in Ethiopia that provide care to people with MDR-
TB.  
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Adama Hospital Medical College and Nekemte Referral Hospital were the two hospitals 
in the Oromia Region where programmatic management of drug-resistant tuberculosis 
was first initiated in 2012 in Ethiopia. As such, these hospitals were selected with the 
assumption that they have adequate experience and data on programmatic 
management of drug-resistant tuberculosis in the Oromia region.  The selected 
hospitals are located in Adama and Nekemte towns. They therefore deserve to be 
described briefly.  
 
  
Figure 3. 2: Map of the Oromia Region in Ethiopia (Source: 
https://www.google.com/search?q=map+of+the+Oromia+region+of+Ethiopia (accessed 14 
November 2017). 
  
s  
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3.3.1. Adama town  
3.3.1.1. Topography, population characteristics and political administration of Adama 
town 
The Adama town was established in 1916. Its establishment aligns with the introduction 
of the Ethio-Djibouti railway at the time. The town of Adama is located at the distance 
of 100 kilometres to the South-eastern part of the capital, Addis Ababa. It is on the road 
that connects the capital with the seaport of Djibouti.  Adama is a busy transport centre 
that connects different regional states to the capital. Administratively, the town of 
Adama is divided into 8 kebeles (the lowest administrative unit in Ethiopia). The town 
is located in the Great Rift Valley Region of East Africa (Adama town Health office. 
2016:1-2).   
 
Adama is located 8°32′ N 39°16′ E / 8.54°N 39.27°E / 8.54; 39.27 and  is situated at an 
elevation of 1712 metres above sea level. The total landmass of Adama town is 
estimated at 13,000 hectars (Adama Town Health Office 2016:2). The total population 
of Adama town for the year 2017, was estimated at 365, 828 (male=181,011 (49.5%) 
and female=184,818 (50.5%) (CSA-E 2017:1). 
 
3.3.1.2. Health service coverage of Adama town  
Currently, Adama town has nine government health centres, 1 government and 5 
private hospitals, 71 private clinics and 104 pharmacies. As such, potential health 
service coverage for the population of Adama town for the year 2017 was 100% 
(Adama town Health office 2016:2). 
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3.3.2. Nekemte Town   
3.3.2.1. Topography, population characteristics and political administration of 
Nekemte Town 
Nekemte (Oromo: Naqamtee, means betrothed) is a market town and one of the 
administrative towns in the western part of the Oromia Region of Ethiopia. Nekemte 
town is located in the East Wollega Zone of the Oromia Region. The town has a latitude 
and longitude of 9°5′N 36°33′E / 9.083°N and 36.550°E / 9.083N; 36.550 respectively 
and an elevation of 2,088 metres. Nekemte town is one of the historical towns of the 
Oromia Region. The town has been the capital of the former Wollega province, and is 
home to the museum of Wollega Oromo culture. Moreover, the Nekemte town is the 
burial place of Onesimos Nesib, a famous Oromo who translated the Bible to Oromo 
Language for the first time in collaboration with Aster Ganno. A central government 
customs office was officially opened in Nekemte in 1905. The town is a host city to the 
newly built Wollega University as of 2017 (Nekemte Town Health Office 2017:1-2).  
The total population of Nekemte town for the year 2017, was estimated at 118,523 with 
the male proportion equals to 60,484 (51%) and the female proportion equal to 58,040 
(49%) (CSA-E 2017:1). 
 
3.3.2.2. Health service coverage of Nekemte town 
The Nekemte town has two government owned hospitas (one was opened in 1932), 
three health centres and many privately owned clinics and speciality centres. The 
health service coverage for the population of Nekemte town for the year 2017 was 
100% (Nekemte Town Health office. 2017:2). 
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3.4. The research design 
This section of chapter three describes the research design adopted for answering the 
research question of this study. It also covers the rationale for choosing the study’s 
research design.  
3.4.1. The research design used in this study  
A research design is a master plan that specifies the methods and procedures that can 
be used for collecting and analysing information or data needed to solve research 
problems (Pandey & Pandey 2015:18). Research design denotes both a process and 
a product. Given that there is no one single blueprint for planning research study, 
research designs are governed by the notion of fitness for purpose. This means that 
the purpose of a research study is what determines the methodology and the research 
design that researchers adopt. For a mixed methods design study, like this one, a 
research design allows the measurement of variables of interest in a particular way 
(Groat & Wang 2013:24). 
 
This study employed a concurrent mixed methods design (Blaikie 2010:200). This 
design has two components, quantitative and qualitative (Hesse-Biber & Johnson 
2015:21-4). See figure 1.3, a diagrammatical representation of the concurrent mixed 
methods design used in this study. 
The quantitative component of this study is more dominant than the qualitative 
component. In this type of design, both quantitative and qualitative data are collected 
and analysed at the same time (Teddlie & Tashakkori 2006:20-21). Analysis of the 
quantitative and qualitative data is conducted separately. Then there is mixing of the 
data generated from the two methods, integrating the information gained from one 
method with that obtained from the other method. This integration of information is 
typically accomplished in the discussion and recommendation section of this study 
(Creswell 2009:2014:15). Each of the components of the design (quantitative and 
qualitative components) addresses specific segments of the main or primary research 
question of the study. Quantitative component was used to assess the treatment 
outcomes of patients with MDR-TB and its determinants for patients with MDR-TB 
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enrolled to the treatment with second-line anti-tuberculosis drugs. However, the 
quantitative data cannot provide detailed information about the context in which 
individuals provide information (e.g., the setting). As such, the qualitative component 
explored the contextual and naturalistic account of patients with MDR-TB and their 
caregivers regarding factors determining the MDR-TB treatment process, patients’ 
perceived quality of care and patient satisfaction and adherence to the treatment of 
MDR-TB.  
 
3.4.2. Rationale for choosing the concurrent mixed methods design in this 
study  
The reason for employing a concurrent mixed methods design in this study, primarily 
emanated from the difficulty the researcher experienced in answering the research 
question investigated. The research question of this study required the use of a 
combination of qualitative and quantitative methods.  The combined use of quantitative 
and qualitative methods helped to examine the different facets of the same 
phenomenon investigated, which in this case, relates to treatment outcomes of patients 
with MDR-TB (Edmonds & Kennedy 2017:181). 
In other words, the quantitative and qualitative components of the research design 
enabled the researcher to investigate the research question from different 
perspectives. In this way, the design elucidates a detailed understanding of the 
research problem investigated. In other words, the qualitative and quantitative methods 
provided an enriched understanding of the factors determining the process and 
outcome of the treatment of patients with MDR-TB, including the patients’ perceived 
quality of care and patient satisfaction with care given. Simply, the use of qualitative 
methods in this study helped to unfold the lived experience of patients with MDR-TB 
and their caregivers regarding the implementation of the MDR-TB programme. This 
indicates that the qualitative methods offered a contextualized understanding and 
explanation of the quantitative results of the MDR-TB programme (Caracelli 2006:86). 
Using either method alone (quantitative or qualitative) could not have fully addressed 
the research problem.  Essentially, use of the mixed methods (quantitative and 
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qualitative methods) illuminated the associational processes and increased the 
interpretability of the results of this study. 
 
The quantitative results were interpreted in conjunction with the qualitative results 
(meanings given by patients with MDR-TB and their caregivers). Thus, the combined 
use of quantitative and qualitative methods provided an increased understanding of 
the layers of meanings of the research problem investigated that could otherwise 
remain hidden (Hesse-Biber & Johnson 2015:88). The study investigated the treatment 
outcomes of patients with MDR-TB and the determinants (objectives 1 & 2 of the 
study).  
The assessment of the treatment outcomes of patients with MDR-TB is the first 
objective of the study. The assessment of factors determining treatment outcomes of 
patients with MDR-TB is the second objective of the study. These two objectives were 
addressed using quantitative methods. The third objective of the study, which relates 
to patients’ perceived quality of care and patients’ satisfaction with care given on MDR-
TB, was addressed using qualitative methods. In this study, the purpose of qualitative 
inquiry was to uncover meanings by eliciting memories of patients with MDR-TB who 
lived through the experience of the lengthy treatment for multi-drug resistant 
tuberculosis using second-line anti-tuberculosis drugs (Creswell 2009:114). The 
qualitative measure was used to supplement the quantitative result by uncovering 
meanings given by patients with MDR-TB and their caregivers (health care workers) 
regarding factors determining the MDR-TB treatment process and its outcome, the 
patients’ level of satisfaction and their adherence to treatment (Stake 2010:31). 
In summary, the quantitative and qualitative forms of evidence generated through 
employing the mixed methods design in this study, allowed stronger inferences to be 
made through complementarity than each method used alone (Gunasekare 2015:362).  
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3.4.3. The common advantages of the concurrent mixed methods design 
Edmonds and Kennedy (2017:181-4) and Andrew and Halcom (2009:32) describe 
generic circumstances for using mixed methods in research studies. They note that 
mixed methods can be used:  
1. to better understand a research problem by converging numeric trends from 
quantitative data and specific details from qualitative data.  
2. when the research purpose and research questions require a combination of 
qualitative and quantitative methods. 
3. to identify variables or constructs that may be measured subsequently through 
the use of existing instruments or the development of new ones;  
4. to obtain statistical, quantitative data and results from a sample of a population 
and use them to identify individuals who may expand on the results through 
qualitative data and results; 
5. to convey the needs of individuals or groups of individuals who are marginalized 
or under-represented.   
6. when the research questions can be formulated to either provide testable results 
(quantitative) or to describe and characterize a phenomenon of  interest 
(qualitative). 
7. When there is insufficient information available in the literature and there is a 
need for exploratory research. 
Some of the above reasons, particularly 1 and 2 are consistent with reasons for using 
a concurrent mixed methods design in this study. The use of this design was guided 
by a specific research paradigm, which is discussed below in detail. 
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3.5. The research paradigm- its assumptions  
Researchers are required to commence research with assumptions that are aligned 
with research methodology, methods of data collection and analysis (Creswell, 2014). 
The researchers’ assumptions that guide the conduct of a research study are 
sometimes referred to as paradigms (Morgan 2007:49; Wagner, Kawulich & Garner, 
2012). A paradigm is a set of beliefs that guide researchers through the research 
process (Morgan 2014: 1046-7). It is a system of presuppositions within a research 
approach and it forms the framework within which solutions are sought for a research 
problem (Almekinders, Beukema &Tromp 2009:253). A paradigm is informed by 
philosophical assumptions about the nature of the truth or reality about a phenomenon 
(ontology), the researchers’ position or stance in understanding the truth or reality of 
that phenomenon (epistemology), the values that researchers may attach or react to in 
the entire research process and the phenomenon under study (axiology) (Creswell 
2014:26). There are commonly agreed worldviews. These are the positivism, post-
positivism, constructivism, transformative and pragmatism worldviews (Saunders, 
Lewis & Thornhill 2007:102). These world views are the ‘legitimated ways of knowing’ 
(Bridges 2017:350). Of these worldviews, the pragmatism worldview is compatible with 
mixed methods research designs (Hall 2013:3-4). The ontology, axiology and 
epistemology that a research endeavour adopts are framed in terms of the choice 
made among the available research philosophies. As a study using a mixed methods 
design, this study adopts the position of the pragmatist philosophy or pragmatist 
paradigm.   
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3.5.1. The paradigmatic assumptions of pragmatic paradigm 
The pragmatic paradigm assumes that reality is that which works and is practical (Ihuah 
& Eaton 2013:938). Pragmatic paradigm is considered as a bridge between qualitative 
and quantitative paradigms (Madondo 2015:7-10). According to the pragmatic 
paradigm, the most important determinant of the research philosophy adopted is the 
research question (Saunders, Lewis & Thornhill 2009:128).  
 
Pragmatists focus on the value of knowledge and its ability to be integrated with a 
person’s practical everyday understandings and choices. Philosophically, the 
pragmatists’ position is against the position held by positivists who argue that reality is 
singular and objective (Neuman 2014:109). Pragmatism, as an alternative paradigm, 
accepts that philosophically, there are singular and multiple realities that are open to 
empirical inquiry. It orients itself towards solving practical problems in the real world. 
According to pragmatism, the measurable real world has different layers, some 
objective, some subjective and some are a combination of the two. Both objective as 
well as subjective inquiry attempt to produce knowledge that best represents reality. 
Thus, pragmatists are pluralists. They call for convergence between quantitative and 
qualitative methods. Moreover, pragmatists hold a view that research attempts should 
be useful or aim at its utility to solve real world problems (Feilzer 2010:8-9). As such, 
pragmatists argue that the most important determinant of the epistemology, ontology 
and axiology a researcher adopts is the research question under investigation. As it 
happens, one approach may be more appropriate than the other for answering a 
particular research question (Andrew & Halcomb 2009:21). 
 
In the pragmatic philosophical view, the uses of both qualitative and quantitative 
methods to resolve a real-life world challenge are admired (Ihuah & Eaton 2013:937). 
Therefore, according to the pragmatist’s view, it is perfectly possible to work with 
variations in one’s epistemology, ontology and axiology. The use of mixed methods, 
both qualitative and quantitative, is not only possible but it is also highly appropriate to 
use within one single study (Saunders, Lewis & Thornhill 2009:109). Therefore, 
pragmatism is a philosophical partner for mixed methods design and is seen as 
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instrumental in achieving the research aims in the mixed methods design. According 
to pragmatism, the practical consequence of the research action is considered to be 
important and the research should be meaningful. Hence, clinical and applied research 
often benefit from the practical and instrumental approach of pragmatism (Johnson & 
Onwuegbuzie 2004:16). Pragmatism is intuitively appealing. It enables the researcher 
to study what is of practical value and uses the results in ways that can bring about 
positive consequences (Saunders, Lewis & Thornhill 2009:109). 
 
Acknowledging this, a pragmatic paradigm is a guiding paradigm in social science 
research methods. It functions both as the basis for supporting work that combines 
qualitative and quantitative methods and as a way to redirect our attention to 
methodological rather than metaphysical concerns (Morgan 2007:48). This study 
adopts the pragmatic paradigm, as its assumptions are congruent with the study’s 
methodology, and methods of data collection and analysis. The world reality 
investigated in this study has quantitative and qualitative layers. Therefore, some of 
the study questions need quantitative (objective) answers while others need qualitative 
(subjective) answers. The two set of answers serve a complementary function.   
3.5.2. Ontological assumptions   
Ontology is the researcher’s view of the nature of reality or being (Porta & Keating 
2008:353). It is an area of philosophy that deals with the nature of being, or what exists 
(Polit & Beck 2003:14). It asks what really is and what the fundamental categories of 
reality are (Neuman 2014:94). As researchers first start by asking philosophical 
questions about the reality they want to study, ontology is the starting point of all 
research (Sefotho 2015:30). Ontological assumptions give rise to epistemological 
assumptions, which in turn give rise to methodological considerations. It follows that 
methodological assumptions give rise to issues of instrumentation and data collection 
(Cohen, Manion & Morrison 2007:13). 
 
Ontological assumptions of reality ask questions like whether reality is external to 
individuals or the product of individual consciousness (Polit & Beck 2004:14). The 
ontological assumptions of the qualitative research are that reality is constructed by 
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the researcher (constructivism). Whereas the ontological assumptions of the 
quantitative research view reality as objective and independent of the researcher 
(objectivism) (Ihuah & Eaton 2013:936) 
 
Ontologically, pragmatists assume that reality is what works and is practical (Andrew 
& Halcomb 2009:186). It assumes that reality is external and multiple. The implication 
of ontological pragmatism for public health practice is that anything that works can be 
used to present the views of the researched (Madondo 2015:7). Pragmatic ontology 
assumes that the value of a research is not only based on whether it discovers the 
truth, but also on the demonstration that the results work with respect to the problem 
that is being studied (Mertens 2015:79). According to the pragmatic ontology, reality is 
both objective (exists independent of the actor) and subjective (that is, understood 
through the meanings that individuals attach to the social phenomena in which they 
live). Thus, a worldview that best enables researchers to answer the particular research 
question should be chosen (Saunders, Lewis & Thornhill 2009:109-10).   
3.5.2.1. Ontological assumptions of this study  
In this study, the research question under investigation has both objective (reality given 
out there in the world), and subjective (reality created by individual’s own mind). 
Ontologically, the researcher’s view is that social reality is one and it can be accessed 
using different methods, which work in conjunction with each other (Johnson, 
Onwuegbuzie & Turner 2007:120). In this study, the researcher’s view is that the 
research question under investigation has different layers. These layers are the result 
of both the physical natural world as driven by the real natural causes (objective) and 
the influence of human experience and interpretation, which is multiple, subjective and 
mentally constructed by individuals (Ӧstlund, Kidd, Wengstrӧm & Rowa-Dewar 
2011;370). As such, both quantitative (objective) and qualitative (subjective) data were 
collected to get full insight into the factors that determine treatment outcomes of 
patients treated for MDR-TB, including patients’ perceived quality of care and patients’ 
satisfaction with care given for MDR-TB. Quantitative data on patients’ socio-
demographic and clinical characteristics were collected using a structured 
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questionnaire. Qualitative (narrative) data were collected using a semi-structured 
interview guide.  
 
3.5.3. The axiological assumptions  
Axiology relates to people’s values, moral principles and how these may influence 
behaviours and the conduct of a research (Harrington 2015:16). In practice, our values 
are the guiding reasons for all our actions. It is a way to consider values along with the 
issues of research ontology, epistemology, and methodology (Creamer 2018:43-48; 
Morgan 2007:58).  
The pragmatic axiological, assumption argues that knowledge is gained in pursuit of 
its desired ends (Saunders, Lewis & Thornhill 2009:119). Therefore, researchers are 
concerned with issues that are good for research (Madondo 2015:7). Pragmatic 
axiology assumes that values play a vital role in interpreting research results using both 
subjective and objective reasoning (Ihuah & Eaton 2013:937). The axiological 
assumption of pragmatism, aligns with the utilitarian theory of ethics. It holds that the 
value of something is a function of its consequences. It describes the ethical stance of 
pragmatism as gaining knowledge in pursuit of its desired ends. This means that rather 
than doing a research for the sake of research interest, pragmatists see the value of 
the research as how it is used and the results of that use (Mertens 2015:79). 
Axiologically, pragmatism is concerned with any value that works and discusses values 
that work (Madondo 2015:7-9). As such, axiology refers to the values that researchers 
may attach to the entire research process (Marcum 2015:215). It is the role that the 
researcher’s own value may play in the research process. This is of great importance 
if the researcher wishes that his or her research results are credible. In a nutshell, 
axiology is about the researcher’s own personal values in relation to the topic studied.  
Thus, the axiological assumption of the pragmatic paradigm is that values play a large 
role in pursuing a research and in interpreting the results of a research (Saunders, 
Lewis & Thornhill 2009:116-19). 
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3.5.3.1. Axiological assumptions of this study 
When registered for a doctoral programme at the University of South Africa, the 
researcher is bound by the ethical principles of beneficence regarding the topic to be 
researched. That is, what benefits would patients with MDR-TB gain from being 
researched (Mertens 2015:77). This principle was guided by the researcher’s 
(inquirer’s) own personal experience with the programme of the management of MDR-
TB in the Oromia Region of Ethiopia. This experience includes that there is lack of 
evidence on the factors determining the management of drug-resistant tuberculosis in 
the Oromia Region of Ethiopia. The lack of evidence has motivated the investigator to 
play a catalytic role in generating evidence that can trigger evidence based decision 
making for the management of MDR-TB. This reason guided the decisions made by 
the researcher at all levels of the research process.  The researcher had the experience 
that individuals affected by MDR-TB face social and economic problems. The 
experience of and the combination of the disease and economic constraint is a difficult 
place to be in for patients with MDR-TB. For patients treated for MDR-TB, this is an 
unrecognized problem. The focus is on the biomedical response to the problem of 
MDR-TB following the international approach to the management of drug-resistant 
tuberculosis.  This results in complaints and sometimes interruption of treatment by 
patients with MDR-TB. This has been a striking experience for the researcher. 
 
As per the researcher’s own experience, no one knows whether patients with MDR-TB 
are comfortable with the current approach to the management of MDR-TB. On the 
other hand, the management of patients with drug-resistant tuberculosis is a recent 
undertaking in the Oromia Region of Ethiopia. Most of the treatment outcomes of 
patients with MDR-TB published so far in Ethiopia, are based on those patients treated 
at the best centres that are funded by non-governmental organizations in collaboration 
with the Ministry of Health of Ethiopia (Meressa et al 2015:1181).   
 
In Ethiopia, the MDR-TB programme is shifted from the primarily hospitalized in-patient 
care model to the ambulatory model of care. It was believed that, as the ambulatory 
model of care is community based, it allows the decentralization of the services given 
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for MDR-TB and thus improves service accessibility to the community (Federal Ministry 
of Health of Ethiopia 2014:10).  However, there is no evidence regarding the treatment 
outcomes of patients with MDR-TB treated in the predominantly outpatient model of 
care. Evidence is also lacking on the perception and experience of patients with MDR-
TB regarding the current approach to the management of drug-resistant tuberculosis. 
The researcher believes that the lack of evidence in these areas has curtailed evidence 
based decisions to institute appropriate intervention measures. As such, the real-life 
experience of the researcher and lack of evidence at programme level has encouraged 
the researcher to be of service to the community. For the researcher, that commitment 
became a reality by uncovering the challenges and factors that affect the programmatic 
management of drug-resistant tuberculosis in the Oromia Region of Ethiopia. As such, 
the investigator hopes that by facilitating evidence informed decision making, the result 
of this study will advance the benefits of patients infected and affected by drug-resistant 
tuberculosis in the Oromia Region of Ethiopia (Greene 2006:93). 
3.5.4. The epistemological assumptions  
Epistemology is about “how we know what we know” (Andrew & Halcomb 2009:121). 
It is about determining the relationship between the knower (researcher) and what is 
known (Greene 2006:93).  Epistemology is concerned with the nature and forms of 
knowledge and how it can be acquired and communicated to others (Cohen, Manion 
& Morrison 2007:7). There is a relationship between ontology and epistemology. 
Ontology is about the nature of the truth out there, and epistemology connects to 
ontology by asking the question about the possibility of knowledge generation 
regarding the truth in the form of ‘objective’ or ‘subjective’ knowledge (Morgan 
2007:57). Epistemologically, pragmatism asks the question of the type of relationship 
between the researcher and the researched. It assumes that there may be distance or 
no distance between the researcher and the researched (Madondo 2015:7-9). For a 
researcher engaged in a particular study, it is more appropriate to think of the 
philosophy of ‘a distance’ and ‘no distance’ when depicting the relationship between 
the researcher and the researched as existing on a continuum rather than occupying 
opposite positions of the continuum. At some points of the continuum, the knower and 
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the known must be interactive, while at other points, one may more easily stand apart 
from what one is studying (Saunders, Lewis & Thornhill 2009:109). 
 
Thus, the epistemological assumptions of pragmatism are that either objective or 
subjective meanings or both can provide facts to a research question. It focuses on the 
practical application to issues by merging views to help interpret data (Ihuah & Eaton 
2013:938). Therefore, in pragmatic epistemology, the researcher is free to develop 
whatever type of relationships with participants that are appropriate for the matter 
under investigation. The nature of the relationship between the researcher and the 
participants is judged in terms of its ability to get the results of the study to be used by 
the intended stakeholders (Mertens 2015:79). Thus, either or both observable 
phenomena and subjective meanings can provide acceptable knowledge dependent 
upon the research question. Pragmatic epistemology focuses on practically applied 
research. It assumes that integrating different perspectives help to better interpret the 
research data (Saunders, Lewis & Thornhill 2009:119).  
3.5.4.1. The epistemological assumptions of this study  
In this study, the reality under investigation has both subjective and objective 
components.  (Johnson, Onwuegbuzie & Turner 2007:120). In relation to the objective 
component, the study made careful observations and acquired empirical evidence on 
the factors that might determine the treatment outcomes of patients with MDR-TB and 
its determinants. In this case, there was minimum space for subjectivity and the 
researcher was independent of the phenomenon investigated. As such, the plausible 
relationship between the independent and the dependent variables of interest stated in 
the hypothesis of the study was tested deductively. On the other hand, factors that 
might determine patients’ perceived quality of care and patient satisfaction with care 
given for MDR-TB were generated through the detailed description of the viewpoints, 
experiences and interpretations of patients with MDR-TB and their caregivers. Here, 
the researcher was always part of the discovery process. The researcher inductively 
observed, interpreted, and reflected on what the patients and caregivers said about the 
programmatic management of drug-resistant tuberculosis. The researcher also 
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simultaneously reflected on his own personal experiences and interpretations 
regarding the same.  
 
In this study, the quantitative and qualitative data were used to answer related aspects 
of the same research question. To respond to specific objectives (1 & 2) of the study, 
the researcher collected quantitative data on treatment outcomes of patients with MDR-
TB and its determinants. Epistemologically, this quantitative data generated objective 
rather than subjective knowledge. Thus, quantitative (objective data) were collected 
using a structured questionnaire. Quantitative data were collected on the patients’ 
socio-demographic and clinical characteristics. More quantitative data were collected 
on patients’ adverse drug-reactions from second-line anti-tuberculosis drugs. For the 
specific objective 3 of this research study, the researcher collected qualitative data on 
patients’ level of perceived quality of care and patients’ satisfaction with care given for 
MDR-TB. Epistemologically, these data generated subjective than objective knowledge 
of the subject studied (Morgan 2007:57). This manner of generating narrative data 
enabled the researcher to come closer to the researched (participants of the study). 
Narrative data were collected using interviews with the help of an interview guide. 
 
3.5.5. Methodological assumptions 
Epistemologically, pragmatism assumes that an investigator is free to develop a 
relationship with a participant that is appropriate for the matter under investigation. This 
relationship is judged in terms of its ability to enable the researcher to achieve the aims 
and objectives desired in a study (Mertens 2015:79-80).  In this way, the underlying 
methodological assumption of pragmatism is that the research method should match 
the purpose of the research (Mertens 2015:79). It assumes that any methodology 
(quantitative or qualitative) can be used provided it brings about valid and reliable 
results. Thus, a research can be conducted deductively or inductively or both through 
the use of both quantitative and qualitative data collection methods (Madondo 2015:7-
9). In other words, pragmatic methodology advocates for choosing a combination or 
mixture of methods and procedures that works best for answering the research 
question under investigation. It however stresses that the research methods used must 
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match the specific research questions and the purpose of the study (Creswell 2009:28-
29). This suggests that one of the primary aims of methodology pragmatism is to 
interrogate a particular question, theory, or phenomenon with the most appropriate 
research methods (Feilzer 2010:13).  Methodology pragmatism stresses on the use of 
a pluralistic approach to study a research problem. In this way, pragmatism is a 
philosophical basis for mixed methods research whereby the inquirers draw liberally 
from both quantitative and qualitative assumptions (Creswell 2009:10).   
3.5.5.1. Methodological assumptions of this study 
The study used a pragmatic methodological approach. This approach enabled the best 
use of the study results to enhance the management of patients with MDR-TB. 
The study combined both deductive and inductive approaches to test the different 
segments of the research hypotheses. The researcher used the deductive approach to 
test hypotheses regarding the treatment outcomes of patients with MDR-TB and its 
determinants. It used empirical observations on purposively selected patients with 
MDR-TB to generate empirical evidence on treatment outcomes of patients with MDR-
TB and its determinants.  Hypotheses were set regarding the plausible relationship 
between the independent and dependent variables included in the study. Variables 
were operationalized, based on international standards and the available literature. 
Data were collected by administering a structured questionnaire to purposively 
selected patients with MDR-TB.   
 
The study also used the views, the perspectives and the interpretations of patients with 
MDR-TB to explore factors determining patients’ perceived quality of care and patient 
satisfaction with care given for MDR-TB. The inductive (subjective and contextual) 
approach was used to understand the meanings that patients with MDR-TB attributed 
to their behaviour and to the external world surrounding the treatment given for MDR-
TB (Porta & Keating 2008:26). The experience and practices of caregivers for MDR-
TB were also used to explore and understand the functionality of the programmatic 
management of MDR-TB at the study sites. Qualitative data were collected by 
interviewing patients with MDR-TB and their caregivers. The feelings, and the 
experiences of the patients with MDR-TB, patients’ perceived quality of care and their 
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satisfaction included how patients coped with the problem of MDR-TB and was 
explored inductively. In the same, the experience and practice of caregivers for MDR-
TB were explored. Specifically, the study:     
 tested quantitative hypothesis by measuring the relationship between the 
quantitative independent and the dependent variables included in the study. It tested 
the relationship between MDR-TB treatment outcome and the socio-demographic 
and clinical characteristics of patients with MDR-TB. These hypotheses were tested 
deductively by collecting quantitative data through the administration of a structured 
questionnaire. Data was collected from purposively selected patients with MDR-TB 
enrolled to treatment for MDR-TB at the two selected hospitals. 
 For the deductive approach, research hypotheses were formulated. The 
hypotheses were generated from the review of the relevant literature on the 
factors determining the treatment outcomes of patients with MDR-TB. Moreover, 
the researcher’s previous experience on the management of patients with MDR-
TB and the desire to contribute to the management of patients with MDR-TB in 
Ethiopia, were sources for the hypotheses generated for  testing deductively 
(Lancaster 2005:23-5).  
 
 
 
 
 
 
 
 
 
 
 
Hypotheses formulation 
Operationalization, i.e., translation of the abstract concepts into 
measurable indicators that enable observations to be made 
 
Testing of the hypotheses through observation of the empirical world 
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Figure 3. 3.  The process of deductively testing the quantitative objectives of the study 
 
 For the qualitative research questions, the study used the interview approach to 
understand the meanings and interpretations that patients with MDR-TB and their 
caregivers attach to the social and environmental factors surrounding the care given 
for MDR-TB (Parvaiz, Mufti & Wahab 2016:72). As such, it explores and describes 
the relationship among patients’ social, financial situations, available patient support 
schemes, the condition of the service set-ups and level of patients’ perceived quality 
of care and patients’ satisfaction with care given for MDR-TB. The second part of 
the research question was tested inductively by collecting qualitative data generated 
through interviewing patients with MDR-TB and their caregivers.    
3.6. Research methods 
3.6.1. Introduction  
Research method refers to the structure of the sequences of actions followed in a 
research process. It covers the choices made regarding what is to be done and the 
order in which it is done (Singh 2006:99). In this research endeavour, there were 
certain practical phases. Polit and Beck (2003:47-58) outlines five basic phases in 
pursuing a given research process. These phases include: 1) the conceptual phase 2) 
the design phase 3) the empirical phase 4) the analytical phase and 5) the 
dissemination phase. These phases were followed in this study and each one is briefly 
described as follows: 
 
3.6.1.1. The conceptual phase  
The selection of the research topic of this study emanated from the researcher’s 
passionate interest to investigate factors that might influence MDR-TB. Such interest 
was rooted in the researcher’s professional experience of the clinical and programmatic 
challenges associated with the management of MDR-TB. Moreover, the researcher 
learnt that there was no evidence on the determinants of treatment outcomes of 
patients with MDR-TB. There was also no evidence regarding patients’ perceived 
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quality of treatment for MDR-TB.  These observations were the root of the researcher’s 
inspiration to conduct a study on MDR-TB. As a result, the research question of this 
study was informed by the researcher’s real-life experience on MDR-TB, which is a 
priority subject in the Oromia Region of Ethiopia.  
  
Then a literature review was conducted to learn about the status of the contemporary 
knowledge of the global approach to the management of MDR-TB. The rationale was 
to identify gaps in knowledge in relation to the management of MDR-TB.  The literature 
revealed that the research question developed and its related research problems were 
complex, and they needed quantitative and qualitative approaches to fully investigate 
them. The literature also led to the identification of the conceptual framework to guide 
the study. The research hypotheses of the study were formulated to investigate the 
associations between the independent and dependent variables of interest.  
3.6.1.2. The design phase  
This study has a main research question and a number of sub-research questions. 
While most of the sub-questions could only be investigated using qualitative methods, 
some could be investigated using quantitative methods. Given this, a decision was 
made regarding the type of research design that could enable the researcher to fully 
investigate the research questions of the study. A design that was considered 
appropriate for achieving this was concurrent mixed methods with quantitative 
dominance.    
 
3.6.1.3. The empirical phase   
At the empirical phase of this study, decisions were made regarding the procedures of 
data collection, the study instrument to be used and procedures of its administration. It 
was made clear that the quantitative component of study used a structured 
questionnaire to collect patient’s clinical data. The questionnaire was developed using 
the extant literature, and opinions of the supervisor and experts in MDR-TB. The 
experts conducted a serial review of the questionnaire before it was subjected to a 
preliminary investigation.  
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The questionnaire was tested in the field and was further refined based on the 
outcomes before its use on the main study participants. Trained data collectors 
administered the final questionnaire. The questionnaires administered to participants 
were given unique codes to ensure anonymity. The qualitative data were collected 
using in-depth interviews with patients with MDR-TB and their clinical caregivers. The 
in-depth interviews were conducted by the principal investigator but he was assisted 
by a trained data collector assistant (note taker). 
 
3.6.1.4. The analytical phase   
At this phase, the decisions regarding the organization of the data, data analysis, 
interpretation and writing of the results of the study, were taken for both the quantitative 
and qualitative data gathered in this study. Using the statistical package for social 
sciences (SPSS) version 23, a template was developed for the quantitative data entry 
and analysis.  The qualitative data and qualitative data were analysed concurrently but 
separately. On completion of the analysis, both quantitative and qualitative data sets 
were integrated at two levels: result section, and discussion section of the study.  
   
3.6.1.5. The dissemination phase   
This phase of the research process is concerned with the communication of the end 
results of a research to an appropriate research community for translation and use by 
the intended beneficiaries. The researcher of this study planned to disseminate the full 
reports of the study to the global research community through the University of South 
Africa’s (UNISA) electronic repository. Moreover, the result of this study will be 
disseminated to individual health professionals globally by means of journals and other 
electronic media.     
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3.7 The study population  
3.7.1. The source population    
The source population is the universe of interest that consists of all the people or other 
entities that researchers would like to study if they had infinite resources (Crano, 
Brewer & Lac 2015:220). In other words, a source population is the entire population 
of people or things to which the results of a study are meant to apply (Field 2009:34). 
The population may be persons, things, or measurements for which we have interest 
at a particular point in time. Our sphere of interest determines a population. Population 
can be finite (consists of fixed number of values) or infinite (consists of an endless 
succession of values) (Khanal 2016:7). Researchers would like to generalize their 
results about the population of interest (Boslaugh 2013:54-5). 
3.7.2. The source population for this study  
The source population for this study was all patients with MDR-TB, those enrolled to 
treatment with second-line anti-tuberculosis drugs at all treatment initiating centres in 
the Oromia Region of Ethiopia.  
 
3.7.3. Study population  
3.7.3.1. Definition of the study population  
Usually we can never have access to the entire source population for inclusion in a 
study (Field 2009:34). Thus, the information required to find answers to the study’s 
questions is obtained from the study population. The study population is defined as 
that of the aggregate of elements to which the researcher can gain access and from 
which the research sample is actually selected (Babbie 2014:207). The results of a 
study apply to that group of the study population. As one narrows the research problem, 
similarly it is crucial to decide very specifically and clearly, who constitutes the study 
population in order to select the appropriate participants (Kumar 2011:43). The study 
population provides a boundary between that segment of the source population that is 
included in the study and that segment that is not included in the study (Boslaugh 
2013:15).   
 
 
125 
 
3.7.3.2. The study population for this study  
It was not practical to access all patients with MDR-TB and all caregivers for MDR-TB 
practicing in the Oromia Region of Ethiopia. As such, patients enrolled to MDR-TB 
treatment and their caregivers at two referral hospitals in the Oromia Region of Ethiopia 
were accessible and constitute the study population. Thus, study population for this 
study was all patients with laboratory confirmed MDR-TB enrolled to the treatment for 
MDR-TB and the caregivers for MDR-TB at the two referral hospitals in the Oromia 
Region of Ethiopia.  
 
3.7.3.3. Eligibility criteria  
3.7.3.3.1. Inclusion and exclusion criteria  
The goal of describing eligibility criteria is to determine who will be eligible to participate 
in a particular study. In any study endeavour, eligibility criteria is used to recruit 
participants to make sure that the ultimate study results address the pre-determined 
research questions. Describing eligibility criteria typically involves describing both 
inclusion and exclusion criteria. Inclusion and exclusion criteria have the goal of 
identifying a population in which it is feasible, ethical and relevant to a particular 
research endeavour. In essence, study participants that can sufficiently enable 
assessment of the risk factors, the quality or the outcomes of interest are selected 
using inclusion and exclusion criteria. (Hulley, Cummings, Browner, Grady & Newman 
2013:143-4):  
 
3.7.3.3.2. Inclusion criteria  
 All laboratory confirmed patients with MDR-TB who had been on treatment for 
MDR-TB for a period of six months and above at the time of data collection were 
included in f the study. 
 All patients with MDR-TB aged 18 years and above at the time of data collection 
were included in the qualitative component of the study   
 Caregivers who were actively giving care to patients with MDR-TB were 
included in the study. 
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3.7.3.3.3. Exclusion criteria  
 All laboratory confirmed patients with MDR-TB who had been on MDR-TB 
treatment for less than six months at the time of data collection were excluded from 
participating in  the study   
 Patients with laboratory confirmed MDR-TB aged below 18 years at the time of 
data collection were excluded from participating in the study. 
 
3.7.3.4. Sampling methods and the sample size: Quantitative component     
In any research endeavour, data are gathered with the aim that it contributes to a better 
understanding of the research question under investigation. Then it becomes 
imperious that selecting the manner of obtaining the necessary data and from whom 
to acquire the data should be done with sound judgement. This is because no amount 
of analysis can make up for improperly collected data. The quality of a research can 
be determined not only by the appropriateness of its methodology and instrumentation, 
but also by the sampling strategy used. Collecting data from the whole population might 
be impossible and expensive. Hence, a sample of a population of interest is often used 
to collect data (Boslaugh 2013: 83-4).  
In this study, certain procedures were followed and decisions were made to select 
samples for the study. By the time of the data collection, a total of 182 patients with 
MDR-TB were registered between 26 December, 2012 and 17 September, 2016 at 
Adama and Nekemte referral hospitals. From the total of 182 registered patients with 
MDR-TB, 46 (25%) did not meet the inclusion criteria so that they were excluded from 
the study. The remaining 136 (75%) of the patients with MDR-TB fulfilled the set 
inclusion criteria of the quantitative component of the study, that is, the need to be on 
treatment for MDR-TB for a period of six months or above at the time of data collection. 
From total patients who met the inclusion criteria for the quantitative component of the 
study, twenty three (23) participants those aged 18 years and above by the time of data 
collection were sampled for the in-depth interviews with patients.  
As such the total sample size for the quantitative component of this study was 136 
patients with MDR-TB. The rationale behind including all the participants who meet the 
inclusion criteria, was to make sure that a sufficient number of the required sample size 
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was included in the study so that the resulting statistics could  help draw conclusions 
and  inferences could be made based on the study sample. Therefore, the 136 sample 
size was used to achieve an acceptable level of power to test the null hypothesis of no 
relationship between the treatment outcomes of patients with MDR-TB and their clinical 
and sociodemographic characteristics (Figure 3.5, below depicts the diagrammatic 
representation of the sampling procedure used for the quantitative component of the 
study).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 4.  Diagrammatic representation of the sampling procedure used for the quantitative 
component of the study. 
 
In this study, statistical power was calculated for the sample included in the study. The 
power of a statistical test is the probability of rejecting null hypotheses that are 
rejectable (Boslaugh 2013:375). As such, statistical power was calculated to make sure 
that the sample taken was sufficiently large to test the null hypothesis of the study. In 
this study, the hypothesis of no difference in the treatment outcomes between patients 
All confirmed patients with MDR-TB registered 
between 26 December, 2012 and 17 
September, 2016 at Nekemte & Adama referral 
hospitals (N=182) 
 
 Confirmed patients with MDR-TB who were on 
treatment for >/= 6 months at the time of data 
collection at the two referral hospitals were 
included in the quantitative methods (N=136) 
Patients who did not meet 
inclusion criteria were excluded 
(N=46 (25%) 
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with different clinical characteristics was a major outcome variable. The major variable 
among the clinical characteristics of patients with MDR-TB was the presence of co-
morbidity with MDR-TB.  
 
There were two groups with respect to this. These groups were patients with co-
morbidity (p1) and patients without co-morbidity (p2) with MDR-TB at the baseline. 
From the literature P1 & P2 for this study were, P1=0.81 and p2= 0.70 (Meressa et al 
2015:1183). Then power calculation formula for one sample proportion was used to 
calculate power for the total sample size used for the quantitative component of this 
study. Accordingly the calculated power for the sample size included in the quantitative 
component of the study was 0.87. It was for this reason that the records of all the 136 
participants who meet the inclusion criteria at the Adama and Nekemte Referral 
hospitals were retrieved and included in the study.   
 
3.7.3.5. Sampling method and sample size: Qualitative component  
Sampling for the qualitative component of this study focused on patients with laboratory 
confirmed MDR-TB and healthcare professionals who were caregivers for patients with 
MDR-TB for the following reasons. Patients with MDR-TB have the unique socio-
demographic and clinical characteristics that the study attempts to investigate. 
Moreover, these patients have the experience of MDR-TB and the lengthy treatment 
associated with the disease. The sampling of this component of the study also focused 
on caregivers with the experience of treating patients with MDR-TB. This professional 
group has the experience in the clinical, programmatic, socio-economic and 
psychological aspects related to the management of patients with MDR-TB.  
 
Patients with MDR-TB and their caregivers were selected using purposeful sampling 
methods in order to elicit their experiences of this condition. Patients with MDR-TB 
were approached to participate in the study during their monthly visits to the Adama 
and Nekemte referral hospitals for their scheduled follow up services at the two 
hospitals.  During the data collection period which was from the 10th of November 2016 
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to the 7th of February 2017, all the 136 eligible patients with MDR-TB had at least a 
one-time visit to the hospitals for their scheduled monthly follow up services. Some of 
these patients were treated as inpatients. From the total number of patients who 
attended the scheduled follow up services at the two hospitals, 22 information rich 
patients with MDR-TB who were aged 18 years and above were purposively sampled 
in collaboration with the attending health nurses and physicians. Some of the 22 
patients with MDR-TB included inpatients at the treatment centres of the two hospitals.  
 
From the total of 23 patients sampled 2 patients did not volunteer to participate while 
the rest (21 patients) volunteered for participation. However, successful in-depth 
interviews were conducted with eighteen (18) patients with MDR-TB. The total of 18 
patients who participated in the semi-structured interviews was determined by category 
saturation. This was the point at which the interviews did not reveal new data relevant 
to the aims and objectives of the study.  
 
In relation to caregivers, a total of 11 (physicians and nurses) were purposively 
sampled and participated in the semi-structured interviews.  The 3 of the 11 caregivers 
were physicians while 8 of them were nurses. The total number of caregivers sampled 
and who participated in the semi-structured interviews was also determined by 
category saturation. The 11 caregivers were all active caregivers for patients with 
MDR-TB, and they were accessible at the time of data collection and participated in 
the in-depth interviews with caregivers.  
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3.8. Data collection  
3.8.1. Data collection tools 
The researcher developed the data collection tools for both components of this study 
(quantitative and qualitative).  The main focus in the development of the study tools 
was to make sure that the responses obtained from participants were valid and reliable. 
(Crano et al 2015:219-20). Hence, the development process of the tools was guided 
by the study’s specific research objectives and followed the standard scholarly 
recommendations.   
3.8.1.1. Data collection tool development: quantitative component   
The data of this component of the study was collected using a structured questionnaire. 
The researcher followed key steps to develop the questionnaire.  
 The researcher reviewed contemporary literature relevant to the study subject area, 
MDR-TB. Variables relevant to the subject area were extracted from the literature 
reviewed.  
 The extracted variables were then examined in line with the aims and objectives of 
the study.  
 The variables extracted were discussed with the supervisor of this study and 
experts in the study area, MDR-TB.  
 The researcher then developed the first draft of the questionnaire. This was 
reviewed three times by the researcher before seeking expert opinion.  
 Experts in the field and supervisor reviewed the draft questionnaire. 
 Comments from experts and supervisor were incorporated to make sure that: 
 The questionnaire is sensitive to measure what it meant to measure, 
 The questionnaire is understood in the same way if used by different 
researchers.  
 Comments from experts and supervisor were incorporated in the questionnaire.  In 
other words, the questionnaire was revised in line with comments offered by the 
supervisor and experts.  
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3.8.1.2. Components of the quantitative data collection tool 
The quantitative tool was made, as comprehensive as needed to capture all the 
necessary data required to fully answer the problem under investigation. As such, it 
had sections that captured data on the different segments of the problem under 
investigation. These included (see annexure 2, part I): 
 Background information on the socio-demographic and socio-economic 
characteristics of the study participants.  
 Participants’ background information on the basic tuberculosis related data, 
including the diagnostic modalities used in the diagnosis of patients with 
presumptive tuberculosis 
 Current MDR-TB related information of the participants  
 Clinical characteristics of the patients with MDR-TB including status of baseline 
co-morbidity with MDR-TB, the presence of malnutrition with the MDR-TB 
disease 
 The status of drug susceptibility test services for patients with MDR-TB 
 The standard clinical management of patients with MDR-TB  
 The status of patient treatment support under daily observable treatment 
 The status of MDR-TB and HIV co-management for patients infected by both 
diseases 
 Collaboration between treatment initiating hospitals and the treatment initiating 
centres in providing a continuum of care for patients with MDR-TB 
 The status of occurrence of adverse drug reactions and its management 
 The programme efforts in MDR-TB infection prevention and control at the health 
facility and community levels.   
 Availability status of clinical, radiological and laboratory follow up services for 
patients on treatment for MDR-TB  
 The inspection of premises of the MDR-TB treatment centres of the two referral 
hospitals  
 Interim and final treatment outcomes of patients with MDR-TB 
 
132 
 
3.8.1.3. Data collection tool development: qualitative component   
The data collection tool of this component of the study was a semi-structured interview 
guide. The interview guide was developed taking into consideration the aims and 
objectives of the study. The development of the interview guide was also shaped or 
underpinned by the literature reviewed. Simply, concepts relevant to the study area 
from the literature reviewed were used in developing the interview guide. It consists of 
a number of open-ended questions, probes and prompts (see annexure 2, part III & 
IV).  
 
3.8.1.4. Components of the qualitative data collection tools 
The qualitative tool used for the in-depth interviews with patients encompassed the 
patients’ socio-demographic status and the patients’ level of awareness of MDR-TB. It 
contained questions on patients’ perception on the socio-economic impact of becoming 
a patient with MDR-TB and the status of the socio-economic support provided for 
patients through the programme of MDR-TB. This part also contained items on the 
level of the accessibility to the care given for MDR-TB both at the hospital and the 
community level. It also contained question items to explore the level of the 
responsiveness of the caregivers in providing a care that is prompt and consistently 
accessible on demand. To that end, the tool contained patients’ perception on the 
quality of the care given for MDR-TB and level of their satisfaction with the overall care 
and services that they obtained on MDR-TB.   
 
The qualitative tool used for the in-depth interviews with caregivers contained question 
items that were used to explore caregivers’ professional background and their 
perception and practices regarding the status of the functionality of the MDR-TB 
programme. This part also contained question items on the practices of caregivers in 
providing the continuum of the clinical and programmatic care needed by patients with 
MDR-TB. It also contained question items that explored the level of the system’s 
support to improve the functionality of the MDR-TB programme including the availability 
of integrated care for patients infected with other diseases on top of the MDR-TB like 
the HIV/AIDS and diabetes mellitus (see annexure 2, part III & IV).  
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3.8.1.5. Piloting the data collection tools 
The questionnaire was piloted on a sample of patients with MDR-TB and caregivers 
for MDR-TB who practice in another hospital similar to the two hospitals selected for 
the main study. The data obtained from the pilot was entered into SPSS version 23. 
The outcome of the analysis resulted in the revision and refinement of the 
questionnaire. The revised questionnaire was used for quantitative data collection in 
the quantitative component of the study (see annexure 2, part I).  
 
The interview guides were also piloted on a sample of patients and caregivers for MDR-
TB. This was done to ensure that the participants understood the questions included 
in the guide. Comments from participants who took part in the pilot led to the revision 
of the interview guide. The revised interview guides were used as data collection tools 
in the qualitative component of the study (see annexure 2, part III & IV).  
3.8.2. Data collectors  
Two data collectors who were healthcare professionals, collected the data for the 
quantitative component of the study. The data collectors were offered a two-day 
training on data collection, which included discussions on the structure, content of the 
questionnaire of the study, and its application. Following training, the data collectors 
actively participated in the pilot of the questionnaire on a sample of patients with MDR-
TB who were receiving treatment in other hospitals similar to those which participated 
in the main study. The rationale for this was to enhance their familiarity with the 
questionnaire and ensure consistency in its use. 
The data of the qualitative component of the study were collected by the principal 
investigator. The principal investigator did not require any training on collecting the 
qualitative data, as he has many years of experience of data collection using individual 
and focus group interviews. The data of this component of the study was collected from 
patients with MDR-TB and their caregivers using a semi-structured interview schedule.   
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3.8.3. Type of data collected: quantitative component. 
Baseline data were collected on participants’ socio-demographics data, including age, 
sex and place of residence and education level. The data collectors, with the help of a 
structured questionnaire, collected the quantitative data from patients’ medical records 
(that is patient clinical charts, the unit MDR-TB register and patient treatment cards.  
Data were also collected on patients’ clinical characteristics. Patients’ clinical data 
included the chemotherapeutic regimens used to treat patients, co-morbidities with 
MDR-TB at baseline and baseline sputum smear status. Data were also collected on 
MDR-TB diagnosis modalities, the patients’ drug-sensitivity test patterns and the 
patients’ previous tuberculosis treatment history. Clinical data collected included the 
patients’ HIV sero-status (T-lymphocyte cell bearing (CD4) count) use of cotrimosaxole 
preventive therapy and anti-retroviral therapy by patients with MDR-TB as well as the 
patients’ MDR-TB and HIV co-infection.   
 
The clinical data collected also included adverse effects from second-line anti-
tuberculosis drugs. The patients’ adherence to the daily observable treatment, 
laboratory and radiography follow up services, and treatment results of patients with 
MDR-TB. 
3.8.4. Type of data collected: qualitative component 
Data were collected on the lived experience of patients with MDR-TB using a semi-
structured interview guide. The data collected focused on the patients’ level of 
awareness of the disease and its treatment, the patients’ level of engagement with 
treatment decision making, patients’ perception and experience on the social and 
economic impact of becoming a patient with MDR-TB, patient support schemes, 
patients’ perceived quality and satisfaction with the care provided. In addition, data 
were also collected from caregivers of patients with MDR-TB on their experiences and 
practices regarding the clinical and programmatic management of MDR-TB. Notes 
were taken during the individual interviews by a trained note-taker. Each of the 
individual interviews was audio-recorded as back up. Notes were taken by a note-taker 
during the process of interviews with patients with MDR-TB and their caregivers. 
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3.9. Data analysis 
3.9.1. Data analysis: quantitative component 
The quality of data analysis is dependent upon the quality of data. Thus, the study data 
of this component of the study were managed before analysis. Data management 
entails working directly with data. It involves cleaning, organizing data for analysis 
(Boslaugh 2013:411-2). Data analysis on the other hand refers to the computation of 
certain measures and searching for patterns of relationships among data groups.  
 
Each completed questionnaire was checked for completeness, and was coded before 
data entry. The Statistical Package for Social Science (SPSS) version 23 was used for 
data entry, data cleaning, data management and analysis. The data were entered into 
SPSS, cleaned, and the researcher familiarized himself with the study variables (like 
numeric and string) before data analysis. The researcher made sure that each variable 
had an appropriate label that linked it to the value in the questionnaire.  
On completion of data cleaning, descriptive statistical analyses for each variable of 
interest were computed taking into account the objectives of the study. Examples of 
the descriptive statistics computed include frequencies, measures of central 
tendencies and dispersion. Frequencies were the first descriptive statistics computed. 
In instances where missing values for variables were observed, this was addressed by 
reverting to the raw data on the questionnaire and re-entering the correct value of the 
variable.  
 
Subsequently, measures of association between the variables of interest were 
computed. The Chi-square, univariate and multi-variate logistic regression analyses 
were employed to identify the independent predictors of the outcome of interest, that 
is, factors associated with the level of MDR-TB treatment outcomes among patients 
treated for MDR-TB.  Confidence intervals and p-values were used to test the 
significance of the observed sample parameters in exploring determinants of MDR-TB 
treatment outcomes (Singh 2006:227). 
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3.9.2. Data Analysis: Qualitative component       
For the qualitative component of this study, coding and analyses was done manually. 
Manual analysis was chosen not to miss nuances or latent meanings. The researchers 
are instrumental to the quality of the research outcomes by the questions they ask, 
how they code and how they explore the underlying meanings (Leavy 2017:147-8). 
Moreover, manual manipulation of the data helps the researcher to focus on the data 
so that manual analyses gives the researcher more control over the data and 
ownership of the work done (Saldaña 2013:26). 
The central issue in the qualitative data analysis is making sure that the research 
participants’ subjective meanings about the social reality under investigation are 
appropriately conveyed in the final report. In qualitative data analysis, meanings are 
conveyed in terms of themes and their related sub-divisions or sub-themes. A theme 
is defined as an attribute, a descriptor or a concept that organizes repeating ideas or 
codes of similar points of reference regarding the subject of inquiry. A theme unifies 
ideas at the interpretive level and it helps answer the study questions. Sub-themes help 
to obtain a comprehensive view of the data and uncover patterns in the participants’ 
accounts (Vaismoradi, Jones, Turunen & Snelgrove 2016:101). 
 
In this study, for every audio-taped interviews, its verbatim transcription was started 
immediately after completion of the interviews and completed within 48 hours. This 
helped to make sure that important ideas were not missed as a result of delays as 
ideas could be forgotten with time. During the whole process of the interviews, the 
preliminary scanning of emerging themes was serially analysed to identify points of 
saturation in each category as ideas were emerging out of the study participants. 
 
The qualitative data analyses were made inductively from the specifics of the 
qualitative data and the coded data into the general themes, patterns and their 
interpretations. As such, the qualitative data was analysed thematically following the 
steps or stages below. Firstly, each audio-recorded interview was transcribed verbatim. 
This was done immediately; meaning the same day the interview was conducted. 
Secondly, each transcript was read at least twice by the researcher to familiarize 
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himself with its contents. Thirdly, each transcript was coded thematically, and similar 
codes were subsequently grouped together. Fourthly, each group of similar codes was 
assigned a name to reflect the generic meaning of the codes. The assigned name was 
what was referred to as a major theme, and its constituents were referred to as sub-
themes.  The data analysis generated 29 sub-themes that were clustered under the 7 
major themes. These major themes and their constituents or sub-themes are illustrated 
in table 3.1 below. These major themes and sub-themes are discussed in the result 
chapter of the study.  
Table 3. 1:   The major theme and sub-themes of the study 
 
Major themes  Constituents or sub-themes 
Functionality of the 
programme of MDR-
TB 
 Patients’ and community knowledge on MDR-TB 
 Health system’s support for the programme of MDR-TB 
 Patient linkage to a continuum of care 
 Recognition for caregivers  
Decentralization of 
the directly 
observed treatment 
(DOT) support  
 Distance from service centre 
 Engagement of community health extension workers  
Management of 
adverse drug 
reactions 
 Impact of adverse drug reactions,  
 Ancillary drugs,  
 Follow up services,  
 Knowledge of caregivers,  
 Prompt emergency care  
 Adherence challenges 
Socio-economic 
support 
 Poverty,  
 Socio-economic impact of MDR-TB, 
 Adequacy of support,  
 Quality of support  
 The use of available resources 
HIV and MDR-TB 
co-management 
 Service integration,  
 Caregivers’ capacity  
 Unfavourable treatment outcomes 
MDR-TB infection 
prevention and 
control 
 Health facility level risk of infection  
 Patients’ household level risk of infection 
 MDR-TB disease transmission among contacts 
Patients’ perceived 
quality of care and 
patients’ satisfaction 
 Patient engagement in treatment decision making,  
 Emergent medical conditions, 
 Caregivers’ responsiveness, 
 Service set ups,  
 Communication between the patient and their caregivers 
 Compassionate care 
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3.10. Quality of the study  
3.10.1. Quantitative component: validity and reliability  
3.10.1.1. Validity  
Validity of research is the extent to which an instrument measures what it is actually 
supposed to measure (Creamer 2018:84) or the extent to which a concept is accurately 
measured (Heale & Twycross 2015:66). Validity addresses the question of how well 
we measure social reality using our constructs about it (Newman 2014a: 212). Validity 
ensures that the evidence gathered supports the type of inferences that are intended 
to be drawn from the measurement (Boslaugh 2013:12).    
 
There are several types of validity, but the focus here is on internal and external validity. 
Internal validity is concerned with the extent to which explanations can be made about 
the observed relationship between the independent and the dependent variables of 
interest. Internal validity entails the elimination of variations in scores on the dependent 
variables that are unrelated to the effects of the independent variable. (Crano et al 
2015:27-32).  
 
External validity is the extent of generalizability that the results can be applied to other 
participant groups in different settings and different ways of operationalizing the 
conceptual variables (Lancaster 2005:163). It demonstrates that the same independent 
variable used in previous works has a similar effect on the dependent variable of 
interest in a different context and with different study participants (Crano et al 2015:142.   
 
In this study, efforts were made to ensure that the research tool accurately measures 
the variables under investigation. The steps taken to ensure validity of this study are 
described below: 
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3.10.1.2. Development of the study instrument  
The development of an instrument used in a study was guided by a salient theoretical 
framework and available literature. This is because validity is inextricably tied to theory 
(Barry, Chaney, Stellefson & Chaney 2011:99). In this study, certain steps were taken 
to make sure that the scores produced by the instrument are valid. As such, the content 
of the instrument was sketched and built in a way that it has a logical link with the 
objectives of the study and also it can appropriately cover all the dimensions of the 
construct under investigation. Efforts were also made to ensure the logical flow or 
coherence of the items in the instrument used. Clear and easy to understand wording 
was used to state each single question in which double-barrelled questions were 
avoided. The implementation of each section of the instrument was guided by clear 
instructions on how to implement it. Screening questions were used as a means of 
transition from one section of the instrument to the other section.  
 
Once developed, the instrument was serially reviewed by the researcher’s supervisor 
and other professionals who had sound concept on research methods and also who 
had the expertise in the construct under investigation (that is, experienced in the 
programmatic management of drug-resistant tuberculosis). The comments obtained 
from experts were incorporated to make sure that the tool is sensitive to measure what 
it meant to measure and also is understood in the same way if used by different experts. 
In this way, efforts were made to maximize the appropriateness of the instrument used 
to measure the constructs and variables under investigation.  
 
3.10.1.3. Training of data collectors  
To make sure that the study questionnaire is understood by all the data collectors 
involved in the data collection process, data collectors were given a two-day training. 
The trained data collectors were also part of the process of pilot testing the 
questionnaire. Data collectors were also re-oriented on the final tool which incorporated 
comments gathered so that they get familiar with updates in the content of the 
questionnaire and how to apply it. 
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3.10.1.4. Monitoring of the data collection process  
In this study, the principal investigator monitored the whole process of the data 
collection. The principal investigator took the lead responsibility in making sure that the 
data collection process was smooth and was implemented as planned. Specific actions 
taken in the field included ensuring the completeness of the individually filled in 
questionnaires; they were checked on the spot. When there were incomplete values in 
a filled in questionnaire, these were addressed immediately by revisiting the source of 
that particular data. It was ensured that written values were legible. Then when it was 
confirmed that a filled in questionnaire was complete, it was coded and filed for 
subsequent use.    
  
3.10.1.5. Reliability  
Reliability is the extent to which a questionnaire or a test or a procedure consistently 
produces the same results that it is measuring on repeated trials. Reliability basically 
refers to the consistency of results obtained in research (Boslaugh 2013:10).  
There are three major attributes of reliability. The first of these attributes is the internal 
consistency or the homogeneity of the study instrument. Internal consistency focuses 
on the extent to which all the items in the study instrument measure the same construct 
under investigation.  The second is stability, which deals with consistency of the scores 
obtained on repeated testing using the instrument. The third is equivalence which deals 
with the consistency of the scores among the different sections of the instrument (Heale 
& Twycross.2015:66-7). 
 
3.10.1.6. Steps taken to ensure reliability of the quantitative component of the 
study 
Steps were taken to ensure the reliability of the quantitative part of the study. Every 
construct under investigation and its sub dimensions were clearly conceptualised and 
its clear and unambiguous theoretical definition was developed. This helped to 
eliminate interfering information so that each measure clearly indicated one and only 
one concept. Moreover, multiple questions were asked per each construct of interest. 
Use of multiple indicators per a construct helped to make the study tool more stable 
and reduce the chance of systematic error from using single indicator per construct of 
 
141 
 
interest  (Newman 2014b:141). Furthermore, reliability of the instrument used was 
tested using the Cronbach’s alpha statistical test. A research instrument is said to be 
reliable if it consistently measures the construct that it is intended to measure. 
Statistically, the Cronbach’s alpha coefficient is the commonly used statistical test for 
establishing the reliability of an instrument. Cronbach’s alpha is an index of the internal 
consistency (reliability) of a set of items in an instrument (Gaur & Gaur 
2009:134).Cronbach’s alpha is a hypothetical value that would be obtained if all of the 
items that could constitute a given instrument were available and randomly combined 
across a large number of tests of equal size (Crano, Brewer & Lac 2015:447). 
Reliability of an instrument is acceptable if the value of its Cronbach’s alpha coefficient 
(α) is equal to or greater than 0.7 to 0.8. For the instrument used in this study, the value 
of the Cronbach’s alpha coefficient (α) was 0.72, that is (α=.72, p=0.001). The value of 
the Cronbach’s alpha coefficient for the instrument used in this study was greater than 
the proposed acceptable value (Field 2009:673-5). 
 
3.10.1.7. Other measures taken to ensure reliability of the quantitative 
component of this study  
Before the main data collection, a pilot test was conducted on patients with MDR-TB 
treated in one referral hospital in the Oromia Region of Ethiopia rather than the two 
referral hospitals selected for the study. This activity created an opportunity to evaluate 
the appropriateness of the instrument used for the quantitative component of the study 
for the researcher and the study team. The experience gained from the pilot testing 
was discussed among the team. Concerns in the level of the clarity or any ambiguity in 
the administration of the data collection instrument was fully addressed.  Moreover, the 
data obtained from the pilot test was entered into SPSS version 23 and the outcome 
of the analysis was used in the refinement of the questionnaire. 
 Experts, other than the principal investigator, were involved in checking the process 
of data analysis. In addition, an experienced statistician and a public health researcher 
who were not part of the whole process of this research endeavour, were invited to 
check the process of data analysis. The comments and input provided by the two 
experts were used in the process of data analysis and report writing.  
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3.10.2. Qualitative component: trustworthiness 
Trustworthiness of a qualitative data is the degree to which the results are credible, 
transferable, confirmable and dependable (Andrew & Halcomb 2009:122).  
3.10.2.1. Credibility  
Credibility is the extent to which the methods used engender confidence in the truth of 
the data and the researcher’s interpretation of the data. Credibility deals with the 
question of how congruent the results of a study are with reality (Edmonds & Kennedy 
2017:324). 
 
3.10.2.2. Steps taken to ensure credibility in this study 
3.10.2.2.1. Triangulation 
Triangulation is verification through the use of multiple sources of data about the same 
phenomena.  It is the use of data from different or multiple sources used to justify the 
themes. Such multiple sources of data may include the use of individual interviews, 
interview notes, focus groups, photos, observations and documents (Creamer 2018:3).  
In this study, data were obtained from different categories of participants. In-depth 
interviews were conducted with caregivers (physicians and nurses) and with patients 
with MDR-TB. Interview data were audio recorded and transcribed verbatim. Notes 
were taken during interviews where data were captured on the feelings and the 
experiences of the study participants.  Data from multiple sources were used to make 
sure that emerging themes were established based on converging different sources of 
data or different perspectives of the segments of the study participants. The data from 
different sources were analysed separately and then compared.  
 
3.10.2.2.2. Member checking  
Member checking is presenting recorded data or interviews or a draft result of the 
research to persons from whom the information was obtained and asking them for 
comments and corrections (Stake 2010:136). This is the moment in which the views 
and the perspectives of the study participants are solicited to ensure the credibility of 
the study results and the interpretations made regarding the results obtained (Creswell 
2012: 259; Creswell 2007:208). In this study, the researcher made sure that the 
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information he captured reflects the views and opinions of the study participants. For 
this, the principal investigator summarized what was discussed at the end of each 
interview. Then each participant was asked if what the researcher captured actually 
matches the intentions and opinions of the participants. Moreover, transcripts were 
given to some literate participants and they were asked if what the researcher captured 
matches their opinions. In the process of the data collection preliminary scanning of 
the emerging themes were made. In such instances some themes were presented to 
same participant and clarification was asked when appropriate.  
 
3.10.2.2.3. Peer scrutiny 
Peer debriefing is the opportunity for a research endeavour to be scrutinized by peers 
and the academic colleagues. This entails the use of their questions and feedbacks 
during the whole process of the qualitative inquiry to enhance accuracy of the construct 
under scrutiny (Creswell 2008:192). In this study, two persons (debriefers) were 
located and the emerging themes and the draft results of the study were frequently 
debriefed with them. The debriefers had experience in social research. The feedback, 
questions and the views of these debriefers were taken into consideration to widen the 
vision of the principal investigator in the interpretation of the construct under 
investigation. 
 
3.10.2.2.4. Frequent debriefing with supervisor 
Both the transcriptions and the emerging themes were communicated to the supervisor 
of the study. As such, the detailed audit made by the supervisor and the comments 
given were used to enhance the accuracy of the interpretations made on the construct 
under scrutiny.  Moreover, the preliminary results of the qualitative data were 
communicated to the supervisor who thoroughly revised the draft results. Comments 
provided by the researcher’s supervisor on improving the credibility of the results were 
used to enhance the vision and accuracy of the construct. This was to make sure that 
the results are data driven and the inferences made are credible.  
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3.10.2.2.5. Thick description of the phenomena under scrutiny 
Thick description is the provision made to make sure that what a researcher defines 
actually conveys the actual situation that is investigated (Creswell 2012:448).  In this 
study, a summary of the results and the interpretations made were presented for each 
theme. Then with the attempt to keep the data rooted in the participants’ own words, 
each of the summaries made was illustrated by using direct quotations or excerpts from 
what the participants were actually providing.  
3.10.2.2.6. Honesty and integrity  
Researchers are required to make sure that a research attempt is conducted according 
to the acceptable standards of practice and without fraud (Walliman 2011:43-5; Blaikie 
2010:31). To get  thorough and correct answers to the interview questions posed to 
the participants, researchers are required to ensure the willingness of the participants 
to provide genuine answers without fear (Polit & Creswell 2012:80).   
3.10.2.2.7. Ensuring honesty and integrity in this study  
In this study, the process of participant selection was made in which participants were 
honestly informed on what was expected of them and their right to refuse participation 
at any point in the process of the interviews (see annex IV) was highlighted.  As such, 
when approached, each participant was told that he or she had the right to refuse 
participation if he or she could not contribute data and talk of their experiences without 
fear. During data analyses and reporting, a full range of the results (both positive and 
negative) was reported on as obtained from the participants.  
 
3.10.2.2.8. Development of early familiarity with the study setting  
Acquiring an intimate understanding of the study setting is the process of maximizing 
the advantage of personal insight to understand the inner feelings and life perspectives 
of the study participants in real social life. It is not being sloppy about data collection 
nor use of evidence selectively but it is used to influence professional judgments 
(Neuman 2014:170). In this study, familiarity with the setting was obtained through 
visiting the study sites before data collection began. The principal investigator and the 
trained data collection assistant visited the Adama and Nekemte Referral hospitals and 
talked to the Chief Executive Officers of the two hospitals. Preliminary knowledge was 
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obtained regarding the study setting, the living conditions of the patients with MDR-TB 
and the routines in the implementation of the MDR-TB programme at the two hospitals. 
Moreover, during the whole time of data collection, the researcher attended and 
facilitated every event of the interviews made with patients and their caregivers. In this 
way, the familiarity with the study setting helped in the process of data collection, 
analysis and report writing.  
 
3.10.2.3. 3.10.2.3. Confirmability 
Confirmability is objectivity. It is the degree to which the results are derived from the 
experience of participants and their context and not from the researcher’s own biases 
(Neuman 2014:218). Confirmability is one of the validation strategies for qualitative 
inquiry. It deals with ensuring that the results of a study are meaningful and applicable 
in terms of the study participants’ own experiences and their understanding of the 
phenomena under investigation (Andrew & Halcomb 2009:129).   
 
3.10.2.4. Steps taken to ensure confirmability in this study  
In this study, all the interpretations and the conclusions reached were supported by 
direct quotations of the excerpts from the raw data and as explained by the participants 
of the study. The complete verbatim transcript produced from the audio-recorded 
qualitative data is made available for reference.   
3.10.2.5. Transferability 
Transferability is the degree to which the results of a qualitative study are transferred 
to other settings. That is, it deals with the applicability of the qualitative results to similar 
settings (Heyvaert, Hannes, Maes & Onghena 2013:7). 
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3.10.2.6. Steps taken to ensure transferability in this study 
To ensure transferability of the study results, attention was given to data saturation and 
to the description of the original context of the data. The detailed description is provided 
to enable readers to decide on the extent of the applicability of the results of this study 
to other settings. 
Through the member checking activity implemented, the verbatim transcripts were 
shared with interviewees to get their approval and to make sure that what was captured 
in the study, reflects their perspectives and the actual context. The preliminary themes 
and results were also communicated to the participants to make sure that the results 
and the interpretations made were reflective of the views of the participants.   
 
3.10.2.7. Authenticity  
Authenticity is fairness. It is the criterion, which deals with the degree to which data 
presents a balanced perspective of the participant’s constructions of reality and the 
underlying values (Hesse-Biber & Johnson 2015:248). 
 
Qualitative studies are more interested in achieving authenticity than realizing a single 
version of truth. Authenticity means offering a fair, an enriched, honest and balanced 
account of social life from the viewpoint of the people who live it everyday. It achieves 
this through the use of data from various sources including photographs, notes and the 
verbatim transcripts of the interviews (Neuman 2014:218). 
 
There are five authenticity criteria. The first is fairness. Fairness deals with the 
researcher’s effort to present the experiences and the views of participants in a 
balanced way that can be honoured by involved groups. The second form of 
authenticity is ontological authenticity. This deals with making sure that reality is 
constructed exactly as it is experienced by those who live it. The third form of 
authenticity is the educative authenticity. This form of authenticity deals with the 
improved understanding of the constructions of others and understand how such 
constructions are rooted in the differing values of those others. The forth form of 
authenticity is catalytic authenticity. According to catalytic authenticity, achieving 
 
147 
 
increased understanding of a reality is not sufficient. Indeed, inquiry must stimulate 
action. The fifth form is tactical authenticity which deals with empowering those who 
have the stake to have the opportunity to control over what is understood and for it to 
be translated to action (Yang & Miller 2008:159).   
3.10.2.8. Steps taken to ensure authenticity in this study  
The data from the various sources were presented in a mutually reinforcing and 
interlocking manner. Moreover, the results and the interpretations made were 
presented back to the study participants. Participants were asked if they agreed with 
the results and the interpretations made by the researcher. All the interviewees agreed 
with the authenticity of the data. They also agreed that the interpretations made 
represent their views and perspectives and they did not add new any information to the 
data and the interpretations made. Added to this, effort was made to make thick and 
rich descriptions of the everyday life experiences of the study participants and all the 
contextual aspects of the research settings. The involvement of the different categories 
of participants (patients and healthcare workers) was to ensure representation of the 
multiple realities of what was under investigation. Thus, member checking was applied 
to ensure that the results fit the experiences and the perspectives of the study 
participants. One of the aims of this study was to develop a model for enhancing the 
management of patients with MDR-TB.  This model will contribute to social change in 
the area being investigated.  
3.10.2.9. Dependability 
The dependability of a qualitative result is the degree to which the results are consistent 
and stable. The audit trails ensure that the findings of the study are consistent and 
repeatable (Edmonds & Kennedy 2017:324). 
3.10.2.10. Steps taken to ensure dependability 
In this study, the dependability audit was conducted through an external auditor. The 
external auditor had multiple years of experience in the field of social research. He also 
had experience in the programme of MDR-TB. He was not directly involved in any part 
of the current research process.  
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The external auditor explored the processes followed in data collection, data analysis 
and the conclusions reached. He confirmed that the results of the study, the 
interpretations made and the conclusions drawn from the findings are supported by the 
data collected for the study.    
3.11. Ethical considerations 
3.11.1.  Permission to conduct the study  
Ethical approval of the research proposal was obtained from Higher Degrees 
Committee (DHDC) of the Department of Health Studies at UNISA (annexure 3.1.). 
Likewise, a support letter was obtained from UNISA, Regional Learning Centre in 
Ethiopia, at Akaki Campus (annexure 3.2).  
Permission to access the targeted hospitals was obtained from Oromia Region Health 
Bureau, the Department of Public Health Emergency Management and the Health 
Research Core process (annexures 3.3-3.4). Next, permission on access to patients 
with MDR-TB, caregivers for MDR-TB and patient records was obtained from the Chief 
Executive Officers (CEOs) of Adama and Nekemte Referral Hospitals. Subsequently, 
access to patients with MDR-TB was obtained through informed permission from the 
caregivers for patients with MDR-TB in each hospital.  
 
3.11.2. Informed consent   
Informed consent is an essential requirement and it is an integral part of clinical and 
public health researches involving human subjects (Council for International 
Organizations of Medical Sciences (CIOMS) 2016:72).  
In this study, the information sheet (see annexure 4) was prepared and used to ensure 
that participation was entirely based on informed consent. The contents of the 
information sheet were read to each patient. Based on the information sheet, an 
explanation was advanced on the objectives of the study and the need for participation 
by patients with MDR-TB and their caregivers. 
 
It was explained that participation of patients with MDR-TB and their caregivers was 
important to get data on their feelings and experiences on the programme of MDR-TB 
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and the services provided for patients. In addition, data generated would be used to 
guide and provide evidence informed decision making data regarding the 
programmatic management of drug-resistant tuberculosis in referral hospitals found in 
the Oromia Region of Ethiopia and other similar hospitals found in Ethiopia.  
 
It was made clear that all the data collected from patients and their caregivers were 
anonymous. This means that participants were not asked about their personal 
identifying information like name and address. Furthermore, confidentiality of 
responses given was adhered to. This means that information collected was used only 
for answering the research question under investigation. The information would not be 
shared with anyone else and would not be analysed and reported on in conjunction 
with participants’ personal identifiers. To that end, participants were told that 
participation was entirely voluntary and they had the right not to participate in the study. 
It was made clear that patient’s decision not to be part of the study would not have any 
negative impact on the care and services that the patients obtained from the hospitals. 
As such, patients with MDR-TB and their caregivers had the full right to withhold 
participation without any precondition.  
3.11.3. Ethical considerations of using patient records as the source of data 
Access to records of patients with MDR-TB from registers and patient charts was 
obtained through permission from hospital management and the caregivers for patients 
with MDR-TB. No data were collected on patient identifiers. Instead, codes were used 
to identify each filled in questionnaire. Confidentiality of all data collected was kept or 
adhered to. 
 
3.11.4. Compensation for study participants   
In any research endeavour, compensation or an incentive is considered as a token of 
appreciation rather than a payment for the participant’s efforts in participating in the 
research. Every effort should be made to prevent the compensation from inducing any 
willingness to participate in the study or prevent it from being considered as a reward 
for the task of participating in the study (Goodwin 2010:59).  
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In this study, patients with MDR-TB who came for their scheduled monthly follow up 
services at Adama and Nekemte referral hospitals participated in the in-depth 
interviews. Some of the patients who voluntarily sacrificed their time to provide 
responses to the interviews were warned that they could miss their buses. That might 
lead to these patients having to pay for snacks due to the delay until late in the 
afternoon before returning to their home areas or they may be exposed to paying extra 
transport fees for using inter-town taxies. 
 
In this study, the issue of compensation for a missed transport schedule resulting in 
the potential financial risk due to the time that participants spent with the researcher, 
was not disclosed until the participant’s informed consent was obtained and the 
interviews were completed.  After completion of the in-depth interviews with each 
participant, the issue of compensation for potential financial risk was discussed with 
the participants themselves and the hospitals nurse focal point for the MDR-TB 
services. To avoid information sharing among participants, the compensation was 
given while the participant exited from the facility. Twelve of the total participants of the 
interviews received 50 Ethiopian Birr (equivalent to 1.8 USD at that time). For the 
remaining participants, there was perceived extra financial risk incurred by the patient 
that needed compensation. This level of compensation was only nominal and served 
to compensate for perceived real financial risk that a participant could incur. No 
compensation was needed for caregivers who volunteered to participate in the 
interviews. 
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3.12. Summary   
This chapter illustrated the principles, ideas and procedures on which this research 
endeavour was based. The chapter summarized the different assumptions or research 
paradigms and the research design used in the study. It indicated that the study 
employed facility based, analytical and a concurrent mixed methods design. The study 
was predominantly quantitative in design which is supplemented by a concurrent 
qualitative inquiry. The chapter also depicted the research setting and population of 
the study. Moreover, it indicated procedures used for sample selection, instrument 
development, data collection and its management. Finally, the chapter presented a 
summary of the procedures used to ensure validity and reliability of the research 
results.  
This chapter describes the philosophical and methodological assumptions used in this 
study. It also describe the specific research design and methodology that guided this 
research endeavour. The next chapter (chapter 4) will present data analysis and the 
result of the research.  
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Chapter 4: Research results  
4.1. Introduction 
In the preceding chapters, the background to the research problem and the scope of 
the research problem investigated in this study were presented. The literature review 
and the methodological procedures used to implement the study were also presented 
in preceding sections. The results of the study are presented in this chapter of the 
study. 
4.2. Results for the quantitative component of the study  
4.2.1. Socio-demographic characteristic of study participants 
From the total of 136 (100%) patients with MDR-TB included in the study, 74 (54%) 
were male while 62 (46%) were female patients with MDR-TB (see figure 4.1). 
According to figure 4.2 and table 4.1, the majority of patients were found to be in the 
productive age group with 128 (94%) of the patients being in the age group of 15-64 
years. Similarly, 28/30 (93%) of the total deaths from MDR-TB occurred in the same 
age group of 15-64 years. About 4 (3%) of patients with MDR-TB were aged less than 
15 years of age while 4 (3%) of them were aged 65 years and above. The mean age 
of the study participants (Mean ± SD) was 32.12 ± 12.53. The actual age range of the 
study participants was 4-73 years (see figure 4.2).  
 
Table 4.1 shows that the majority, 70 (53%) of patients were self-employed. This was 
followed by 46 (35%) who were not employed. Seven (5%) of patients were formally 
employed while 9 (7%) of the patients were in the other response category comprising 
mainly of students and housewives. In this study, the interviews conducted with 
patients with MDR-TB revealed that, 53% self-employment was described as 
employment in the informal labour workforce with minimum daily wages. 
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Figure 4. 1:  Sex distribution of study participants at Adama and Nekemte referral hospitals, 
Oromia, Ethiopia, December, 2012-September, 2016 (n=136) 
 
 
Figure 4. 2: Age distribution of the study participants at Adama and Nekemte referral hospitals, 
Oromia, Ethiopia, December, 2012-September, 2016 (n=136) 
  
Male
74 (54%)
Female
62 (46%)
Pie Chart showing sex distribution of study 
participants (%)
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Table 4. 1: Socio-demographic and socio-economic characteristic of the study participants at 
Adama and Nekemte referral hospitals, Oromia, Ethiopia, December, 2012-September, 2016 
(n=136). 
Parameter N (%) 
Sex (n=136): 
       Male 73 (54) 
       Female 63 (46) 
Age category (n=136) 
       <15 years 4 (3) 
15-44 years  110 (81) 
45-64 years  18 (13) 
>/=65 years  4 (3) 
Patients’ employment status (n=132) 
Formally employed 7 (5.3) 
Self employed 70 (53) 
 Unemployed 46 (35) 
Other 9 (7) 
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4.2.2. Clinical characteristic of the study participants 
4.2.2.1. Type of the MDR-TB cases and patients’ registration groups 
At registration, patients with MDR-TB who were included in this study were grouped 
based on the type of tuberculosis they suffered from, their previous treatment history 
and the outcome of their latest tuberculosis treatment. Table 4.2 shows that the 
majority of the patients with MDR-TB, about 134 (98%) were bacteriologically 
confirmed pulmonary MDR-TB cases. One patient (1%) was bacteriologically 
confirmed extra-pulmonary MDR-TB and one patient (1%) was clinically diagnosed as 
an extra-pulmonary MDR-TB case. 
 
The analysis of the patients’ registration group revealed that the majority, 90 (66%) of 
the patients, were diagnosed with Rifampicin Resistant TB or MDR-TB after the failure 
of the re-treatment regimen with the first-line tuberculosis treatment regimen. This was 
followed by 17 (13%) patients diagnosed with MDR-TB after the failure of treatment 
with the new standard 6-month regimen with first-line anti-tuberculosis drugs. Fourteen 
(10%) of patients were those registered for treatment after a relapse, while 11 (8%) 
were new cases of RR/MDR-TB who did not have any history of treatment with anti-
tuberculosis drugs. About 4 (3%) of the patients were those diagnosed among patients 
returning after being lost to follow ups. Only 1 patient had a history of treatment with a 
regimen containing second-line anti-tuberculosis drugs. This patient was a patient who 
returned after being lost to follow ups while on treatment for MDR-TB. 
4.2.2.2. Drug-resistance pattern of the patients with MDR-TB   
At the baseline from the total patients included in this study, 89 (65%) were diagnosed 
as Rifampicin Resistant (RR) cases by the GeneXpert machine. About forty-seven   
(35%) of patients were diagnosed as MDR-TB cases. The drug-susceptibility test result 
both for rifampicin and isoniazid is obtained from the culture and drug-susceptibility 
test. As a result, all patients registered as MDR-TB had a documented drug-
susceptibility test result for both rifampicin and isoniazid anti-tuberculosis drugs. Thirty-
four (26%) of the patients with a documented HIV test result were co-infected with 
HIV/AIDS. One hundred and thirty four (98%) of the total tuberculosis cases were 
pulmonary, while 2 (2%) were extra-pulmonary cases of tuberculosis. From the total 
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(n=132) of patients with a documented baseline sputum microscopy test, 27 (21%) 
were sputum smear negative while 105 (79%) were sputum smear positive patients 
with MDR-TB. An analysis of the initial bacillary load at diagnosis (n=132) revealed that 
the initial bacillary load for 59 (45%) patients was scanty, moderate for 41 (31%) and 
high for 5 (4%) patients. From the total patients documented, diagnostic radiology was 
used for 37 (27%) of the patients. For forty one (30%) of the patient’s, diagnostic 
radiography was not used and instead, diagnosis was made based on other diagnosis 
tools. For fifty-eight (43%) of patients, there was no evidence on the status of the use 
of diagnostic radiography. 
4.2.2.3. Drug-susceptibility test status of the patients to tuberculosis drugs  
Table 4.2 shows that at diagnosis, 135 (99%) patients had a drug-susceptibility test 
result for Rifampicin and were resistant to Rifampicin. Only fifty-eight (43%) of the total 
135 patients had a drug-susceptibility test result for Isoniazid and were resistant to 
Isoniazid. Three (2%) patients had a drug-susceptibility test result for Streptomycin and 
were resistant to the drug. All patients (n=136) did not have a drug-susceptibility test 
result for Ethambutol and Pyrazinamide drugs. Furthermore, no drug-susceptibility test 
results were available for any of the second-line anti-tuberculosis drugs used to treat 
MDR-TB. 
 
Scholars, cited that the limited availability of diagnostic drug-susceptibility test service, 
leads to the use of an inappropriate regimen which in turn leads to the further 
amplification of resistance. In view of such recommendations, the availability status of 
diagnostic drug-susceptibility test for patients with MDR-TB of those included in this 
study, seems to be sub-optimal (Dobler, Korver, Batbayar, Nyamdulam, Oyuntsetseg, 
Tsolmon, Surmaajav, BayarjargalB & Marais 2015:1451; Minion et al 2010:941). 
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4.2.2.4. Status of the baseline co-morbidity associated with MDR-TB  
As shown in table 4.2, from the total of 133 (n=133) patients for whom data was 
available on any co-morbidity with MDR-TB at the baseline, 41 (31%) had some form 
of co-morbid condition at baseline. From the total of 41 MDR-TB associated co-
morbidities at baseline, 34 (83%) of the co-morbidity at baseline was due to co-infection 
with HIV while 5 (12%) was co-morbidity with diabetes mellitus. This was followed by 
other types of co-morbidities 2 (5%) including cardio-vascular diseases, kidney 
diseases, co-pulmonale and anemia. Furthermore, the study revealed that 87 (64%) of 
the patients with MDR-TB had a body mass index (BMI) of less than 18.5kg/m2, 
indicating the presence of malnutrition as a co-morbid condition with MDR-TB.   
 
Table 4. 2: Clinical characteristics of the study participants at Adama and Nekemte referral 
hospitals, Oromia, Ethiopia, December, 2012-September, 2016 (n=136). 
 
Parameter N (%) 
Patients’ drug-resistance type at diagnosis (n=136)  
Rifampicin resistant tuberculosis (RR-TB) 89 (65) 
MDR-TB 47(35) 
HIV test result (n=131):  
                         HIV positive 34 (26) 
                         HIV Negative 97 (74) 
Presence of co-morbidity at baseline (n=133) 
Yes  41(31) 
No  92 (69) 
Type of co-morbidity at baseline (n=41) 
HIV/AIDS 34(83) 
Diabetes mellitus  5 (12) 
Other  2(5%) 
Was sputum smear used for diagnostic (n=135) 
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Yes 133 (98) 
No 2 (2) 
Was GeneXpert used for diagnosis (n=136) 
Yes 86 (63) 
No 50 (37) 
Was LPA used for diagnosis (n=135) 
Yes 49 (36) 
No 86 (64) 
Was culture used for diagnosis (n=135) 
Yes 21 (16) 
No 114 (84) 
Site of the TB  disease (n=136) 
Pulmonary 134 (98) 
Extra-pulmonary 2 (2) 
Type of the TB case (n=136) 
Bacteriologically confirmed pulmonary TB 134 (98) 
Bacteriologically confirmed extra-pulmonary TB 1 (1) 
Clinically diagnosed extra-pulmonary TB 1 (1) 
Result of diagnostic sputum smear examination (n=132) 
Smear positive 105 (79) 
Smear negative 27 (21) 
Sputum bacillary load reported at diagnosis (n=132) 
No AFB seen 27 (20) 
Scanty 59 (45) 
Moderate 41 (31) 
High 5 (4) 
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4.2.2.5. Clinical management of patients with MDR-TB       
4.2.2.5.1. Approaches to the clinical management of patients with MDR-TB  
The study revealed that all patients (n=136) were treated using the WHO 
recommended standardized treatment regimen for MDR-TB which is 8 (Z-Cm6-Lfx–
Pto (Eto)–Cs for the intensive phase and 12 (Z-Lfx–Pto (Eto)–Cs for the continuation 
phase.  
Caregiver participants in the qualitative in-depth interviews, mentioned that an 
injectable capreomycin (second-line tuberculosis drug) is given six days per week. The 
MDR-TB treatment regimen given for all 135 (99%) of patients contained four second-
line anti-tuberculosis drugs not previously used in the patient’s tuberculosis treatment 
regimen. 
An analysis of the number of total tablets taken per day by a patient with MDR-TB 
showed that 32 (23%) patients were taking 12 tablets or less per day. Fifty seven (42%) 
of patients took 13 to 14 tablets per day while 46 (34%) of patients took 15 or more 
tablets of the second-line anti-tuberculosis daily.  
The in-depth interviews with caregivers revealed that there was no standard 
registration system for total tablets given to treat adverse drug-reactions from second-
line drugs. Therefore, the question asked in order to capture the average number of 
daily tablets that a patient with MDR-TB took could only be captured from the number 
of tablets of second-line drugs included in the standard MDR-TB treatment regimen. 
This may imply that patients experiencing adverse drug reactions may be taking more 
tablets than the specific question captured in this study. One hundred and sixty six 
(85%) of the patients who passed the treatment phase from intensive to continuation 
phase were put on the WHO recommended standard treatment regimen of 12 (Lfx-Eto-
Cs-Z) for the continuation phase.  
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4.2.2.5.2. Status of the MDR-TB and HIV/AIDS co-management  
From the total number of patients enrolled to treatment for MDR-TB at the two 
hospitals, 131 (96%) of the patients had a documented HIV test result. From total 
number of those tested, 34 (26%) were positive with HIV, which means that 26% of the 
patients with MDR-TB were co-infected with HIV/AIDS. As depicted in the figure 4.3 
that follows, 4 out of 10 (40%) of the patients with MDR-TB who were registered on a 
single page of the unit MDR-TB register were reactive (R) for HIV. 
  
Figure 4.  3: Status of MDR-TB and HIV co-infection among patients with MDR-TB treated at the 
two referral hospitals, Oromia, Ethiopia, December, 2012-September, 2016. 
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The study revealed that from all (n=31) patients with documented evidence on 
tuberculosis and HIV co-management, 30 (98%) had documented evidence that they 
were given cotrimoxazole preventive therapy and anti-retroviral treatment. However, 
none of the HIV and MDR-TB co-infected patients had documented T–lymphocyte cell 
bearing (CD4) count at the initiation of treatment for MDR-TB. 
 
4.2.2.6. Adverse reactions from second-line anti-tuberculosis drugs  
4.2.2.6.1. Prevalence of adverse drug reactions from second-line drugs 
From the total number of patients included in the study, complete data on adverse drug 
reactions from second-line drugs were retrieved for 91 (67%) patients. All the 91(100%) 
patients with data on adverse drug reactions from second-line drugs experienced at 
least one episode of some form of adverse drug reactions from second-line drugs in 
the course of their treatment for MDR-TB. The adverse drug reactions involved major 
body organs. The median number of the adverse drug reactions from second-line drugs 
per patient included in this study was found to be four.  
From the total of 91 patients, 31(34%) of them experienced five or more episodes of 
adverse drug reactions from second line drugs. Twenty-two (24%) of the patients 
experienced two episodes of adverse drug reactions while 14 (15%) of them 
experienced three episodes of adverse drug-reactions from second-line drugs. Twelve 
(13%) of the patients experienced four episodes of adverse drug reactions and same 
12 (13%) of them experienced one episode of adverse drug reactions from second-line 
drugs.  
4.2.2.6.2. Occurrence of adverse drug-reactions by body organs involved  
Systemic differentials for the occurrence of adverse drug reactions from second line 
anti-tuberculosis drugs revealed that, from the total of 91 patients, 73 (80.2%) of them 
experienced at least one episode of adverse drug reactions involving the gastro-
intestinal tract. Analysis of the gastro-intestinal tract related adverse drug reactions by 
site of involvement of the gastro-intestinal tract, revealed that from the total of 73 
patients who experienced gastro-intestinal tract related adverse drug reactions, 34 
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(46.6%) experienced nausea and vomiting and 51 (70%) experienced gastritis 
including diagnosis with peptic ulcer disease.   
Neurological related adverse drug reaction was also found to be the second most 
common adverse drug reactions in which 35 (38.5%) of the patients developed this 
type of adverse drug reactions from second-line drugs. Most common neurological 
adverse drug reactions found among the patients included in this study were peripheral 
neuropathy and headache. The 35% prevalence of the neurologic related adverse 
revealed in this study, was higher than the 6% neurologic related adverse drug 
reactions reported by Akshata et al (2015:31).  
The study also revealed that musculoskeletal related adverse drug reactions from 
second-line drugs was the third common adverse drug reaction among patients with 
MDR-TB. As such, 26 (28.6%) of the patients experienced musculoskeletal related 
adverse drug reactions from second-line drugs. In the same way, 24 (26.4%) of 
patients developed cardio-vascular related adverse drug reactions from second-line 
drugs. 13 (14.3%) patients experienced electrolyte disturbances while 11 (12%) of the 
patients developed psychiatric related adverse drug reactions.  
The 12% psychiatric disorder revealed among patients with MDR-TB in this study is 
much higher than the 1.6% reported by Akshata et al (2015:31) but it is similar to the 
13% prevalence of psychosis reported by Bloss et al (2010:277) among patients with 
MDR-TB in Lativia. Moreover, 9 (10 %) patients experienced vestibular (ear) related 
adverse drug reactions while 7 (7.7%) developed dermatologic related adverse drug 
reactions. Five (5.5%) and 3 (3%) of patients developed eye and immune related 
adverse drug reactions respectively. 
Irreversible or fatal cases of adverse drug reactions from second-line drugs were 
revealed in some patients. As such 7 (7.7%) developed permanent loss of hearing from 
the adverse drug reactions. There was 1 (1%) of patient died by suicide. The cause of 
the suicide was associated with a clinically presumed psychiatric problem from second-
line drugs. This was retrospectively mentioned by the attending physician in the 
patient’s clinical chart.   
The other type of adverse drug reactions found among patients was hypokalemia, that 
is, decreased blood calcium level.  The majority of the patients, 13 (14%), who 
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experienced hypokalemia, developed clinically apparent hypokalemic-tetani. Some of 
the cases with hypokalemic-tetani were documented in the patients’ clinical charts to 
be fatal, that is, such patients died of this specific adverse drug reaction.   
The study showed that, from the total of 91 patients, the treatment regimen was 
modified or permanently changed for 3.3% (3/91) patients due to adverse drug 
reactions from second-line drugs.  
  
4.2.2.6.3. Trend of the occurrence of adverse drug reactions in the course of 
patient treatment for MDR-TB 
The trend of the occurrence of second-line drugs related adverse drug-reactions during 
the course of the MDR-TB treatment was assessed to determine the trend of 
occurrence of the adverse drug reactions in the course of treatment. As such, the study 
revealed that the majority of the adverse drug reactions occurred during the initial 
months of the intensive phase of MDR-TB treatment. Except for few adverse drug 
reactions like the musculo-skeletal and neurological related adverse drug reactions 
which continued to occur beyond the intensive phase of the MDR-TB treatment, most 
of the adverse drug reactions were found to occur during the intensive phase months 
of patient treatment. 
The consecutive data depicted in figure 4.4 below show the trend of occurrence of the 
common adverse drug reactions in the course of patient treatment. As depicted in the 
figure, there was a decreasing trend in the occurrence of most of the adverse drug 
reactions related to the major body organs.  The common gastro-intestinal related 
adverse drug reactions from second-line drugs occurred, on average, during the initial 
five to six months of the patients’ treatment for MDR-TB. As in figure 4.4A, anorexia 
was common during the first five months of the treatment after which it decreased 
sharply. Similarly, nausea and vomiting (figure 4.4B), was commonly encountered by 
patients during the first four to six months of the treatment. Moreover, gastritis and 
symptoms of peptic ulcer diseases (figure 4.4C), commonly occurred during the first 
five months after commencing treatment. Common to all of the gastro-intestinal related 
adverse drug reactions was that they started immediately after commencing the 
treatment for MDR-TB. Compared to other adverse drug reactions, peripheral 
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neuropathy started later in the course of the treatment but it continued to occur over a 
longer period in the course of the patient’s’ treatment. As in figure 4.4D, peripheral 
neuropathy was common among patients on treatment until the twelfth month after 
commencing the treatment for MDR-TB.  
 
 
                                     ‘A’                                                                                    ‘B’ 
 
 
                                 ‘D’                                                                                                                 
                               ‘C’ 
Figure 4. 4: Trend of occurrence of second-line drug related adverse drug reactions by months of 
MDR- TB treatment among study participants at Adama and Nekemte referral hospitals, Oromia, 
Ethiopia, December, 2012-September, 2016 (n=91). 
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4.2.2.7. Adherence to treatment  
4.2.2.7.1. Status of patients’ adherence to the daily Directly Observed treatment 
schedule  
From the total of 136 (n=136) patients included in the study, full data on patients’ daily 
directly observable treatment attendance status were available for 93 (n=93) of the 
patients treated for MDR-TB. The study revealed that, for 100 (74%) of the patients, 
the daily directly observable treatment service was arranged at the treatment follow up 
centres as part of the outpatient treatment of MDR-TB. Thirty-six (26%) of the patients 
with MDR-TB attended their daily directly observable treatment at treatment initiating 
centres (hospitals).   
 
The assessment of the patient’s attendance at the standard daily treatment for MDR-
TB through the daily directly observed treatment service, revealed that from total of 93 
patients with data, there was strict daily directly observed treatment attendance by 53 
(57%) of patients.  For the 57% of the patients, there was no evidence of missed daily 
drug doses. However, for 28 (30%) of patients, the rate of attendance at the daily 
directly observable treatment, was found to be good but there was evidences of some 
missed daily drug doses as captured from the patients’ chart.  Furthermore, for 12 
(13%) of the patients, attendance at daily directly observable treatment was found to 
be irregular with substantial doses of drug doses missed in the course of treatment.  
In general, the study revealed that the majority, 81 (87.1%) of the patients included in 
the study, had an acceptable daily directly observed treatment attendance rate, given 
the repeated drug toxicities and the associated challenges it posed on patients’ 
adherence.  
In this study, all the 91 patients assessed for adverse drug reactions experienced at 
least one episode of adverse reaction from second-line drugs and also, 41 (31%) of 
patients had some form of co-morbidity at baseline of which 34 (83%) were due to 
HIV/AIDS. Given these and the reports of the above scholars, the 87.1% attendance 
rate at daily directly observed treatment revealed by this study seemed presumably 
acceptable.  
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4.2.2.8. Status of laboratory follow up services for patients with MDR-TB in the 
course of patients’ treatment   
From the total of the patients included in this study, data on documented routine 
laboratory follow up service during treatment was obtained for only 39 (n=39) patients. 
From the 39 patients, 6 (15%) had satisfactory levels of access to routine follow up 
laboratory services. 33 (85%) had access to follow up services and only very few of 
the WHO recommended and nationally adopted standard laboratory follow up services. 
For the rest of the patients with MDR-TB, there were no data found on the patients’ 
clinical follow up chart regarding the follow up laboratory services during treatment. 
This indicated the absence of standard laboratory follow up services for patients with 
MDR-TB while on treatment.  
 
4.2.2.9. MDR-TB infection control practices  
4.2.2.9.1. Status of tracing the household and the close contacts of patients 
with MDR-TB    
The study revealed that from a total of the patients with MDR-TB that lived with at least 
one household close contact (n=114), contact tracing was conducted for 60 (53%) of 
the patients. For the rest of 54 (47%) of patients, it was unknown whether any of their 
household contacts were traced.  The study revealed that, from the total of 136 patients 
with MDR-TB included in this study, 8 (6%) of the patients were those diagnosed from 
household contacts of the index patients with MDR-TB. Separate analysis of the eight 
patients with MDR-TB diagnosed from close contacts revealed that four patients were 
close contacts of an index case with MDR-TB in one family.  
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4.2.2.9.2. Coordination of the hospital level MDR-TB infection control practices  
It was found that the hospital has a panel team responsible for coordinating the overall 
programmatic management of drug-resistant TB in the hospital. The hospital MDR-TB 
panel team, is composed of caregivers from various disciplines including nurses and 
physicians trained on the clinical and programmatic management of MDR-TB. 
Moreover, laboratory, pharmacy, environmental health professionals and psychiatrists 
were also part of the team.  
The MDR-TB panel team coordinates the activity of the MDR-TB infection control by 
the hospitals. The MDR-TB panel team coordinates the implementation of the annual 
plan on tuberculosis infection control at the premises of the MDR-TB service centres. 
There is evidence, like archived minutes of discussions held on issues of TB infection 
control during the scheduled meeting by the hospitals. 
It was revealed that supportive staff members were given orientation on the basics of 
TB infection control at the meetings. At the MDR-TB treatment centre, there were no 
staff members dedicated for MDR-TB infection control. However, it was reported that 
the control of MDR-TB infection is the responsibility of all caregivers and persons who 
are entering into the MDR-TB treatment centre including the patients with MDR-TB.  
 
4.2.2.9.3. Status of the hospital level MDR-TB infection control practices    
 
4.2.2.9.3.1. Adequacy of the inpatient rooms and MDR-TB infection control 
practices at the inpatient department of the MDR-TB centres   
The result of the quantitative checklist used to observe the premises of the MDR-TB 
treatment centres of the hospitals revealed that the available rooms for patient treated 
as inpatient at the hospitals have opposite windows. The opposite windows were 
opened on the day of the observation with signs of good air circulation. The rooms 
have access to natural light in the morning and in the afternoons. In most inpatient 
rooms, the average distance between adjacent patient beds was found to comply with 
the recommendation of the Federal Ministry of Health (FMOH) 2014:143). But it was 
found that in some cases the distance between adjacent patient beds was less than 
the national recommendations and that happens during times when higher numbers of 
patients are admitted to the centre. 
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There was evidence that patients use plastic container with lids that they used for the 
collection and disposal of expectorates. The hospital MDR-TB nurse reported that there 
were adequate N95 masks for use by attending physicians, nurses and those who 
serve food for patients. It was also observed that patient attendants from family 
member use N95 mask. It was also reported that the hospital had adequate surgical 
facemasks for patients.   
In general, it was observed that there was evidence of good practice and alertness on 
tuberculosis infection prevention by all those entering into the premises of the MDR-
TB treatment units. The premises of the MDR-TB treatment units were clean but there 
was no recreation centre dedicated for patients with MDR-TB while they are in the 
hospitals. As a result, it was reported that there were times when patients with MDR-
TB escape through the fences of the hospital MDR-TB centre and inadvertently mingle 
with the community, which was perceived as a potential risk for MDR-TB transmission 
to the community.  
 
4.2.2.9.3.2. Hospital practices on isolation of infectious patients with MDR-TB   
Caregivers at the treatment initiating hospitals were found to be well aware of the 
danger of MDR-TB infection. At hospital level, there was evidence of the practice of 
isolation of infectious patients with MDR-TB. It was revealed that culture converted 
patients with MDR-TB who are admitted to hospital MDR-TB centres due to any clinical 
events including adverse drug reactions were kept in separate admission rooms. Newly 
admitted patients with MDR-TB were kept separately from old cohorts of patients on 
treatment. Hospital practices in separating culture positive and culture negative 
patients are in conformity with the recommendations of the Federal Ministry of Health 
of Ethiopia. Yet all cohorts of patients with MDR-TB share the same lavatory and 
common recreation area that is dedicated for the MDR-TB centres. Moreover, when 
many patients share a single room, the distance between adjacent beds in a room were 
not consistent with the minimum of 1.8 metres distance between adjacent patient beds’ 
that is recommended by the Federal Ministry of Health of Ethiopia. 
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4.2.2.9.4. Community level MDR-TB infection control practices  
 
4.2.2.9.4.1. Means of patient transport from hospitals to the community level 
MDR-TB treatment follow up centres  
The study revealed that during the initial patient linkage to the community level 
treatment follow up centres, 97 (92%) of patients were escorted by the nurse caregivers 
from treatment centres of the hospitals. The hospital ambulances were used to 
transport patients from the hospitals to treatment follow up centres.  
Given that the hospital ambulances were not consistently available to transport all 
patients with MDR-TB, patients used public transport services to reach the treatment 
follow up centres and back to their home area as well.  Most of the patients linked to 
the community level MDR-TB treatment follow up centres were not culture converted. 
As such, the practice of using the conventional public transport service by patients with 
MDR-TB seemed to be a potential risk factor for MDR-TB transmission to the general 
community. 
Caregivers from both the study sites mentioned that the hospital ambulance vehicles 
were primarily dedicated for transporting emergency medical cases especially 
maternal medical emergencies. Thus it was only when the ambulance was freely 
available that the ambulance was used to transport patients with MDR-TB. Caregivers 
also mentioned that whenever the ambulance service was used to transport patients 
to treatment follow up centres, it was used to transport newly diagnosed patients from 
peripheral health facilities to hospitals. That is, the ambulance was used to transport 
newly diagnosed patients who were transported to the hospitals for initiation of 
treatment for MDR-TB.  
Once patients with MDR-TB were initiated on second-line drugs, they consistently used 
public transport to return to the nearby treatment follow up centres. Thereafter, patients 
use the conventional public transport during their monthly travels to attend the monthly 
MDR-TB clinic at the hospitals and back to their respective treatment follow up centres 
and their homes. 
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4.2.2.9.4.2. Household level MDR-TB infection control practices 
Analysis of the status of MDR-TB infection control was conducted for 105 (77%) 
patients with MDR-TB (n=105) for whom data on household level MDR-TB infection 
control was available. There was no housing arrangement prepared before the patient 
with MDR-TB was linked back to the community. There were no MDR-TB infection 
control arrangements at the patient’s household level as well. The result of this study 
revealed that, 8 (6%) of the total patients with MDR-TB included in this study were 
diagnosed among household contacts.  
 
Caregivers found at the hospitals and the treatment follow up centres were not 
implementing the activities recommended on household level MDR-TB infection 
prevention and control recommended by the Ethiopian National Programmatic 
Management of Drug-resistant tuberculosis (PMDT) guidelines. Caregivers were 
expected to ensure minimum MDR-TB infection control practices at the patient’s 
household level for patients linked to community level MDR-TB treatment and follow 
up services.  Yet, this study revealed that caregivers at the treatment follow up centres 
were not visiting the home area of a patient linked to the community. Thus, the following 
core activities on MDR-TB infection prevention and control at the patient’s household 
level were not implemented including: 
 Collecting information on the number of living quarters available in the patient’s 
home and on the number of household members. 
 Educating the family on the support expected from patient’s family to enable the 
patient with MDR-TB to properly adhere to MDR-TB treatment. 
 Inspecting the patients’ living quarters to make sure that it can address the 
requirements of respiratory MDR-TB infection prevention at household level 
 Ensure that each family member can follow the minimum tuberculosis infection 
control precautions. 
 Making sure that the household level family members who are caretakers of the 
patient with MDR-TB use respirators as a personal protective measure against 
MDR-TB infection.   
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In this way, in view of the MDR-TB infection control recommendations of the national 
programmatic management of drug-resistant tuberculosis in Ethiopia, the study 
revealed that there was no practical attempt made by the system on mitigating the 
problem of MDR-TB infection control at the patient’s household level. 
In a nutshell, the study revealed that the current practice in the study areas failed to 
comply with the minimum community level MDR-TB infection control practice 
recommended by the national programmatic management of drug-resistant 
tuberculosis (PMDT) of Ethiopia.  
 
4.2.2.10. Decentralization of the MDR-TB treatment services to the community   
It was found that patients with MDR-TB were initiated on treatment for MDR-TB at the 
hospitals. Once they were stabilized, patients are linked to the community level 
treatment follow up centres, which are health centres.  
The study has shown that from a total of 136 patients included in the study, 100 (73%) 
were linked to the community level MDR-TB treatment and follow up services. For all 
the 100 (73%) patients who were linked to the community the responsibility of providing 
daily observed treatment support for the patients was assigned to caregivers found at 
the treatment follow up centres. Yet, for most of the patients linked to the community 
level treatment follow up centres data on the daily directly observed treatment support 
was not complete.  
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4.2.2.11. Treatment outcomes of patients with MDR-TB at Adama and Nekemte 
referral hospitals   
4.2.2.11.1. Interim (six month) treatment outcome of patients with MDR-TB  
For all patients with MDR-TB those enrolled to the treatment for MDR-TB, treatment 
outcome is evaluated at two phases. These are the interim treatment outcome which 
is determined at six-month after commencing the treatment for MDR-TB. The other 
treatment outcome is called the final treatment outcome which is determined at the 
completion of the treatment for MDR-TB.  As shown in the table 4.3 below, analysis of 
the interim treatment outcome of patients by month six showed that from the total of 
136 patients, 97(71%) were culture negative. Twenty-seven (20%) of the patients died 
by month six. However, the six-month treatment outcome was not evaluated and 
documented for 12 (9%) patients. 
 
Table 4. 3: Interim (six month) treatment outcome of patients with MDR-TB among study 
participants at Adama and Nekemte referral hospitals, Oromia, Ethiopia, December, 2012-
September, 2016 (n=136) 
Interim (six month) treatment outcome (N=136)  Number (%) 
Culture Negative  97 (71%) 
Culture positive  0 (0%) 
Died by six month  27 (20%) 
Six month treatment outcome not evaluated   12 (9%) 
Culture Positive  0 (0%) 
LTFU 0 (0%) 
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4.2.2.11.2. Final treatment outcome of patients with MDR-TB 
As shown in table 4.4, from the total of 136 patients included in the study, the final 
treatment outcomes was determined and was available for 110 (81%) of the patients. 
Twenty six (19%) of the patients were still active and were on treatment by the time of 
data collection.  From the total of 110 (n=110) patients for whom treatment outcome 
was assigned at time of data collection, 76 (69%) had successfully completed their 
treatment. From those who successfully completed treatment for MDR-TB, 65 (59%) 
patients were those who were declared cured. The remaining 11 (10%) patients did 
not have documented laboratory follow up results but had successfully completed their 
treatment for MDR-TB. Thus the composite treatment success rate for patients 
included in this study was 69%. Death was the second higher treatment outcome for 
patients with MDR-TB included in this study. As such, 30 (27%) of the patients with 
MDR-TB died from the disease by the twenty-forth months after commencing the 
treatment for MDR-TB. The treatment outcome of 3 (3%) patients with MDR-TB were 
not evaluated mainly due to transfers of patients to other treatment follow up centres 
and reports on their treatment outcomes were not returned  to the treatment initiating 
centres. One patient (1%) was lost to follow ups and the patient was not retrieved until 
the time of data collection. The details of the patients’ final treatment outcomes are 
shown in table 4.4 below.  
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Table 4. 4: Final treatment outcome of patients with MDR-TB among study participants at 
Adama and Nekemte referral hospitals, Oromia, Ethiopia, December, 2012-September, 2016 
(n=110). 
1. Final treatment outcome assigned (n=110)  Number (%) 
─Cured 65 (59) 
─Treatment completed 11 (10) 
─Composite treatment success rate (cured & treatment 
completed) 
76 (69) 
─Died 30 (27) 
─LTFU  1 (1) 
─Not evaluated 3 (3) 
2. Active and on treatment  26 (19) 
 
Final treatment outcomes of patients with MDR-TB was disaggregated by the hospitals 
to show differences in the final treatment outcomes of patients by the site of treatment. 
As shown in tables 4.5 and 4.6, the treatment outcomes of patients with MDR-TB 
differed by the site of treatment. The 72% treatment success rate among patients 
treated at Nekemte Referral Hospital was much higher than the 44% treatment success 
rate among patients treated at the Adama Hospital Medical College. Moreover, there 
was higher proportion of death among patients treated at the Adama Hospital Medical 
College (29%) compared to the proportion of death among patients treated at the 
Nekemte Referral Hospital (12%). The details of the final treatment outcomes by site 
of treatment are shown in tables 4.5 and 4.6 below.  
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Table 4. 5: Final treatment outcome of patients with MDR-TB among study participants at 
Adama Hospital Medical College, Oromia, Ethiopia, December, 2012-September, 2016 (n=79). 
1. Final treatment outcome assigned (n=79)  Number (%) 
─Cured 32 (40.5) 
─Treatment completed 3 (4) 
─Composite treatment success rate (cured & treatment 
completed) 
35 (44) 
─Died 23 (29) 
─LTFU  1 (1) 
─Not evaluated 2 (2.5) 
2. Active and on treatment  18 (23) 
 
 
Table 4. 6: Final treatment outcome of patients with MDR-TB among study participants at 
Nekemte Referral Hospital, Oromia, Ethiopia, December, 2012-September, 2016 (n=57). 
1. Final treatment outcome assigned (n=57)  Number (%) 
─Cured 33 (58) 
─Treatment completed 8 (14) 
─Composite treatment success rate (cured & treatment 
completed) 
41 (72) 
─Died 7 (12) 
─LTFU  0 (0) 
─Not evaluated 1 (2) 
2. Active and on treatment  8 (14) 
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4.2.2.11.3. Factors determining the treatment outcomes of patients with MDR-
TB  
Both bivariate and multivariable logistic regression analyses were used to test the null 
hypothesis of no relationship between the treatment outcomes of patients with MDR-
TB and the patients’ socio-demographic and clinical characteristics(Gaur & Gaur 
2009:92-98; Healey 2009:293).  Table 4.7 shows the status of the treatment outcomes 
of patients with MDR-TB (n=110) regarding various clinical characteristics of the 
patients included in the study.   
 
Table 4. 7: Summary of MDR-TB treatment outcome by various clinical characteristics of the 
study participants at Adama and Nekemte referral hospitals, Oromia, Ethiopia, 
December, 2012-September, 2016 (n=110). 
 
Variable Category Favourable 
treatment 
outcome (cured 
or treatment 
completed) (n/%) 
Unfavourable 
treatment outcome 
(Death) (n/%) 
Total 
(n/%) 
Sex Male 50 (77) 15 (23) 65 (59) 
Female 26 (58) 19 (42) 45 (41) 
BMI <18.5Kg/m2 40 (60) 26 (39) 66 (60) 
>/=18.5Kg/m2 36 (82) 8 (18) 44 (40) 
Any co-
Morbidity at 
baseline 
Yes 18 (53) 16 (47) 34 (31) 
No 58 (76) 18 (24) 76 (69) 
HIV  Positive 14 (52) 13 (48) 27 (25) 
Negative 62 (75) 21 (25) 83 (75) 
Smear 
Status  
Smear 
Positive 
61 (75) 20 (25) 81 (74) 
Smear 
Negative 
15 (52) 14 (48) 29 (26) 
Resistance 
type  
RR-TB 39 (61) 25 (39)  64 (58) 
MDR-TB 37 (80)  9 (20) 46 (42) 
Initial 
Bacillary 
load 
Moderate to 
high 
50 (68) 23 (32) 73 (66) 
No AFB to 
scanty 
26 (73) 11(30) 37 (34) 
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4.2.2.11.4. Bivariable analyses of the factors determining the treatment outcomes of patients with MDR-TB 
At the bi-variable analysis level, the relationship between the dependent variable and each of the predicator variables of 
interest was explored. This is shown in table 4.8. 
Table 4. 8: Summary of bivariate analyses on the determinants of MDR-TB treatment outcomes of the study participants at Adama 
and Nekemte Referral Hospitals, Oromia, Ethiopia, December, 2012-September, 2016 (n=110). 
Variable Category Favourable treatment 
outcome (cured or 
treatment completed) 
(n/%) 
Unfavourable 
treatment 
outcome 
(Death) (n/%) 
Total 
(n/%) 
Crude OR Wald x2 
test 
result 
P-
value 
95% CI 
Sex Male 50 (77) 15 (23) 65 (59) ____ _____ ____ ______ 
Female 26 (58) 19 (42) 45 (41) 2.436 4.459 <0.035 1.066-5.566 
BMI >18.5Kg/m2 36 (82) 8 (18) 44 (40) ____ _____ ____ ______ 
</=18.5Kg/
m2 
40 (60) 26 (39) 66 (60) 2.925 5.327 <0.021 1.176-7.277 
Any co-
Morbidity 
at 
baseline 
No 58 (76) 18 (24) 76 (69) ____ _____ ____ ______ 
Yes  18 (53) 16 (47) 34 (31) 2.864 5.802 <0.016 1.217-6.743 
HIV  Negative  62 (75) 21 (25) 83 (75) ____ _____ ____ ______ 
Positive 14 (52) 13 (48) 27 (25) 2.741 4.795 <0.029 1.112-6.761 
Resista
nce type  
RR-TB 39 (61) 25 (39) 64 (58) ____ _____ ____ ______ 
MDR-TB 37 (80)  9 (20) 46 (42) 2.635 4.608 <0.032 1.088-6.384 
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From the total of 65 (100%) patients who were cured from the MDR-TB disease, 43 
(66.2%) were male while 22 (34%) were female patients. Of the total of 30 (100%) 
deaths that occurred among all patients with MDR-TB included in the study, 19 (42%) 
were female patients and 15 (23%) were male patients.  
As shown in table 4.8, the study revealed a relationship between the sex of the patients 
and the treatment outcomes of the patients with MDR-TB.  Compared to the male 
patients with MDR-TB, a higher proportion of death and a lower proportion of 
favourable treatment outcomes were observed among female patients with MDR-TB 
(Crude OR=2.436; X2 =4.459; P<0.035; 95%CI=1.066-5.566). 
 
The study also revealed a relationship between some co-morbidity with MDR-TB at the 
baseline and the treatment outcomes of patients with MDR-TB.  The odds of death 
from MDR-TB among patients with MDR-TB who had some co-morbidity with MDR-TB 
at the baseline was higher than the odds of death among patients without any co-
morbidity with MDR-TB at the baseline (Crude OR=2.864; X2 =5.802; P<0.016; 
95%CI=1.217-6.743), (See table 4.8). 
Moreover, a separate analysis of the patients’ cure rate by patients’ HIV sero-status 
revealed that the treatment outcomes of patients differed by the status of MDR-TB co-
infection with HIV. Compared to HIV and MDR-TB co-infected patients, a higher cure 
rate was observed among HIV negative patients with MDR-TB. From the total of 65 
(100%) patients who were cured from the MDR-TB disease, 52 (80%) of the cured 
patients were HIV-negative. HIV co-infected patients with MDR-TB constituted only 13 
(20%) of the total patients cured from the disease. A separate analysis of the risk of 
death between patients with MDR-TB and those patients with MDR-TB co-infected with 
HIV/AIDS revealed that compared with patients without co-infection with HIV/AIDS, a 
higher risk of death was observed among patients with MDR-TB co-infected with 
HIV/AIDS  (Crude OR=2.741; X2 =4.795; P<0.029; 95%CI=1.112-6.761), (See table 
4.8) 
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The study also revealed a relationship between death and patients’ body mass index 
(BMI). As such, the study revealed that the odds of death among patients with low body 
mass index , that is, BMI <18.5Kg/m2 was about 3 times higher than the odds of death 
among patients with body mass index greater than or equal to 18.5Kg/m2  (Crude 
OR=2.925; X2 =5.327; P<0.021; 95%CI=1.176-7.277), (See table 4.8). 
 
Likewise, the study revealed a relationship between the type of drug resistance and 
the treatment outcomes of patients with MDR-TB. Compared to patients diagnosed as 
rifampicin resistant tuberculosis (RR-TB), the odds of death from MDR-TB was higher 
among patients diagnosed as MDR-TB (Crude OR=2.635; X2 =4.608; P<0.032; 
95%CI=1.088-6.384) (See table 4.8) 
 
Furthermore, at the bivariate analyses level, the study showed an association between 
the presence of fibrotic (extensive) lung lesion and the treatment outcomes of patients 
with MDR-TB. As shown in table 4.9, the presence of a fibrotic cavitary lung disease at 
diagnosis, which is indicative of advanced disease status, was found to have a 
significant relationship with MDR-TB treatment outcome. From the total of four patients 
with MDR-TB who had fibrotic lung disease at diagnosis, three patients died of the 
disease (Phi X2 =0.405, P<0.017).  
  
Table 4. 9: MDR-TB treatment outcome by presence of fibrotic lung lesion at diagnosis of the 
study participants at Adama and Nekemte referral hospitals, Oromia, Ethiopia, December, 
2012-September, 2016 (n=35). 
Variable Category Death 
(n/%) 
No death 
(n/%) 
Total Phi X2 
test result 
P-Value  
Fibrotic 
Lung 
Lesion  
Fibrotic lung 
lesion exists  
3  1 4  
0.405 
 
0.017 
No fibrotic 
lung lesion  
 25 6 31 
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4.2.2.11.5. Multivariable logistic regression of the factors determining the 
treatment outcomes of patients with MDR-TB 
The determinants of the treatment outcomes of patients with MDR-TB treated for MDR-
TB at the two study sites is presented in table 4.8. Regression analysis was used to 
determine which of the socio-demographic and clinical characteristics best explain 
variations in the treatment outcomes of patients with MDR-TB (Clark &Creswell 
2015:31). Logistic regression model was used to determine independent predictors of 
the treatment outcomes of patients with MDR-TB. Logistic regression model can fairly 
be visualised with small number of predictor variables, even though it can be used with 
up to ten or more predictor variables (Field 2009:211). 
Predictor variables with p-values of less than 0.25 are cited in the literature as 
established factors determining the treatment outcomes of patients with MDR-TB. As 
such, predictor variables of interest (patients’ socio-demographic and clinical 
characteristics) those with p-values of less than 0.25, that is, predictor variables those 
effectively predicting the treatment outcomes of patients with MDR-TB  were fitted into 
the final logistic regression model.  
For the final multivariable logistic regression analyses, all the assumptions of analyses 
were checked and were appropriate for the statistical tests used. These included, the 
normality of continuous variables and multicollinearity effect between independent 
factors. Moreover, an analysis of the model fit showed that there was no difference 
between the observed and expected sample values (Hosmer and Lemeshow Test 
showing P value of 0.757).  
 
4.2.2.11.6. Results of the multivariable logistic regression of factors 
determining the treatment outcomes of patients with MDR-TB 
As shown in table 4.10, the final multivariable logistic regression analyses revealed 
that the odds of death among patients with MDR-TB who had some co-morbidity with 
MDR-TB at the baseline was significantly higher than the odds of death among those 
patients with MDR-TB who were without any co-morbidity with MDR-TB at the baseline 
(AOR=4.260, 95%CI: 1.607-11.297; P<0.004). 
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Moreover, the odds of death from MDR-TB among patients with low body mass index 
(MBI), that is, BMI < 18.5kg/m2 was found to be 2.7 times higher than the odds of death 
from MDR-TB among patients with body mass index greater than or equal to 
18.5Kg/m2  (AOR=2.734, 95%CI: 1.01-7.395; P<0.048).  
Furthermore, the odds of death from MDR-TB among female patients with MDR-TB 
was significantly higher than the odds of death among male patients with MDR-TB 
(AOR=2.511, 95%CI: 1.005-6.272; P<0.049).  
In summary, about 26% of the total deaths from MDR-TB revealed in this study were 
explained by the three final independent determinants of the treatment outcomes of 
patients with MDR-TB. These were the presence of some co-morbidity with MDR-TB 
at the baseline, low body mass index (BMI) (that is, BMI <18.5kg/m2) and being a 
female patient with MDR-TB (Nagelkerke R Square=0.257). 
 
 
Table 4. 10: Results of the multivariable analysis using logistic regression on factors associated 
with unfavourable MDR-TB treatment outcome of the study participants at Adama and Nekemte 
referral hospitals, Oromia, Ethiopia, December, 2012-September 
 Variable  
Crude 
OR* 
95% CI P-Value AOR** 95% CI P-Value 
Presence of any 
co-morbidity at 
the baseline 
 
2.864 
 
1.217-6.743 
 
0.016 
 
4.260 
 
1.607-
11.297 
 
0.004 
Body Mass 
Index (BMI)  
 
2.925 
 
1.176-7.277 
 
0.021 
 
2.734 
 
1.01-7.395 
 
0.048 
Sex  2.436 1.066-5.566 0.035 2.511 1.005-6.272 0.049 
HIV  2.7.41 1.112-6.761 0.029 0.088 _ 0.767 
Drug-resistance 
type 
2.635  
1.088-6.384 
 
0.032 
 
2.630 
 
_ 
 
0.105 
OR* =Odds Ratio; AOR*=Adjusted Odds Ratio 
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4.3. Results for the qualitative component of the study  
4.3.1. Introduction to the qualitative result from the interviews with patients  
A total of 18 adult participants, that is, patients with MDR-TB (9 females and 9 males) 
aged above 18 years was included in the in-depth interviews. Three of the 18 (≈17%) 
patients openly identified themselves as having some co-morbid conditions with MDR-
TB. Two of the 3 patients with MDR-TB were co-infected with HIV while one was a 
patient with MDR-TB who developed diabetes in the course of the treatment given for 
MDR-TB.  
At the end of each excerpt are initials and a number to indicate the number of the 
participant and their sex. For example, “P-2M”, with “P-2” indicating participant 2, and 
“M” indicating the male gender of the participant.   
4.3.2. How did the patients with MDR-TB know that they had MDR-TB?  
The study revealed that the first trial of tuberculosis diagnosis was made at the nearby 
health centre for all the patients who participated at the interviews. The first level of 
tuberculosis diagnosis was made by the use of the basic diagnostic tools including the 
direct sputum microscopy and the use of radiography.  
Many patients with MDR-TB were diagnosed with MDR-TB after the failure of the 
generic first-line tuberculosis treatment regimen. Indeed, some of the tuberculosis 
patients reported that the time they spent taking first-line anti-tuberculosis drugs 
delayed them in the initiation of the second-line anti-tuberculosis drugs given for the 
MDR-TB. The excerpt taken from one of the patient confirms this: 
 
“…. I completed the six month treatment given for tuberculosis and the cough 
decreased but did not disappear completely… there was expectoration and cough 
despite the treatment I was taking…then the nurse told me that I had to start the eight 
month treatment regimen,… after fifteen days, I submitted sputum and they told me 
that the type of tuberculosis I suffered from was resistant to the drugs I was taking and 
I was sent to this hospital,…[P-2M]”. 
On the other hand, some of the patients with tuberculosis were promptly diagnosed of 
MDR-TB after failure of the first six months based tuberculosis treatment regimen.  The 
excerpt below illustrates this. 
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 “…On the same day I completed the six-month treatment, the sputum result was 
returned,…I completed the six month treatment in the morning and in the afternoon  I 
was called back to the hospital and when I went back, they told me that it is drug-
resistant tuberculosis and told me to go to Nazareth, that is Adama hospital…[P-12F]”. 
 
Participants mentioned that the larger community does not have insight about the 
MDR-TB disease and its way of transmission. As such, all the patients included in the 
in-depth interviews knew that they had MDR-TB only after failure of the generic anti-
tuberculosis treatment regimen that they were taking. The below excerpt clarifies low 
community awareness on MDR-TB: 
  
“…Yea, at our village, people do not know much about MDR-TB. They do not know 
that the disease is difficult to cure. They do not perceive it as a serious disease…but 
because now I know about the disease, I refrain from mingling with people… [P-1F]”.  
 
The low public awareness of MDR-TB and how transmission occurs may be 
contributing factors for the higher proportion (6%) of the total 136 patients with MDR-
TB who were diagnosed among contacts of the index patients with MDR-TB. The 
interviews with patients revealed that 2 (11%) of the eighteen patients with MDR-TB 
who participated in the in-depth interviews were those who contracted MDR-TB from 
index patients within their own family. One of the two patients blamed health caregivers 
for not informing her about the possibility of the transmission of MDR-TB from person-
to-person.                                                                                                                                                                       
 
“…I caught the disease while I was taking care of my husband... the health centre did 
not tell us that it can be transmitted … [P-6F]”. 
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4.3.3. Patients’ perceived quality of the clinical care and services provided for 
MDR-TB at the Adama and Nekemte Referral Hospitals 
4.3.3.1. Level of patients’engagement in the MDR-TB treatment and services 
related decision making  
The main theme from responses forwarded by all participants interviewed, revolved 
around the counselling and adherence preparation provided by the caregivers for 
MDR-TB at treatment initiating centres. 
The majority of the participants reported that they had discussions with their caregivers 
regarding the treatment they take for MDR-TB. The main issues of discussions 
between patients and their caregivers included MDR-TB treatment, the drugs taken 
and the duration of the treatment. The majority of participants mentioned that they were 
told what to do in case they encountered unexpected problems during the course of 
the treatment given for MDR-TB. Thus, the main theme of the reported discussions 
between patients and their caregivers revolved purely around the medical treatment 
and services that the patients were getting from clinical caregivers. Patients mentioned 
that they were not part of the decision made regarding the non-medical services 
including nutrition for patients with MDR-TB and the financial support they got from the 
hospitals. The next excerpt clarifies absence of the use of patients’ views in nutrition 
related decision making:   
 
“… I mean it is just three months since I started the treatment, the types of services I 
get are bed accommodation and food… there is a problem on this issue.  I am not given 
the food that I need, that is good for persons like me who is treated for MDR-TB.  We 
eat the same type of food every day and the same is true throughout the week… we 
always complain but there are no changes in the type of food we eat….[P-3M].  
 
In this way, it was revealed that the hospitals were not using the views and opinions of 
the patients with MDR-TB in the planning and implementation of the socioeconomic 
support provided for patients in the form of nutrition and financial reimbursement. Thus, 
interviews participants reported that the socio-economic support could not address the 
needs and preferences of patients with MDRTB. 
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4.3.3.2. Patients’ perception on the responsiveness of the care given for MDR-
TB  
Discussions were held with patients regarding the caregivers’ prompt availability when 
demanded by patients with MDR-TB. As such, the majority of patients with MDR-TB 
mentioned that caregivers were not promptly available to the care demand of the 
patients with MDR-TB. The case was reported to be serious when caregivers were not 
available in the case of emergent medical events that patients with MDR-TB 
encountered. A patients who went into comatose status due to absence of prompt care, 
nervously explained the traumatic experience. 
 
  “… at one time I was seriously ill and I was brought by car to this centre. When we 
arrived, there was no doctor. Then, I fainted and was near death. He came five hours 
after he was called and that was when I lost consciousness, at that time it means that 
I was dead…it would have been good if the doctor was here and I was treated on time 
and  I could tell him about the pains and problems I had,…”[P-1F]. 
 
Most of the patients with MDR-TB were too weak to help themselves cope with routine 
personal care they needed. When such patients encountered clinical emergencies that 
worsened their physical strength, they faced difficult challenges to survive the disease 
and its treatment. A participant narrated how the absence of prompt clinical care has 
made patients suffer to the point that they could not cope up with the disease and its 
treatment.   
 
“…now I am getting stronger, I don’t have a  problem but for other patients who are 
weak, it is serious that the caregivers are not available here the whole day, they do not 
attend to the patients when needed and they only come after the patient enters into 
coma. I have seen that the situations are endangering many patients in this centre… 
[P-3M]”. 
 
An excerpt of another participant further illustrates the absence of health caregivers: 
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“…To tell you the truth, in this compound, this nurse is the only one sister who prudently 
accomplishes her duty. She is good and when she is on duty, she spends the whole 
night in this compound but we do not get to see the others…[P-5F]”.  
 
The majority of patient participants reported that at the MDR-TB treatment initiating 
centres (hospitals), the communication between caregivers and the patients with MDR-
TB was good. Yet, patient participants consistently mentioned that, at the hospitals, 
the caregivers for MDR-TB were not accessible during emergent disease conditions 
that patients with MDR-TB face. The excerpt below illustrates how a patient with MDR-
TB who encountered an emergent medical condition experienced lack of prompt 
clinical care for the emergent medical condition that she experienced:   
 
“…we pass a day with our pain and even if we die we die alone… [P-5F]”.   
 
Patient participants reported that the difficulty in accessing a doctor for emergent 
medical conditions is even worse during out of the normal working hours.  
 
“…it is challenging overnight, they only come through if there is a telephone call alerting 
them…[P-9M]”.     
 
If the patient-caregiver communication was good, the complaints that patients with 
MDR-TB raised would be associated with the lack of full-time physicians who are 
dedicated exclusively for taking care of the patients with MDR-TB. The interviews with 
physicians revealed that taking care of the patients with MDR-TB is only one of the 
many clinical care duties that the physicians are assigned to perform in their hospital.  
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4.3.3.3. Patients’ perception on the status of communication between patients 
and the caregivers for MDR-TB 
Participants invariably mentioned that they were very friendly with caregivers at the 
treatment initiating hospitals. Some participants reported that the relationship they 
have with their caregivers at hospitals, surpasses the normal patient-caregiver 
relationship. It was reported that caregivers at hospitals see patients with MDR-TB as 
members of their own families.  
 
“….the doctor has been suffering with me and he pays for my transport from his own 
pocket and also gives me money for my lunch… [P-8F]”. 
 
From the interviews with caregivers for MDR-TB, it was revealed that clinical caregivers 
were involved in non-clinical services provided by the hospital for the patients with 
MDR-TB. The next excerpt from interviews with a physician illustrates this;  
 
“…in many instances, we personally prepare the breakdown of the financial and 
nutrition services provided for patients and we submit it to the finance department…in 
many cases, they are nurses who handle the monthly payments made for patients… 
we have debates around the budget with them…[P-5F]”.  
 
On the other hand, a few participants reported that the way caregivers found at the 
treatment follow up centres treated them was discouraging. Patients mentioned that 
they were stigmatized by the caregivers of the treatment follow up centres. The excerpt 
below illustrates the level of communication between patients and their caregivers at 
the treatment follow up centres:  
 
“…But the attendance and the care given here at this hospital is very different from the 
care given at other treatment follow up centres; the care at the health centre is very 
weak. There are times when caregivers close their doors against us and abandon us 
and these are educated professionals. There are times when they deny us treatment 
 
188 
 
for two to three days and we end up phoning   the hospital to complain about the 
situation. …[P-5F]. 
 
4.3.4. Patients’ perceptions and experiences on the status of the nutrition 
support available for patients with MDR-TB 
A qualitative inquiry was made into the perception of participants on the status of the 
nutrition support that was provided to patients with MDR-TB by the hospitals. 
Participants reported that an Ethiopian cultural food called ‘injera’ with Ethiopian 
cultural sauce called ‘shiro’ was the most commonly served food type for patients with 
MDR-TB admitted at the hospitals.  
‘Injera’ is the most readily available and commonly served staple food in Ethiopia. 
‘Injera’ is a type of bread prepared from a local grain called ‘teff’. ‘Shiro’ sauce is 
prepared from peas. Participants also mentioned that patients were served with a meat 
sauce. However, the meat sauce was served to patients irregularly and was of poor 
quality. They called it a ‘watery sauce'. 
 
Participants reported that patients at the outpatient phase of the MDR-TB treatment, 
got nutrition and transport support during their monthly hospital visits to attend the 
monthly MDR-TB Clinic Days. The food items that participants received   on a monthly 
basis at the outpatient phase of their treatment included edible oil, lentils, milk powder 
and grain flour. Both outpatients and inpatients treated at hospitals described   the 
quality and the quantity of the food items that they were getting as poor. Almost all 
participants were nervous when the issue of nutrition support they get from the hospital 
was presented for discussion. The excerpts below clarifies this: 
 
“…about the food, it is better not to discuss it [P-9M]; “…we are hurt… every morning, 
at lunch-time and at  dinner, you are given ‘injera’ with ‘shiro’ sauce and that is all… 
[P-1F]. 
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Participants were dissatisfied with the food they were served or given, stating that it is 
far from being adequate for patients with MDR-TB. An excerpt taken from a participant 
who was in the outpatient phase of his treatment illustrates this:   
 
 “…the food given by the hospital cannot be enough for one month,…not enough 
unless there is support from parents and relatives …[P-2M]” 
 
Another participants echoed the issue of inadequacy of food for patients: 
 
 ; “…no, it is not sufficient, how can 10 kilogramme of grain flour be sufficient for one 
month? It is certainly not adequate [P-8F]”.  
 
Sometimes we miss some of the daily meals like breakfast…they say ‘we do not have 
this and that....’, how can we take these drugs without having our breakfast?…if we 
have some money, we go out and eat some ‘shiro’  and then take the drugs….such 
problems exist… and in terms of food, we better not  talk…[P-9M]”. 
 
 
 
The second issue most frequently reported by participants was associated with the 
quality of the nutrition support provided for patients with MDR-TB. Participants reported 
that the food they were served was tasteless. This means that, participants asserted, 
patients who had a poor appetite could not eat.  
 
 “….even a healthy persons cannot eat the food they give…previously, they used to 
give us milk, but this time they are not giving us the milk and the drugs are burning me 
up and how can I digest the drugs that burn me inside? …[P-10M]”.  
 
Some participants reported that the MDR-TB disease decreases the appetite of 
patients and the poor quality of food that they were served at hospital further puts them 
in a difficult position and they cannot take the treatment on a daily basis. 
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“…until three months ago, I was only eating fried peas and because I could not eat the 
food I was served at the hospital… [P-4M]”. 
 
The poor quality of the food served at the hospitals was further explained by another 
participant as illustrated in the excerpt below: 
 
“…when they serve us meat sauce, it is just watery…we could not eat that…it is 
tasteless, they do not have the ethics…there is a serious problem with regard to the 
food...[P-5F]”. 
 
It was apparent that some participants did not want to engage in discussions releted to 
the state of the food served in the hospital. But when probed, they narrated their 
experiences. 
 
 “‘They served the same type of food every day and it has no taste…sometimes 
delicious food is needed…important food like eggs are not served’…[P-12F]”. 
 
It was also revealed that participants lacked the financial capacity to supplement the 
food they were given by the hospitals. Many participants reported that they live in rental 
houses and live on an income that they used to get from daily wage from labour work. 
It was mentioned that most of the patients were enrolled to the treatment for MDR-TB 
after a long journey and after at least one course of treatment with first-line anti-
tuberculosis drugs. Participants reported that by the time patients were admitted for 
MDR-TB treatment, they had spent much of what they had for their livelihood. 
Ultimately, participants highlighted, the MDR-TB disease and the second-line drugs 
given for the treatment of MDR-TB weakened them. From the participants’ point of 
view, this meant that most patients would not have the strength to continue doing 
labour work. In a nutshell, the participants noted that patients were not happy both with 
the quantity and the quality of the nutrition support that they were given by the hospitals. 
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4.3.4.1. Patients’ perception and experience on the status of financial support 
available for patients with MDR-TB  
The qualitative data revealed that patients with MDR-TB were reimbursed for the 
transport costs that they had incurred. Patients went to hospitals on a monthly basis to 
attend their monthly clinical follow up services and also to collect the nutrition support 
that they were given by the hospitals.  
Participants reported gaps in the financial support that patients with MDR-TB received 
from hospitals. Firstly, they noted that hospitals reimbursed transport costs if the 
patients produced official receipts. Participants also mentioned that patients  could only 
obtain transport receipts  from vehicles that travel long distances and  had  not obtained 
receipts from local transporters like taxies and carts even though they had made 
payments during their monthly travel to and from the main bus stations. This meant 
that, participants emphasised, transport costs for taxies and carts remained unnoticed 
and were not refunded.  Secondly, participants noted that during the long outpatient 
phase of their treatment, patients pay transport costs for transporting the food items 
that they were given on a monthly basis. They highlighted that the cost of transporting 
the food items, from the hospitals to their home, was not considered in the financial 
support that they get from the hospitals.  Thirdly, patients and caregivers equally 
reported that there were times when patients were given less financial support than the 
amount they needed for their monthly visits to the hospitals. The next excerpt from a 
caregiver illustrates this: 
 
“… there were incidences when patients were paid  for single trip transport 
costs…….as a result,  we had debates on budget; they said that the budget had been 
used up, even when the funds were actually available….[P-5F]. 
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4.3.4.2. Patients’ perception and experience on the conditions of service-
setups at the hospitals                    
The majority of participants reported that the open compound within the premises of 
the MDR-TB treatment units in the hospital was clean. Thus, most participants were 
happy with the cleanness of the compound of the hospital MDR-TB units.  
On the other hand, participants narrated that the patients’ living rooms and the toilets, 
including the shower rooms, were not clean. Participants mentioned that the toilets 
dedicated for patients’ use, were not emptied timely. Participants stressed that there 
were times when the toilets were full and spilt over, making it difficult for patients to use 
them. In the same way, the living rooms of patients treated as inpatients were not 
cleaned on a daily basis mainly because of the absence of a dedicated cleaner who 
could daily clean the toilets, the shower rooms and the living rooms of patients treated 
as inpatients. 
Participants claimed that patients were not allowed to go out of the premises of the 
MDR-TB treatment unit. Yet, participants noted that there was no recreation quarter 
dedicated for patients with MDR-TB on the premises of the MDR-TB treatment units. 
According to participants, it was for this reason that patients were bored of staying in 
the premises of the hospitals MDR-TB units.  The next excerpt taken from a participant 
treated as inpatient at a hospital clarifies how a social exclusion started at home further 
worsened by the situation at the hospital MDR-TB treatment units:   
 
“… the social life, you cannot live with others. I know what happened to me…before I 
came here, all the neighbours and all family members avoided me….when they brought 
me to this hospital, here also there was no recreation and that affected me mentality 
until now, they give me food and you can say that it is a prison for me. It is difficult to 
be separated from family. It is what God gave me and I did not buy the disease… [P-
14M]”. 
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4.3.4.3. Level of patients’ satisfaction with the overall care and services given 
for MDR-TB at the Adama and Nekemte Referral Hospitals  
A substantial number of participants reported that patients were satisfied with the 
clinical care that they were getting at the hospitals. They mentioned that, when 
available, caregivers at the hospitals were respectful and caring towards patients with 
MDR-TB. They also mentioned that most of the hospital caregivers were approachable 
to discuss patients’ treatment related issues.  
 
“…wow! it is unparalleled, especially the female nurse, I do not know or you may ask 
all patients but  they will tell you the same thing… …she calls us when we are at home 
and I have two cell phones of her…[P-18F]”. 
 
The friendliness of the hospital level caregivers was consistently reported upon by the 
majority of the participants. They noted that the hospital level caregivers are caring 
when they are available in the MDR-TB treatment centre. Most participants were 
thankful for the clinical care they were given at the hospitals.  
 
“…With respect to the treatment given I think it is enough…since I started the 
treatment, all doctors have been supporting me…today I completed the treatment given 
for MDR-TB… …I want to thank them all…[P-17M]”.  
 
Participants reported that a patient with social problems, stayed at the treatment 
initiating hospital for the first 8 months of the treatment, until the injection based 
treatment is completed. A participant who had social problems and who was allowed 
to stay at the hospital until he completed the injection based treatment narrated that he 
was happy with the care and services provided by caregivers at the hospital.   
 
“… I stayed here for a long time and it is very good and I want to say God bless… they 
did not harm me and also I have seen them attending to other patients as 
well…regarding those who die, it is because their date of death is due, otherwise they 
are good in treating us…[P-10M]”. 
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Another participant reported similar feelings of happiness expressed by patients about 
the clinical care and services that they received at the treatment initiating hospitals.  
 
 “…I can say that the sister giving me the drugs is my mother… I have the same respect 
that I have for my mother. I was about to commit suicide because of the drugs but her 
advise saved me… [P-4M]”.  
 
However, there were a few participants who angrily reported that caregivers at the 
treatment follow up centres mistreated them. They also reported that there were times 
when the patients were denied routine societal norms of interaction like salutations by 
some caregivers at the treatment follow up centres. The next excerpt clarifies this: 
  
“…there are times when the caregivers at the treatment follow up centres closed their 
doors against us and abandoned us…they do this even though they are educated 
professionals…there are times when we missed drugs for two or three days… we 
phoned the hospital and complained about the situation…[P-10M]”. 
 
4.3.4.4. Patients’ perception and experience on the social impact of becoming 
a patient with MDR-TB 
Participants reported a range of social and economic impacts caused by being a patient 
with drug-resistant tuberculosis.  Separation from family members and the feeling of 
loneliness are the most frequently encountered forms of the social impact of being a 
patient with MDR-TB. The main reason for separation from immediate friends and 
family members was reported to be the fear of disease transmission to others.  
 
“…it separated me from people… you do  not work because you do not have the 
strength to work, and also the attitude of people towards the disease is not good…it 
means living alone, sitting alone and it is just lonely living…[P-1F]”. 
 
Participants reported that the public does not have insight on MDR-TB and how it is 
transmitted. Instead, patients with the disease try to take care of the community around 
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them, based on the information they obtained from caregivers for MDR-TB. The next 
excerpt shows this: 
 
  “…because people do not know about the disease, they do not consider it to be a 
serious disease but because I know about the disease, I refrain from them… [P-1F]”. 
 
On the other hand, participants noted that when familities and close friends know the 
dangers of MDR-TB transmission, they tend to avoid patients with the disease. 
Participants also noted that the way in which caregivers taught families and friends on 
MDR-TB was not appropriate as it made them frustrate about the disease. As the 
result, in some instances patients were denied the support they needed from families 
and close friends.The excerpt below clarifies this:  
  
“……before I came to this hospital, the health workers came to our home and they said 
that the disease transmits at the distance of one meter,… and all the neighbours, 
friends and all family members avoided me….[P-14M].” 
4.3.4.5. Stigma on patients with MDR-TB  
Participants mentioned that the community does not have knowledge of the disease, 
MDR-TB. On the other hand, when they got to know about the dangers of MDR-TB 
and the risk of its transmission to family members and neighbours, patients were 
discriminated against by their own families and their neighbours. 
  
 “…you cannot live with other people, I know what happened to me, all the neighbours 
and all my family avoided me and that hurt me very much mentally.  Even now in the 
hospital I live alone and it is a state of prison for me. It is difficult to be separated from 
family. It is what God gave me and I did not buy the disease… the disease discriminates 
patients from their own family, now I look forward to seeing the day when I will sit in 
the family’s saloon again… [P-14M]”. 
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Discrimination was repeatedly talked about by participants. They claimed that there 
were patients who were discriminated or avoided by their own family members and 
their friends. Moreover, participants mentioned that patients with MDR-TB were even 
blamed by own family for developing the disease-MDR-TB.  
  
“…compared to their attitude before the disease, I mean the attitude they have towards 
me has changed and they say to me ‘go away’, ‘stay there’…I know that it is important 
to separate utensils and living room but the way they approach me does not show any 
respect...they say to me ‘you brought this disease unto us’ ‘go away!’…[P-9M]”. 
 
Some participants also reported that the way in which caregivers tell the community 
about MDR-TB makes the community to panic and avoid patients. The participants 
attributed the discriminatory practices of the community to the incorrect manner in 
which the families and friends were taught about MDR-TB by the hospital and the 
health centre level caregivers. 
The interviews with the patients also revealed that patients with MDR-TB were also 
discriminated by caregivers, especially those at the treatment follow up centres. An 
excerpt from a patient illustrated this:  
 
 “…I was a first year university student…I discontinued my education to be treated and 
cured from this disease but I have discovered that only a few people provide services 
with respect. Some of them do not even consider us as human…they do not act 
professionally and sometimes we wait for five to six hours to get the daily medication 
we need…[P-13M].” 
 
Most participants felt that all human beings who breathe in air are at risk of MDR-TB. 
Thus, avoiding patients with MDR-TB is not a good practice. An excerpt taken from a 
participant who experienced stigma due to becoming a patient with MDR-TB clarifies 
this: 
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“…This disease is not what someone caters from somewhere else, but it is caused 
incidentally…when people know that we have this disease, they discriminate us 
more…[P-9M].”  
 
Pointing to the healthcare givers at the treatment follow up centres, participants were 
particularily angry while reporting the issue of stigma from the caregivers.  
 
“…as we are victims of the disease we should patiently wait for the drugs but to properly 
control the disease and to prevent the disease from transmitting to the community the 
best treatment should be given for us as patients, …,if they abandon us what kind of 
attitude and response we will have for the community…we should have learnt good 
things from them. I have been asking about this but there is no any response I get from 
them,…there was one female nurse who provides us the treatment and if she is not 
there we have to suffer and we need to go to the directors’ office and complain,…even 
when we enter the health centre compound they run away, and while knowingly that 
we should be given medication they run away not to give us the drugs…[P-13M].” 
  
In these ways, patients with MDR-TB experienced stigma from family members, close 
friends, neighbours and the health care givers.   
 
4.3.4.6. Patients’ perception and experience on the economic impact of 
becoming a patient with MDR-TB 
15 of the 18 participants of the indepth interviews with patients mentioned that they 
were not engaged in any income generating work at the time of this data collection. 
The same participants mentioned that before being diagnosed of MDR-TB, they used 
to cater for their daily subsistence by engaging in different types of labour work from 
which they received daily wages. Among the participants, there were two drivers and 
one soil technician with degree level training. The two drivers and the soil technician 
were all employed by private companies. All participants reported that they quit their 
jobs after enrolment to the MDR-TB treatment, maily as the result of enrollement to the 
treatment for MDR-TB. Stigma on patients with MDR-TB and lack of the physical 
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strength to continue work were also noted by participants as the cause for the 
interruption of employment. The next excerpt clarifies this:   
 
“…yes, before I got the disease, I was free to move around and cater for myself.  But 
after I got the disease there was a big problem, people did not welcome me and their 
attitude became negative  towards me and also, I did not have the strength to work like 
before…[P-2M]”. 
 
Some participants reported that termination of employment due to MDR-TB and its 
treatment has resulted in such patients face difficulty to continue taking care of their 
family dependents. The next excerpt was narrated by a participant who was weeping 
while telling his story: 
 
 “…I was formally employed… I am a soil laboratory technician and I have a degree in 
that science… as I was employed by a private company, my income was discontinued 
since I caught this disease and could not continue the job... I also could not support my 
family, so that the disease brought big problems in my life. That is it!... [P-3M]”.   
 
Some participants also believed that their poor economic status and the poor quality of 
food that they used to eat have put them at risk of contracting the MDR-TB disease.  
 
“…yes, there is an economic problem and I used to work on daily labour work with the 
privates,…I eat when I get food and do not eat when I do not have something to eat 
and because of this, I cought the disease and the disease affected me  a lot and I 
became extremely unwell [P-5F]”. 
 
Another participant used a similar phrase to associate poverty with the MDR-TB 
disease: 
 
“…I think it may be from hunger and thirst that I caught the disease because I was 
employed in daily labour work and I worked in the deserts where there was no food 
and water…[P-15M]. 
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As a result, there were some poor patients who considered being a patient with MDR-
TB as a sign of bad luck. Because such patients thought that they contracted such a 
bad disease, the treatment of which is intolerable. An excerpt taken from a patient 
participant who could not define his life situation makes clear the impact of MDR-TB 
on the patients’ life as follows: 
 
 “…I usually asked myself why I had caught this disease and why I took such 
drugs…[P-3M]". 
 
4.3.4.7. Status of patients’ adherence to the MDR-TB treatment and associated 
factors    
The majority of the participants reported that they adhered to the instructions and 
advises of the caregivers for MDR-TB. Despite the fact that the second-line drugs were 
difficult to be taken on a daily basis, participants mentioned that they knew about the 
danger associated with interrupting the treatment given for MDR-TB. These 
participants also reported various factors that challenge patients’ strict adherence to 
the treatment given for MDR-TB. These factors are illustrated in the sections that 
follow.   
 
4.3.4.7.1. Perceived seriousness of the disease   
The study revealed that some of the patients with MDR-TB were doubtful about the 
chance of getting cured from the MDR-TB disease. The perceived seriousness of the 
disease MDR-TB was heart-breaking for some of the patients with the disease. 
Perceived seriousness of the disease as one of the reasons that made some patients 
pessimistic while still taking the treatment given for MDR-TB is captured in the next 
excerpt:   
  
 “…the disease is deadly…out of five of us that were admitted at the same time to this 
hospital, only two of us were discharged alive and the other three patients died of the 
disease… [P-4M]”. 
 
200 
 
 
Participants reported that patients’ perceived seriousness of the disease was one of 
the factors detracting patients’ commitment to continue treatment. While tolerating the 
drug related adverse drug reactions from the second-line drugs, some patients still 
worried about the outcome of their treatment.   
 
“…the treatment is good but there are patients that do not improve at all and do not 
return home alive…[P-2M]”. 
 
It is clear from the above excerpts that the patients’ perceived seriousness of the 
disease, MDR-TB, is one of the clinical service areas needing attention by the 
caregivers for MDR-TB.  
  
4.3.4.7.2. Adverse drug-reactions from second-line drugs  
The study also revealed that adverse drug reactions from second-line drugs were   
noteworthy factors that put patients in a difficult position in terms of adhering to the 
standard treatment given for MDR-TB. All of the 18 patients who participated in the 
interviews with patients had the experience of second-line drugs related adverse 
reactions while on treatment. Participants reported that the drugs taken for MDR-TB 
were miserable and it was too difficult for them to take the drugs daily. The next excerpt 
shows the experience of a patient taking second-line drugs for the treatment of MDR-
TB: 
“…above all, the drugs are miserable, especially the last two drugs were very 
dangerous and were not even good for mankind to take. Indeed, they made my blood 
vessels and my eye to burn up. It was very difficult to take them, I would be happy if 
those drugs were changed to injections or other drugs. If I took the drugs and drank 
milk, I vomited; it was as if there was   poison in the food I ate and I vomited. I felt as if 
my body was tied up with a rope and my mind stopped working and even I could not 
properly see at that time…[P-7F). 
 
 The same experience was reported by another participant regarding the challenges 
that patients face from adverse drug reactions, as in the next excerpt: 
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 “…for at least three hours after taking the drugs, you felt different …especially after 
taking the two drugs…[P-3M]”.  
 
Another participant had the same experience as evidenced in the excerpt below: 
 
“…I took the drugs and immediately went to sleep or else I would not feel good …[P-
18F]”. 
While still continuing the treatment given for MDR-TB, some patients feared picking up 
another disease due to the adverse drug reactions. For some of the patients, the severity 
of the adverse drug reactions affected their joints.  
“…once I developed the disease I tried to tolerate all the burnings…I usually ate a piece 
of sugarcane just to sooth my body…I had  pain in the joints but  the doctor said that it 
would  disappear and I should take it easy but still, it continued and became more 
severe…[P-10M]”. 
 
As such, the above excerpts makes it clear that adverse drug reactions from second-
line drugs, is one of the clinical factors challenging patients’ adherence to the standard 
treatment given for MDR-TB.   
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4.3.5. Perception and practices of caregivers for MDR-TB on the functionality 
of the programmatic management of MDR-TB 
4.3.5.1. Introduction to the qualitative result from the interviews with 
caregivers for MDR-TB 
The qualitative inquiry was also used to explore the perceptions and the practices of 
caregivers for patients with MDR-TB regarding the functionality of the programmatic 
management of MDR-TB at the Adama and Nekemete Referral Hospitals. Eleven 
caregivers for patients with MDR-TB participated in the in-depth interviews with 
caregivers. The interviews with the caregivers included three male medical doctors and 
eight nurses (5 female and 3 male) who were active caregivers for patients with MDR-
TB at the two study hospitals included in this study.  In the same way as for the 
qualitative report for the patients with MDR-TB, at the end of each excerpt are initials 
and a number to indicate the number of the participant and their sex. For example, “P-
2M” , with “P-2” indicating participant 2, and “M” indicating the male  gender of the 
participant.  
 
4.3.5.2. Caregivers’ perception and experience on the adequacy of the 
nutrition support provided for patients with MDR-TB  
The study revealed mixed experiences of caregivers regarding the status of the 
nutrition and financial support given for patients with MDR-TB. About half of the 
caregiver   experienced that the nutrition support that patients with MDR-TB got from 
the hospitals while they were treated as inpatients at the hospitals was relatively 
adequate. However, the same participants mentioned that the nutrition support that 
patients with MDR-TB got during the outpatient phase of the MDR-TB treatment was 
virtually inadequate and of poor quality.  
 
“…patients with MDR-TB are very poor…they do not have anything…we give them 
Plamynut...it is not enough, it is very difficult for poor patients to take the drugs without 
adequate food,…there are many complaints from patients,…[P-4F]”. 
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Similarly, a participant who was responsible for the care of patients with MDR-TB at a 
treatment follow up centre narrated that while the drugs and supplies are available for 
the patients, the problem associated with the nutrition support given for patients was a 
challenge. 
 
“…from the perispective of distance, from the perispective of finance, nutritionally there 
is visible problem. But the provision of drugs is very good, there is enough supplies, 
and there was no incidences of interruption,…[P-2F.” 
 
Only a small proportion of caregivers who participated in the interviews reported that 
the nutrition support and the cost of transport that patients with MDR-TB were given 
was acceptable. 
 
 
4.3.5.3. Caregivers’ perception and experience on the quality of the nutrition 
support provided for patients with MDR-TB  
The study revealed that the quality of the food items that patients with MDR-TB were 
given was one aspect of the challenges associated with it. Caregivers reported that the 
food items that were provided for patients lacked protein and in the meantime, patients 
with MDR-TB need high protein rich food.  An attending physician described the 
situation in the next excerpt: 
 
 “…as a physician treating patients, I do not believe, patients should get a variety of 
food items and it should be given based on their preferences ,…they are given 10 
kilogramme of grain flour per month, 2 packs of pasta and half (½) a kilogramme of 
milk powder. The majority of the food items are not body building, the food items given 
currently are sources of more of carbohydrates, how does the grain flour help and those 
foods given simply because it is food …I do not support much because patients should 
get variety of food and also based on their interest; I have also seen that patients want 
to select the type of food that they want to eat,… even for patients with basic TB those 
treated for six months, we need to give high protein diet. We get those high protein 
diets from food items like the egg, milk and it can be from other foods like the beans. 
 
204 
 
But the food items currently given for MDR-TB patients are more of carbohydrates,…it 
is not like egg, even though milk is available in the form of powder, it is not what patients 
prefer. Therefore to say that it really builds their body and prevent their body from this 
disease evev as the science states it should be protein foods like egg and milk,…[P-
7M.”] 
 
Thus, it is made clear in the above excerpt that patients with MDR-TB need to be 
provided with body building food items they prefer and like and must satisfy the clinical 
nutrition needs of each individual patient. For this, participants in the interviews, 
recommended the need to establish a strong monitoring mechanism from the Regional 
Health Bureaus to make sure that patients with MDR-TB are actually getting the right 
nutrition and the full benefit from the package of treatment enabler schemes which they 
are eligible to. 
 
4.3.5.4. Caregivers’ perception and experience on the management of the 
nutrition and financial support schemes for patients with MDR-TB 
It was invariably and desperately reported that the personnel in charge of facilitating 
the implementation of patient support schemes, at the hospitals, were virtually not 
cooperative. Therefore, caregivers for MDR-TB reported that on top of the technical 
healthcare they provide for patients, nurses and physicians were also responsible for 
facilitating the execution of the monthly patient transport and nutrition support activities.  
 
 “…there are times when the finance department does not volunteer to go and make 
payments for the patients,…they mistreat us saying ‘your patients’  as if the patients 
with MDR-TB were our family members,…sometimes they say that the budget is used 
up even when the funds are  actually available. In most cases   it is the nurses who 
handle the payment for patients, nurses also arrange and distribute nutrition items to 
each patient. The problem is not the absence of money but it is the way it is utilized…[P-
8M].”   
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One of the issues that the study revealed is that patients with MDR-TB are expected 
to pay towards transporting the food items they were given by the hospitals. Most of 
the patients were from distant rural areas, using public transport. The impact of the 
cost that patients incurred to transport food items was mentioned by the majority of the 
caregivers who participated in the interviews. This cost, as was revealed, was an 
overlooked cost from the point of view of the programme of MDR-TB but it was 
important for patients with MDR-TB.  
 
4.3.5.5. Caregivers’ perception on level of health system’s support to the 
programme of MDR-TB  
Some caregiver participants mentioned that there was positive support from the 
management of the respective town, provincial and district health management offices. 
There were also reports that the management of the hospitals and the treatment follow 
up centres in some facilities were supportive to the programme of MDR-TB. An excerpt 
taken from one of the participants makes this clearer: 
 
 “...the town health office comes and supervises me…I ask questions and they 
encourage and support me and in my opinion, that is good… [P-1M]”. 
 
However, the majority of caregivers bitterly noted that they do not feel supported by 
the management of the immediate health offices and the management of their own 
health facilities. This was mentioned in terms of the absence of supportive supervision 
visits from the immediate district and provincial health offices. Participants added that 
the management of the immediate health offices did not even make telephone calls to 
them unless they needed reports in three months’ time.  
 
“…regarding the MDR-TB I don’t think that the district health office even knows the 
problem...[P-2F]” 
 
It was mentioned that the immediate technical managers managing the same premises 
of the health facility, did not emphasise the management of drug-resistant tuberculosis. 
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Caregivers cited that there were clear incidences whereby individuals and employees 
working in the same health facility and in the same hospital or health centre, feared 
approaching the patients with MDR-TB and even entering into the centres where these 
patients were treated.   
 
“…I think that the managers at a higher level did not focus attention on the programme 
of MDR-TB and that is why the heads of the health centres did not give priority to the 
issue of MDR-TB…[P-3M]” 
 
Similarly, some clinical caregivers who were responsible for initiating patients with 
MDR-TB on the second-line drugs, mentioned that the technical management and 
those responsible for facilitating the use of the budget allocated for the programme of 
MDR-TB were not supportive of the programme. 
  
“…a physician who is assigned to the MDR-TB clinic is responsible for everything. If 
water and electricity are discontinued, it is the physician assigned there who ensures 
that these needs are provided. We are also logisticians as we take the responsibility of 
patient transport; we are finance personnel as we are responsible for arranging 
payments for patients;…this is because they do not support us. We are pharmacists 
because we receive and dispense drugs for the patients. We are laboratory 
technologists it is us who collect and send the laboratory samples…around the hospital 
management there is no question that the support is very poor. It is very poor. We 
debate repeatedly and have criticized them repeatedly…I have notified the Oromia 
Region Health Bureau, they do not perceive the issue of MDR-TB as you do…[P-5M] 
 
Participants also mentioned that the number of trained caregivers at the treatment 
initiating centres was inadequate. It was further indicated that the number of caregivers 
for MDR-TB who were trained and deployed by the health management system, 
especially at the treatment follow up centres, was inadequate. The caregivers 
mentioned that at the MDR-TB treatment follow up centres, there was only one 
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caregiver who was responsible both for the generic programme of tuberculosis and for 
the programmatic management of drug resistant tuberculosis.  
 
4.3.5.6. Caregivers’ experience on management of MDR-TB and HIV/AIDS co-
infection 
All participants reported that the substantial number of patients with MDR-TB who had 
enrolled to the treatment of MDR-TB was co-infected with HIV. Caregivers mentioned 
that the clinical management of patients with MDR-TB who are co-infected with HIV 
was challenging. Moreover, participants reported that the majority of the deaths from 
MDR-TB were observed among the HIV co-infected patients.  
 
 “…thirty percent to forty percent of the MDR-TB patients who have been receiving 
treatment had both HIV and MDR-TB. The mortality rate for this co-morbidity is very 
high and the patients’ chance to die is very high…[P-7M]”. 
 
The idea of the above excerpt was also supported by what was captured through a 
photograph taken from the patients’ MDR-TB unit register as shown in figure 4.5 below. 
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Figure 4.  5: Status of MDR-TB and HIV co-infection among patients with MDR-TB treated at the 
two referral hospitals, Oromia, Ethiopia, December, 2012-September, 2016. 
 
Participants reported that the MDR-TB centres were not providing services for HIV.   
Caregivers for MDR-TB were not trained on HIV care and support services. As 
caregivers for MDR-TB did not have the training, they were not prescribing anti-
retroviral drugs for patients with MDR-TB who were co-infected with HIV.  Also, the 
MDR-TB treatment centres did not have anti-retroviral drugs as the anti-retroviral drugs 
were not kept in the MDR-TB treatment centres.  This problem was found both at the 
treatment initiating centres and at the treatment follow up centres.  
It was revealed that the MDR-TB treatment initiating centres were providing HIV test 
services for patients enrolled to the treatment for MDR-TB. But they did not have the 
training and the drug supplies to prescribe anti-retroviral drugs for those patients with 
MDR-TB whose HIV test result were positive. Thus, all the participants who were 
caregivers, consistently reported that patients with MDR-TB who were co-infected with 
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HIV/AIDS were referred to other centres for the treatment and care that they needed 
for HIV. As such, this patient group suffered a lot of inconveniences in seeking care for 
both diseases at different centres and from different caregivers. 
  
 “…in our hospital, there is a separate centre where services for HIV are given and 
patients  are referred  to them but there is no system in place whereby we collaborate 
and work jointly…this is an area where we have been facing problems…[P-8M]. 
 
A similar excerpt was obtained from another participant’s narrative: 
 
“…In our setting, the hospital and the MDR-TB centre are not in the same 
compound,…the patients’ main follow up place for the anti-retroviral therapy is a 
separate clinic so  they have to go there…it would have been best and could have 
improved many things if anti-retroviral therapy were given at the MDR-TB clinic 
itself…[P-5M]”. 
 
A physician participant who was treating MDR-TB and HIV/AIDS co-infected patients, 
desperately narrated an  incident of a sudden death that occurred to an MDR-TB and 
HIV/AIDS co-infected patient on his 17th month of the treatment given for MDR-TB. The 
patient was on anti-retroviral treatment for seven years before he was diagnosed of 
MDR-TB.  
 
The main explanation reported was that co-infected patients focused on the new 
problem of MDR-TB and the challenges associated with taking both the second-line 
drugs and the anti-retroviral drugs. After he had enrolled to the treatment for MDR-TB, 
the patient could not follow the routine follow up services given for patients on treatment 
for HIV/AIDS. As such, while the patient was hopefully completing his treatment for 
MDR-TB, he died possibly because of failure of the treatment given for HIV/AIDS. The 
failure of the anti-retroviral drugs was not diagnosed until the patient was found fell 
down in the street.  
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“…The patient was found in the street. The patient had been on anti-retroviral therapy 
for seven years. Then they brought him in and when I saw him, his T-lymphocyte cell 
bearing (CD4) count was forty. I believe he died because of anti-retroviral therapy 
failure. The patient had been on MDR-TB treatment for seventeen months and had 
converted culture…therefore I believe that if there had been follow up services on HIV 
at our hospital it would have saved the life of the patient….[P-5M]”. 
 
4.3.5.7. Caregivers’ experience on the occurrence and the management of 
adverse drug-reactions from second-line drugs  
Participants reported that the majority of patients treated with the second-line anti-
tuberculosis drugs experienced various forms of adverse drug reactions.  
 
“…patients said that the drugs burn them up...and also complained that the drugs 
changed the colour of their urine…the behaviour of patients taking these drugs was 
also changed…[P-2M]”.  
 
In some patients, the adverse drug reactions were challenging both to diagnose and 
treatment them. Many caregivers desperately talked about the adverse drug reactions 
that patients with MDR-TB encountered and the challenges of detecting and managing 
them. The diagnosis of some of the adverse reactions needed laboratory follow ups 
which were not readily available in the hospital.  
 
“… well, in our hospital, organ function tests are available but others like the thyroid 
function test and the electrolyte tests are not available, it would have been very good 
if they were available and were done at the hospital. As a result of these tests not being 
available, there were problems like the incidence of the sudden death of patients that 
occurred. I felt the pain as an individual and as a physician who is working there. I hope 
the situation will improve… [P-7M]”.  
 
Moreover, caregivers noted that there were times when they face shortage of the drugs 
needed to treat adverse drug reactions among patients with MDR-TB.  
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4.3.5.8. Caregivers’ experience on the challenges associated with the adverse 
drug reactions from second-line drugs  
The study revealed that adverse drug reactions caused both social and medical 
problems on patients who were affected by the problem. The first problem on patients 
affected by adverse drug reactions was social in terms of misunderstandings by the 
patients’ family and close friends. This was expressed by the majority of the 
participants. For example, the incidence of drug induced psychological problems 
created misunderstanding between patients with MDR-TB and their families. There 
were patients with psychological derangement caused by adverse drugs reactions and 
who were seen to disagree both with their families and their health caregivers. A nurse 
caregiver narrated an incident whereby a psychiatric problem arising from second-line 
drugs in a female patient with MDR-TB resulted in a misunderstanding with her family 
members.  
 
“…she was living with her mother and father, but when I went there, she had nothing 
to eat.  She had brothers but they could not understand her. I had also talked to her 
brothers about the prevailing situation. At that time, she was also psychologically 
disturbed.  It was observed that these drugs have a psychological effect on patients. 
Patients taking these drugs usually change their behaviour, they are not their usual 
selves.  Her brothers had a different perception about her behaviour…[P-3M].  
 
From the above excerpt, it is clear that family members of the patients did not 
understand the causes of the changes in the patient’s behaviour. The majority of the 
caregivers for MDR-TB knew that patients with MDR-TB who are initiated with second-
line drugs face challenges associated with adverse drug reactions. Some caregivers 
reported incidences whereby patients with MDR-TB developed permanent loss of 
hearing. There were also patients who developed depression, as was noted, among 
which there was one case of suicide. Caregivers also mentioned that a substantial 
number of patients with MDR-TB were repeatedly readmitted to the hospitals due to 
the repeated occurrence of adverse drug reactions. There were complaints related to 
gastritis and musculo-skeletal pain like joint pains, myalgia and arthralgia, which were 
identified as the most commonly occurring adverse drug reactions from second-line 
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anti-tuberculosis drugs.  Sometimes when the reactions are severe, caregivers 
discontinued the drugs. 
  
“…when I discontinued cycloserine, the joint pains disappeared… [P-3M]”. 
 
During the incidences of adverse drug reactions, caregivers found at the treatment 
follow up centres contacted physicians at the hospitals. As such, caregivers of the 
treatment follow up centres managed the adverse drug reactions according to the 
advice they got from physicians at the hospitals. A physician mentioned that some of 
the adverse drug reactions like the hypokalemic tetani which are common among 
patients on injectables are killers. Moreover, such adverse drug reactions were 
reported to be difficult to detect clinically as they do not show apparent clinical signs 
and symptoms until they are at the advanced stage. The next excerpt illustrates this: 
 
“…detection of electrolyte disturbance needs advanced laboratory with functional 
electrolyte test which we do not usually have…’“[P-5M].”  
 
Caregivers also mentioned that except those physicians who were well experienced 
on the clinical management of MDR-TB and on the clinical management of drug related 
adverse drug reactions, others usually do not even suspect the physiological 
derangements that result among the patients taking second-line drugs  
 
“…she was 21 and they told me that she was seizing with hypokalemic tetani and she 
went to a private clinic and they told her that she had hypertension and put her on 
nefidipine…, I said no!…it cannot be hypertension. When I measured her blood 
pressure it was normal but when her electrolyte was tested, she had severe 
hypokalemia with clinical hypokalemic-tetani and also hypomagnesemia, [P-5M]”. 
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4.3.5.9. Caregivers’ experience on patient management under daily observed 
treatment support  
Some of the participants mentioned that patients were given treatment under daily 
observation by the health caregivers. 
  
“…I can speak with full confidence on that... I do not have any hesitation on the daily 
observed treatment, we have close communication with patients at treatment follow up 
centres…they all have our contact address and if they encounter any problems like 
missing a daily drug dose, they phone us directly at treatment initiating centres… [P-
5M]”. 
 
Another participant reaffirmed the same situation on the availability of reliable daily 
observed treatment support for the patients with MDR-TB after patients were linked to 
treatment follow up centres. 
  
“…we are sure of their continuing treatment under daily observed treatment because 
we have telephonic contact with health caregivers working there and we discuss 
matters on the condition of patients. Secondly, we contact caregivers at MDR-TB 
catchment area meetings, where we get reports on the treatment status of each 
patient…, the other evidence is that our patients continue to show improvement and 
their lab follow ups show improvement. We also visit treatment follow up centres during 
the monthly MDR-TB clinical mentorships sessions… [P-6M]”. 
 
On the other hand, participants reported inconsistencies in the quality of the 
implementation of patient treatment under the standard daily observation, especially 
after patients were linked to the treatment follow up centres. This was captured in an 
excerpt taken form a caregiver practising at the hospital.  
 
“…there were areas on the strengths and gaps...in some places, caregivers were 
concerned and they gave the daily observed treatment …but there were some places 
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where the caregivers filled out the register before providing the daily observed 
treatment … a one-week course of drugs was given to the patients’ home…[P-7M]”. 
 
In the case of patients living far from treatment follow up centres, participants, who 
were caregivers, reported that they used MDR-TB treatment supporters from family 
members who signed and took a one-week drug-dose and supervised patient’s taking 
the drugs on a daily basis at home. Some participants mentioned that if one is well-
educated and made committed at the start of the treatment, the patients with MDR-TB 
did not opt to discontinue treatment even during events of drug side effects and other 
challenges. Based on these points of argument, these participants expressed their 
belief in the need to decentralize the daily observed treatment support to be supervised 
by community health workers or by family members of the MDR-TB patients. Use of 
family level treatment supporters were reported to be  the better option especially when 
the patient with MDR-TB live far away from the community level treatment follow up 
centres.  
 
“…when patients live far it is a serious condition…it is difficult for them to attend the 
daily observed treatment given at the treatment follow up centres …some patients live 
8 kilometres or more away from the follow up centres and that is the main challenge 
we have’ …[P-1M]”.  
 
However, given the fact that a huge number of tablets of each of the second-line drugs 
were taken by an MDR-TB patient per day, no convincing practice was mentioned by 
participants on the quality in which the second-line drugs that were handed over to the 
patients’ homes were handled.  Moreover, for the majority of the patients with MDR-TB 
who live far from treatment follow up centres, there was no reliable supportive system 
to ensure the quality of the daily observed treatment support given at the patients’ 
home areas.    
 
Furtheremore, participants mentioned that for patients coming from remote rural areas, 
it is difficult for them to attend the daily treatment especially when injections are taken 
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daily. It was reported that health extension workers who are living and working at 
community level were not supporting MDR-TB patients with the daily observed 
treatment support. The next excerpt clarifies this: 
 
“…in our ‘kebele’, health extension workers are not providing daily observed treatment 
support and even for the susceptible TB… [P-2F]” 
 
Thus, it was mentioned that some patients with MDR-TB were forced to rent houses in 
the towns of the treatment follow up centres in order to be close to the MDR-TB 
treatment follow up centres. Yet, participants mentioned that there was no patient 
support scheme by the programme of MDR-TB whereby patients from remote areas 
were supported with the cost of accommodation at MDR-TB treatment follow up 
centres.   
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4.3.5.10. Caregivers’ experience on status of follow up laboratory services for 
routine patient monitoring  
Participants mentioned that baseline laboratory investigations were done for all 
patients initiated on second-line drugs. Monthly sputum smear microscopy and culture 
were mentioned as the main laboratory based monitoring parameters for patients on 
treatment. It was mentioned that patients are also eligible for other follow up laboratory 
investigations like complete blood count, organ function tests and electrolyte tests. 
Some participants felt that the current functionality status of facility laboratory and the 
sample transport system are encouraging. Yet, many participants at the two study sites 
mentioned that there are persisting gaps in the laboratory service needed for the follow 
up of patients with MDR-TB. 
At the level of the referral regional laboratory, there is a problem in transporting sputum 
samples from hospitals to regional labs where monthly culture follow ups are done for 
patients on treatment. Reasons mentioned were that the national postal system that 
was introduced for sample transport was not fully functional. Therefore, the turnaround 
time for the result of the sputum culture from regional labs to the hospitals was reported 
to be very long. Participants, who are caregivers, pointed out that the delay with culture 
results hampers timely clinical decision making by caregivers and contributes to the 
incidences of loss of life. 
At the hospitals level, the shortage of laboratory reagents and failure of laboratory 
machines were reported as the main factor limiting patients’ access to the standard 
laboratory follow up services. Repeated failure of electrolyte machines and the lack of 
local capacities to maintain them promptly, were mentioned as examples for the causes 
of the problems in laboratory services. Moreover, lab tests on hormonal assay like the 
thyroid function test, are totally unavailable.  
 
“…due to lack of reliable follow up laboratory services for prompt diagnosis and 
treatment of treatment related adverse effects, there were problems like the incidence 
of a sudden death of patients, and thus both as an individual and as a physician treating 
the patients, I am feeling the pain…[P-7M]”.   
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The other factor mentioned regarding laboratory related problems was the lack of 
cooperative team work between the caregivers and the hospital laboratory personnel. 
Participants noted that as not enough attention was given to the programme of MDR-
TB by the hospital management, there was no cooperation from the hospital laboratory 
personnel in collecting and processing samples of the patients with MDR-TB.  
 
“…they rejected the lab requests we made and did not process them,…unless they 
were paid for that, they are not cooperative…[P-5M]”. 
 
Similarly the other participant mentioned this:  
 
“…they did not collect, label and pack samples properly …so the samples got lost while 
on transit …[P-2F]”. 
 
Moreover, caregivers for MDR-TB perceived the shortage of laboratory human power 
at hospitals as another problem. As it happened, available laboratory personnel were 
occupied with providing routine services for the general hospital polyclinic attendants. 
Thus, it was reported that the hospital laboratory services which was originally 
established for providing services for the general hospital polyclinic could not 
adequately provide the routine laboratory services needed for the patients with MDR-
TB. Therefore, participants who were caregivers recommended for the need to 
establish a laboratory unit which is dedicated to the MDR-TB treatment centres of the 
hospitals. 
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4.3.5.11. Caregivers’ experience on the social and economic challenges posed 
by MDR-TB on patients with the disease   
 
4.3.5.11.1.  The social impact of MDR-TB on the patients with the disease  
Participants at the interviews mentioned that a substantial number of patients treated 
for MDR-TB were those living in desperate economic and social conditions. The 
participants reported that there was a stigma attached to them and there was 
discrimination against patients with MDR-TB. The stigma is not only against the 
patients with MDR-TB but it is also against the caregivers for MDR-TB. There is huge 
fear both by the community and particularly by the health care givers regarding the 
MDR-TB disease. 
 
“…MDR-TB is seen as something strange and is seen as a disease not found in other 
places on earth,… both caregivers working there and the MDR-TB patients are 
perceived as strange persons,…MDR-TB caregivers themselves are stigmatized by 
co-workers in the same way as the MDR-TB patients are.…”[P-7M]. 
 
Thus, participants recommended that the health system should consider MDR-TB and 
integrate its services into the care and services given on chronic diseases like diabetes.  
 
Patients with MDR-TB, as noted, were also stigmatized by the community. When 
patients with MDR-TB are known to the community, they are discriminated against and 
are systematically separated from routine social life and from work. 
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4.3.5.11.2. The economic impact of MDR-TB on the patients with the disease  
There were patients who lost their lives to the combined problems of MDR-TB, lack of 
adequate food, finance and social support. There were patients living alone and had 
no one to take care of them and help them especially with food. Some participants 
mentioned that there were very poor patients whose treatment for susceptible 
tuberculosis failed and were put on second-line anti-tuberculosis drugs. Still, such 
patients took second-line drugs in very poor living conditions and caregivers felt that 
response to treatment by such patients was not encouraging.  
 
“… he is 46 and he failed to gain weight,…he also had his own social problems with 
food and finance and in  all aspects,….he had a daughter who had been taking care of 
him but she died last September, now he is readmitted to the hospital…his kidney is 
failed and moreover he has hypokalemia,…[P-1M].” 
 
Participants also reported that poverty challenges patients’ ability to adhere to the 
treatment given for MDR-TB. For example, during the outpatient phase of the 
treatment, patients were expected to attend the daily injection and daily observed 
treatment at the treatment follow up centres or health centres.  For most patients who 
were coming from remote rural areas, treatment follow up centres were described to 
be very far from patients’ living homes. Such patients had to pay for house rent at the 
home town of the treatment follow up centre. As there was no accommodation 
allowance for patients linked to the treatment follow up centres, the condition was 
reported as an additional challenge for the poor patient with MDR-TB.  
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4.4. Results for the mixed methods objectives component 
4.4.1. How the interviews with patients with MDR-TB help to explain 
quantitative results. 
 
4.4.1.1. The socio-economic impact of becoming a patient with MDR-TB 
The quantitative component of the study revealed that 128 (94%) of the patients were 
in the productive age group (age group of 15-64 years). Yet, the majority 70 (53%) of 
the patients with MDR-TB were self-employed mainly in the informal sector, and a 
considerable number 46 (35%) were not employed. The 70 (53%) of patients who were 
employed, were either self-employed or employed in the informal sector. 
 
The interviews with patients revealed that self-employment was employment in the 
daily labour workforce whereby daily wages were paid. Participants reported that 
physical strength is needed to be employed in the daily labour workforce.  As such, the 
participants highlighted that patients with MDR-TB were often unwell because of the 
disease and thus could not continue to work or perform their daily functions in their 
daily labour work as expected. Thus, patients encountered financial problems and the 
associated problems when they lost jobs as a result of the disease. On the other hand, 
participants mentioned that the social support offered to patients with MDR-TB by the 
MDR-TB programme in the form of nutrition and financial support was inadequate. 
Hence, the results of the qualitative component of this study clearly indicated that the 
majority of patients with MDR-TB were living in poverty. The next excerpt clarifies this:  
 
“…yes before, I used to cater for myself by running here and there. But after I was 
diseased there was a problem, people had a negative attitude towards me and also I 
did not have the strength to work as I used to …I had to accept the food that I was 
given from here. I could not do or say anything but accept it. What could I do  after 
all?…it was the same thing for the whole month!... no it was not enough…some 
patients may get support from parents or relatives, but for others the food we are given 
by the hospital cannot be enough for one month…[P-2M].  
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4.4.1.2. Treatment outcomes of patients with MDR-TB  
The results of the quantitative component revealed that from the total of 110 patients 
for whom treatment outcomes were assigned, 76 (69%) of the patients had 
successfully completed the treatment given for MDR-TB. However, 30 (27%) of the 
patients enrolled to treatment died from the disease by month 24. Thus, death was 
found to be the second higher treatment outcome among patients with MDR-TB 
enrolled to treatment at the two study sites.  
 
The qualitative in-depth interviews conducted with patients with MDR-TB, clarified the 
dynamics in the process of MDR-TB treatment that were associated with patients’ 
deaths. Participants attributed the deaths to the seriousness of the MDR-TB disease 
itself and the difficulty of adhering to its treatment. Participants mentioned that some 
patients with MDR-TB are repeatedly admitted to the hospitals due to drug related 
adverse events and other complications. Some of the patients who encountered 
treatment related complications and were readmitted to hospitals, were died of the 
disease. An excerpt taken from a patient on treatment who survived severe adverse 
drug-reactions from the second-line drugs, clarified how the patient lost many of his 
fellow patient cohorts due to the disease: 
  
“…thanks to God that now I am attending to the treatment alive,…when I came the first 
time, I was very weak,…the doctor advised me to take the drugs and then my condition  
improved and I got up from the bed,… from patients who were admitted with me to this 
hospital for treatment, …out of five of us who were admitted at the same time to this 
hospital, only two of us were discharged alive and three patients died from the disease 
before they were discharged. Also, there were many patients who were died but for 
me, may my God be blessed that now I am attending the treatment and I am alive,…[P-
4M]”. 
 
The above excerpt states an eye witness account and the lived experiences of the 
patients that the disease, MDR-TB, is perceived as a deadly disease.  
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4.4.1.3. MDR-TB infection control  
The quantitative component of the study revealed that 105 (77%) of patients with MDR-
TB were linked to the community level MDR-TB treatment and follow up services. On 
the other hand, an analysis of the community level MDR-TB infection control practices 
of the caregivers revealed that for all patients linked to the community level MDR-TB 
treatment, there were no housing arrangements made before the patients were linked 
to the community. This meant that caregivers at the treatment follow up centres did not 
visit patients’ homes to inspect patients’ living quarters and educate the family 
members on the dangers of MDR-TB transmission to household contacts. The 
caregivers did not implement the community level MDR-TB infection prevention and 
control practices that were strictly recommended by the national guideline for 
community level MDR-TB treatment and patient care (Federal Ministry of 
Health/FMOH/ 2014:150-51). For example, for 64 (47%) of the patients with MDR-TB 
who were on treatment, MDR-TB infection control services were not given through 
contact tracing. Thus, 8 (6%) of the total of the 136 patients included in this study were 
those diagnosed from the household contacts of the index patients with MDR-TB.  
 
The qualitative interviews with patients revealed that patients did not have insight about 
the risk of MDR-TB infection and its transmission to their close contacts and household 
members. The reason mentioned was the absence of adequate education on the 
danger of MDR-TB transmission from patients to their household and close contacts. 
The excerpt taken from a patient on treatment elucidated this: 
 
“…I caught the disease while I was taking care of my husband. I had never had TB 
before... he was my husband…while I was taking care of him, I did not know about the 
disease because both of us did not have this disease before. They put him on the six-
month treatment and at that stage, they did not tell us about any precautions, and no 
advice was given for him also. When he started the treatment, I did not think that the 
disease transmits and in fact he is my husband and I could not abandon him because 
he was sick and I could not go away. If we were told that it transmits, I would have 
taken care and he also would have taken care of me…[P-6F]”. 
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The above excerpt makes it clear that patients with MDR-TB and their families were 
not given the information they needed on MDR-TB.  
Moreover, the patients with MDR-TB who participated in the study reported that the 
education given to the general public on MDR-TB was inadequate. A participant noted 
that patients had the interest to teach the public about MDR-TB and the challenges 
associated with taking the treatment given for it. An excerpt taken from a patient 
participant illustrates this.  
 
“…having passed through many challenges, about this disease let alone my family but 
the whole society if there is someone who takes the message from me I am very 
interested to teach others and to share the experience I passed through so far… So if 
the public learns and knows the problem, the public will not be hurt by the disease [P-
5F].  
 
The quantitative result identified the risk of MDR-TB transmission to the community 
due to the unregulated practice of patient transportation from hospitals to the 
community and back to the hospitals for the scheduled monthly follow up services. 
During the initial patient linkage to the community, only 97/105 (71%) of the patients 
were transported from treatment initiating centres (hospitals) to treatment follow up 
centres using hospital ambulances. The rest of the patients with MDR-TB were left to 
use public transport starting from the inception of their treatment.  
A more elaborative understanding on patient transport was obtained from the results 
of the qualitative component of the study on the practice of patient transport. 
Participants (caregivers) reported that patient transport using the hospital ambulance 
was provided only during the initial patient linkage to community level MDR-TB 
treatment and follow up centres. After the first patient linkage to the community, 
patients use the conventional public transport services for the whole duration of the 
two years’ treatment period for whatever movements they make to seek care for MDR-
TB. These movements included attendances to the programmatically scheduled 
monthly clinical follow ups at the hospitals and the daily movements that patients make 
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between their areas of residence to the treatment follow up centres for collecting daily 
drug doses. The excerpt below, taken from a physician who was caring for patients 
with MDR-TB, clarified the risk of MDR-TB infection to the community as a result of 
unregulated patient movement during the course of their treatment: 
 
“…When they go from here to the treatment follow up centres, we cannot say hundred 
percent. There are patients transported by ambulance for the first time. But as there 
are not adequate numbers of ambulances, they go by public transport. We advise them 
on what we can advise them and what they should do. But the ambulance is not 
available most of the time…[P-5M]”. 
 
Thus, the study revealed that the inadvertent patients’ movement to take their daily 
treatment and to attend to their monthly clinical follow up services at the hospitals is a 
potential risk in transmitting MDR-TB to the general public. Even though they could not 
easily avoid the risk of the disease transmission to the community, patients with MDR-
TB well understood the danger of the disease to the public.  
  
“…the disease is not something that is seen as an ordinary disease even for myself I 
usually get stressed with the disease when I approach others. In fact, I should take 
care of others, I get stressed about how difficult it is to take the drugs. The drugs are 
very hard, I for example, usually feel pain when I take the drugs… as an Ethiopian 
citizen I caution that this disease is not easy a disease to deal with. It is good that the 
government treats patients in one dedicated centre and persons go back to the 
community after completing their treatment, otherwise we may infect others … [P-9M].”  
  
 
225 
 
4.4.2. How the interviews with caregivers help to explain quantitative results 
 
4.4.2.1. Management of MDR-TB and HIV/AIDS co-infected patients  
The result of the quantitative component revealed that 34 (26%) of the patients with 
MDR-TB were co-infected with HIV/AIDS. Yet, the quantitative result could not identify 
how patients with MDR-TB those co-infected with HIV were managed for both 
diseases. However, the qualitative component revealed the dynamics of the 
management of patients co-infected with both MDR-TB and HIV/AIDS. 
 
Caregivers for MDR-TB mentioned that there is a higher level of MDR-TB and HIV co-
infection among patients treated for MDR-TB. However, the services for both MDR-TB 
and HIV/AIDS were not available in one centre. Caregivers at the MDR-TB centre did 
not have the training to prescribe anti-retroviral drugs for patients co-infected with 
HIV/AIDS. Moreover, the MDR-TB centres did not have the supplies of the anti-
retroviral drugs.  
 
Caregivers attribute the higher level of death observed among MDR-TB and HIV co-
infected patients, included in this study, to the absence of an optimum continuum of 
care and follow up services that patients affected by both MDR-TB and HIV/AIDS 
needed. A physician, who was treating MDR-TB and HIV/AIDS co-infected patients, 
desperately narrated the incident of a sudden death that occurred to an MDR-TB and 
HIV/AIDS co-infected patient in the 17th month of his treatment for MDR-TB.  
 
“…the patient was on anti-retroviral therapy for seven years and then he caught MDR-
TB and was on treatment for MDR-TB for 17 months. The patient focused on the new 
problem of MDR-TB and the challenges associated with taking both second-line and 
anti-retroviral drugs. In such scenarios, the patient’s anti-retroviral clinic did not provide 
the routine laboratory evaluation that the patient needed to make sure of the continued 
success of the anti-retroviral therapy in suppressing the patients’ viral load. While 
hopefully completing his MDR-TB treatment, one day the patient suddenly fell in the 
road and comatosed. Then the patient was taken to the hospital where the MDR-TB 
treatment was initiated. The patient was evaluated at the MDR-TB treatment centre 
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and it was discovered that his T-lymphocyte cell bearing (CD4) count was only 40 cells 
per cubic millilitre which indicated failure of the patient’s anti-retroviral treatment and 
that may have been the possible cause of the patient’s death,…the anti-retroviral 
therapy failure was not diagnosed until the patient was found fallen down on the 
road,….[P-5M]. 
 
As the patients who were MDR-TB and co-infected could not get optimum follow ups 
and care for the HIV disease from the MDR-TB centre, patients were obliged to visit 
another facility and another caregiver to get care and treatment for the problem of 
HIV/AIDS. An excerpt taken from a caregiver also illustrates the grievances that 
patients encounter due to the absence of integrated care for MDR-TB and HIV/AIDS in 
one centre.  
 
“…for the HIV problem, patients’ main follow up centre is the anti-retroviral therapy 
clinic. When there are problems, we refer patients to the caregivers for HIV/AIDS,… 
[P-8M]”. 
 
4.4.2.2. Management of adverse drug reactions from second-line anti-
tuberculosis drugs  
The quantitative component of this study revealed that, adverse drug reactions from 
second-line drugs, among patients included in this study, were common. It was shown 
that all of the 91 (100%) patients with MDR-TB for whom data on adverse drug 
reactions were available, experienced at least one episode of adverse drug reaction in 
the course of their treatment for MDR-TB. moreover, from the total of the 91 patients, 
31 (34%) of them experienced five or more episodes of adverse drug reactions from 
second line drugs.  
 
An analysis of the patients’ access to routine laboratory follow up services showed only 
15% of the patients enrolled to treatment had access to the standard follow up 
laboratory services recommended by the World Health Organization and that adopted 
by the Programmatic Management of MDR-TB in Ethiopia. Thus, the majority of the 
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patients on treatment were not getting the programmatically recommended routine 
laboratory follow up services.  
The qualitative component of the study, through the interviews with caregivers, clarified 
the dynamics around patients’ access to the standard laboratory follow up services 
recommended for patients with MDR-TB while on treatment. The status of patients’ 
access to the basic diagnostic and follow up laboratory services was elaborated in the 
actual context of the study sites. It was revealed that the hospital MDR-TB treatment 
units lacked laboratory units dedicated for patients treated for MDR-TB. The hospital 
MDR-TB treatment units shared the hospital general laboratory facilities which were 
originally established for providing services for the general hospital polyclinic; which 
could not adequately provide the routine laboratory services needed for patients with 
MDRTB. It was clarified that absence of dedicated, comprehensive and consistently 
functional laboratory challenged the process of clinical decision making in many ways.   
The caregivers mentioned that the majority of the patients with MDR-TB develop 
adverse drug reactions in the course of their treatment for the disease. It was made 
clear that some of the adverse drug reactions were easily diagnosed using clinical 
signs and treated accordingly. Yet, for some of the adverse drug reactions, the 
diagnosis needs routine laboratory follow up tests.    
As such, caregivers mentioned that some of the adverse drug reactions which are 
difficult to diagnose clinically usually go unnoticed and lead to severe complications 
which can be fatal. At the rural treatment follow up centres, adverse drug reactions 
from second-line drugs were not diagnosed early or they were usually misdiagnosed 
and mistreated. As a result, patients with MDR-TB usually encounter clinical 
complications from adverse drug reactions and are readmitted to the hospitals for 
treatment. The next excerpt was on a patient’s story narrated by the physician caring 
for her in which absence of advanced lab tests challenge early diagnosis and prompt 
management of adverse drug reactions from second-line drugs.     
 
“…The practical challenges are, firstly for the drug side effects, the chance to clinically 
detect them is very difficult. Many of them are known through advanced laboratory 
diagnosis like for example, the electrolyte analysis and it is a very big killer problem. 
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You may not detect it symptomatically, I mean until it is in the advanced stage. These 
things, especially at treatment follow up centres are challenging. They cannot be 
detected without laboratory tests. I can mention one patient as an example. She 
developed hypocalcemia and what she did was, as she has money, she went to a 
private clinic. When she got there, they told her that it is hypertension and they gave 
her anti-hypertensive drugs. She was seizing, the problem was hypocalcemic tetani. 
But, they made her start on nefidipine. She is 21 years old. At that time, I called a 
catchment area meeting. Then when we were talking, they told me that the patient was 
diagnosed with hypertension and she is admitted. I told them this could not be 
hypertension and I asked them to bring the patient to me on the next day and I told 
them that I would admit her and follow her up. Then, she was admitted. When we 
followed up, her blood pressure was normal. Meanwhile, had developed hypocalemic 
tetani. When we measured it, it was severe hypocalcemia with hypokalemia and 
hypomagnesemia. The symptomatic identification of these side effects is challenging, 
it is very difficult to detect them. Even at our hospital electrolyte test is not 
done…especially these days nothing is done at our laboratory. At one time there was 
reagent shortage. The other time, laboratory technicians were not cooperative. We took 
the sample and they told us that the sample had expired. But most of the time they say 
the machine is not functional. Most of the time it is reagent and the machine, that 
created very huge problem,… …[P-6M]”. 
 
The quantitative component revealed that all the 91 patients with MDR-TB for whom 
data were available on adverse drug reactions from second-line drugs experienced at 
least one episode of adverse drug reactions. On the other hand the qualitative inquiry 
through interviews with caregivers revealed that the ancillary drugs used to treat 
adverse drug-reactions from second-line anti-tuberculosis drugs were not consistently 
available through the national programme of MDR-TB. Instead, the hospital MDR-TB 
centre uses the routine hospital pharmacy stores to get ancillary drugs for patients with 
MDR-TB who need treatment for adverse drug reactions. The next excerpt clarifies 
how caregivers use different mechanisms to get ancillary drugs for patients: 
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“…the problem of ancillary drugs, what we do at our hospital is that we discuss the 
problem with the main hospital pharmacy, we as caregivers do this as the programme 
is our responsibility and as it this is our own issue,… we reached an agreement and 
we take drugs from them and give the drugs to the patients…patients get drugs for 
free,…[P-5M”]. 
 
4.4.2.3. Patients’ attendance to the daily Directly Observed treatment schedule 
The quantitative component of this study revealed that, from the total number of 
patients with MDR-TB included in this study, data on the patient’s attendance at daily 
observed treatment were available for 93 (68%) of the patients on treatment. The 
assessment of patients’ level of attendance at daily Directly Observed treatment 
revealed that there was evidence of strict daily observed treatment attendance by 53 
(57%) of the patients. For this group of patients, there was no evidence of missed daily 
drug doses.  
The interviews with caregivers revealed that efforts were made to make sure that 
patients take their daily treatment under observation. Such efforts were made both for 
patients treated at the hospitals and those linked to the community level MDR-TB 
treatment and follow up centres. For patients linked back to the community after 
treatment initiation at hospitals, patients were given contact addresses of the 
caregivers found at the hospitals (the treatment initiating centres). Patients were told 
to contact their hospital level caregivers if they encounter any problem at the treatment 
follow up centres. This was described by an excerpt taken from a physician treating 
patients with MDR-TB: 
 
 “…As a practicing physician I can speak with full confidence on that…once we send 
patients from here to the community, we have communication with caregivers at the 
treatment follow up centres and we confirm if the patients have reached them… In 
addition, all patients have my cell phone. They personally phone me. If the caregiver 
is absent, the patient himself calls me. Patients themselves phone me even before 
caregivers at the treatment follow up centres call me and they tell me if they missed 
the drug dose of the day…. not only this, when we call for the catchment area meeting, 
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we get the full report of patients treated at follow up centres. If there is something 
beyond their capacity, if adherence problem is encountered, we agreed that if a patient 
misses a one-day drug dose, we have to know on the second day. If they encounter 
any problem, they will tell us…, maybe that is the main reason for the low rate of lost 
to follow ups in our case…[P-5M]”. 
 
Yet, there were patients who did not strictly adhere to the scheduled daily treatment 
under the direct observation of a treatment supporter. For the 28 (30%) of the patients, 
adherence or attendance to the daily observed treatment was poor and there was 
evidence of missed daily drug doses. For some 12 (13%), patients adherence or 
attendance to the daily observed treatment was irregular or erratic.  
 
The quantitative result also revealed that 53% of the patients were self-employed in 
the informal sector mainly in the daily labour work space while 35% of the patients were 
not employed at all. 
 The qualitative part of the study has clarified the dynamics at play around the patient’s 
attendance to the scheduled daily treatment under direct observation by a treatment 
supporter.  The qualitative result revealed that, patients with MDR-TB face social and 
financial hardships due to the inadequate income they get. Most patients could not 
strictly adhere to the conventional daily labour work as a result of losing their physical 
strength to the disease, MDR-TB. On the other hand, the service on patients’ treatment 
under the daily direct observation was not formally decentralized beyond the treatment 
follow up centres. The reason for that, as was mentioned by caregivers, was that there 
is lack of involvement by the community health extension workers in the provision of 
daily treatment support for patients with MDR-TB those linked to the community. A 
nurse caregiver for MDR-TB mentioned the lack of involvement of the health extension 
works in MDR-TB treatment support as follows: 
 
“… the community health extension workers providing the daily observed treatment 
support for patients with MDR-TB, No! There is no such practice in our situation, I do 
not know what happens at other places,…[P-1M]”.  
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As clarified in the above, a combination of socio-economic problem and absence of 
strictly patient centred daily observed treatment support challenges patients’ coping 
ability to the standardised schedule of treatment under daily observation.   
  
4.4.2.4. Community level MDR-TB infection control  
From the quantitative data, it was found that for all patients linked to community level 
MDR-TB treatment support (n=105), no housing arrangement was prepared before the 
patient was linked to the community. For these patients, no household level MDR-TB 
infection control arrangements were made. It was also found that from the total of 136 
patients with MDR-TB included in this study, 8 (6%) patients with MDR-TB were 
diagnosed from household contacts of the index patients with MDR-TB 
 
The result of the interviews with caregivers for MDR-TB supported the quantitative 
result on community level MDR-TB infection control. Caregivers found at the treatment 
follow up centres were not visiting patients’ homes to make arrangements for MDR-TB 
infection prevention at the patient’s household level. As such, families of the patients 
with MDR-TB and the surrounding community were not getting information and insight 
about the disease.   
 
The qualitative interviews with patients revealed that patients who contracted MDR-TB 
from household members did not have insight about the risk of MDR-TB infection and 
its transmission to their close contacts and household members. The reason 
mentioned was the absence of adequate education on the danger of MDR-TB 
transmission from patients to their household and close contacts. The excerpt taken 
from a patient on treatment elucidated this: 
 
“…I caught the disease while I was taking care of my husband. I had never had TB 
before... he was my husband…while I was taking care of him, I did not know about the 
disease because both of us did not have this disease before. They put him on the 
sixmonth treatment and at that stage, they did not tell us about any precautions, and 
no advice was given for him also. When he started the treatment, I did not think that 
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the disease transmits and in fact he is my husband and I could not abandon him 
because he was sick and I could not go away. If we were told that it transmits, I would 
have taken care and he also would have taken care of me…[P-6F]”. 
 
Moreover, some of the patient participants of the interviews mentioned that the wider 
community lacked adequate insight about MDR-TB. Thus, patient participants reported 
that because the people around them do not have information about MDR-TB, the 
responsibility of caring for others rests on the patient.  
 
 “…I refrain from mixing with people… they say ‘he refrains from us because he might 
be losing hope  ...’… the community knows nothing about the disease….it is very 
important that the public is taught on this problem…[P-4M]”. 
 
It was also reported that the effort of patients to care for others in order to prevent the 
transmission of the disease MDR-TB fades with time. This might be due to the absence 
of ongoing efforts to encourage and support patients and their families on the continued 
need for the prevention of MDR-TB infection.  
 
“… in our family we use masks for one or two months and then we may stop using the 
masks and start living without the mask…[P-9M]”. 
 
As a way out for preventing the risk of MDR-TB infection to the larger community, some 
of the participants of the interviews recommended the need to treat patients with MDR-
TB in a dedicated centre where patients can complete the entire treatment given for 
MDR-TB before going back to the community. Caregivers mentioned multiple problems 
hindering the smooth implementation of community level treatment of MDR-TB. The 
factors mentioned were the absence of strong monitoring by the respective health 
management, inadequate commitment by caregivers at the treatment follow up centres 
and inadequate logistic arrangement, like motor bics, to visit every patient’s home.  
These problems were perceived to contribute to the transmission of MDR-TB among 
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household contacts. A nurse providing clinical care for patients at a hospital mentioned 
the problem as follows:  
 
“…By the way, tuberculosis, as it is well known, is a disease of the poor. I mean, I think 
you understand me, there are many issues like well-ventilated living rooms, there are 
many, many factors, there are gaps in quickly picking up and diagnosing those with a 
two weeks cough; I mean we see it in general. Additionally, we see that from the side 
of TB patients, after you have diagnosed them, there is problem with providing daily 
observed treatment services,…[P-3M]”. 
4.5. Summary  
This chapter has presented the results of the quantitative, qualitative and that of the 
mixed methods objectives. The next chapter, chapter 5, presents the steps used for 
the development of the model for enhancing the treatment of patients with MDR-TB in 
Ethiopia. Moreover, chapter 5 presents the application of the various components of 
the model for enhancing the management of patients with MDR-TB. 
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Chapter 5: Model development   
5.1. Introduction  
The previous chapter presents the result of the study. This chapter is on the 
development of a model for enhancing the management of patients with MDR-TB. The 
conceptual model is developed using the results of the study, expert opinions, the 
researcher’s clinical experience and the extant literature.  
 
5.2. The key concepts of a model  
5.2.1. Definition of a model  
A model is a symbolic representation of concepts or variables and the interrelationships 
among them (Jaccard & Jacoby 2010:28-9). A model is a conceptual basis for how a 
programme is supposed to work. It can be presented as a figure or as a text. It serves 
to objectify and present key aspects of a programme, including the   functions of those 
aspects (Modest & Tamayose 2004: 85-6). 
5.2.2. Elements of a model.  
Based on the literature review, models are made up of variables, constructs and theory. 
A theory is an interrelated set of constructs that specify the relationship among 
variables. Theories help to explain or predict phenomena that occur in the real world 
(Creswell 2009:51-2). Constructs are higher order concepts that are constructed from 
concepts. Constructs enable us to have an understanding of the real world. Constructs 
encompass a universe of possibilities. Yet, constructs often lack clarity. Thus, 
constructs need to be expressed in a way that is clear and precise so that it can be 
shared (Jaccard & Jacoby 2010:12-13). 
When a construct is assigned a specific property and can be measured it is called a 
variable. Variables are characteristics of individuals or organizations that can be 
measured or observed (Fertman & Allensworth 2010:59-60). Variables are important 
because entities in the real world differ depending on differences in the variables that 
describe them (Jaccard et al 2010:13).  The value of each of these variables affects 
the systems’ functional state. If any of the variables changes in some way, it affects 
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the entire function of the system (Reid, Compton, Grossman and Fanjiang 2005:37-
38).   
In a healthcare system, a model helps to guide addressing a specific health problem 
or health events (Fertman et al 2010:433). A model of healthcare defines the way 
health services are delivered. In other words, through the application of a set of service 
principles; a healthcare model outlines the best practice for the delivery of care for the 
patient (Government of Western Australians 2006:4). 
5.2.3. General approach to model building 
In the Western countries, systematic analyses of the quality and cost effectiveness of 
healthcare have been done for decades. Use of the condensed information from such 
analyses has helped in the development of guidelines and practice standards. Use of 
these guidelines and best practice information by healthcare practitioners has enabled 
them to improve the quality and cost-effectiveness of the care they give to their 
patients. The Joanna Briggs Institute (JBI) model of evidence-informed healthcare is 
the best example of the identification, appraisal, syntheses and use of the best 
available research evidence to inform and improve health services. As a form of 
decision making, the process of evidence-informed practice involves evidence 
generation, evidence synthesis, evidence transfer and the utilization of the evidence in 
routine clinical care (Pearson, Field & Jordan 2007:6). As such, the basic steps for the 
development and application of a model for healthcare include understanding the policy 
context, understanding the current state of practice (evidence) and translating 
evidence into best practice using the model of care. Models of care can be developed 
for diseases, conditions or population groups that deliver services that meet both 
community health needs and nationally set health outcomes.     
5.2.4.  Evidence generation 
The first step in model development is often the generation of ideas about the 
explanatory constructs and the relationships among them regarding the phenomena 
that one tries to explain. Then ideas generated are subjected to more careful analytic 
scrutiny to elaborate on more promising ideas that are pursued further (Jaccard & 
Jacoby 2010:39-40). As such, healthcare evidence generation is the first step in the 
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process of evidence-informed practice. This is because it is difficult to have evidence-
informed practice without evidence. Evidence is the basis for belief. Evidence is the 
substantiation or confirmation that is needed in order for us to believe that something 
is true. Regarding healthcare, evidence can be generated about different segments of 
a healthcare. These include the feasibility, appropriateness, meaningfulness and 
effectiveness of the evidence. 
5.2.5.  Evidence synthesis  
Evidence synthesis is the second step in model development. It concerns the analysis 
of research evidence and opinions on specific topics of interest. In other words, 
evidence synthesis involves the pooling of research findings. The pooled research 
findings help to effectively determine the interventions, activities or phenomena that 
the evidence supports. There are certain core elements in the process of evidence 
synthesis. The development of a theoretical understanding of the nature of the reality 
together with the role of evidence in healthcare forms an important element of evidence 
synthesis. Moreover, operationalization of the evidence synthesis and the systematic 
review of the relevant literature on a particular condition form other crucial elements of 
evidence synthesis. Evidence synthesis entails the integration of results that are 
obtained through various methods. A pluralistic approach to evidence synthesis 
involves the analysis and use of evidence generated via both quantitative and 
qualitative inquiry (Pearson, Field & Jordan 2007:21-2). Moreover, data interpretation 
needs to reflect both statistical significance and its importance to stakeholders. Thus, 
the summary of the information will help to present a balanced report that addresses 
the value of the phenomena to the different stakeholders (Harris 2010:133). 
Quantitative result may be synthesized using statistical analysis. It measures the effect 
of the predicator variable on the dependent variable. Qualitative results are synthesized 
to create the summary of the meanings of the phenomenon under study. In the 
development of the model for enhancing the care of patients with MDR-TB, the various 
segments of the research results were combined logically and reasonably. Study 
results that reflect relationship among phenomena are put in category so as to reach a 
coherent whole that can inform practice. Evidence synthesis facilitates decision making 
in healthcare. 
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5.2.6. Transfer of evidence or knowledge 
This is the third step in model development. This component of model building is 
concerned with the act of transferring knowledge to individual health professionals, 
health facilities and the healthcare system. This is done through publications, electronic 
media and other decision support systems. Knowledge transfer is more than the 
dissemination of information. It needs careful identification of strategies that identify the 
target audience such as clinicians, managers and policy makers and consumers and 
the design, packaging and transfer of information that is comprehensive and useable 
in decision making. Effective knowledge transfer entails an understandable and 
audience appropriate message that is conveyed through organizational systems in a 
cost effective way. 
In the development of the model for enhancing the programmatic management of 
patients with MDR-TB, the target audiences in the programmatic management of MDR-
TB were identified. These include all level clinicians providing care for patients with 
MDR-TB, programme managers at hospitals and the general health care management 
within the regional health bureau and policy makers. For these actors, the model 
developed represents the evidence or knowledge transfer component. The model has 
educational and information delivery role for programme managers and caregivers in 
the programme. As such, transfer of evidence to those who are in a position to 
implement the knowledge in practice is central to the evidence-informed process. 
Moreover, the result of this study will be disseminated to individual health professionals 
globally by means of journals and other electronic media. 
      
5.2.7. Evidence utilization  
This is the fourth step in model development. Evidence utilization is the 
implementation, in practice, of the evidence or knowledge possessed by healthcare 
professionals. In the context of the current study area, the gaps in the implementation 
of the programmatic management of MDR-TB was identified by each level or 
component of the programme. In the model, each component was described and its 
application to enhancing the programmatic management of patients with MDR-TB was 
clarified. Such implementation of evidence in practice helps to change the routine care 
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practices. Through changing organizational practice, evidence utilization will ultimately 
impact the process of care and health outcomes.  Moreover, utilization of evidence 
helps to base routine practice on best available evidence. It also addresses the context 
in which the care is given, client preferences and professional judgement of caregivers. 
In this view, the model developed to enhance the management of patients with MDR-
TB will serve as a vehicle to drive the required change to mitigate the gaps in the 
management of patients with MDR-TB. 
5.3. Data sources for the development of the model    
Data for the development of the model for enhancing the care of patients with MDR-
TB were gathered from different sources. These sources included the literature 
reviewed, results of the study on the treatment outcomes of patients with MDR-TB and 
its determinants and the researcher’s own experience on the programmatic 
management of MDR-TB in the Ethiopian context.   
5.3.1. The literature review  
Development of a conceptual model depends on the powers of observation, grasping 
a problem of interest and knowledge of prior research results. The observations are 
often the results and conclusions of a research endeavour (Polit & Beck 2003: 132).  
As such, a critical analysis of the available literature is intrinsic to concept analysis 
(Yazdani & Shokooh 2018:34). The literature review is a process of presenting 
theoretical explanation for the variables and constructs under investigation (Sumerson 
2014:45). 
In this study, the literature review was used to identify theories and ideas for the 
research. Guided by a conceptual framework, the boundary to the scope of the 
literature search was set by the aims, objectives and the hypotheses of the study 
(Crano, Brewer & Lac 2015:5-6; Imenda 2014:186). The adopted framework of the 
study, the Donabedian framework, enabled the researcher  to assess a range of factors 
associated with the treatment of patients with MDR-TB and with the quality of the care 
given for patients with MDR-TB (Donabedian 2005:695). The literature identified 
important ideas and concepts on the treatment outcomes of patients with MDR-TB and 
its determinants. Thus, the concepts synthesized through the literature review were 
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used to develop the model for enhancing the care of patients with MDR-TB and 
patients’ satisfaction with care given for MDR-TB. 
 
5.3.2. The research result  
The result of the study has enabled the researcher to identify the clinical and 
programmatic system related determinants of the outcomes of patients with MDR-TB, 
patients’ perceived quality of care and patients’ satisfaction with the care they receive 
for MDR-TB. These factors are a potential risk for the unfavourable treatment outcomes 
of patients treated for MDR-TB. The research result has revealed a list of the potential 
risk factors for the unfavourable treatment outcomes of patients treated for MDR-TB 
and patients’ satisfaction with the care they receive on MDR-TB. The result of the study 
has led to the development of insight into the clinical and non-clinical (economic, social, 
psychosocial) factors that determine the process and outcome of patients treated for 
MDR-TB. The quantitative result captured the socio-demographic and socio-economic 
characteristics of the study participants. The quantitative result also identified the status 
of the treatment outcome of patients with MDR-TB and the factors associated with the 
observed level of the treatment outcomes of patients treated for MDR-TB. On the other 
hand, the qualitative in-depth interviews with patients with MDR-TB and their 
caregivers, revealed factors that might determine patients’ perceived quality of the care 
provided for MDR-TB and the satisfaction of patients with the care given for MDR-TB. 
The qualitative inquiry also led to an understanding of caregivers’ and the patients’ 
perceived facilitators and barriers to the management of the patients treated for MDR-
TB. In summary, the results of this study contributed to the development of the 
conceptual model of the study. 
5.3.3. The researcher’s own experience  
The clinical and programmatic experiences of the researcher were used in the 
synthesis of the evidence generated from the literature and the study results. The 
researcher’s experience was also used during the structuring of the model developed 
for the management of patients with MDR-TB. Moreover, the comments obtained from 
the researcher’s supervisor and from experts who reviewed the sections of the 
research result were used in the synthesis and the structuring of the model developed.  
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5.4. Approaches used for concept analyses for model development   
The Walker and Avant (2011:58) strategy for concept identification and analyses was 
used to analyse and synthesise the concepts used in the development of the model for 
enhancing the care of patients with MDR-TB. The practice of concept analysis is an 
essential step to understanding logical thinking related to the terms and their meanings 
and their use in model development (Brush, Kirk, Gultekin & Baiardi 2016:160-1). 
According to the Walker and Avant strategy, the development of a conceptual model 
begins with the identification of key concepts relevant to the problem of interest. It is 
from the key concepts that one can move to the identification of the interrelated 
variables or attributes of these concepts (Zeng, Sun, Gary, Li & Liu 2014:6731). 
Concept analyses is an analytical method used to gain an understanding of the 
concepts or phenomena of interest. Concepts are created by words that enable people 
to communicate their meanings to the world, and they provide meanings to the 
phenomena that are experienced directly or indirectly (Bousso, Poles & Cruz 
2013:142).  In this study, the main purpose of concept analyses is to develop a 
conceptual model for clinical decision making in the care of patients with MDR-TB in 
the Oromia Region of Ethiopia and the other regions of Ethiopia.  The model helps to 
demonstrate the concepts of interest and their defining attributes.    
 
The concepts used in the model development and their attributes were synthesised 
from different sources including the literature review, study results and the researcher’s 
own experience. The literature enabled the researcher to get a thorough understanding 
of the problem under investigation. In the literature, factors relevant to the treatment 
outcomes of patients with MDR-TB, patients’ perceived quality of care and patient 
satisfaction with care given for MDR-TB are defined explicitly. Moreover, the specific 
attributes of each of the major concepts are explicitly defined. From the literature, 
concepts most relevant to the treatment outcomes of patients with MDR-TB include the 
socio-demographic and socio-economic characteristics of patients with MDR-TB. 
Clinical conditions including adverse drug reactions from second-line drugs and co-
morbid conditions with MDR-TB are concepts most cited in the literature. Likewise, 
concepts relevant to the patients’ perceived quality of care and patients’ satisfaction 
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with the care given for MDR-TB were patient-caregiver communication and the quality 
of care. Added to this, the duration of treatment, the effect of stigma and discrimination 
on patients with MDR-TB, status of available psychosocial and economic support, the 
service setups and the caring practice of caregivers were concepts relevant to patients’ 
satisfaction with care given for MDR-TB.  
 
The above concepts were analysed, re-structured or re-named in some instances using 
the framework of Walker and Avant (2011) approach for model development. The 
outcome of the analysis and re-structuring was a conceptual model to offer guidance 
for clinical practice in the programmatic management of patients with MDR-TB in the 
context of Ethiopia.  
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 Figure 5. 1: A Conceptual model for enhancing the management of patients with MDR-TB in Ethiopia
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5.5. Description of the components of the model and its practical application  
A model cannot be understood in the absence of its components. As such, this section is 
devoted to describing the components of the model and its practical application to 
enhancing the management of patients with MDR-TB. In each section, two important issues 
are presented. First, a description of a component is presented. Second, the application of 
the component for enhancing the management of patients with MDR-TB is presented. The 
components of the model include the socio-economic, the community, the healthcare 
system and the patient and the careteam components (see figure 5.1). Implementation of 
the recommended activities for each component improves the management of patients with 
MDR-TB.   
 
5.5.1.  Socio-economic and programme policy component  
In Ethiopia, the design for the management of patients with MDR-TB is a clinic based 
ambulatory model of care. Socio-economic support for patients with MDR-TB is a key 
component of the management of patients with MDR-TB (Federal Ministry of Health of 
Ethiopia 2014:16-17).  
Yet, evidence from the current study demonstrates that patients with MDR-TB suffered from 
socio-economic problems associated with becoming a patient with MDR-TB. Patients with 
MDR-TB lost employment due to the disease. This was associated with the stigma 
associated with the disease and lack of the strength to continue jobs in the informal daily 
labour works. On the other hand, the available socio-economic support provided by the 
programme of MDR-TB was inadequate. Moreover, the system of delivery of the available 
socio-economic support was not patient-centred, as it is provided at the hospitals. To 
transport the nutrition items from the hospitals to their home areas, patients with MDR-TB 
incurred an unpaid cost of transportation. Moreover, there was weak system of check by 
the regional health bureau regarding the appropriate implementation of the patients’ socio-
economic support by the hospitals.  Moreover, the financial reimbursement made by the 
programme to cover patients’ transport costs, could not consider costs paid to local 
transport systems like the taxis, carts and the motor bikes on which patients could not 
present official receipts.  
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Furthermore, some patients linked to the community treatment follow up centres incurred 
cost to continue treatment. As the community health extension workers were not involved 
in providing daily treatment support for patients with MDR-TB, patients living in remote rural 
areas could not access their daily treatment within walking distances. Such patients were 
forced to rent houses in the towns of the treatment follow up centres in order to be close to 
the MDR-TB treatment follow up centres. Yet, there was no accommodation allowance for 
the remote rural patients linked to the treatment follow up centres. 
  
5.5.1.1. Application to enhancing the management of patients with MDR-TB     
There is national enabling policy platform for the application of the socio-economic 
component related recommendations of the model. The National Health Account shows 
that, in Ethiopia, health shares 5.2 percent of the gross domestic product which meets the 
5% of gross domestic product recommended by the World Health Organization (Federal 
Ministry of Health 2014:16). There is regular flow of fund for the MDR-TB programme from 
the regional health bureau to the hospitals that are managing MDR-TB (Federal Ministry of 
Health of Ethiopia 2014:86).  
In this regard, the programme policy component can facilitate decisions about patient care 
or the organization and delivery of the clinical and other services based on the needs and 
preferences of patients with MDR-TB. Moreover, actors in the programme policy 
component (policy-makers, managers, clinicians) have the capacity to facilitate 
implementation of the recommendations included in this model inline with programme 
priorities and the availability of resources. 
To this end, the Oromia Regional Health Bureau need to revise the current approach to the 
socio-economic support provided for patients with MDR-TB. The support should address 
the needs and preferences of patients with the disease. The study revealed differing socio-
economic support need by patients with differing social status. Thus, the current socio-
economic support need to align with the socio-economic support need of a particular patient 
with MDR-TB than the current ‘one size fits all’ or uniform approach for all patients with 
MDR-TB.  
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Moreover, the mode of delivery of the nutrition support should be patient-centred, that is, 
the support (nutrition items) should be delivered as near to the patients’ home area as 
possible.  
Furtheremore, this model recognizes that the regional health bureau need to monitor the 
accountable and cost-effective use of available programme resources. Moreover, the 
regional health bureau need to address the invisible indirect cost incurred by the remote 
rural patients in their effort to continue treatment after linkage to the community treatment 
follow up centres, This can be done, through the decentralisation of the daily treatment 
service closer to the patient’s home area, preferably through the active involvement of the 
health extension workers.  To tackle the stigma associated with MDR-TB, the regional 
health bureau need to strengthen community education on MDR-TB. Moreover, the model 
is a reminder for the hospital level leadership to support the programme of MDR-TB through 
taking the lead responsibility to make sure that socio-economic support provided for 
patients with MDR-TB addresses the needs and preferences of patients with the disease. 
The hospitals’ management should use the views and opinions of patients with MDR-TB 
and the views of the caregivers for MDR-TB in the planning and implementation of the 
socio-economic support given for patients with MDR-TB. Furthermore, the hospitals should 
disburse nutrition items closer to the patients’ home area, or at least at the level of the 
community based treatment follow up centres for MDR-TB.  
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5.5.2. The community component    
In Ethiopia, the community is part of the outpatient based ambulatory model of care for 
patients with MDR-TB. The community supports case finding and patients’ treatment 
support at family level. The health extension workers, who are responsible for supporting 
patients with MDR-TB through daily treatment observation are found in the community. 
Health extension workers also lead the activity of community education and respiratory 
MDR-TB infection prevention at the community and household levels (Federal Ministry of 
Health of Ethiopia 2014:21).  
 
However, this study revealed that there was no clear direction on the specific roles of the 
community in patient treatment support. Moreover, the health extension workers were not 
involved in the patient treatment support and respiratory MDR-TB infection prevention at 
the level of the community and patients’ homes. The competencies of the health extension 
workers and patient families regarding treatment support, the issue of patient confidentiality 
and prevention of stigma was not known. The involvement of patient families in patient 
treatment support was erratic. Given the fact that a huge number of tablets of each of the 
second-line drugs are taken by an MDR-TB patient per day, no evidence on the quality of 
handling the second-line drugs at home and on the quality of daily drug provision under 
observation. 
There was no practice of making sure that the patients’ household conditions ensure the 
respiratory MDR-TB infection control requirements. Furthermore, there was no system of 
monitoring implementation of the nationally recommended community level interventions 
on MDR-TB.  Because of lack of appropriate education to the community and the patients’ 
families on MDR-TB, substantial proportion (6%) of the total patients included in this study 
were diagnosed among close contacts of the index patients with families.  
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5.5.2.1. Application to enhancing the management of patients with MDR-TB   
The model has identified the gaps between the programme recommendations and the 
implementation of the recommended community level interventions on MDR-TB. As such, 
implementation of the model facilitates clarification of the specific roles for the health 
extension workers and the family treatment supporters. Moreover, it helps to devise a 
means of checking for the competencies of the health extension workers and families to 
implement community level activities on patient treatment support, prevention of stigma 
and MDR-TB infection prevention. Likewise, the model guide revision of the specific roles 
of the caregivers at the hospitals and the treatment follow up centres to monitor the 
implementation of community level activities on MDR-TB programme.  
 
5.5.3. The healthcare system component 
Based on the ambulatory model of care for patients with MDR-TB, arrangements are made 
whereby patients are initiated on treatment at hospitals and then linked to the health centres 
for continuation of treatment and follow ups (Federal Ministry of Health of Ethiopia 2014: 
18-19). Patients’ daily treatment support is arranged at the health centres or at the level of 
the community by the health extension workers or family members.     
However, the result of this study demonstrated that the programme lacked practical 
decentralization of clinical follow ups and socio-economic support that patients need after 
linkage to the community. Patients were expected to attend a compulsory monthly visits to 
the hospitals to attend MDR-TB clinic days and also to get the socio-economic support 
disbursed at the hospitals. The views and opinion of the patients with MDR-TB was not 
used in the planning and implementation of the socio-economic support given for patients 
with MDR-TB. Thus, both patients with MDR-TB and their caregivers perceived that the 
socio-economic support, particularly the nutrition support received by patients, did not meet 
the needs and service preferences of patients with MDR-TB. Moreover, there was no strong 
monitoring mechanism from the Regional Health Bureau to make sure that patients with 
MDR-TB were actually getting the right package of the socio-economic support for which 
the patients were eligible.  
At the hospitals, there was no physician dedicated for the MDR-TB treatment centre so that 
physicians were not readily accessible for patients’ emergent medical conditions. 
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Furthermore, the MDR-TB treatment centre was not providing integrated service on MDR-
TB and co-morbidities with it, especially co-infection with HIV/AIDS. The system was not 
tracking engagement of the health extension workers in patient treatment support and in 
MDR-TB infection prevention at the community level. Available programme support from 
the management of the hospitals and the general healthcare management was weak. At 
the hospital level, the setups in which care was given for patients with MDR-TB lacked 
cleanness and recreation facilities.  
Additionally, most of the treatment follow up centres were not accessible to the majority of 
patients who live in the remote rural areas. As such, most patients linked to the community 
had to move away from their home area and dwell in the home town of the treatment follow 
up centres. This has caused financial consequences on patients as patients had to pay for 
house rent. This was a concealed financial grievance on the remote rural patients with 
MDR-TB.  
 
5.5.3.1. Application to the programmatic management of patients with MDR-TB 
The healthcare system related recommendations of the model can be implemented within 
the available programme platform and available resources. The hospitals need to revise 
the current approach to the clinical follow ups and socio-economic support given for 
patients with MDR-TB. Patients should get clinical follow-ups by a physician and the socio-
economic support at the community based treatment follow up centres. This reduces the 
financial and time burden of patients who travel long distances to hospitals to get these 
services. The hospitals need to solicit the views and opinions of patients with MDR-TB in 
the planning and implementation of the socio-economic support available for patients with 
MDR-TB. At the hospitals, a physician dedicated only for the MDR-TB treatment centre; 
and who is 24 hours accessible for patients’ emergent medical conditions should be 
assigned. At the MDR-TB treatment centre, integrated treatment and follow-up services 
should be available on MDR-TB and associated co-morbidities, particularily HIV/AIDS 
under one roof and by the same caregiver. The healthcare system should urgently engage 
the health extension workers on patient treatment support, respiratory MDR-TB infection 
prevention at household level and the reduction of stigma against patients with MDR-TB. 
For this, the healthcare system need to clarify the roles of each actor in the implementation 
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of community level interventions on MDR-TB. In cases when family members are 
considered to provide daily treatment support for patients with MDR-TB, the healthcare 
system should provide tablet bags to facilitate safe handling of the second-line drugs at the 
patients’ homes. The managements at the hospitals, health centres and the general health 
system should be closely steering implementation of the continuum of care and services 
available for patients with MDR-TB.   
 
5.5.4. The patient with MDR-TB and the healthcare team component  
The approach in which the healthcare team provides care and services determine patients’ 
satisfaction with the care given (Višnjić et al 2012:54). The meaningfulness of the evidence-
informed practice is determined by the way in which it is experienced by the patient who 
uses the services. Thus, the outcomes of any health intervention is considered desirable if 
it reflects the patients’ preferences rather than the caregivers’ (Pearson, Field & Jordan 
2007:20).  In Ethiopia, the healthcare team for the MDR-TB programme is composed of a 
panel of experts with varying disciplines from the hospitals, the general health management 
and other stakeholders. The panel team is responsible for steering the clinical and non-
clinical services given for patients with MDR-TB (Federal Ministry of Health of Ethiopia 
2014:23).   
In this study, it was noted that the prevailing approach to the management of patients with 
MDR-TB could not address the needs and preferences the patients with MDR-TB. 
Specifically stated, there was weak effort in the identification of the socio-economic, 
behavioural and motivational support needed by patients with MDR-TB. Patients were not 
active role players in the decisions made regarding the socio-economic support and the 
clinical care they receive on MDR-TB. There was no smooth communication and 
information sharing between patients and their caregivers, particularly at community level 
treatment follow up centres where patients could not get empathic and caring services. 
Moreover, the awareness of patients and their families on MDR-TB was very low. Thus, 
family caregivers were at risk of respiratory MDR-TB infection. 
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5.5.4.1. Application to the programmatic management of patients with MDR-TB 
The healthcare team need to transform the current passive service recipient status of 
patients towards a fully informed and motivated patients who can share responsibility on 
the care they receive for MDR-TB. For this, collaborative communication should be 
strengthened between patients and their caregivers with emphasis to the treatment follow 
up centres. At treatment inception, the healthcare team need to identify the peculiar socio-
economic and clinical support need of a patient with MDR-TB and tailor patient’s supports 
towards his or her needs and preferences. The hospital management need to consider the 
recommendations of the healthcare team in planning clinical and socio-economic services 
for patients with MDR-TB. Furthermore, the healthcare team should strengthen community 
awareness on MDR-TB, prevention of respiratory MDR-TB infection and the stigma against 
patients with MDR-TB.                                     
5.6. Strengths and limitations of the model 
Implementation of the recommendations of this model are feasible as it can be implemented 
within the available programme context and the available programme resources. Moreover, 
the interventions in the model are meaningful for patients with MDR-TB as it addresses the 
values and the preferences of the patients who use the services given for MDR-TB. In 
summary, implementation of the model improves patients’ satisfaction with care given for 
MDR-TB, patients’ adherence to treatment and the treatment outcomes of patients treated 
for MDR-TB.   
Therefore, the researcher believes that the model will have extensive use in guiding 
programmatic and clinical practice in the care of patients with MDR-TB. The model has 
incorporated important concepts that are known to determine the process and the 
outcomes of patients treated for MDR-TB and patients’ satisfaction with care given for 
MDR-TB. The multiple concepts incorporated into the model have the potential to serve as 
a reference for caregivers on MDR-TB. The model will also guide coordination among main 
programme actors in the health system. As such, the model will aid decision making 
technically and programmatically. Therefore, the researcher believes that this model will 
have a multi-attribute additive value for improving the clinical and programmatic 
management of patients with MDR-TB. The researcher also believes that the model will 
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guide policy makers in the development of a patient-centred approach to the management 
of patients with MDR-TB. Hence, the model will highly improve treatment outcomes of 
patients with MDR-TB. It will also improve patient satisfaction with the care and services 
given for MDR-TB. 
However, development of the model is based on data from two treatment centres. The 
programmatic context at the two centres may be different from the context of other centres. 
This may limit application of the model beyond the context of the treatment centres included 
in this study.    
 
5.7. Summary   
Chapter five presented discussions on model development. The term model was defined 
and its uses were described on a conceptual basis for representing how a programme was 
supposed to work. The strategy used for the development of a model was discussed. The 
chapter also discussed the various sources of data for the development of the model for 
enhancing the treatment for patients with MDR-TB. Ultimately, the chapter presented the 
components of the model developed and the application of each component in enhancing 
the programmatic management of patients with MDR-TB.  The next chapter, chapter 6, 
presented a detailed discussion on the major results of the study. 
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Chapter 6: Discussions  
6.1. Introduction  
The results of this study were presented in the previous chapters. This chapter presents 
the discussions of the results in line with the available literature. In this chapter quantitative 
and qualitative results are discussed together. Moreover, implications of the results of this 
study on the current practice in the clinical and programmatic management of MDR-TB in 
the Oromia Region of Ethiopia are shown.  
6.2. Discussions on key results   
6.2.1. Treatment outcomes of patients treated for MDR-TB  
6.2.1.1. Interim treatment outcomes  
This study revealed that at six month after commencing treatment, 71% of the patients were 
culture negative. Yet, 20% of the patients were died of MDR-TB by month six. The 71% 
culture negative rate by the end of six month revealed in this study is more than the 62% 
rate of culture conversion reported among patients treated at treatment centres in Amhara 
and Oromia Regions of Ethiopia. But the 27 (20%) death rate revealed in this study is more 
than 10% reported among the same (Molla, Jerene, Jemal, Nigussie, Kebede, Kassie, 
Hiruy, Aschale,  Habte, Gashu, Kebede, Melese  & Suarez 2017: 31).  
The result of this study is consistent with the study conducted in South Africa in which it 
was found that, compared with the HIV negative patients with MDR-TB, HIV positive 
patients with MDR-TB had a lower chance of culture conversion and a higher chance of 
death (35.2% deaths among HIV positive patients with MDR-TB was compared to the 
16.2% death among HIV negative patients with MDR-TB, P-value<0.0001) (Lange et al 
2014:47). 
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6.2.1.2. Final treatment outcomes of patients with MDR-TB  
This study revealed a composite treatment success rate of 69% and a death rate of 30 (27) 
% among patients with MDR-TB included in the study. The 69% treatment success rate is 
less and the 27% death rate is higher respectively than the 75% treatment success rate 
and the 15% death rate reported respectively by Molla et al (2017:31). Moreover, this level 
of treatment outcome is lower than the composite treatments success rate of 78.6% 
reported by Meressa et al (2015:1181). On the other hand, the 69% treatment success rate 
revealed in this study is similar to the 70.6% treatment success rate reported by Anderson 
et al (2014:406) Moreover, the 1% rate of lost to follow ups revealed in this study is less 
than both the 5.9% reported by Meressa et al (2015:1183) and the 8% lost to follow ups 
reported by Molla et al (2017:31).  
According to the report by Anderson et al (2013:406), HIV co-infection with MDR-TB is 
associated with a higher rate of default from treatment and death from MDR-TB. In the view 
of the report by Anderson et al (2013:406), the relatively low treatment success rate 
revealed in this study compared to the report by Meressa et al (2015:1181), might be due 
to the higher proportion of any co-morbidity (31%) with MDR-TB at baseline and higher 
MDR-TB and HIV/AIDS co-infection (25%) among patients included in this study. Moreover, 
the intensive nutrition support and the intensive management of adverse drug reactions 
from second-line drugs through the direct support of a non-governmental organization 
collaborating with the Ministry of Health as reported by Meressa et al (2015:1183), was not 
comparable with the desperate nutrition support reported by patient with MDR-TB and their 
caregivers included in this study. Such differences might also explain the lower treatment 
success rate among patients with MDR-TB included in this study.  Despite the high MDR-
TB and HIV co-infection rate revealed in this study, the 1% lost to follow ups is presumably 
encouraging.   
In Georgia, low monthly household income and unemployment were predictors of poor 
treatment outcomes among patients treated for MDR-TB (Djibuti, Mirvelashvili, 
Makharashvili & Magee 2014:1). In this view, the higher proportion of unemployement 
(35%) and employement in the informal labour works (53%), revealed in this study, might 
explain the higher rate of death among patients included in this study.  
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6.2.2. Determinants of the treatment outcomes of patients with MDR-TB  
6.2.2.1. Socio-demographic and socio-economic characteristics and the treatment 
outcomes of patients with MDR-TB 
The study revealed that 94% of the patients included in the study were in the productive 
age group of 15-64 years. It is worth noting that 93% of the total deaths from MDR-TB was 
also occurred in the same age group. Moreover, the study revealed that only 5% of the 
study participants were employed in the formal sector. Thirty five percent of the patients 
were not employed and 53% were self-employed in the informal sector; which shows the 
low socio-economic status of patients with MDR-TB included in this study.  
On the other hand, the interviews conducted with patients with MDR-TB revealed that, the 
53% self-employment was described as employment in the informal labour workforce with 
minimum daily wages. It was also revealed that, some patients lost job and income as a 
result of failing to engage in their usual business activities like the labour work, which needs 
physical strength. Sixteen out of the total 18 patients with MDR-TB who participated in the 
interviews with patients did not have any means of getting an income. Such patients 
depended on the socio-economic support provided through the programme of MDR-TB.  
However, the socio-economic support obtained from the programme was reported to be 
inadequate. The nutrition support provided by the programme is not adequate both in terms 
of its quantity and quality.  
Termination of job due to MDR-TB and its treatment has caused multiple challenges on 
patients with the disease. Patient participants of the interviews associated poverty with the 
occurrence of MDR-TB. Some participants believed that poor economic status and the poor 
quality of food that they used to eat have put them at risk of contracting the MDR-TB 
disease. Participants also experienced that poverty challenges patients’ ability to adhere to 
the lengthy treatment given for MDR-TB. The disease hampered patients’ ability to cope 
up with both the disease and the treatment given for it.  For example, the poor rural patients 
could not afford the daily indirect expenses incurred to attend to the daily treatment at the 
treatment follow up centres. Moreover, participants perceived that MDR-TB becomes more 
severe among the poor patients who could not get adequate food, in which the disease 
was described that it easily collapses patients with poor nutrition status.  
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On the other hand, the nutrition and financial support provided for patients by the 
programme of MDR-TB was revealed to be inadequate. The study revealed that most 
patients with MDR-TB depend on the income of their families. This helps when the patient 
with MDR-TB has a family with a monthly income. However, the qualitative inquiry revealed 
that families of most of the patients with MDR-TB did not have monthly income and live on 
subsistence income. 
Furthermore, some of the patients with MDR-TB are bread winners for their family and have 
dependents to take care of. Patients with MDR-TB who had dependents but no income to 
take care of their dependents were obliged to share the food (nutrition) they got from the 
MDR-TB programme with their dependents. Such patients expressed the desperate 
condition associated with becoming a patient with MDR-TB. Such patients bitterly 
expressed the difficulty of taking the multiple drugs given for MDR-TB in the absence of 
adequate food to eat daily. Patients claimed that the MDR-TB disease aggravated the 
already poor living condition they had.   
On the other hand, patients with MDR-TB faced stigma that separated them from their 
family members and from continuing the usual daily labour work in which they were 
employed before. Moreover, the stigma was reported to have resulted in the termination of 
employment including by those who were professionally employed. As such, patients could 
not continue with their usual social roles once they were diagnosed with MDR-TB and 
started on treatment. This resulted in the worsening of the patients’ economic status that 
affects not only the patients themselves but also their dependents and families.  
 
As such, this study revealed that low socio-economic status and the inadequate socio-
economic support that patients received through the programme of MDR-TB has 
challenged patients’ coping ability to the challenges associated with being a patient with 
MDR-TB. The study revealed that patients with MDR-TB faced multiple adverse outcomes 
from MDR-TB. On the top of the body ailments from the disease, patents with this disease 
faced economic or financial problems, social problems like stigma, psychosocial problems 
including the discontinuation of employment.  
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The result of this study reminds us the theory of fundamental causes of disease. The theory 
of fundamental cause states that social and economic conditions are fundamental causes 
of inequalities in health and disease. According to the theory of fundamental cause, the use 
of resources to benefit health, by groups and individuals, is purposeful. Thus, the health 
advantage of high socioeconomic status is not a coincidental. The theory argues that the 
deliberate use of resources by individuals and groups to benefit health is essential in 
producing the enduring association between socioeconomic status and disease and 
mortality (Phelan, Link, Diez-Roux, Kawachi & Levin 2004:268-70).  
According to the theory of fundamental cause, social conditions influence multiple disease 
outcomes, meaning that it is not limited to one or a few disease or health problems. Second, 
it affects these disease outcomes through multiple risk factors. Third, the association 
between the fundamental cause and health is reproduced overtime via the replacement of 
the intervening mechanisms. Fourth, the essential feature of the fundamental social causes 
is that it involves access to resources that can be used to avoid risk factors or minimise the 
consequences of a disease once it occurs. In this way, the theory states that,  individuals 
with low socio-economic status lack resources like money, knowledge, prestige, power and 
beneficial social connections that protect health irrespective of what mechanism is available 
to combat the adverse outcomes of a given disease entity (Phelan, Link & Tehranifar. 2010: 
S29-30). In this study, poverty and the lack of adequate food was perceived by patients as 
a precursor for their catching the disease, MDR-TB. Once dignosed with the disease, 
patients with MDR-TB encountered worsening socio-economic and psychosocial problems 
including lost jobs and stigma associated with the disease.  
The result of this study is consistent with the report by Dheda et al (2014:342) and the 
report by Djibuti et al (2014:1). These reports indicated that low monthly household income, 
living in poverty and unemployment are predictors of poor treatment outcomes among 
patients with MDR-TB. In view of these reports, the high rate of unemployment revealed 
among patients with MDR-TB included in this study, seems to be a potential challenge for 
patients with MDR-TB to adhere to the standard schedule of the treatment given for MDR-
TB. Moreover, the result of this study is consistent with the report of the World Health 
Organization which states that patients with tuberculosis are too weak to continue working 
so that their families are obliged to pay for the expenses needed for care seeking. 
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Acknowledging this, patients with MDR-TB suffer direct costs that they incur in seeking care 
for the disease and indirect costs as a result of lost jobs due to the disease (WHO 2013b:7). 
The qualitative interviews also revealed that there were patients who noted that they were 
infected with MDR-TB because of the lack of adequate food. Moreover, patients perceived 
that lack of adequate food has challenged their coping ability with the treatment.  This result 
is consistent with the report that MDR-TB imposes socio-economic problems on patients 
affected by the disease. In the presence of free treatment for MDR-TB, patients incur 
indirect costs through income loss due to the disease. As such, reduced monthly income 
due to unemployment is a predictor of poor treatment outcome among patients with MDR-
TB (Djibuti, Mirvelashvili, Makharashvili & Magee 2014:1).  
The stigma and discrimination on patients with MDR-TB, revealed in this study, is 
consistent with the report of  Cremers et al (2015:2) in which 82% of patients with 
tuberculosis in Urban Zambia encountered some form of stigma due to tuberculosis. In 
Sudan, stigma due to tuberculosis was higher among the unemployed and the rural patients 
(Suleiman et al 2013: 390-92).  In this view, the higher proportion of unemployment among 
patients included in this study might contribute to the experience of stigma reported by the 
patients included in this study.   
   
6.2.2.2. Clinical characteristics and treatment outcomes of patients with MDR-TB  
This study has shown a composite treatment success rate of 69%. Moreover, it revealed a 
27% death rate from MDR-TB by the end of month 24. One of the clinical factor that was 
associated with the treatment outcomes of the patients was co-morbidity with MDR-TB. 
Forty one (31%) of the patients with MDR-TB had some form of co-morbidity with MDR-TB 
at the baseline. From the total, co-morbidity with MDR-TB at baseline, 34 (83%) was due 
to co-infection with HIV while 5 (12%) was due to co-infection with diabetes mellitus.  The 
treatment success rate among patients included in this study was lower than the 78.6% 
treatment success rate reported among patients treated at Gondar Health Science Hospital 
and the St Peter’s Hospital in Addis Ababa.  Moreover, the 31% of co-morbidity with MDR-
TB at the baseline and the 26% rate of MDR-TB co-infection with HIV are higher than the 
21.7% reported among patients with MDR-TB in Ethiopia.  Likewise, the 27 % death rate is 
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more than the 13.9 % death rate reported among the same patients (Meressa et al 
2015:1181).  
This study revealed that the presence of any co-morbidity with MDR-TB at the baseline is 
significantly associated with the occurrence of death among patients with MDR-TB 
(AOR=4.260, 95%CI: 1.607-11.29; p<0.004).  This result is consistent with the study 
conducted in the United Kingdom (Anderson et al 2013:406), in which it was cited that the 
presence of any co-morbidity with MDR-TB at the baseline is a risk factor for death 
(p<0.0005). Moreover, this result is consistent with the reports of Gandhi et al (2012:90) 
and Babatunde et al (2013:213), in which it was cited that immunosuppression among 
MDR-TB and HIV-co-infected patients is associated with poor treatment outcomes and high 
mortality among patients treated for MDR-TB. 
 
6.2.2.3. Malnutrition and the treatment outcomes of patients with MDR-TB  
The study revealed that 64% of the patients included in this study had a body mass index 
(BMI) of less than <18.5kg/m2, which is indicative of malnutrition associated with MDR-TB.   
This study revealed that the low body mass index (BMI), is significantly associated with 
unfavourable treatment outcomes of patients with MDR-TB (AOR=2.734, 95%CI: 1.01-
7.395; P<0.048). It is cited in the literature that pre-existing malnutrition among patients 
with MDR-TB and the lack of proper nutrition in the course of patients’ treatment affects 
patients’ response to treatment and hampers recovery which in turn results in poor 
treatment outcomes among patients with MDR-TB (Caminero 2013:201). 
As such, the result of this study commensurate with the report by the World Health 
Organization (WHO) (2013b:8), that low Body Mass Index (BMI) and lack of adequate 
weight gain is associated with death and relapse of tuberculosis. Moreover, a low body 
mass index (MBI<18.5kg/m2) increases the chance of occurrence of adverse drug reactions 
from second-line drugs. Thus, the 64% prevalence of malnutrition among patients included 
in this study is an indication of disease severity and poor patient response to treatment. 
The association between malnutrition and unfavourable treatment outcomes revealed in 
this study is also consistent with other studies. It was reported by Yuan et al (2013:1) that 
malnutrition is an established risk factor for poor treatment outcomes among patients with 
MDR-TB. Moreover, the result is consistent with the report by Vishakha and Sanjay 
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(2013:57), in which it was cited that malnutrition with MDR-TB is associated with a low cure 
rate and a high rate of death among the poor patients with MDR-TB in Ahmedabad. Thus, 
addressing malnutrition presenting with tuberculosis is crucial for improving patient 
response to tuberculosis treatment (Whitney et al 2008:197). 
 
6.2.2.4. Status of the availability of integrated care for MDR-TB and HIV co-infected 
patients 
The interviews held with caregivers in the qualitative component of this study has revealed 
that despite the high level of MDR-TB and HIV/AIDS co-infection rate among patients 
included in this study, the current programme of MDR-TB is not providing services for MDR-
TB and HIV/AIDS under one roof and by the same caregiver. Information on the 
management of HIV for co-infected patients were not available at the MDR-TB treatment 
centre. Therefore, data on MDR-TB and HIV/AIDS co-management, if any, is obtained only 
from the patients’ verbal reports. First, caregivers practicing at the MDR-TB treatment 
centre did not have the training on the treatment of HIV/AIDS so that they could not 
prescribe anti-retroviral drugs (ART). Second, the MDR-TB treatment centres do not handle 
anti-retroviral drugs. Thus the management of MDR-TB and HIV co-infected patients entails 
the involvement of different caregivers from different health facilities, departments or 
settings. In this way, the MDR-TB and HIV/AIDS co-infected patients were obliged to visit 
different caregivers in different settings to get care and services for both diseases. 
The study revealed that none of the HIV and MDR-TB co-infected patients had documented 
T–lymphocyte cell bearing (CD4) count at the initiation of treatment for MDR-TB. As 
revealed by the interviews with caregivers, the absence of optimum care for patients co-
infected with HIV might be due to the fact that HIV/AIDS related services were not provided 
in the same centre as the MDR-TB treatment centres.  
The report by Babatunde et al (2013:213) and Tadesse (2015:65) indicated that the 
presence of co-infection with HIV is associated with poor MDR-TB treatment outcomes. In 
view of these reports, the absence of full information on the management of HIV/AIDS for 
patients infected by both MDR-TB and HIV/AIDS, revealed in this study, may explain the 
poor treatment outcomes of the HIV co-infected patients with MDR-TB.  
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As reported by Tadolini et al (2012:102-103) and the WHO (2010:15-16), globally, universal 
access to patient-centred treatment and care, is recommended for patients affected by the 
dual burden of HIV and MDR-TB. In view of these reports, the absence of integrated care 
under one roof that is provided by the same caregiver for patients affected by both 
diseases, as revealed in this study, indicates that the programme is not addressing the 
patients’ right to patient-centred treatment and care on HIV/AIDS and MDR-TB and the 
protection of populations affected by both MDR-TB and HIV/AIDS.  
 
Both MDR-TB and HIV/AIDS are chronic illnesses. They need regular clinical and 
laboratory follow ups. Thus, in the absence of an integrated care and follow up services for 
both diseases, co-infected patients face difficulty to comply with attending the treatment 
and the follow up care needed for both diseases as they visit different caregivers at different 
facilities. When they are enrolled to the treatment for MDR-TB, the routine follow up 
services that patients need for the HIV are not continued as usual. The reasons include 
that patients usually focus on the MDR-TB disease and the challenges of coping with taking 
the multiple second-line drugs daily and the associated adverse drug reactions. As such, 
patients usually revert their attention from the HIV/AIDS to the new problem of MDR-TB. 
Thus, there were incidences of anti-retroviral treatment failure and repeated incidences of 
sudden patient death among patients with MDR-TB who were co-infected with HIV/AIDS. 
Added to this, participants reported that patients do not often have the physical strength to 
visit different facilities to adhere to the prescribed treatment and follow up schedules of both 
diseases. 
 
In summary, the absence of integrated care on HIV/AIDS and MDR-TB have created a lot 
of inconveniences on patients.  Moreover, the caregivers for MDR-TB who participated in 
the in-depth interviews claimed that patients with MDR-TB are infectious to others 
especially to people living with HIV and those visiting the anti-retroviral therapy (ART) clinic. 
Caregivers reported that patients with MDR-TB and HIV who visit different centres to get 
services on HIV/AIDS and MDR-TB put the community at risk of respiratory infection with 
MDR-TB.    
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Furthermore, Ethiopia is one of the high burden countries for MDR-TB and HIV/AIDS co-
infections (Falzon, Jaramillo, Wares, Zignol, Floyed & Raviglione 2013:690). Therefore, the 
absence of integrated services and care for MDR-TB and HIVAIDS under one roof was 
found to be associated with patients’ dissatisfaction with the care given for MDR-TB. It also 
hampers patients’ coping ability to attend to the separately located treatment and follow up 
requirements of both diseases. Therefore, the absence of integrated service for both MDR-
TB and HIV/AIDS will continue to challenge the subsequent national effort in the prevention 
and control of drug-resistant tuberculosis in Ethiopia. 
 
6.2.2.5. Status of the drug-susceptibility test (DST) service for patients with MDR-
TB   
The majority (99%) of the patients with MDR-TB included in this study had drug-
susceptibility test done only for rifampicin. Fifty eight (43%) of the patients had documented 
drug-susceptibility test result for both rifampicin and isoniazid. For the rest of first and the 
second line anti-tuberculosis drugs, drug-susceptibility test result status of the patients with 
MDR-TB was unknown. This indicated that the status of the drug-susceptibility test service 
that patients obtained through the programme was limited.  Scholars cited that limited 
availability of drug-susceptibility test services for patients with MDR-TB leads to the use of 
inappropriate regimens. In turn, the use of inappropriate regimens leads to the further 
amplification of resistance (Dobler et al 2015:1451). In the view of such recommendations, 
the current status of the drug-susceptibility test services available for the patients with 
MDR-TB included in this study seems to be sub-optimal.  
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6.2.2.6. Adverse drug-reactions and the treatment outcomes of patients with MDR-
TB  
In this study all the patients with MDR-TB for whom data on adverse drug reactions from 
second-line drugs was available, experienced at least one episode of a form of adverse 
drug reactions in the course of their treatment for MDR-TB. The magnitude of occurrence 
of the adverse drug-reactions from second-line drugs ranged from the minimum of one 
episode to five episodes per patient. 
The magnitude of adverse drug reactions revealed in this study is higher than the overall 
78% and the median of three adverse drug reaction events per patient reported by Bloss 
et al (2010:275). Moreover, this rate of adverse drug reactions among patients included in 
this study is higher than the 71.7% reported by Akshata et al (2015:28) and also more than 
the 57.14% prevalence of adverse drug reactions reported by Vishakha and Sanjay 
(2013:55). But the prevalence of adverse drug reactions among patients with MDR-TB 
included in this study is similar to the 72/73 (99%) rates of adverse drug reactions reported 
by Bezu et al (2014:147) among patients treated at government health centres in Addis 
Ababa, Ethiopia.  
According to the report of the World Health Organization (WHO 2014b:85; WHO 2012b:65) 
and that of Caminero (2013:172), the presence of co-morbidities with MDR-TB that demand 
the simultaneous use of several drugs and presence of malnutrition with MDR-TB (WHO 
2013b:7) are risk factors for the occurrence of adverse drug reactions. In this view, the high 
proportion of co-morbidity with MDR-TB including malnutrition with MDR-TB, revealed in 
this study, might explain the occurrence of adverse drug reactions among patients included 
in this study.  
Analysis of the trend of occurrence of adverse drug reactions showed that the majority of 
the adverse events occurred during the injection based initial months of the intensive phase 
of MDR-TB treatment. The study revealed that except in the case of ototoxicity and 
musculo-skeletal and neurological adverse drug reactions, the occurrence of adverse drug 
reactions from second-line drugs decreased after the first six months of patient treatment. 
The decreasing trend in the occurrence of most of the adverse drug reactions from second-
line drugs revealed in this study is consistent with the trend reported by Bloss et al 
(2010:277). This result signifies the need for intensive management of adverse drug 
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reactions and close patient management during the initial intensive phase months of the 
management of MDR-TB.      
The qualitative inquiry revealed that the management of adverse drug reactions from 
second-line drugs was not adequate, on which patients were dissatisfied. The reasons 
described by patients with MDR-TB included absence of prompt treatment of adverse drug 
reactions when patients face the problem. Patients faced adverse drug reactions at any 
point in time in the course of their treatment be it at the hospital or at the treatment follow 
up centres. At hospital level, physicians were not reliably available for managing patients’ 
emergent medical conditions from adverse drug reactions, especially during times out of 
the normal working hours.  
 
Patients linked to the treatment follow up centres usually came back to the hospitals due to 
adverse drug reactions. In such cases, there were incidents when patients could not get 
immediate medical attention once they arrived at the hospitals. This was mainly associated 
with the absence of physicians dedicated 24 hours of the day for the MDR-TB treatment 
centre.  
Caregivers for patients with MDR-TB mentioned multiple factors challenging the optimum 
management of adverse drug reactions from second-line drugs. These included absence 
of dedicated and reliable laboratory service to promptly diagnose adverse drug reactions 
related complications. This impedes caregivers’ ability to timely diagnosis of adverse drug 
reactions. Moreover, caregivers at the hospitals felt that the caregivers at the treatment 
follow up centres lack adequate clinical skills to timely identify adverse drug reactions and  
refer patients back to the hospitals. There were also insufficient ancillary drugs that are 
required to treat the adverse drug reactions from second line drugs. 
 
Available literature states that some of the severe adverse drug reactions like hypokalaemia 
and electrolyte wasting including hypoglycemia are common among patients treated for 
MDR-TB, particularly among those co-infected with HIV. Hypokalaemia results from both 
the anti-tuberculosis and anti-retroviral drugs. In this group of patients, renal insufficiency 
may occur due to repeated vomiting and dehydration resulting in lethal outcomes 
(Caminero 2013:141; Caminero 2010:624).  In line with the reports of these scholars, the 
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high prevalence of adverse drug reactions revealed in this study is a potential risk factor for 
unfavourable treatment outcomes among patients with MDR-TB. Moreover, the absence of 
dedicated and reliable laboratory for the MDR-TB treatment centre challenges early 
diagnosis and prompt management of the adverse drug reactions among patients included 
in this study.  
 
6.2.2.7. Status of the socio-economic support provided by the programme of MDR-
TB for patients with MDR-TB   
The study revealed that, the social and financial support provided by the programme of 
MDR-TB in terms of nutrition and financial support was inadequate. The condition was 
reported to be serious especially for patients who do not have relatives to support them. 
The nutrition provided was not sufficient both for patients treated as inpatients at the 
hospitals and those patients treated as outpatient at the treatment follow up centres.  
On the other hand, significant proportion (35%) of the patients included in this study were 
not employed while 53% were employed in the informal sector like the daily labour work. 
Moreover, the qualitative inquiry revealed that most patients lost jobs to the disease which 
further aggravated their poor economic status. Futhreomore, some patients had family 
dependents to take care of. As such, it was shown that patients with MDR-TB who had 
dependents but no income to take care of their dependents were obliged to share the food 
(nutrition) they got from the MDR-TB programme with their dependents. For such patients, 
being a patient with MDR-TB created a desperate condition.  
It was repeatedly cited that lack of adequate food for patients with MDR-TB is an 
established risk factor for unfavourable treatment outcomes among patients with MDR-TB 
(Heemskerk et al 2015:9). In this study 64% of the patients had low body mass index, which 
was indicative of malnutrition with MDR-TB. According to Caminero (2013:201), pre-
existing malnutrition among patients with MDR-TB and the lack of proper nutrition in the 
course of patients’ treatment affects patients’ response to treatment and hampers recovery 
which in turn results in poor treatment outcomes among patients treated for MDR-TB.  
As such, the high prevalence of malnutrition and the inadequate nutrition support for 
patients included in this study is an urgent problem needing immediate attention by the 
programme of MDR-TB. Firstly, the nutrition support was quantitatively inadequate. 
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Second, it is disbursed at the hospitals which is very far from the residence area of most 
patients. So that patients incurred an unnoticed cost to transport nutrition items from the 
hospitals to their home. 
Moreover, the financial support provided by the programme to cover the cost of transport 
was revealed to be inadequate. Participants mentioned that the financial support considers 
only the round trip costs paid for the intercity transport fees paid for buses between the 
patients’ hometown and the hometown of the hospital treatment initiating centres. Financial 
support does not consider the transport fees that patients pay between their home areas to 
the formal bus stations using carts and motorcycles. Patients who are linked to the 
community based MDR-TB treatment follow up centres and who live far away from the 
treatment follow up centres also face difficulty in attending the daily observed treatment 
schedule arranged at the health centres. This is because, there was no housing allowance 
or accommodation arrangements for patients living far away from the MDR-TB treatment 
follow up centres. Thus, such patients were forced to pay for accommodation in the 
hometown of the MDR-TB treatment follow up centres.    
In summary, poverty or the low socio-economic status of patients and their family 
caregivers is a challenge for both the latter and former. Poverty aggravates the challenges 
associated with being a patient with MDR-TB. Therefore, for the success of the 
programmatic management of MDR-TB in the Oromia Region of Ethiopia,   the programme 
needs to address the socio-economic challenges that patients with MDR-TB face equally 
as treating the MDR-TB disease. In the context of this study setting, patients treated for 
MDR-TB need, at least, adequate social support in terms of nutrition and financial support. 
This can potentially improve patients’ adherence to the standard treatment schedule for 
MDR-TB and the treatment outcomes of patients treated for MDR-TB.  
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6.2.2.8. Patients’ adherence to the treatment given for MDR-TB and status of 
decentralization of the MDR-TB treatment to the community  
In this study, 87.1% of all the patients with MDR-TB enrolled to treatment had an optimum 
level of adherence to the treatment given for MDR-TB. For the rest of the patient’s, 
adherence to the lengthy treatment was noted with evidence of missed daily drug doses. 
In this study, all the 91 patients assessed for adverse drug reactions experienced at least 
one episode of adverse reaction from second-line drugs and also, 41 (31%) of the patients 
had some form of co-morbidity with MDR-TB at baseline. Given this fact, the 87.1% rate of 
adherence revealed in this study was encouraging. This level of patients’ adherence is 
better than the 60% non-adherence reported by Robinson et al (2010:87). It is also more 
than the 50% non-adherence reported by Bosworth et al (2006:147). 
However, the level of adherence revealed in this study is lower than the recommendation 
of the World Health Organisation which recommends that patients’ non-adherence to 
standard tuberculosis treatment, should not exceed 5%.  The World Health Organisation 
stresses that patient’s adherence to treatment plays a key role in achieving optimum 
treatment outcomes and in the prevention of drug resistant tuberculosis (HerreroI et al 
2015:288). 
 
In this study various factors were implicated in patients’ failure to strictly adhere to the 
standard treatment given for MDR-TB. This included, the social and financial hardships 
associated with inadequate income and lost income due to the disease, MDR-TB. In this 
study over half (53%) of patients with MDR-TB were employed in the informal sector. Such 
employment was described by patients to be mainly in labour work with minimum daily 
wages.  Moreover, 35% of the patients with MDR-TB were not employed and were found 
to live on income from their family members. Such socio-economic difficulties put patients 
into difficulties to adhere to the lengthy treatment schedule for MDR-TB. This result is 
consistent with the report by Arakawa et al (2011:1000) in which it was cited that poverty 
and its associated factors impede patients’ adherence to tuberculosis treatment. In this 
way, failure of patients to strictly adhere to the treatment given for MDR-TB due to social 
and economic constrains and absence of social protection contributes to poor treatment 
outcomes and further transmission of drug-resistant tuberculosis (WHO 2014b:10-11). 
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This study revealed that, for most patients, the daily observed treatment support was not 
easily accessible after patients are linked to treatment follow up centres.  The reason was 
that, the health extension workers who are living in the community were not engaged in the 
provision of daily treatment support for patients with MDR-TB at the patients’ nearby home 
area. Therefore, patients with MDR-TB were forced to attend the daily observed treatment 
at treatment follow up centres, which were far from the patient’s village. This is a difficult 
situation for the patients who live in remote rural areas and who cannot afford 
accommodation fees to live in the hometown of the treatment follow up centres. This 
difficulty negatively impacts on patients’ adherence to the lengthy treatment given for MDR-
TB.  Some of the caregivers for MDR-TB mentioned that, for some patients who live far 
from the treatment follow up centres, a one week dose of the second-line drug is given to 
the patients’ homes. However, given the fact that a huge number of tablets of each of the 
second-line drugs are taken by an MDR-TB patient per day, no convincing practice was 
mentioned on the quality in which the second-line drugs were handled at the patients’ 
homes. 
 
This result is similar to the report by HerreroI et al (2015:295) in which the absence of strong 
community level treatment support was cited to be associated with patient non-adherence 
to treatment. Moreover, the result is consistent with the report by Alobu et al (2014:782-3) 
that in tuberculosis high burden countries such as Ethiopia, Indonesia, Pakistan and 
Nigeria, service inaccessibility to the remote rural patients is associated with poor 
adherence to treatment and a high death rate from tuberculosis. The study also revealed 
that patient’s perception of high disease severity was found to hamper adherence to 
treatment. Due to hopelessness, perception of high disease severity affects patients’ 
adherence to the treatment for MDR-TB. For example, some patients who faced severe 
adverse drug reactions mentioned that they lost hope of being cured by taking the drugs, 
which are toxic.  This result is consistent with the report by Bosworth et al (2006:249) in 
which the perception of high disease severity is a factor associated with non-adherence to 
treatment perhaps due to pessimism about the ability of the treatment to alter the outcome 
of a serious illness. 
 
268 
 
6.2.2.9. Follow up laboratory services for patients with MDR-TB 
This study revealed that the usage of laboratory services available for patients with MDR-
TB is sub-optimal in the study areas. It is revealed that only 15% of patients with MDR-TB 
had satisfactory levels of access to routine follow up laboratory services in the course of 
their treatment for MDR-TB. For the 85% of the patients access to follow up services was 
limited to only very few of the WHO recommended and nationally adopted standard 
laboratory follow up services. As such, the observed level of available follow up laboratory 
services, indicates that the programme was not providing the  standard follow up laboratory 
services recommended by the WHO for follow up of patients with MDR-TB while on 
treatment (WHO 2014b:146). Caregivers who participated on the in-depth interviews 
mentioned that it made it difficult for them to recognize and promptly treat some of the life 
threatening adverse drug reactions that could only be known only through routine laboratory 
tests.  
 
The qualitative interviews with care givers also revealed that the MDR-TB centres lacked 
dedicated laboratories to provide follow up services for patients with MDR-TB. Moreover, 
available general hospital laboratory services lacked the key laboratory test services 
needed for the patients with MDR-TB. For example, the laboratories lacked the basic 
laboratory reagents needed to perform hormonal and electrolyte tests which are essential 
for patients on treatment. Caregivers reported incidences of apparent clinical signs of 
severe adverse drug reactions from second-line drugs like the hypokalemic tetani that could 
have been prevented if an adequate follow up laboratory services were available for the 
MDR-TB centre. Caregivers perceived that some of the sudden patient deaths observed 
during treatment might be due to drug adverse reactions that could have been prevented 
or promptly diagnosed through close laboratory follow ups. 
 
As such, the result of this study revealed that in the current study area, follow up services 
through laboratory tests for which patients with MDR-TB were eligible were not available 
according to the national programme guideline (Federal Ministry of Health of Ethiopia 
2014:119-131). Thus, patients were not getting the minimum package of the routine follow 
up laboratory services nationally recommended for follow up of patients with MDR-TB while 
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on treatment (Federal Ministry of Health of Ethiopia 2014:76).  On the other hand, it is well 
documented that severe adverse drug reactions like hypokalemia and electrolyte wasting 
are common, especially among MDR-TB and HIV co-infected patients who are treated for 
both diseases. These adverse drug reactions increase the risk of renal insufficiency leading 
to lethal outcomes among patients with MDR-TB co-infected with HIV (Caminero 
2013:141). Thus, it seems very difficult for caregivers in the study area to diagnosis and 
promptly treat some of the life threatening adverse drug reactions from second-line drugs 
that are diagnosed only through routine laboratory follow ups. 
 
6.2.3. Patients’ perceived quality of care and their satisfaction with the care given 
for MDR-TB 
The study revealed that, patients with MDR-TB were satisfied with the clinical care that they 
received from caregivers found at the hospitals. Hospital level caregivers were described 
as empathic and caring. But at hospitals, patients were dissatisfied with the absence of a 
reliable care by a physician during patients’ emergent medical conditions. Moreover, 
patients with MDR-TB were dissatisfied with the poor quality, inadequate quantity and the 
mode of delivery of the nutritional support they received from the hospitals and with the 
absence of patient involvement in nutrition related decision making process. Similarly, 
patients were dissatisfied with the amount of financial support they received and with the 
lack of recreation facilities within the premises of the hospital MDR-TB treatment centres 
and also with the lack of cleanness of the utilities found in the MDR-TB treatment centres. 
On the other hand, patients with MDR-TB were dissatisfied with the clinical care that they 
received from the caregivers found at the community level MDR-TB treatment and follow 
up centres. The patients experienced that caregivers found at the treatment follow up 
centres were not empathic and caring. Caregivers found at the treatment follow up centres 
were described, by patients, as non-communicative and alienating. Thus, patients with 
MDR-TB felt desperate, vulnerable and alienated, a situation revealed to determine 
patients’ perceived quality of care and their satisfaction with the care given for MDR-TB. 
According to the philosophy and science of caring, one’s own philosophy and value system 
affects the encounters, relationships and the moments we have with ourselves and others. 
Emotions of love, kindness, gentleness, compassion, equanimity, and so on are intrinsic to 
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all humans. These emotions and experiences are the essence of what makes us human 
and deepens our humanity and connection with human spirit. This awareness gives us the 
energy to live beyond our individual ego-self and reminds us that we belong to the universe 
of humanity. For patients with MDR-TB, hospitalization and the challenges associated with 
taking the treatment given for the disease, is an event that can lead patients to a loss of 
human dignity (Watson 2008:42-3). Thus, it is the responsibility of the healthcare givers to 
help maintain and restore that dignity among patients treated for MDR-TB.  
In the efforts made to advance the management of patients with MDR-TB the healthcare 
system (leadership of the hospitals and the caregivers for MDR-TB) should capture and 
utilize the   views and experiences of the patients with MDR-TB and their families to pursue 
evidence informed decision making. The views and opinions of patients with MDR-TB, 
families of patients  and the views of the caregivers for MDR-TB to identify treatment related 
issues and service needs and find the best solutions, options or strategies to address them.  
 
6.2.4. MDR-TB infection control practices  
6.2.4.1. Hospital level MDR-TB infection control practices  
At the hospital level the activity of respiratory MDR-TB infection control was coordinated by 
the hospital MDR-TB panel team, which is composed of different categories of healthcare 
professionals.  The study revealed that at treatment initiating centres (hospitals) there was 
optimum level of alertness and sound practice on respiratory MDR-TB infection prevention 
and control. Separation of infectious patients from culture converted ones, strict use of N95 
and face masks and safe disposal of sputum cups are practiced at hospitals. However, as 
the premises of the hospital are not patient friendly, patients with MDR-TB usually 
inadvertently escape from the premise of the hospital MDR-TB treatment centre and mingle 
with the community. This was reported to be a potential risk for MDR-TB transmission to 
the community. The practice of escaping from the premises of the hospital by patients with 
MDR-TB is consistent with the report by Gandhi, Nunn, Dheda, Schaaf, Zignol, Soolingen, 
Jensen & Bayona 2010:1838) in which patients escaped from hospitals and even threaten 
or assault hospital staff and other patients in this regard. 
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6.2.4.2. Household level MDR-TB infection control practices 
The result of this study noted that in the current programmatic management of MDR-TB 
there was no system for respiratory MDR-TB infection control at community, especially at 
the patients’ household level. The proportion of MDR-TB cases infected by household 
contacts of an index patient with MDR-TB of this study was 8 (6%). Moreover, four of the 
eight cases diagnosed among contacts were diagnosed among household contacts of a 
single case in one family. This seems to be a warning sign regarding household level risk 
of respiratory MDR-TB infection in the study areas. 
In a nutshell, the study revealed that the current practice of the programmatic management 
of MDR-TB in the study areas did not implement the minimum community (household) level 
respiratory MDR-TB infection control practice recommended by the national guideline on 
the programmatic management of MDR-TB in Ethiopia (Federal Ministry of Health 
2014:150-51). 
The result from the qualitative interviews with patients with MDR-TB and their caregivers 
revealed that, if family members attend to a patient with MDR-TB at the hospitals, the family 
members were given respirators (N95) as personal protective equipment. But once the 
patient is discharged from the hospital, the family member caregivers were not given 
respirators that they could use at household level. This means that, during patient 
admission to hospitals, patient attendants who are family members were given N95 if they 
attended to the patient with MDR-TB. But family members who were taking care of patients 
with MDR-TB at household level were not using respirators (N95) as a personal protective 
measure tool against MDR-TB infection.   
The community and household level risk of infection to close contacts, revealed in this 
study, commensurate with the report by Caminero 2013:49-50, which indicated that 
household contacts to patients with MDR-TB are at an increased risk of infection with MDR-
TB. The 6% proportion of MDR-TB infection among close contacts revealed in this study is 
higher than the 3% to 5.4% of MDR-TB diagnosed among close contacts reported in Peru 
(Becerra et al 2011:147).  
As such, the absence of a functional system for respiratory MDR-TB infection prevention 
at community level, seemed to be a plausible risk factor for the observed high proportion of 
MDR-TB cases diagnosed among household contacts of index patients with MDR-TB. 
 
272 
 
There was no system or practice whereby caregivers from hospitals and treatment follow 
up centres visit patient’s home to make arrangements regarding the living quarters of the 
patients with MDR-TB. Similarly, families of patients with MDR-TB were not oriented on the 
issue of respiratory MDR-TB infection. Furthermore, at household level, caretakers were 
not using respirators as personal protective tools. As a result, it is revealed in this study 
that significant numbers of patients with MDR-TB were diagnosed among household 
contacts of index patients with MDR-TB. 
 
In summary, the increased actual risk of MDR-TB transmission to close contacts amplifies 
disease occurrence within families. The poor MDR-TB infection control and high prevalence 
of HIV among patients with MDR-TB, revealed in this study, allow an increase in the number 
of patients with MDR-TB in the community (Scardigli & Caminero 2013:208; Seddon et al 
2012: 1343-44). 
 
6.2.5. The model for enhancing the management of patients with MDR-TB  
Development of a model for enhancing the management of patients with MDR-TB was one 
of the aims of the study. The objective of model development is to offer guidance in 
addressing the specific health problem in the programmatic management of MDR-TB 
(Fertman et al 2010:433). A healthcare model outlines the best practice for the delivery of 
care for the patient with a particular disease entity. A model facilitates implementation of 
the required change to improve the care and services that the patient receives (Pearson, 
Field & Jordan 2007:6). 
The model for enhancing the management of patients with MDR-TB, has enabled 
understanding of the socio-demographic, socio-economic, clinical and programme policy 
context surrounding the care of the patient with MDR0-TB. Moreover, the model has 
identified the current state of practice in the care of patients with MDR-TB. The evidence 
generated was appraised, synthesed and used to inform all actors in the programme of 
MDR-TB through a model. According to Harvey & Kitson (2015:37,175), negotiations, 
spirits of collaboration and joint responsibility between clinicians caring for patients and the 
different departments who share the responsibility for the care and services needed by 
patients are important to overcome complex issues. For this, emphasis on shared 
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leadership that operates at multiple levels involving different people those works through 
strong communication is more effective than the role of individuals in leadership role. In this 
regard, the study revealed that, the communication among hospital managers, programme 
managers at provincial and town health offices and the caregivers for MDR-TB was weak. 
Moreover, the views and opinions of patients with MDR-TB and their families was not used 
to promote joint decision-making regarding the clinical care of patients with MDR-TB, and 
also in the planning and delivery of other services needed by patients with MDR-TB. To 
address these gaps the model has made recommendations that align with the national 
priority intervention to mitigate the problem of MDR-TB.  
Thus, the model will assist evidence-informed practice by caregivers and programme 
managers at all levels. As such, the model will serve as a vehicle to drive the required 
change to mitigate the gaps in the management of patients with MDR-TB. 
6.3. Summary  
Chapter six presents the discussions on the results of the study in-line with the available 
literature. The next chapter, chapter 7, presents the conclusions and recommendations 
made based on the results of the current study. 
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Chapter 7: Conclusion and Recommendations  
7.1. Introduction    
This research endeavour employed a facility based cross-sectional, analytical, and a 
concurrent mixed methods design. Patients with MDR-TB from two different referral hospitals 
in the Oromia Region of Ethiopia were included in the study. The study has enabled to gain 
insight into the treatment outcomes of patients with MDR-TB and its determinants.  The study 
has also enabled the researcher to understand the factors determining patients’ perceived 
quality of care and level of patients’ satisfaction with the care given for MDR-TB. To that end, 
a conceptual model was developed that was designed to enhance the management of 
patients with MDR-TB in the Oromia Region of Ethiopia and possibly in the other regions of 
the country.  This chapter summarizes the key results of the study, conclusions, the limitations 
of the study and the recommendations made to improve the treatment outcomes of patients 
with MDR-TB. Recommendations were also made to improve patients’ perceived quality of 
the care they received on MDR-TB and patients’ satisfaction with the overall care and services 
offered for patients with MDR-TB. 
7.2. Key results of the study  
 There was high co-morbidity with MDR-TB among patients included in this study with 31% 
of the patients having had some co-morbidity with MDR-TB at the baseline and the majority 
of the co-morbidity was due to HIV/AIDS.  
 A substantial number (64%) of the patients with MDR-TB had body mass index (BMI) of less 
than <18kg/m2 at baseline, which was indicative of malnutrition.  
 The composite treatment success rate for patients with MDR-TB included in this study was 
69%, 
 27% of the patients with MDR-TB who were enrolled to the treatment for MDR-TB, died from 
the disease by the end of 24 month after commencing treatment.   
 Compared to previous studies conducted in Ethiopia, there was a high death rate and a 
lower treatment success rate among patients with MDR-TB included in this study.  
 Even though there was high MDR-TB and HIV/AIDS co-infection in the study area, the 
services needed for patients affected by both disease were not provided under one roof and 
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by the same caregiver. As such, patients affected by both diseases were obliged to seek 
care for HIV/AIDS in different facilities and with a different caregiver.  
 Absence of standard laboratory based follow up services for patients on treatment for MDR-
TB is evident  
 The presence of any co-morbidity with MDR-TB at baseline including malnutrition was 
associated with an increased chance of death among patients with MDR-TB.  
 Malnutrition among patients included in this study was further aggravated by the patients’ 
weak social and economic status and the inadequate socio-economic support available for 
the patients by the programme of MDR-TB. 
 The majority of patients treated for MDR-TB in the study areas were those who live under 
social and economic difficulties. 
 The majority of patients with MDR-TB were employed in the informal sector with minimum 
daily wages 
 MDR-TB results in loss of job and thereby loss of income. As such, MDR-TB aggravates 
already existing poor living conditions of the patients with MDR-TB and their families  
 The current nutrition support given for patients with MDR-TB was not adequate both in terms 
of its quality and quantity. Some poor patients with MDR-TB who have dependents but do 
not have extra income, shared the nutrition items they were given with their family level 
dependents like the children 
 The mode of delivery of the nutrition items was not patient centred. Patients were given a 
bucket of nutrition items at hospitals and they have to make an uncovered payment for 
transporting the nutrition items to their home areas.   
 The financial support given for patients was inadequate to cover the direct and the indirect 
costs that patients with MDR-TB and their families incur due to the disease and in the course 
of their seeking care for it.  
 The poor economic status of the patients and the inadequate level of nutrition support by 
the programme was a challenge for patients with MDR-TB to strictly adherence to a standard 
treatment schedule of MDR-TB. This impacts the patients’ daily adherence to the lengthy 
treatment given for MDR-TB. As such, patients’ social and economic difficulties had a 
potential impact on the treatment outcomes of patients with MDR-TB.  
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 For patients who live in remote rural areas and far away from the MDR-TB treatment follow 
up centres, no accommodation arrangements were made in the hometown of the treatment 
follow up centres. Such patients were exposed to an extra but unnoticed expense as they 
were obliged to pay for accommodation in the hometown of the treatment follow up centres 
until they completed the injection based intensive phase of the treatment given for MDR-TB.  
 There was an encouraging level of communication between caregivers and patients at 
hospitals. The behaviour of the hospital level caregivers were described as empathic and 
caring. Yet, the status of communication between the caregivers and patients at the 
treatment follow up centres was revealed to be alienating.  
 Patients’ perceived quality of the care given for MDR-TB and patients’ satisfaction with the 
overall care given for MDR-TB was suboptimal. Patients’ satisfaction was affected by the 
inadequate socio-economic support, poor communication between patients and their 
caregivers and the low involvement of patients and their family caretakers in the patients’ 
treatment decision making process.  
 The absence of promptly responsive clinical care for patients’ emergent medical care needs 
and the suboptimal service setups, including the cleanness of the patient’s living rooms and 
toilets and the absence of recreational facilities in the compound of the hospital MDR-TB 
centres, has negatively affected the patients’ perceived quality of care and their satisfaction 
with the care given for MDR-TB.  
 There is a weak level of MDR-TB infection control practice at the community and the 
household level by the programme of MDR-TB.  
 Adequate health education was not given to patients with MDR-TB, families of the 
patients with MDR-TB and the community at large 
 Caregivers at the treatment follow up centres were not going to the patients’ household 
level to provide health education for the family on MDR-TB. Moreover, inspection of 
the household level patients’ living quarters was not done by caregivers to make 
arrangements for respiratory MDR-TB infection control at the household level before 
the patient was sent back to the community. 
 Patients with MDR-TB use the conventional public transport for whatsoever movement 
they make to seek care for MDR-TB including for the scheduled monthly follow up 
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services at the hospitals. The practice was found to be a potential risk factor for the 
transmission of MDR-TB to the community. 
 There was a high risk of MDR-TB transmission to household contacts of diagnosed 
index patients with MDR-TB. Family level caregivers of the patients with MDR-TB were 
not given personal protective equipments like the respirators.     
 Community health extension workers were not involved in the current community based and 
ambulatory model of the treatment given for patients with MDR-TB.  
7.3. Contribution of the study  
In the Ethiopian context of the programmatic management of drug-resistant tuberculosis, 
this study assessed multiple factors that determine the treatment outcomes of patients with 
MDR-TB. It also assessed factors determining the process of the treatment given for MDR-
TB, patients’ adherence to treatment, patients’ perceived quality of care and patients’ 
satisfaction with the overall care given for MDR-TB.    
As such, the result of this study has led to an understanding of the dynamics in the current 
programmatic management of MDR-TB in the Oromia Region of Ethiopia. The result of the 
study is expected to be useful in facilitating evidence informed decision making in the 
current national effort to scale up the programmatic management of MDR-TB in Ethiopia. 
The study has identified the dynamics in the healthcare delivery system and those at the 
level of healthcare facilities providing care for patients which determine the treatment 
outcomes of patients with MDR-TB, patients’ perceived quality of care and patients’ 
satisfaction with the care given for MDR-TB. The major contributions of this study are 
bulleted as follows:  
 The study has identified the magnitude of the treatment outcomes of patients with 
MDR-TB who were enrolled to the treatment for MDR-TB 
 Factors determining the treatment outcomes of patients with MDR-TB, patients’ 
perceived quality of care and patients’ satisfaction with care given for MDR-TB were 
identified. 
 A conceptual model for enhancing the management of patients with MDR-TB (depicted 
in figure 5.1) was developed. The model depicts the relationship among the socio-
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economic, programme policy, healthcare system, the patient and caregivers in 
determining the programmatic management of patients with MDR-TB. 
 Based on the result of this study, the model will facilitate implementation of the various 
interventions to enhance the management of patients with MDR-TB.   
 
7.4. Scope and limitations of the study 
In an effort to get a maximally enriched understanding of the research problem, both 
quantitative and qualitative data were used to explain the different segments of the same 
research problem under investigation.  
However, this study focused only on two referral hospitals found in the Oromia Region of 
Ethiopia, Adama Hospital Medical College and Nekemte Referral Hospital. These hospitals 
and the patients with MDR-TB who attended the same, might be different from patients with 
MDR-TB who attended hospitals in other regions of Ethiopia. The study used purposive 
sampling to identify and recruit participants. The qualitative component of the result was 
based on the reported experiences of the study participants. This is potentially subject to 
memory bias. It can also be subject to social desirability bias whereby participants might 
have told the researcher what they think is good to hear. Thus, the outcome of this study 
may be generalised with caution. 
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7.5. Recommendations  
In view of the results of this study, the following were recommended for the scale up of the 
programmatic management of drug-resistant tuberculosis in the Oromia Region of Ethiopia:  
7.5.1. Improve the socio-economic support for patients with MDR-TB 
 Strengthen patient treatment enablers to improve patient adherence with the lengthy 
treatment given for MDR-TB. This should include the provision of adequate nutrition 
and financial support. The package of nutrition support given for patients, should 
consider family dependents of the patient with MDR-TB.  
 By using locally available nutrition items, establish a scientifically appropriate and 
standard approach to the nutrition support provided for patients with MDR-TB. 
 The system of delivery of the nutrition support should be patient centred. Hospitals 
should transport food items to the catchment treatment follow up centres so that the 
transportation cost incurred by patients to transport the food items to their household 
level decreases.  
 Establish a system which will involve patients with MDR-TB and their family caretakers 
in shared decision making regarding the treatment and care of the patients and the 
nutrition and financial support that patients get from the programme of MDR-TB.  
 The Health Bureau of the Oromia Region of Ethiopia needs to monitor and make sure 
that the food items included in the package of nutrition service provided to patients is 
adequate both in terms of quantity and quality to meet the nutrition requirements of 
patients with MDR-TB.   
 The Health Bureau of the Oromia Region of Ethiopia needs to establish a strong 
monitoring mechanism to make sure that MDR-TB patients are getting the full package 
of the nutrition and financial support for which they are eligible.  
7.5.2. Provide integrated service for MDR-TB and HIV co-management  
 Build the capacity of caregivers for MDR-TB on the comprehensive clinical 
management of HIV/AIDS. 
 Establish a system for the provision of drugs and supplies on HIV/AIDS to the MDR-
TB centres and establish an anti-retroviral dispensing centre in the MDR-TB treatment 
centres. 
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 Provide services for both MDR-TB and HIV/AIDS under one roof and by the same 
caregivers at the MDR-TB treatment centres. 
 Patients affected by both MDR-TB and HIV/AIDS, should be provided with clinical and 
laboratory follow up services by the same caregivers at the MDR-TB treatment centre. 
 
7.5.3. Management of adverse drug reactions from second-line drugs  
 Establish a dedicated laboratory unit for the MDR-TB treatment initiating centres of the 
hospitals so that second-line drug related adverse drug reactions could be diagnosed 
early.   
 Strengthen the supply of ancillary drugs that are needed to treat the adverse drug-
reactions from second-line drugs.   
 Create compassionate and caring health caregivers at the MDR-TB treatment follow 
up centres.   
 As the prevalence of adverse drug reactions is at its peak during the intensive phase 
of the treatment for MDR-TB, the provision of intensive service for the management of 
adverse drug reactions during the initial months of patient treatment for MDR-TB 
should be strengthened.  
7.5.4. Emergency care for patients with MDR-TB   
 Assign clinicians dedicated for the MDR-TB unit of the hospitals 7 days of a week and 
24 hours of the day for patients with MDR-TB.  
 Arrange a standby transport service to transport physicians when they are needed for 
emergency patient care.   
 Continuously build the clinical skills of caregivers at the treatment follow up centres 
both through regular training and on-the-job clinical mentorship by caregivers at the 
hospitals.  
7.5.5. Improve collaborative patient-caregiver communication 
 Build the communication skills of the caregivers based at   at the MDR-TB treatment 
follow up centres  
 Improve the communication between caregivers and the patients with MDR-TB with a 
focus on caregivers practicing at the treatment follow up centres. Allocate 24 hour 
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emergency number for patients in order to improve communication between patients 
and caregivers.  
 Improve the intensive involvement of psychiatric professionals with patients with clinical 
psychiatric problems   
 The intensive involvement of the patients with MDR-TB in their treatment decision 
making process, will improve the perception of patients about caregivers and the 
perceptions of caregivers about patients with MDR-TB.  
 Use the views and opinions of patients with MDR-TB and that of their families to identify 
gaps in the programmatic management of MDR-TB so that patient centred care and 
services can be provided.   
 Build on the values and the experiences of patients with MDR-TB to strengthen 
programmatically effective and culturally appropriate communication practices. 
 Provide empathic and caring clinical care along the continuum and help mitigating the 
multiple adverse effects of the treatment given for MDR-TB.  
 
7.5.6. Improve the physical comfort of the premises of the MDR-TB treatment 
initiating centres at the hospitals 
 Make the premises of the MDR-TB treatment initiating centre of the hospitals to be 
clean and recreative for patients treated at the MDR-TB treatment centres of the 
hospitals. Key interventions recommended include: 
 Assigning full-time cleaners to the hospital MDR-TB centre who can take care of the 
cleanness of the patients’ living rooms (the beddings, floors), the toilets and the 
shower rooms.  
 Keep the compound and the hospital MDR-TB centre clean and create a homely 
environment to restrain patients from escaping from the treatment unit and highlight 
the importance of preventing transmission of the disease into the community. 
 Establish functional recreative facilities in the compound of the MDR-TB centre that is 
dedicated for the patients with MDR-TB only: 
 Install functional television inside the patients’ living rooms which helps prevent 
patients’ being lonely and bored while staying in the MDR-TB centre. Alternatively, 
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there should be a comfortably designed TV room in the centre for patients as a 
group.   
 Enable patients to have access to religious services by installing religious channels 
both for Christians and Muslims on the television. Through providing the hope of 
recovery for patients with MDR-TB, religious channels help to reduce the effect of 
drug related psychiatric problems among the patients.  
 Provide easy to play games in the compound of the MDR-TB centre (bingo bowls, 
chess, or ‘gebeta’ (Ethiopian traditional game), etc). 
 
7.5.7. Community based ambulatory treatment for patients with MDR-TB  
 To help strengthen patients’ coping ability to MDR-TB and its treatment, the 
programme of MDR-TB should strengthen community awareness on MDR-TB, with 
particular emphasis on the prevention of stigma against patients with the disease 
 Engage the community health extension workers in the community based patient 
treatment support, MDR-TB infection prevention and tackling of stigma against patients 
with MDR-TB.  
 Build the capacity of the health extension workers on the basics of the programmatic 
management of MDR-TB: 
 Train health extension workers on the basics of MDR-TB and on the skills of the 
daily observed treatment support provided for patients with MDR-TB in each county 
(kebele) from which a patient with MDR-TB is diagnosed.  
 The health extension workers shall take the lead responsibility in supervising the 
administration of the daily patient treatment under observation that is provided by 
the patients’ family.    
 Through the health extension workers, make sure that patients can freely discuss 
their views and interests regarding the treatment they receive for MDR-TB. Provide 
and circulate brochures at schools and public spaces on MDR-TB. Local Radio 
stations in each area should broadcast programmes on MDR-TB. There should be 
a dedicated channel at the hospitals and treatment centres on MDR-TB  issues, 
highlighting ways MDR-TB is transmitted, the need for adherence and why, the value 
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of nutrition while on treatment, the importance of cleanliness, when and how to take 
drugs for best results.   
 At the patients’ home level, the health extension workers should provide ongoing 
counselling and treatment support and notify caregivers at  the treatment follow up 
centres if and when a problem  occurs   
 Arrange accommodation services for patients with MDR-TB who live in rural areas and 
places far away from the treatment follow up centres who take a daily injection at the 
hometown of the treatment follow up centres.  
 
7.5.8. MDR-TB infection control 
 Raise the knowledge of patients, their household caregivers and the community on the 
danger of MDR-TB transmission among close contacts, especially household contacts 
 Emphasise the high possibility of transmission through close contacts to the patients 
with MDR-TB. Caregivers at the treatment follow up centres and the health extension 
workers should implement the programmatically recommended MDR-TB infection 
control at the community and the household level. 
 Before linking patients from the hospitals to the community based treatment and follow 
up services, arrangements should  be made on respiratory MDR-TB infection control 
including the following:  
 Caregivers from the health centres should visit patients’ living home space and 
inspects it, in collaboration with the patient’s family, arrange a separate living room 
for the patient with MDR-TB.   
 Through community health education, raise the awareness of the general 
community on the basic concepts of MDR-TB, ways of its transmission and on the 
means of controlling its transmission  
 For families from whom a patient with MDR-TB is diagnosed, orient all members of 
the family on the basics of MDR-TB and its treatment and the role and responsibility 
of each family member in assisting the patient to complete the treatment given for 
MDR-TB 
 Orient the family on the dangers of the transmission of MDR-TB to the household 
contacts and other close contacts of the patient. 
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 Provide a respirator (N95) to household level caregivers of the patient with MDR-
TB.     
 Caregivers found at the treatment follow up centres should visit all patient’s homes 
every quarter to track how the family is coping with the challenge of continuing to 
encourage the patient to adhere to the MDR-TB treatment, provide appropriate 
counselling, identify gaps and take timely action in collaboration with stakeholders in 
the healthcare system and the community.   
 The health extension workers should  provide regular health education for the family 
affected by MDR-TB and provide support on prevention of MDR-TB infection to 
household members of the diagnosed patients with MDR-TB 
 Conduct active tracing of MDR-TB contacts and active MDR-TB case finding among 
household contacts of all diagnosed patients with MDR-TB. 
 To mitigate the risk of possible MDR-TB infection at health facilities due to MDR-TB 
and HIV co-infected patients visiting different centres to seek care for MDR-TB and 
HIV/AIDS, provide services for both MDR-TB and HIV/AIDS under one roof.   
 Caregivers from the treatment follow up centres should work towards enabling 
household contacts to visit health facilities for clinical evaluation quarterly and do so 
for a period of at least 2 years.   
 Patients with MDR-TB use the conventional public transport during their monthly visit 
to the hospitals. The practice was found to be a potential risk factor for the transmission 
of MDR-TB to the community. Hospitals shall arrange, a monthly clinical follow up at 
the treatment follow up centres by a physician so that the risk of MDR-TB infection to 
the community is minimized.  
 Ensure that a dedicated vehicle is available for the transportation of the patients, for 
linking patients back to the community level MDR-TB treatment and during the patients. 
 Moreover, arrange a dedicated vehicle for transporting infectious patients from 
peripheral health facilities to hospitals.  
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7.6. Recommendations for future research  
In the perspective of the results of this study, the following areas deserve further 
investigation: 
1. Risk of respiratory MDR-TB infection among household contacts of index patients with 
MDR-TB and its determinants in Ethiopia. 
2. Gender based differentials of MDR-TB treatment outcomes in Ethiopia.  
3. Replicate the study in a different location, context, sample size and timeframe. 
7.7. Conclusion 
If the problem of MDR-TB and the factors determining the treatment outcomes of patients 
with MDR-TB are to be tackled successfully, the factors determining the treatment 
outcomes of patients with MDR-TB and factors determining patients’ perceived quality of 
care and patients’ satisfaction with the care given for MDR-TB need to be identified. In this 
regard, this study has identified socio-demographic and clinical factors that determine the 
treatment outcomes of patients with MDR0-TB. Moreover, the study has identified factors 
determining patients’ perceived quality of care and patients’ satisfaction with the care given 
for MDR-TB. Furthermore, the study has developed a conceptual model for enhancing the 
treatment of patients with MDR-TB in the study sites. Implementation of the model will 
effectively facilitate implementation of the required change to mitigate factors determining 
the treatment of patients with MDR-TB, patients’ perceived quality of care and patient 
satisfaction with care given for MDR-TB.  
In conclusion, it is with high confidence that the results from this study will enable health 
decision makers and caregivers for MDR-TB in the Oromia Region of Ethiopia to make 
evidence informed decisions regarding the MDR-TB programme design, programme 
management and resource allocation decisions during the subsequent national effort to 
expand the programmatic management of MDR-TB in Ethiopia. 
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Annexes 
Annexure 1: Results of the logistic regression model    
 
Logistic Regression 
 
Notes 
Output Created 28-FEB-2017 12:09:42 
Comments  
Input 
Data 
C:\Users\KeneaM\Desktop\Feb 
Analysis\ANALYSIS_FINAL 
DATA.sav 
Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data File 110 
Missing Value Handling Definition of Missing 
User-defined missing values are 
treated as missing 
Syntax 
LOGISTIC REGRESSION 
VARIABLES OUTCOME 
  /METHOD=FSTEP(LR) q3_SEX 
q7_8_BMI2 q16_AFB 
q21_RESTyp q25_COMORBID 
q57_HIV 
  /CONTRAST 
(q3_SEX)=Indicator(1) 
  /CONTRAST 
(q7_8_BMI2)=Indicator(1) 
  /CONTRAST 
(q16_AFB)=Indicator(1) 
  /CONTRAST 
(q21_RESTyp)=Indicator(1) 
  /CONTRAST 
(q25_COMORBID)=Indicator(1) 
  /CONTRAST 
(q57_HIV)=Indicator(1) 
  /PRINT=GOODFIT CI(95) 
  /CRITERIA=PIN(0.05) 
POUT(0.10) ITERATE(20) 
CUT(0.5). 
Resources 
Processor Time 00:00:00.03 
Elapsed Time 00:00:00.03 
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Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases 
Included in Analysis 110 100.0 
Missing Cases 0 .0 
Total 110 100.0 
Unselected Cases 0 .0 
Total 110 100.0 
a. If weight is in effect, see classification table for the total number of cases. 
 
Dependent Variable Encoding 
Original Value Internal Value 
Favourable treatment outcome 0 
Unfavourable treatment outcome 1 
 
Categorical Variables Codings 
 Frequency Parameter coding 
(1) 
Patients HIV test result 
0 83 .000 
Positive 27 1.000 
BMI Categorized 
0 44 .000 
=<18.5 66 1.000 
Result of the diagnostic sputum 
smear examination 
0 29 .000 
Smear Positive 81 1.000 
What is the TB patient’s 
resistance type 
0 46 .000 
RR 64 1.000 
Any co-morbid condition at 
baseline 
0 76 .000 
Yes 34 1.000 
Sex of the patient 
Male 65 .000 
Female 45 1.000 
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Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed Predicted 
 
Treatment category Percentage 
Correct 
 Favourable 
treatment outcome 
Unfavourable 
treatment outcome 
Step 0 
Treatment category 
Favourable treatment outcome 76 0 100.0 
Unfavourable treatment outcome 34 0 .0 
Overall Percentage 
  
69.1 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -.804 .206 15.199 1 .000 .447 
 
Variables not in the Equation 
 Score df Sig. 
Step 0 
Variables 
q3_SEX(1) 4.564 1 .033 
q7_8_BMI2(1) 5.562 1 .018 
q16_AFB(1) 5.562 1 .018 
q21_RESTyp(1) 4.764 1 .029 
q25_COMORBID(1) 6.010 1 .014 
q57_HIV(1) 4.980 1 .026 
Overall Statistics 23.368 6 .001 
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Block 1: Method = Forward Stepwise (Likelihood Ratio) 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 
Step 5.819 1 .016 
Block 5.819 1 .016 
Model 5.819 1 .016 
Step 2 
Step 6.919 1 .009 
Block 12.737 2 .002 
Model 12.737 2 .002 
Step 3 
Step 5.431 1 .020 
Block 18.168 3 .000 
Model 18.168 3 .000 
Step 4 
Step 3.974 1 .046 
Block 22.142 4 .000 
Model 22.142 4 .000 
 
Model Summary 
Step -2 Log likelihood Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 130.223a .052 .073 
2 123.304a .109 .154 
3 117.874a .152 .215 
4 113.899b .182 .257 
a. Estimation terminated at iteration number 4 because parameter 
estimates changed by less than .001. 
b. Estimation terminated at iteration number 5 because parameter 
estimates changed by less than .001. 
 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 .000 0 . 
2 1.266 2 .531 
3 1.314 5 .933 
4 4.198 7 .757 
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Contingency Table for Hosmer and Lemeshow Test 
 Treatment category = Favourable 
treatment outcome 
Treatment category = Unfavourable 
treatment outcome 
Total 
Observed Expected Observed Expected 
Step 1 
1 58 58.000 18 18.000 76 
2 18 18.000 16 16.000 34 
Step 2 
1 44 45.042 10 8.958 54 
2 17 15.958 10 11.042 27 
3 14 12.958 8 9.042 22 
4 1 2.042 6 4.958 7 
Step 3 
1 21 21.000 2 2.000 23 
2 23 24.011 8 6.989 31 
3 5 4.621 1 1.379 6 
4 10 9.459 3 3.541 13 
5 9 8.368 7 7.632 16 
6 7 6.530 7 7.470 14 
7 1 2.011 6 4.989 7 
Step 4 
1 15 15.031 1 .969 16 
2 6 6.025 1 .975 7 
3 14 15.303 4 2.697 18 
4 10 9.545 2 2.455 12 
5 9 9.013 4 3.987 13 
6 9 6.435 1 3.565 10 
7 6 6.855 6 5.145 12 
8 3 3.709 6 5.291 9 
9 4 4.084 9 8.916 13 
 
318 
 
Classification Tablea 
 
Observed Predicted 
 
Treatment category Percentage 
Correct 
 Favourable 
treatment outcome 
Unfavourable 
treatment outcome 
Step 1 
Treatment category 
Favourable treatment outcome 76 0 100.0 
Unfavourable treatment outcome 34 0 .0 
Overall Percentage 
  
69.1 
Step 2 
Treatment category 
Favourable treatment outcome 75 1 98.7 
Unfavourable treatment outcome 28 6 17.6 
Overall Percentage 
  
73.6 
Step 3 
Treatment category 
Favourable treatment outcome 68 8 89.5 
Unfavourable treatment outcome 21 13 38.2 
Overall Percentage 
  
73.6 
Step 4 
Treatment category 
Favourable treatment outcome 69 7 90.8 
Unfavourable treatment outcome 19 15 44.1 
Overall Percentage 
  
76.4 
a. The cut value is .500 
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
q25_COMORBID(1) 1.052 .437 5.802 1 .016 2.864 1.217 6.743 
Constant -1.170 .270 18.807 1 .000 .310   
Step 2b 
q16_AFB(1) -1.255 .483 6.765 1 .009 .285 .111 .734 
q25_COMORBID(1) 1.247 .465 7.184 1 .007 3.479 1.398 8.659 
Constant -.360 .397 .822 1 .365 .698   
Step 3c 
q7_8_BMI2(1) 1.117 .500 4.991 1 .025 3.056 1.147 8.142 
q16_AFB(1) -1.142 .496 5.311 1 .021 .319 .121 .843 
q25_COMORBID(1) 1.369 .486 7.928 1 .005 3.930 1.516 10.191 
Constant -1.209 .569 4.523 1 .033 .298   
Step 4d 
q3_SEX(1) .921 .467 3.883 1 .049 2.511 1.005 6.272 
q7_8_BMI2(1) 1.006 .508 3.922 1 .048 2.734 1.010 7.395 
q16_AFB(1) -1.171 .502 5.446 1 .020 .310 .116 .829 
q25_COMORBID(1) 1.449 .498 8.484 1 .004 4.260 1.607 11.297 
Constant -1.571 .609 6.657 1 .010 .208   
a. Variable(s) entered on step 1: q25_COMORBID. 
b. Variable(s) entered on step 2: q16_AFB. 
c. Variable(s) entered on step 3: q7_8_BMI2. 
d. Variable(s) entered on step 4: q3_SEX. 
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Model if Term Removed 
Variable Model Log 
Likelihood 
Change in -2 Log 
Likelihood 
df Sig. of the Change 
Step 1 q25_COMORBID -68.021 5.819 1 .016 
Step 2 
q16_AFB -65.111 6.919 1 .009 
q25_COMORBID -65.356 7.409 1 .006 
Step 3 
q7_8_BMI2 -61.652 5.431 1 .020 
q16_AFB -61.635 5.397 1 .020 
q25_COMORBID -63.103 8.333 1 .004 
Step 4 
q3_SEX -58.937 3.974 1 .046 
q7_8_BMI2 -59.040 4.182 1 .041 
q16_AFB -59.722 5.545 1 .019 
q25_COMORBID -61.453 9.006 1 .003 
 
 
Variables not in the Equation 
 Score df Sig. 
Step 1 
Variables 
q3_SEX(1) 5.258 1 .022 
q7_8_BMI2(1) 6.592 1 .010 
q16_AFB(1) 7.173 1 .007 
q21_RESTyp(1) 4.143 1 .042 
q57_HIV(1) .062 1 .803 
Overall Statistics 18.432 5 .002 
Step 2 
Variables 
q3_SEX(1) 5.224 1 .022 
q7_8_BMI2(1) 5.228 1 .022 
q21_RESTyp(1) 3.328 1 .068 
q57_HIV(1) .020 1 .887 
Overall Statistics 11.887 4 .018 
Step 3 
Variables 
q3_SEX(1) 3.991 1 .046 
q21_RESTyp(1) 2.630 1 .105 
q57_HIV(1) .033 1 .855 
Overall Statistics 6.856 3 .077 
Step 4 
Variables 
q21_RESTyp(1) 2.964 1 .085 
q57_HIV(1) .088 1 .767 
Overall Statistics 3.026 2 .220 
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Annexure 2: Data collection tools   
 
Part I: Structured questionnaire for the collection of the data on the clinical and 
programmatic management of patients with MDR-TB  
General instruction: Data collector captures data available on MDR-TB patient chart; unit MDR-
TB register; patient treatment card. When there is no data filled into any of the sources mentioned 
for any particular question, write ‘no data’. 
Date Questionnaire filled in: 
DD/MM/YY:________________Location/Facility:_______________________________
_________ 
Questionnaire ID #:______________________________ Name of data 
collector:___________________________________ 
Date the First Ever MDR-TB patient registered on facility Register? DD/MM/YY 
_____________________________________  Date the Last MDR-TB patient registered 
on facility Register: DD/MM/YY__________________________________________ 
 
Questions to assess programmatic management of drug-resistant tuberculosis at the 
two study sites 
Source of data:  Unit MDR-TB register, individual MDR-TB patient chart & MDR-TB patient 
treatment card.  
Questions Related to MDR-TB Patient’s Socio-demographic Data 
1. Patient Medical Registration Number (MRN):_______________________ 
2. Patient’s unique MDR-TB Registration Number:_____________________ 
3. Sex of the Patient: 1. Male 2. Female 
4. Age of the patient in completed years____________ 
5. Permanent residential address of the patient: Region___________ 
Zone/Province/_____________; District/town_____________   
6. Patient’s employment status. 1. Formally employed 2. Self-employed 3. Unemployed 4. 
Other (Specify)_____________________ 
7. Initial (pre-treatment) Weight (in Kgs):_________________________________ 
8. Patient Height (in CMs)_____________ BMI 
(kg/m2):___________________________________________ 
322 
 
9. Date patient escorted to the MDR-TB Treatment Initiating Centre:_________/ 
_________/_________ (Date/Month/Year) 
10. Date patient initiated on second-line drugs:____/_______/_____(Date/Month/Year) 
11. Does the TB patient have designated treatment supporter outside the TIC? 1. Yes 2. No 3. 
Unknown [if ‘No' skip to 13] 
12. If yes to question no. 11, who is the patient’s treatment supporter? 1. Caregiver at TFC 2. 
Health Extension worker 3. Family member 4. Other 
(specify)___________________________________________  
Current MDR-TB related Information of the Patient  
13. What diagnostic method(s) was/were/ used to diagnose the patient with MDR-TB? [circle 
all that apply] 1. Bacteriology (Smear microscopy) 2. Bacteriology (culture) 3. Genotypic 
(using GeneXpert) 4. Genotypic (using Line Probe Assay) 5. Clinical (CXR & 
histopathology) 7. Other 
(specify)_________________________________________________________________ 
14. Site of the TB Disease: 1. Pulmonary 2. Extra pulmonary 3. Both pulmonary & Extra 
pulmonary TB 
15. What is the type of the TB case? 1. Bacteriologically confirmed pulmonary TB 2. 
Bacteriologically confirmed extra pulmonary TB 3. Clinically diagnosed pulmonary TB 4. 
Clinically diagnosed extra pulmonary TB 5. Other (specify)_____________________ 
16. If TB is pulmonary and sputum smear examination was done, what is the result of the 
diagnostic sputum smear examination?  1. Smear Positive 2. Smear Negative 3. Unknown  
17. If TB is pulmonary and diagnostic sputum was done, what was the semi-quantitative 
bacillary load reported at diagnosis? 1. No AFB (Negative)=0 AFB /100 HPF 2. Scanty 
(1+) =1-9 AFB/ 100 HPF 3. Moderate (2+) =10-99 AFB/100HPF 4. High (3+) = (1-10 
AFB/1HPF/ 5. Very High (4+)/>10 AFB/1 HPF/ 
Use of Diagnostic Radiological Examination (Instruction: Data source is individual 
patient file/chart) 
18. Was diagnostic radiological examination used for the patient? 1. Yes 2. No 3. Unknown [If 
‘No’ or ‘Unknown’, skip to question 21] 
19. If diagnostic radiography was used, what the extent of the baseline lung disease was as 
revealed by radiography: 1. Normal 2. Unilateral lesion 3. Bilateral lesion 4. Cavitation 5. 
Fibrosis 6. Other finding (specify)___________________________________ 
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20. If there was lung cavitary lesion at baseline, what is the extent of the cavitatary lesion? 1. 
Unilateral 2. Bilateral 3. Other type (specify) __________________ NB: This data is 
collected from individual patient medical file/patient chart/. 
21. What is the TB patient’s resistance type: 1. RR 2. MDR-TB 3. Pre-XDR-TB 4. XDR-TB 5. 
Poly-resistant 6. Unknown  
22. What is the MDR-TB patient’s Registration group? 1. New 2. Relapse 3. Treatment after 
lost to follow ups 4. Treatment after failure of new regimen 5. Treatment after failure of re-
treatment 6. Transfer in patient (T) 7. Other previously treated TB (O) 
23. Does the patient have history of treatment with regimen containing any of the second-line 
anti-tuberculosis drugs?    1. Yes 2. No 3. Not known (If ‘No’ skip to Question 25) 
24. If the patient has history of previous treatment with regimen containing second-line drugs, 
what was the patient’s treatment outcome during treatment with regimen containing 
second-line drugs? 1. Cured 2. Treatment Completed 3. Treatment Failed 4. Lost to 
Follow Ups 5.Not evaluated (not known) 
25. Is there any co-morbid condition at baseline? 1. Yes 2. No 3. Unknown (If ‘No’ skip to 
question 27) 
26. If there is any co-morbidity at baseline, what was the co-morbid condition?: 1. Diabetes 2. 
Kidney Diseases 3. Hypertension 4. COPD 5.Liver Disease 6.HIV/AIDS 7. Psychiatric 
illness 8.HIV/AIDS related opportunistic infection (OIs) 9. Seizers 10. Other co-
morbidities 
(specify)_____________________________________________________________ 
27. Is there any co-morbidity diagnosed in the course of patient treatment for MDR-TB? 1. Yes 
2. No 3. Unknown (NB: This co-morbidity may be newly diagnosed for patients without co-
morbidity at baseline & additional co-morbidity for patients with any co-morbidity at 
baseline) 
28. If there is any co-morbidity diagnosed in the course of patient treatment, what was the co-
morbidity? 1. Diabetes 2. Kidney diseases 3. Hypertension 4. Liver Disease 5. 
Psychiatric illness 6.Seizers 7.Other(specify) 
_________________________________________________________________ 
Questions related to practice of tracing household & close contacts of the index 
patient with MDR-TB  
29. Number of household/close/ contacts living with the index patient. 1. None (alone) 2. 1-3 
persons 3. 4-6 persons 4. 7-8 persons 5. 9-10 persons 6. Not Known (no evidence at TIC) 
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30. If the patient has contacts, are any of the contacts of the index MDR-TB patient traced? 1. 
Yes 2. No 3. Unknown (No evidence at the TIC) 4. Other practice 
(specify)_____________________________(If ‘No’ or ‘Unknown’, skip to question 38 
below) 
31. If yes to question 30, how many household or close contacts of the index MDR-TB patient 
were traced? ____________________ 
32. If yes to question 30, how many of the traced household or close contacts were evaluated 
for TB clinically or through lab? _____ 
33. If yes to question 30, were there contacts screen positive for TB (presumptive TB)? 1. Yes 
2. No [if ‘no’ skip to # 38] 
34. Is DST done for contacts those found to be screen positive for TB? 1. Yes 2. No 3. 
Unknown  
35. If DST was done for TB screen positive contacts, answer questions 35.1-35.5 (# of 
answers determined by # of DST available) 
35.1. DST result for contact 1? 1. No MTB 2. MTB detected but no RR/MDR 3. RR/MDR 
detected 4. Indeterminate result  
35.2. DST result for contact 2? 1. No MTB 2. MTB detected but no RR/MDR 3. RR/MDR 
detected 4. Indeterminate result 
35.3. DST result for contact 3? 1. No MTB 2. MTB detected but no RR/MDR 3. RR/MDR 
detected 4. Indeterminate result 
35.4. DST result for contact 4? 1. No MTB 2. MTB detected but no RR/MDR 3. RR/MDR 
detected 4. Indeterminate result 
35.5. DST result for contact 5? 1. No MTB 2. MTB detected but no RR/MDR 3. RR/MDR 
detected 4. Indeterminate result 
36. How many of the clinically or lab evaluated contacts of the index RR/MDR-TB patient were 
diagnosed with susceptible TB _____ 
37. How many of the clinically or lab evaluated contacts of index RR/MDR-TB were diagnosed 
with RR/MDR-TB? _______________ 
38. If there is practice of tracing household and close contacts, what is the frequency of 
evaluation of contacts of known RR/MDR-TB patients? 1.Done only once  2.Quarterly 
3.Every six month 4.Every year 5.Other schedule (specify) _____________________ 
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39. For how long is a household/close/ contact of a confirmed RR/MDR-TB patient is 
followed? 1. For six months 2. For one year 3. For two years 4. For three years 5. For four 
years 6. Other practice or schedule (specify)________________________________  
40. Result of drug-susceptibility testing (DST) for the patient: Enter all available DST results 
for the specified anti-tuberculosis drugs. [Note: R=Resistant; S= Susceptible; I= 
Indeterminate; U= DST result unknown or not done ] 
Drug R H E S K
M 
C
m 
O
fx 
A
m 
Lf
x 
M
fx 
Et
o 
Pt
o 
C
s 
P
A
S 
Oth
er 
Oth
er 
Othe
r 
Resistance 
status 
                 
41. Date intensive phase MDR-TB treatment started 
(DD/MM/YY)_______________________________________________ 
42. What is the MDR-TB regimen that the patient is taking (took) during intensive phase: (write 
regimen  that is,  drugs and 
duration)__________________________________________________________________ 
43. What is the number of presumed effective second-line drugs used in the patient’s MDR-TB 
treatment regimen during intensive phase (NB: do not count any first-line anti-tuberculosis 
drugs included in the regimen as one of presumed effective drug)? 
1. 2 drugs 2. 3 drugs 3.  4 drugs 4. 5 drugs 5. Other 
(specify)__________________________________________ 
44. Total # of daily tablets given to the patient in the second-line regimen during intensive phase 
(include tablets of ancillary drugs, if 
any):_____________________________________________________________________
_________________________________________________________________________ 
45. Date continuation phase MDR-TB treatment started (DD/MM/YY) ____________[If patient 
died before entering continuation phase, skip to question 49] 
46. What is the MDR-TB regimen that the patient is taking (took) during continuation phase: 
(write regimen  that is drugs and 
duration)__________________________________________________________________
______________________________________________________________________ 
47. What is the number of presumed effective second-line drugs used in the patients’ MDR-TB 
treatment regimen during continuation phase? 1. 2 drugs 2. 3 drugs 3. 4 drugs 4. 5 drugs 5. 
Other (Specify)____________________________________________________________ 
48. Total # of daily tablets given to the patient in the SLD regimen during continuation phase 
(include tablets of ancillary drugs, if any): 
____________________________________________________________________ 
49. MDR-TB patient’s Daily Observed Treatment (DOT) attendance:[Instruction: Note that the 
box is subdivided into upper and lower parts to fill in Daily Observed Treatment status for 
morning and evening does respectively in case a drug is given in divided doses. If daily 
dose of a given drug is given once, use upper box. Fill in: 3=if dose taken is Directly 
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Observed by treatment supporter; 2=if dose is taken by patient but not directly observed by 
treatment supporter and 1= if dose of the day not taken by the patient. 
 DAYS IN A MONTH (ETHIOPIAN CALENDAR) 
Month 1 2 3 4 5 6 7 8 9 1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
2
4 
2
5 
2
6 
2
7 
2
8 
2
9 
3
0 
0                               
1                               
2                               
3                               
4                               
5                               
6                               
7                               
8                               
9                               
10                               
11                               
12                               
13                               
14                               
15                               
16                               
17                               
18                               
19                               
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50. Has the patient ever missed the daily dose of SLD? 1. Yes 2. No 3. Unknown (If ‘No’ or 
‘Unknown’ skip to question 53). 
51. If yes to question # 50, what is the number of daily dose of SLDs missed? 
___________________________________ 
52. If yes to question # 50, what was the reason for missing the doses? 1. Drug stock out 2. 
Patient failure to come for appointment 3. Drug-related adverse reactions 4. Other reason 
(specify)__________________________________________ 
53. Did the patient have history of treatment interruption (treatment discontinuation for less than 
2 months) while on MDR-TB treatment? 1. Yes 2. No 3. Unknown 
54. Did the patient have history of lost to follow ups (treatment discontinuation for two months 
or more) while on MDR-TB treatment? 1. Yes 2. No 3. Unknown 
55. Is the patient tested for HIV? 1. Yes 2. No 3. Unknown (If ‘No’ skip to 63) 
56. If tested for HIV, date HIV test done (DD/MM/YY)________/______/______ 
57. If tested for HIV, HIV test Result of the patient. 1. Positive 2. Negative 3. Indeterminate (If 
answer is ‘2’ skip to question # 63 
58. If patient was positive for HIV, what was the baseline T-lymphocyte cell bearing (CD4)  
count (cells/mm3):________________ 
59. If patient was positive for HIV, was the patient given cotrimoxazole preventive therapy 
(CPT)? 1.Yes  2.No  3.Unknown (If ‘No’ skip to # 61) 
60. If cotrimoxazole preventive therapy was given, Date the cotrimoxazole preventive therapy 
was started (DD/MM/YY)________/______/______  
61. If Positive for HIV was patient initiated on ART? 1. Yes 2. No 3. Unknown (If ‘No’ skip to # 
63) 
20                               
21                               
22                               
23                               
24                               
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62. If ART was initiated, Date ART started (DD/MM/YY)________/______/______ 
 
Questions related to assessing MDR-TB Patients’ Bacteriological & Radiological 
follow up service status   
63. MDR-TB patient’s Bacteriologic (sputum smear and culture) follow up status and its 
result: 
Instruction: Write ‘N’ for Culture (C) Negative result; ‘P’ for Culture (C) Positive Result; ‘N’ for 
sputum (S) negative result and ‘P’ for sputum (S) positive result and ‘ND’ if test not done or 
result not available both for culture and sputum for a scheduled  month. NB: Date Specimen 
collected from a patient for a given follow up month is the same as date of follow up culture & 
sputum result of that month. 
Type of 
Follow up 
MONTH (0-24 month) 
0 1 2 3 4 5 6 7 8 9 1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
2
4 
Sputum (S)                          
Culture (C)                          
 
64. Patient’s Radiological Follow up status and its result (If 2 or 3 skip to 66): 
Availability of follow up radiological exam at each phase 
For each column fill: [1=If Done/available/    2=If not done 3=Unknown (no data)] 
At Baseline At End of Intensive Phase At End of Treatment 
   
 
65. Result of Follow up Radiological examination at each scheduled follow up time:  
Result of Follow up Radiological exams at each phase: [Fill in: 1=Improved; 2=No change; 
3=Deteriorated; 4=follow up result not available 
At Baseline At End of Intensive Phase At End of Treatment 
   
 
66. If there was cavitary lesion at baseline (answer option ‘4’on Q19), what are the subsequent 
radiological changes in the lung cavitary lesion during scheduled radiological follow-ups? 
[Fill in: 1=Improved; 2=No change; 3=Deteriorated 4=follow up result not available (If 
there was no cavitary lesion at baseline skip to 67). 
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Level of Lung Cavities at each radiological examination 
At Baseline At End of Intensive Phase At End of Treatment 
   
 
Questions to assess availability of continuum of care for patients with MDR-TB   
67. If the patient was linked to catchment MDR-TB treatment follow up centres (TFCs), ask the following 
questions and if the patient is treated at TIC,  that is ‘No’ to question # 11,  skip to question # 68] 
Note for data collector: The following activities are expected to be performed for an MDR-
TB patient linked to TFCs. Data is obtained from individual patient file and from interview with 
TIC MDR-TB focal person (nurse): 
67.1. Has contact tracing been completed for the patient?  1. Yes 2. No 3. Unknown (no 
evidence)  
67.2. Has the discharge summary been completed for the patient?  1. Yes 2. No 3. 
Unknown (no evidence) 
67.3. Are all SLDs related adverse event issues addressed for the patient linked to 
TFC? 1. Yes 2. No 3. Unknown (If treated at Tic, skip to 67.23). 
67.4. Have housing arrangements been confirmed for the patient? 1. Yes 2. No 3. Not 
known (no evidence) 
67.5. Have household level TB infection control arrangements been confirmed for the 
patient? 1. Yes 2. No 3. Unknown 
67.6. How is the patient taken to TFC? 1. Escorted by TIC level caregivers; 2.Escorted 
by TFC level caregivers; 3.Escorted by immediate public health office; 4.Patient 
sent alone 5. Other means (specify) 
______________________________________ 
67.7. Has a copy of the patient’s treatment record been handed over to the patient or 
future care giver? 1. Yes 2. No 3. Unknown 
67.8. On date of discharge has the date of the first follow-up appointment been arranged 
for the patient? 1. Yes 2. No 3. Unknown 
67.9. Is the list of current medication (drugs) known to the patient?  1. Yes 2. No 3. 
Unknown (no evidence) 
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67.10. Is the list of current medication (drugs) known to the caregiver at TFC?  1. Yes 2. 
No 3. Unknown (no evidence) 
67.11. For patients linked to TFCs, has access to medication been secured? 1. Yes 2. No 
3. Unknown (no evidence)  
67.12. Has the Daily Observed Treatment support been organized for the patient at TFC? 
1. Yes 2. No 3. Unknown 
67.13. Level where this patient gets Daily Observed Treatment support? 1. Health centre 
2.Community/health post/ 3. Other (specify) _____ 
67.14. Is there confidence/evidence of certainty/ that the patient will continue taking the 
medication? 1. Yes 2. No 3. Unknown 
67.15. Has a hospital contact number/person/ been handed over to the patient for 
advice? 1. Yes 2. No 3. Unknown 
67.16. Has a hospital contact number/person/ been handed over to caregiver at the TFC 
for advice? 1. Yes 2. No 3. Unknown 
67.17. Is the contact detail of the TB treatment supporter at TFC known to the hospital 
care giver? 1. Yes 2. No 
67.18. Is the patient’s contact address known to the hospital care giver? 1. Yes 2. No 3. 
Unknown 
67.19. Is the patient’s address known to the immediate public health office? 1. Yes 2. No 
3. Unknown 
67.20. Are treatment support services (e.g. nutrition & house rent, transport) available for 
the patient? 1. Yes 2. No 3. Unknown 
67.21. Is the patient aware of the monitoring schedule during the outpatient phase of 
treatment? 1. Yes 2. No 3. Unknown 
67.22. Is the care giver at TFC aware of the monitoring schedule during the outpatient 
phase of treatment? 1. Yes 2. No 3. Unknown 
67.23. Do the hospital MDR-TB physician(s) have supportive contact with the national 
MDR/XDR-TB consilium (consulting group of professionals)?  1. Yes 2. No 3. Not 
known 
331 
 
67.24. If ‘yes’ to 67.23, what are the purpose of contact? 1. Management of difficult cases 
2.Treatment of adverse drug reactions 3. Drugs and supplies related 4. Other 
(specify)___________________________________________________________ 
 
Questions to assess adverse events associated with treatment with second-line anti-
tuberculosis drugs  
68. Adverse drug associated with second-line drugs [source of data: MDR-TB Patient 
Treatment Card & Individual Patient Chart/file]  
Instruction:  ‘1’ in 
the appropriate cell 
when the specified 
adverse drug 
reaction occurs & ‘2’ 
when the adverse 
drug reaction does 
not occur at 
specified month 
 
 
  Months of MDR-TB treatment  
 Months of 
treatment  
0 1 2 3 4 5 6 7 8 9 1
0 
1
1 
12 1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
2
4 
I. Gastro intestinal Disorders 
Nausea & Vomiting                          
Abdominal pain                          
Diarrhea                          
Anorexia/appetite 
loss 
                         
Gastritis                           
Pubtic ulcer disease                           
II. Vestibular/ Ear / Disorders  
Dizziness                          
Problem of 
imbalance 
                         
Hearing loss                          
III. Eye Related Disorders  
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Blurred vision                          
Photophobia                          
Decreased visual 
acuity 
                         
IV. Changes in clinical chemistry  
Decreased K, Ca                          
Elevated ALT                          
Elevated creatinine                          
Elevated uric acid                          
hypomagnesemia                          
Hypothyroidism 
(TSH) 
                         
V. Musculo-skeletal disorders 
Myalgia (muscle 
pain) 
                         
Arthralgia (joint pain)                          
Arthritis 
(inflammation 
involving the joint)   
                         
VI. Neurological Disorders 
Dysgeusia (Metallic 
taste ) 
                         
Peripheral 
neuropathy 
                         
Headache                          
Seizures                          
VII.Psychiatric Disorders 
Anxiety                          
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Insomnia                          
Psychosis                          
Depression                          
Suicidal attempts                          
VIII.Dermatological Disorders   
Rash                          
Pruritus (itching)                          
Pain at site of 
injection 
                         
IX.Cardiovascular Related Disorder 
Palpitation                          
Generalized 
weakness  
                         
Cor- pulmonale                          
Other cardiovascular 
disorders  
                         
X.Hypersensitivity reactions/immune related  
Bronchospasm                          
Generalized 
urticarial/angioedem
a 
                         
Breathing  difficulty                           
Anaphylaxis                           
Jaundice                          
Hemoptysis                           
Herpes zoster                           
XI.Other adverse drug reaction, if any (specify) 
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69. For this patient has the MDR-TB treatment regimen ever been modified or permanently 
changed due to adverse drug reaction? 1. Yes 2.No 3. Unknown (If ‘No’ skip to question 71) 
70. If the MDR-TB treatment regimen of the patient has ever been modified or permanently 
changed, what was/were/ the second-line anti-tuberculosis drug suspected? 
_______________________________________________________________ 
71. Level of patient access to baseline and follow up clinical laboratory tests [Instruction for data 
collector: The patient weight in Kg is obtained from MDR-TB patient treatment card and the 
other lab results are attached to individual patient medical record/file so that patient file is 
source for all other lab test results except for weight; NB. At each month lab tests are done for 
ALT/SGPT, AST/SGOT, Creatinine, K, Ca, TSH, Hgb, WBC and pregnancy test. If test not 
done write “ND”, if test is done write the actual lab result for that follow up month] 
 
MONTH Dat
e 
Weight 
(Kg) 
ALT/S
GPT 
AST/SG
OT 
Creatini
ne 
Uric 
Acid 
K/
Ca 
M
g 
TS
H 
Hg
b 
W
BC 
Pregn
ancy 
Test 
Pre-
treatment  
            
Month 0             
1             
2             
3             
4             
5             
6             
7             
8             
9             
10             
11             
12             
13             
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72. MDR-TB patient interim treatment outcome at 6 month of follow up? [asked for patients on 
treatment at least for 6-month] 1. Culture negative 2.  Culture positive 3. Patient lost to follow 
ups 4. Died by 6-month 5. treatment outcome at 6 month not evaluated [If answer is ‘4’ skip 
to 78] 
73. What is current treatment status of the patient? 1. Currently on treatment 2. Treatment 
stopped/terminated 3. Other (specify)___________________ [If answer is ‘1’, skip to 78] 
74. If treatment was stopped/terminated, date treatment stopped 
(DD/MM/YY)___________________________________ 
75. Reason for termination of treatment: 1. Treatment successfully completed 2. Died 3. Lost to 
follow ups 4. Treatment Failed 5. Could not tolerate the regimen (ADRs) 6. Other reason 
(specify)____________________________________ 
76. What is the patient’s treatment outcome (ask for those that completed treatment or those for 
whom treatment outcome is assigned & circle the appropriate answer)? 1. Cured 2. 
Treatment Completed 3. Treatment Failed 4. Died 5. Lost to Follow Ups 6. Treatment 
outcome not evaluated   
77. Date MDR-TB treatment outcome assigned for the patient 
(DD/MM/YY)________________________________________ 
 
 
 
 
 
14             
15             
16             
17             
18             
19             
20             
21             
22             
23             
24             
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Post treatment follow up services for patients with MDR-TB (facility) 
78. Is there practice of patient follow ups for patients released from treatment after completion of 
treatment? 1. Yes 2. No (If ‘No’ skip to question 81) 
79. If yes to question 78, what is the frequency of follow ups? 1. Monthly 2. Quarterly 3. Bi-annually 4. 
Annually 5. Other (specify)____ 
80. If yes to question 78, for how long are patients followed after released from treatment? 1. Only once 
2. For one year 3. For two years 4. Other 
(specify)__________________________________________________________________________ 
81. Are there cases of relapse among patients released from treatment after completion of 
treatment? 1. Yes 2. No 3. Unknown  
82. Level of completeness and quality of data on each data source (that is Unit MDR-TB 
register, patient treatment cards, medical files, etc: 1. Good 2. Satisfactory 3. 
Unsatisfactory 4. Other observations (specify) ____________________  
 
Part II: Checklist to assess status of hospital tb infection control implementation 
[Instruction: General questions on MDR-TB infection control are filled through 
interview with hospital level focal person for MDR-TB] 
1. Is there a functional l infection prevention (IP) committee in the hospital? 1. Yes 2. No  
2. Is the MDR-TB focal person/nurse/ member of the hospital IP Committee? 1. Yes 2. No  
3. Is TB infection risk assessment of the facility done and documented for the current fiscal 
year? 1. Yes 2. No 
4. Does the facility have TB infection control plan for the current fiscal year? 1. Yes 2. No 
5. Are the health care professionals providing care in the MDR-TB unit trained on TB IP? 1. 
Yes 2. No 
6. Are the non-health care professionals providing care in the MDR-TB unit trained on TB 
IP? 1. Yes 2. No 
7. Is the facility TB IC activity monitored (plan vs performance) and documented?  1. Yes 2. 
No 
[Instruction: For the following questions, data is filled through observation of hospital’s 
MDR-TB treatment unit & tape metre is used to measure distance between adjacent beds] 
8. Is there room for isolation of inpatient MDR-TB patients? 1. Yes 2. No 
9. If yes to question # 8, what type of MDR-TB patients are isolated? 1. Sputum positives 2. 
Culture positives 3. All pulmonary MDR-TB cases 4. All type of RR/MDR-TB patients are 
isolated from one another 
10. If yes to question # 8, is one cohort of inpatient MDR-TB patients isolated from another 
cohort of MDR-TB patient? 1. Yes 2. No 3. Unknown 
11. If no to question # 10, what is the major reason for not practicing isolation of MDR-TB 
patients of differing cohorts? 1. Absence of adequate room 2. Not usually enforced by the 
PMDT programme 3. Did not see the danger of infection 4. Other 
(specify)________________________________________________________________ 
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12. Does the inpatient MDR-TB room have adequate cross ventilation (opposite 
windows/doors open all day)? 1. Yes 2. No 
13. Do(es) the inpatient MDR-TB room(s) have access to natural light? 1. Yes 2. No 
14. What is the distance between two adjacent beds of two MDR-TB patients? (measure 
distance from this patient’s bed to all other adjacent beds & record average distance in 
metres):_______________________________________________________________ 
15. Does each individual inpatient MDR-TB patient have sputum disposal container with 
proper lid 1. Yes 2. No 3. Unknown 
16. Does every MDR-TB patient with pulmonary TB have a face mask? 1. Yes 2. No 
17. Is there a shortage of supplies for MDR-TB infection control (N95 & facemasks)? NB: 
according to national guidelines one caregiver that is, nurse/doctor/paramedics needs 2 
pieces of N95 per capita per week/? 1. Yes 2. No 3. 4. Unknown 
18. What are practical challenges on TB IC in the facility? 
__________________________________________________________________ 
Part III: Semi-structured guide for in-depth interview with patients’   with MDR-TB 
 
I. Participants’ socio-demographic background  
Background information of the participants: 
 Sex, age, marital status and residence, religion,  occupation and level of education, 
 History of incarceration; Condition of use of substances (Alcohol, Khat and 
Cigarettes) 
 History of treatment for tuberculosis so far 
II. Participant’s level of awareness about MDR-TB and its risk factors   
 What do you understand by the disease called MDR-TB?  
 How do you think a person gets MDR-TB? 
 Do you think that MDR-TB can be cured, explain?  
 For how long do you think you are expected to take drugs given to treat your MDR-
TB? 
 Do you know the type of drugs you are expected to take for treatment of MDR-TB, 
describe? ____________________  
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III. Level of patient engagement in decisions making treatment initiation, follow up 
plans & issue of ADRs from SLDs. 
 What discussions and agreements did you make with your caregivers at the 
inception of your treatment, please explain?  
 Where place options are where you can take your treatment on MDR-TB (places 
where you can take your daily drugs) that you were told of at the beginning of your 
treatment? 
 What do you think can be your role or responsibility while on treatment for MDR-
TB? 
 What type of health problems, if any, do you expect that you may encounter 
because of your taking drugs given for treatment of MDR-TB? 
IV. Participant’s perceived socio-economic impact of becoming MDR-TB patient  
 What costs do you think you or your families incur because of your catching MDR-
TB and undergoing treatment for MDR-TB, explain?   
 Do you think that your catching MDR-TB has deprived you of your regular income? 
If so describe in what ways? 
 Do you think that your catching MDR-TB has deprived you of your regular social 
roles? If so, describe in what ways 
 Who is responsible for taking care of other member of your family i.e. (if there are 
dependents)?  
 During your stay at hospital (as inpatient), do you feel that you can be engaged in 
some livelihood activities i.e. able to work and earn some income, please explain! 
 How do you describe your /your family’s/ financial ability to cover expenses 
associated with seeking diagnosis and treatment services for MDR-TB?  
V. Available treatment support schemes (treatment enablers) for MDR-TB Patients  
 What is/are your means of making a living? 
 Do you get nutrition support while on treatment for MDR-TB at this hospital, 
describe: 
 If you get nutrition support, what are the packages in the food support that you get, 
describe! 
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 Do you get nutrition support when following treatment at follow up centres (health 
centres), please explain the situation including the packages in the food support 
you get. 
 What challenges do you perceive with regards to nutrition support that you get 
(adequacy, patient centredness, etc.)? 
 What things do you suggest that need to be improved regarding nutrition support 
done for MDR-TB patient like you? 
 Do you get financial support to cover expenses related to seeking treatment for 
MDR-TB, please describe. 
 What things do you suggest that need to be improved regarding financial support 
done for MDR-TB patient like you? 
VI. Patients’ level of satisfaction with Quality of clinical Care obtained on 
management of drug side effects!  
 How do you describe your experience regarding overall quality of services you get 
from the hospital (TIC) & health centre (TFC) (explain by comparing what you 
actually get against what you expect from the hospital)  
  How do you explain staff willingness to promptly help you on services you need both 
at TIC & TFC? 
 How do you describe reliability of the staff and management of this hospital in 
providing promised services for MDR-TB patients, please explain. 
 How do you describe your experience regarding availability of basic utilities (beds, 
toilets, utensils, etc) including place for recreation at the MDR-TB unit of this 
hospital? 
 How do you interpret your experience regarding the sanitation of available basic 
utilities (beds, toilets, utensils, etc) including sanitation of the premises of the MDR-
TB unit of this hospital? 
 How do you interpret your experience regarding caregiver’s willingness & 
commitment in providing the promised services (i.e. dependably/reliably/consistently/ 
and accurately)? 
 In case you encounter health problems/complaints/pains/ while in hospital (TIC) or 
health centre (TFC), whom do you contact first? 
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 How do you explain your satisfaction with the quality of the medical treatment you 
receive from your caregivers for your complaints/pains?  Explain. 
 Do your caregivers listen to you carefully about your concerns and questions? 
Please explain. 
 Are you treated with courtesy/politeness & respect by all staff that you encount here, 
describe:  
VII. Condition of patients’ accessibility to treatment initiating and treatment follow 
up centres  
 How far is your permanent residence area from this hospital/town/? (KM)=_______ 
 How often do you come to this hospital to get the services you need, describe? 
______________________________ 
 Do you face challenges in attending appointments with this hospital, please mention! 
_________________________ 
 How often do you go to the Health Centre where you follow your treatment, what 
problems do you face?  
 What good things did you experience during your treatment for MDR-TB? What 
challenges/bad things did you experience? 
 What things do you recommend be improved for MDR-TB patients like you to enable 
them to comfortably follow their treatment?  
 Is there anything, if any that you want to add or recommend that you feel need 
improvement to assist MDR-TB patients like you?  
Part IV: Semi-structured interview guide for in-depth interview with caregivers for 
MDR-TB   
I. Caregiver’s Professional background:  
 Professional background 
 Department of assignment in his/her facility 
 Types of in-service trainings taken by the participant 
 Experience in years   
II. Caregiver’s practice in providing the daily directly observable treatment 
(DOT)support for MDR-TB patients on second-line drugs (SLDs) 
1. What is the number of directly observable treatment days’ per week for the oral 
second-line drugs?   How many are the daily directly observable treatment days for 
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oral second-line drugs do you have per week? 
________________________________________ 
2. What is the number of directly observable treatment days’ per week for the 
injectable second-line drugs? How many are the directly observable treatment days 
for injectable second-line drugs do you have per week? 
______________________________________ 
3. What scheme is available (responsible body) to make sure that patients are treated 
under strict Daily Observed Treatment support at: 1. Treatment initiating centre 
(hospital)? __________ 2.Treatment follow up centre (health centres)? _________ 
4. What treatment enablers, if any, are available for MDR-TB patients? 
____________________________________ 
5. If there is a scheme to provide enablers for patients, does the facility have written 
records/evidence on treatment enablers given to the patient, describe (like data on 
disbursement of food or finance)._____________________________________ 
6. What is your view on the need for an incentive scheme for caregivers for MDR-TB? 
________________________________________________________________ 
7. If you recommend an incentive schemes for MDR-TB caregivers, what do you think 
should be the form of the incentive?____________________________________ 
III. Management of second-line drug (SLDs) related adverse drug reactions  
8. What are the most frequently encountered challenges in the clinical management 
of MDR-TB patients? _____________________________________________ 
9. What factors determine the management of adverse events from SLDs immediately 
& appropriately? _________________________________________________ 
IV. Hospital practice on MDR-TB patient Follow ups: 
10. How do you communicate with your MDR-TB patients after they are linked to 
satellite health centres to continue treatment? 
___________________________________________________________________ 
11. If there is a prescheduled date for contact between caregivers & patients followed 
at the health centres, what are the major support activities given during contact 
(clinical and non-clinical)? ____________________________________________ 
12. What supportive system is available to deal with challenges faced during the 
lengthy patient treatment (like tracing patients lost to follow ups/is the hospital 
management and immediate health authority supportive? ___________________ 
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13. What forums are available for contact between caregivers at this hospital and those 
found at the catchment MDR-TB treatment follow up centres?________________ 
14. How do you describe functionality status of referral linkage between your hospital & 
catchment TFCs? ___________________________________________________ 
15. Are there schemes in place for follow ups of MDR-TB patients that have completed 
treatment? 1. Yes 2. No. If yes, what is the frequency and duration of follow ups 
after treatment is completed? _________________________________________ 
16. How do you describe the current status of MDR-TB patients in taking responsibility 
for their own treatment? What do you recommend be done in the future? 
_________________________________________________________________ 
V. TB Laboratory Specimen Referral, Transportation and feedback related questions 
17. Is there a system for referral of samples of MDR-TB patients? (diagnostic & 
referral) 1. Yes   2. No 3. Does not know 
18. Please describe your level of satisfaction with available sample referral 
system________________________________________________________ 
19. Are laboratory results available when 
needed?describe_______________________________________________ 
20. Is there interaction between central lab staff and clinicians at your hospital? 1. Yes 
2. No 
21. If yes, go to question 24, what is the main mode of this interaction? Pplease 
describe _______________________________________________________ 
22. What is the average number of samples of MDR-TB cases for whom culture sample  
are sent to a referral lab per month? 
23. What is the average number of culture specimens on which feedback result are 
obtained per month?  
24. What are the challenges you face in the current specimen referral system? 
_____________________________________________________________ 
25. What improvements would you like to see in the specimen referral system? 
_____________________________________________________________ 
26. What are the things you feel need improvement in the implementation of PMDT in 
this hospital/country? [explain briefly]_______________________________ 
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VI. Health System support to the PMDT at the hospital 
27. Do you feel supported by the hospital management on PMDT? (please 
describe)__________________________________________________________ 
28. Do you feel supported by the immediate health office on PMDT? (please 
describe)__________________________________________________________ 
29. Is the MDR-TB programme perceived as a district/zone/town health problem and 
not as MDR-TB treatment centre problem? (please describe) 
30. Are staff members at PHCU adequately trained to manage MDR-TB patients 
referred to TFCs? __________________________________________________ 
VII. Level of integration of services on MDR-TB and comprehensive HIV/AIDS services  
31. Have you ever had MDR-TB patients who are co-infected with HIV? 
________________________________________________________________ 
32. Are the caregivers for MDR-TB found at this facility trained on comprehensive 
HIV/AIDS including ART? ___________________________________________ 
33. Are the MDR-TB and HIV services integrated (ART service available in the MDR-
TB unit for the co-infected)? 
Describe:___________________________________________________________  
34.  If the MDR-TB and HIV services are not integrated, where do the MDR-TB-HIV co-
infected patients get services on HIV/AIDS? 
__________________________________________________________________ 
35. Is the PMDT data/clinical practice & expertise of this hospital used by central 
consulium for national PMDT decision making or management of M(X)DR-TB 
patients (describe)_________________________________________________ 
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Annexure 3: Ethical clearance certificates 
 
Annexure 3.1. Ethical clearance certificate from the the University of South Africa-
Department of Health Studies Higher Degrees Committee   
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Annexure 3.2. Ethical clearance certificate from the University of South Africa-
Ethiopia Centre for Graduate Studies    
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Annexure 3.3. Ethical clearance certificate from the Oromia Region Health Bureau, 
Public Health Emergency management and Health Research core-
process to the Adama Hosptal Medical College   
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Annexure 3.4:  Ethical clearance certificate from the Oromia Region Health Bureau, 
Public Health Emergency management and Health Research core-
process to the Nekemte Referral Hospital   
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Annexure 4: Information sheet & informed consent for participants of the in-depth     
interviews with patients with MDR-TB and their caregivers 
Good morning/afternoon…My name is “Mengistu Kenea Wakjira” and I am a PhD student at 
UNISA. Currently I am collecting data for my thesis entitled Factors determining treatment 
outcomes among MDR-TB patients enrolled to second-line anti-tuberculosis drugs at Adama 
Hospital Medical College and Nekemte Referral hospital. 
I would also like to explore MDR-TB patients’ perceptions on the quality of care and services they 
receive at this hospital and their satisfaction. The main objective of this research is to contribute to 
improving quality of care and clinical services provided for MDR-TB patients in hospitals like this. 
Thus, the research will come up with findings and recommendations that guide resource allocation 
and decision making regarding programmatic management of drug-resistant TB so that the services 
could possibly be improved.   
In this way, I would like to know your views on quality of MDR-TB care that you are given at this 
hospital (patients); your practices & perceptions on the programmatic management of drug-
resistant TB at this hospital (caregivers). Your participation will be appreciated. The results of this 
study will help to better understand factors determining satisfaction of patients like you towards 
the care given and factors determining MDR-TB treatment outcomes.  Your participation in this 
research is entirely voluntary and if you feel uncomfortable and decide to withdraw at any time, 
you are free to withhold participation. Your decision not to participate will not have any impact on 
the care and services you get at this hospital.  
Moreover, if you deciding to continue participating in the study and you feel uncomfortable to 
respond to some of the questions or to discuss some issues, you can skip such questions and 
discussions without any precondition. The interview will last about 30 minutes. The interview will 
be strictly confidential and the responses will not be shared with anyone. We would like to ask 
for your permission to tape record the interview in order to record your responses accurately and not 
miss any of your valued input. Your interview responses will be combined with responses from other 
respondents and no one will be able to identify your individual responses and link them back 
to participants. The information gathered will only be used for the stated purpose. We will not mention 
your name or address anywhere outside this room. I will be using a number code instead of names 
which will further conceal your identity and guarantee confidentiality. 
In case you need assistance on issues related to MDR TB and its treatment or want to discuss 
personal issues at any time while on treatment for MDR-TB or beyond this discussion, you may 
contact me: Mengistu Kenea Wakjira; Address: Addis Ababa, Cell phone:+251-911-30-25-68; 
Email:-mkenea@yahoo.com; mengistukenea@gmail.com  or 57661626@mylife.unisa.ac.za  
By signing below, you confirm that this form has been explained to you and that you understand 
its contents. 
1. AGREE TO PARTICIPATE 2. I DO NOT AGREE TO PARTICIPATE 
Instruction for data collector:  If the answer is 2 (above), thank the patient and allow him/her to 
depart. If the answer is 1 (above), first ask the participant to sign on the line below and continue the 
interview: 
 
Interviewee’s signature _________________________ Date___________________  
 
